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Abstract 
 
Nitric oxide (NO) functions as a signalling molecule throughout the brain where, via 
the intracellular generation of cGMP, it participates in many functions, such as in 
synaptic plasticity. The initial experiments were based on the finding that, in optic 
nerve, NO released from blood vessels tonically depolarises axons. The aim was to 
test the hypothesis that the tonic NO production is maintained by phosphorylation of 
endothelial NO synthase (eNOS). The results from extracellular recordings of changes 
in  the  axonal  membrane  potential  suggested  that  PI3  kinase-mediated  eNOS 
phosphorylation  is  partially  responsible.  The  subsequent  aim  was  to  determine  if 
blood vessel-neuron communication may be more widespread, by investigating if this 
mechanism accounts for basal NO production in the developing rat hippocampus. For 
this purpose, measurements of cGMP were chosen as a sensitive index of the local 
NO concentration. Contrary to expectations, no clear evidence for a dominant role of 
either eNOS or the neuronal NO synthase emerged, although the data suggested that 
NO formation was calcium-dependent. The next step was to characterise the target 
cells of endogenous and exogenous NO in the hippocampus, particularly in the light 
of  findings  that,  with  a  better  tool  for  inhibiting  the  dominant  phosphodiesterase 
activity  (phosphodiesterase-2),  much  higher  cGMP  levels  could  be  evoked  than 
previously.  Accordingly,  instead  of  a  predominant  location  in  astrocytes,  cGMP 
immunocytochemistry  showed  widespread  staining  of  neuronal  elements  (somata, 
dendrites, neuropil) throughout the tissue. The final objective was to begin to analyse 
NO transduction in cells in real-time, using a newly developed fluorescent cGMP 
sensor. Cell lines expressing various levels of guanylyl cyclase and phosphodiesterase 
were selected for study. Cellular responsiveness to extremely low NO concentrations 
(down  to  3  pM)  could  be  detected.  Moreover,  the  findings  illustrated  how  the 
interplay  between  guanylyl  cyclase  and  phosphodiesterase  activities  serves  to 
generate distinct cellular cGMP profiles. 
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1.1   NITRIC OXIDE EMERGING AS A BIOLOGICALLY    
SIGNIFICANT MOLECULE 
 
Nitric oxide (NO) was first discovered by Joseph Priestley in 1772, describing it as a 
colourless, toxic gas, with a lifetime of only a few seconds. Indeed, NO first came to 
medical prominence as a poison when Sir Humphrey Davy spoke of a terrible burning 
in his tongue, throat and chest upon inhaling NO during his investigations into nitrous 
oxide and other gases as anaesthetic agents (Sprigge, 2002). The rediscovery of NO as 
a  poison  owed  to  the  tragedy  reported  in  1967  wherein  a  contaminated  stock  of 
nitrous oxide killed one patient and gravely injured a second (Clutton-Brock, 1967). 
Nonetheless, although being a noxious constituent of car fumes and cigarette smoke, 
and having long been regarded as a harmful pollutant, a string of seminal experiments 
which will be outlined below provided the stepping stone for NO to rise to biological 
fame. Having been proclaimed as the molecule of the year by the journal Science in 
1992, the importance of the discovery of NO was further recognised by awarding the 
1998-Nobel Prize in Physiology and Medicine to the late Robert Francis Furchgott, 
Louis Ignarro, and Ferid Murad. By the end of the 20
th century the plethora of NO’s 
implications was spanning almost every area of biomedicine, including cardiovascular 
function, neurotransmission and neuropathology, pain, diabetes, wound healing and 
tissue  repair,  skin,  cancer,  immune  function,  infection,  respiratory  function,  eye 
physiology  and  pathology,  and  many  others.  It  continues  to  be  one  of  the  most 
researched molecules. 
 
Prior to the groundbreaking work in the 1980s, the first implications of NO in biology 
date back as far as the late 1860s when Alfred Nobel discovered nitroglycerin to have 
an anti-anginal effect. He utilised nitroglycerin in his factories to synthesise dynamite, 
in the course of which he observed that some of his workers complained of recurrent 
headaches, which  would disappear over the  weekends, while those suffering from 
angina  pectoris  often  reported  relief  from  chest  pains  during  the  working  week. 
Although  initially  attributed  to  the  vasodilatory  action  of  nitroglycerin,  about  a 
century  later  the  underlying  mechanism  was  elucidated  to  involve  metabolic 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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conversion of nitroglycerin to NO (Arnold et al., 1977; Ignarro et al., 1981). The 
potential of NO as a vasodilator was further confirmed by experiments conducted by 
Gruetter and colleagues, demonstrating relaxation of the vascular smooth muscle in 
experiments in which a gaseous mixture of NO in nitrogen or argon was delivered 
into an organ bath containing isolated pre-contracted strips of bovine coronary artery 
(Gruetter et al., 1979).  
In  1980,  Furchgott  and  Zawadzki  initiated  the  avalanche  of  NO  research. 
Initially interested in studying the difference between in vivo and in vitro responses of 
blood vessels to acetylcholine, in vitro preparations generally contracting in response 
to  stimulation  by  acetylcholine,  experiments  usually  utilised  only  “pure”  smooth 
muscle preparations where isolated arteries had been cleared of both the adventitia 
and the endothelium. On one occasion, Furchgott’s technician, John Zawadzki, forgot 
to  remove  the  endothelium  in  their  rabbit  aorta  preparation  and,  to  their  surprise, 
acetylcholine caused a potent relaxation (Furchgott, 1999). This culminated in the 
first serendipitous discovery in the NO story in which Furchgott demonstrated that 
endothelial cells produce a relaxing factor in response to acetylcholine in vessels with 
intact  endothelium,  which  was  termed  endothelium-derived  relaxing  factor  or 
“EDRF”  (Furchgott  &  Zawadzki,  1980).  In  this  study,  Furchgott  established  that 
arterial relaxation in response to acetylcholine strictly required the presence of the 
endothelium,  and  found  relaxation  to  be  prevented  by  atropine,  implying  that 
acetylcholine  was  acting  on  muscarinic  receptors  to  initiate  the  production  of  a 
diffusible  substance,  which  could  ultimately  reach  the  smooth  muscle  to  evoke 
relaxation.  At  that  time,  the  vasorelaxant  effect  of  nitrovasodilators  such  as 
nitroglycerin and sodium nitroprusside had already been linked to stimulation of the 
enzyme guanylyl cyclase and resultant rise in cGMP, and also NO, which was known 
to  be  spontaneously  liberated  from  sodium  nitroprusside,  was  shown  to  increase 
cGMP  (Arnold  et  al.,  1977;  Gruetter  et  al.,  1981;  Feelisch  &  Noack,  1987). 
Moreover,  the  endothelium-dependent  relaxation  was  thought  to  be  mediated  by 
cGMP and cGMP-dependent phosphorylation (Rapoport & Murad 1983; Rapoport et 
al., 1983). Nevertheless, a direct connection between NO and Furchgott’s discovery 
was  not  made  until  nearly  a  decade  later.  Following  numerous  studies  indicating 
striking similarities between the properties of NO and EDRF, it was only in 1987 that 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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two separate laboratories published direct evidence that NO and EDRF were in fact 
one and the same molecule (Palmer et al., 1987; Ignarro et al., 1987a; Ignarro et al., 
1987b). The group of Ignarro showed that EDRF derived from the pulmonary artery 
and vein with intact endothelium had identical vasorelaxant properties to NO applied 
to endothelium-denuded tissue preparations. They also provided chemical evidence 
that EDRF released from both artery and vein is NO, demonstrating that EDRF also 
reacts with haemoglobin and causes an identical shift in the absorbance spectrum as 
authentic  NO.  More-or-less  at  the  same  time,  Palmer  and  colleagues  found  that 
cultured  endothelial  cells  release  an  unstable  vasodilating  agent  upon  exposure  to 
bradykinin  with  identical  biological  activity  to  NO.  Moreover,  using  a 
chemiluminesence technique, Palmer et al. provided direct evidence that the vaso-
active molecule produced in their experiments was NO.  
 
Only about one year after the identification of EDRF as NO, it was discovered that 
NO is also produced in the brain following activation of the N-methyl-D-aspartate 
(NMDA) class of glutamate receptors in neurons, proposing that it may relay signals 
to neighboring cells (Garthwaite et al., 1988). The potential of NO to diffuse between 
its sources and targets was particularly evident as NMDA elicited relaxation of rat 
aorta  only  in  the  presence  of  cerebellar  cells  (Garthwaite  et  al.,  1988).  This 
groundbreaking  discovery  was  preceded  by  a  string  of  evidence  indicating  the 
presence of a transmitter which evokes accumulation of cGMP upon NMDA receptor 
stimulation.  Already  in  the  mid-1970s,  Ferrendelli  and  colleagues  speculated  that 
there could be an intermediate transmitter between glutamate-evoked Ca
2+ influx and 
resultant cGMP elevation, observing a rise in cGMP in mouse cerebellar slices upon 
exposure to glutamate, which was found to be dependent on the presence of Ca
2+ 
(Ferrendelli et al., 1974; Ferrendelli et al., 1976). About a year later, Arnold et al. 
reported an increase in the activity of the guanylyl cyclase in brain homogenates upon 
exposure to pure NO  gas (Arnold et al., 1977), which was later found to closely 
resemble  the  increase  in  enzyme  activity  induced  by  L-arginine  (Deguchi  & 
Yoshioka, 1982). In 1985, the glutamate-evoked rise in cGMP was finally linked to 
NMDA  receptor  activation  by  pharmacological  means  (Garthwaite,  1985). 
Eventually, the experimental evidence indicating NO to be the connective element 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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between  NMDA  receptor  activation  and  cGMP  accumulation  (Garthwaite  et  al., 
1988)  potentially  explained  the  earlier  finding  in  the  cerebellum  of  cGMP 
accumulation not predominantly occurring in the same cells stimulated by NMDA, 
suggesting  an  intercellular  messenger  (Garthwaite  &  Garthwaite  1987).  More 
evidence that it was indeed NO that was the missing transmitter followed rapidly 
when  it  was  demonstrated  that  NMDA  receptor  activation  failed  to  evoke  cGMP 
accumulation when the enzyme synthesising NO was inhibited, while this remained 
intact and was augmented in the presence of L-arginine (Garthwaite et al., 1989). NO 
as a neurophysiological messenger was discovered, initiating the extensive research 
into NO signalling in the central nervous system. 
 
Around the same time of NO being discovered to be a transmitter in the brain, parallel 
unrelated investigations identified the potential of NO to also serve in the immune 
system. Previously, it had been shown that urinary levels of nitrate (NO3
-) exceeded 
dietary intake, indicative of a synthetic pathway (Green et al., 1981). Following an 
inflammatory stimulus, the synthesis of NO3
- was increased (Wagner et al., 1983), 
which echoed findings of increased urinary nitrate excretion in patients suffering from 
diarrhoea and fever (Hegesh & Shiloah, 1982). This was later attributed to activated 
macrophages (Stuehr & Marletta, 1985). The dependence of the cytotoxic action of 
activated macrophages on L-arginine (Hibbs et al., 1987) led to the confirmation of 
NO being part of the repertoire of defenses against foreign organisms (Hibbs et al., 
1988), exerting its cytotoxicity via mechanisms such as metabolic inhibition of DNA 
synthesis and mitochondrial respiration, which eventually culminates in the induction 
of apoptosis (MacMicking et al., 1997).  
 
These three diverse functions – smooth muscle relaxation, neural communication, and 
immune defense – remain at the core of NO biology and are mediated largely by the 
processes outlined in the following sections. 
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1.1  FORMATION OF NO 
 
1.2.1   Nitric oxide synthases 
 
The  identification  of  EDRF  as  NO  was  rapidly  followed  by  the  discovery  of  the 
synthetic machinery for NO. The group of enzymes responsible for NO production 
was first described in 1989 to be the Ca
2+/calmodulin (CaM)-dependent NO synthases 
(NOS), and was subsequently characterised throughout the 1990’s. The isolation and 
cloning of NOS from rat cerebellum (Bredt & Snyder, 1990; Bredt et al., 1991a) was 
rapidly conjoined with immunohistochemical evidence demonstrating NOS not only 
to be localised in endothelial cells but also to be highly expressed in the brain (Bredt 
et  al.,  1990;  Vincent  &  Kimura,  1992),  being  discretely  localised  in  neuronal 
populations (Bredt et al., 1991b; Vincent & Kimura, 1992).  
 
Currently  there  are  three  acknowledged  isoforms  of  NOS  responsible  for  NO 
production throughout the mammalian system, each of which catalyses the conversion 
of the amino acid L-arginine and molecular oxygen to L-citrulline and NO. There are 
three distinct genes in the mammalian genome encoding, respectively, the neuronal 
(n)NOS in neurons, endothelial (e)NOS in endothelial cells of the vasculature, and 
inducible (i)NOS. Inducible NOS is not found in any healthy cell but is instead, as the 
name implies, induced in various cell types, including macrophages and microglia, 
generally occurring in response to products of infection, such as bacterial endotoxin, 
or to inflammatory mediators, including cytokines, interleukin-1 and tumour necrosis 
factor, resulting in long-term NO production to cytotoxic levels.  
Splice  variants  of  some  of  the  NOS  isoforms  have  also  been  reported. 
Identified variants of nNOS include nNOSa, nNOSb and nNOSg. A fourth variant 
termed nNOS-2 has been reported in the mouse brain, but only at its mRNA level 
(Ogura et al., 1993). The most relevant nNOS variant is the a-variant as it is the only 
one known to physically associate with NMDA receptors in synapses (Brenman et al., 
1996 and see later) and appears to be the most abundant nNOS subtype, accounting 
for approximately 95% of all enzyme activity in the brain (Huang et al., 1993). In 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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contrast, both the b- and g-variants appear to lack capacity to associate with NMDA 
receptors, the former being up-regulated in some brain regions (including striatum, 
hippocampus, brain stem and cortex) at its protein level in mice devoid of the nNOSa 
and suggested to be the only functional alternative to nNOSa, since the g-variant 
appears to have little or no enzymatic activity (Brenman et al., 1996; Eliasson et al., 
1997; Langnaese et al., 2007). No splice variants of eNOS have so far been reported, 
while  relatively  little  information  exists  on  iNOS  variants.  Alternatively  spliced 
mRNA  transcripts  of  iNOS  have  been  detected  in  human  epithelial  and  alveolar 
macrophages (Eissa et  al., 1996). Due to its principal importance in host defence 
mechanisms as well as pathology, being largely irrelevant to the work presented in 
this thesis, iNOS will not be considered in much further detail. 
 
1.2.2   NOS structure and reaction mechanism  
 
NOS proteins are dimers, each monomer comprising a N-terminal oxygenase domain 
and  a  C-terminal  reductase  domain,  these  two  domains  being  linked  by  a  CaM-
recognition site (Fig. 1.1). The oxygenase domain possesses binding motifs for haem, 
the cofactor tetrahydrobiopterin (BH4), and the substrate L-arginine, BH4 thought to 
be  predominantly  promoting  and  stabilising  the  active  dimeric  form  of  all  NOS 
isoforms. The reductase domain is equipped with the binding sites for NADPH, FAD 
and FMN.  
The  synthesis  of  NO  by  NOS  involves  electron  flow  through  the  enzyme, 
which is facilitated by Ca
2+-CaM binding to the CaM-recognition site, and a two-step 
oxidation  of  L-arginine  to  L-citrulline  with  the  concomitant  generation  of  NO. 
Functionally,  electrons  are  donated  by  NADPH  to  the  reductase  domain  and  are 
transported  through  the  reductase  domain  by  the  FAD  and  FMN  redox  carriers, 
eventually reaching the oxygenase domain of the opposite monomer. Upon arrival of 
the electrons at the oxygenase domain, the haem iron is initially reduced from Fe
3+ to 
Fe
2+, allowing it to bind molecular oxygen, the cleavage of which in turn leads to the 
oxidation of L-arginine at the catalytic site, the end-products being L-citrulline and 
NO (Alderton et al., 2001). 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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Fig. 1.1 Synthesis of NO by NOS: structure and catalytic function. Proposed arrangements of monomers; activity 
requires the dimeric interaction between two oxygenase domains and CaM binding between the reductase and 
oxygenase domains, which triggers electron transfer. The reductase reduces NADPH to NADP+, yielding 
electrons, which are then carried onto the haem moiety in the oxygenase domain of the other monomer via the 
bound flavins FMN and FAD. Subsequently, two cycles of L-arginine oxygenation occur. The first cycle yields the 
intermediate product N-hydroxyl-L-arginine (NHA) via oxygenation of the guanidine group of L-arginine to a N-
hydroxyl group, a reaction that requires BH4 as a cofactor. In the second cycle, NHA is converted to L-citrulline 
and NO by oxidative cleavage. Adapted from Alderton et al., 2001 
 
 
1.2.3   Catalytic modulation 
 
CaM and Ca
2+ 
 
The binding of Ca
2+-CaM is a pivotal requisite for NOS activity (Bredt & Snyder, 
1990), functioning as a sensor of intracellular Ca
2+ concentrations, where the binding 
of Ca
2+ to CaM promotes CaM interaction with NOS. A conformational change in the 
NOS dimer upon CaM binding supports the flow of electrons within the reductase 
domain as well as the interdomain electron transfer (Panda et al., 2001). The Ca
2+-
dependence varies among NOS isoforms in that both eNOS and nNOS require higher 
concentrations than iNOS. The iNOS is held in an activated state even at low Ca
2+ 
levels as it binds CaM very tightly, rendering it largely Ca
2+-independent. The varying 
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Ca
2+-sensitivity of the different NOS isoforms is determined by the presence of an 
auto-inhibitory  loop  insert  of  40-50  amino  acids  in  the  FMN-binding  subdomain. 
While  absent  in  iNOS  (Salerno  et  al.,  1997),  this  insert  acts  to  destabilise  CaM 
binding to eNOS and nNOS at low Ca
2+ concentrations, thereby preventing the flow 
of  electrons  to  the  haem  moiety.  Upon  CaM  binding,  this  insert  polypeptide  is 
displaced, initiating the ability of CaM to gate electron flow through NOS (Salerno et 
al., 1997). 
 
Phosphorylation 
 
nNOS: 
 
Although having long been regarded to be predominantly Ca
2+-dependent, it is now 
clear that enzyme activity of both eNOS and nNOS may also be influenced via protein 
phosphorylation  on  several  putative  sites.  The  first  indication  that  NOS  can  be 
regulated by many different factors came from cloning studies, revealing recognition 
sites not only for NADPH, CaM, and flavins, but also phosphorylation sites (Bredt et 
al., 1991a). 
 
Phosphorylation of nNOS on Ser-847 by CaM-dependent protein kinases has been 
demonstrated to reduce nNOS activity. Initial studies on purified nNOS from rat brain 
found Ser-847 to be phosphorylated by several CaM-dependent kinases, which was 
confirmed  by  the  lack  of  phosphorylation  observed  upon  mutation  of  this  site 
(Hayashi et al., 1999). Phosphorylation of Ser-847 was found to result in an overall 
50-60% reduction in enzyme activity, attributed partially to suppressed CaM binding. 
Later studies in cultured hippocampal neurons confirmed this finding, demonstrating 
NMDA receptor-dependent phosphorylation of nNOS-Ser-847 by Ca
2+-CaM protein 
kinase  II  (CaMKII)  in  dendritic  spines,  which  was  slow  in  onset  (Rameau  et  al., 
2004).  An  interesting  observation  made  by  Rameau  and  colleagues  was  that  of  a 
bidirectional  regulation  of  this  phosphorylation  process  depending  on  the 
concentration  of  glutamate  applied  to  the  neurons.  While  low  micromolar 
concentrations of glutamate elicited enhanced nNOS phosphorylation, concentrations 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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in  the  several  hundred-micromolar  ranges  were  associated  with  reduced 
phosphorylation  of  the  enzyme,  indicating  that  the  alleviation  of  this  negative 
feedback control on nNOS activity may be a potential mechanism contributing to 
excessive NO output under conditions of excitotoxicity. Sustained CaMKII-mediated 
phosphorylation of nNOS-Ser-847, evoked by low glutamate concentrations, was also 
detected in cultured cortical neurons (Rameau et al., 2007). 
Other sites on nNOS the phosphorylation of which have been suggested to 
cause a reduction in nNOS activity are Ser-741 by CaMKI (Song et al., 2004), and 
Thr-1296 (Song et al., 2005), where the latter study employed phosphatase inhibitors 
and mutations mimicking Thr-phosphorylation to come to their conclusion. However, 
both studies based their conclusions on observations made either in HEK cells or in a 
neuroblastoma cell line transfected with nNOS (and CaMKI in the case of Song et al., 
2004).  
Phosphorylation  of  Ser-1412  on  nNOS,  mediated  by  the  Ser/Thr  protein 
kinase Akt in a NMDA receptor-dependent manner, has also been proposed based on 
studies  in  cultured  cortical  neurons  (Rameau  et  al.,  2007).  In  contrast  to  Ser-847 
phosphorylation, however, this was found to occur more rapidly in response to low 
glutamate concentrations and to lead to rapid enhancement in nNOS activity.  
 
eNOS: 
 
While a fairly new concept in the field of nNOS research, protein phosphorylation on 
a number of putative sites by various types of protein kinases is a well-established 
feature of eNOS activity regulation. In fact, phosphorylation is now considered to be 
one of the most important mechanisms by which eNOS activity is controlled.  
 
The two most extensively studied phosphorylation sites on eNOS have been Ser-1179, 
which is located in the reductase domain close to the C-terminus of eNOS, and Thr-
497, which is located in the CaM-binding site. Phosphorylation of Ser-1179 enhances 
eNOS activity by reducing the enzyme’s Ca
2+-dependence (Chen et al., 1999) with an 
increase in the rate of NO production (Dimmeler et al., 1999; Fulton et al., 1999), 
while  phosphorylation  of  Thr-497  reduces  enzyme  activity  by  increasing  the 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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Ca
2+/CaM  dependence  of  eNOS  (Chen  et  al.,  1999;  Fleming  et  al.,  2001). 
Physiologically, phosphorylation and dephosphorylation of these sites are regulated in 
a highly balanced manner. For instance, selective stimulation of eNOS by means of 
exposure of endothelial cells to bradykinin results in a transient dephosphorylation of 
the inhibitory site Thr-497 in conjunction with Ser-1179 phosphorylation (Fleming et 
al., 2001; Harris et al., 2001). Under unstimulated conditions Thr-497 appears to be 
strongly  phosphorylated,  with  weak  phosphorylation  of  Ser-1179  (Fleming  et  al., 
2001). Phosphorylation of eNOS is thought to be able to regulate eNOS activity in a 
Ca
2+-independent  fashion  (Corson  et  al.,  1996;  Fleming  et  al.,  1998),  the 
physiologically most important pathway for eNOS activation being fluid sheer stress. 
The activation of eNOS by fluid sheer stress is unique in that it can be maintained 
over hours and occurs in the absence of extracellular Ca
2+ (Kuchan & Frangos, 1994; 
Ayajiki  et  al.,  1996).  Moreover,  mimicking  Ser-1179  phosphorylation  enhances 
eNOS activity, even in the absence of Ca
2+ (Dimmeler et al., 1999). 
 
While being the target of multiple protein kinases, various studies have implicated a 
key signal transduction pathway in which activation of phosphatidylinositol-3-kinase 
(PI3 kinase) and the Ser/Thr protein kinase Akt results in eNOS phosphorylation on 
the Ser-1179 site. Initial studies demonstrated that treatment of endothelial cells with 
vascular endothelial growth factor (VEGF) or insulin stimulates NO synthesis in a PI3 
kinase-dependent manner, PI3 kinase inhibition partially preventing NO release (Zeng 
&  Quon,  1996;  Papapetropoulos  et  al.,  1997).  Subsequently,  the  kinase  Akt,  a 
downstream effector of PI3 kinase, was found to activate eNOS in endothelial cells 
exposed  to  shear  stress,  leading  to  enhanced  NO  production  via  Ser-1179 
phosphorylation and cGMP accumulation, where inhibition of PI3 kinase or mutation 
of Ser-1179 attenuated phosphorylation and prevented eNOS activation and cGMP 
formation  (Dimmeler  et  al.,  1999).  This  was  joined  by  the  finding  that  Akt 
phosphorylates  eNOS-Ser-1179  directly,  thereby  activating  basal  NO  output  from 
eNOS in endothelial cells, which is diminished upon mutation of the Ser-1179 site 
(Fulton  et  al.,  1999).  The  detection  of  Akt  in  immunoprecipitates  of  eNOS  from 
bovine aortic endothelial cells suggests that Akt and eNOS associate in vivo (Michell 
et al., 1999). Apart from fluid shear stress, a number of eNOS agonists, including 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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VEGF,  insulin,  and  bradykinin,  can  also  increase  eNOS  activity  through  the  PI3 
kinase-Akt-Ser-1179 phosphorylation pathway (Dudzinski et al., 2006).  
The phosphorylation of eNOS is preventable by PI3 kinase inhibition, the two 
main inhibitors of PI3 kinase in use being wortmannin and LY 294002. Wortmannin 
is a fungal metabolite, isolated from Penicillium wortmannii, and inhibits PI3 kinase 
at a low nanomolar IC50. The synthetic compound LY 294002 has a reported IC50 
value for PI3 kinase inhibition in the low micromolar range (Walker et al., 2000; 
Djordjevic & Driscoll, 2002). Both of these compounds are competitive inhibitors of 
ATP binding. X-ray crystallography revealed that both wortmannin and LY 294002 
bind in the ATP binding site of the PI3 kinase that is located in a cleft between the N- 
and C-terminal lobes of the catalytic domain. However, while the interaction of LY 
294002 with PI3 kinase is reversible, wortmannin causes irreversible inhibition of the 
kinase by forming a covalent complex with a lysine residue in the catalytic site, which 
leads to a large conformational rearrangement (Walker et al., 2000). Both compounds 
were  shown  to  be  selective  towards  PI3  kinase  at  the  concentrations  used  in  the 
present work (Davies et al., 2000).  
 
Other eNOS phosphorylation sites include Ser-635, the phosphorylation of which is 
also stimulatory, and Ser-617 and Ser-116. The impact of the latter two on eNOS 
activity remains controversial, based on mixed findings from different laboratories 
observing  either  no  change  in  enzyme  activity,  or  enhanced  or  reduced  activity, 
depending on the stimulating factor used (Mount et al., 2007). 
 
Protein-protein interactions 
 
nNOS: 
 
A number of proteins have been identified that may bind and regulate nNOS. These 
include the termed protein inhibitor of NOS (PIN), the C-terminal PDZ ligand of NOS 
(CAPON),  heat  shock  protein  90  (hsp90),  and  NOS  interacting  protein  (NOSIP). 
Overall, however, their functions remain poorly understood.  
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PIN, identified as a dynein light chain, may contribute to axonal transport of nNOS as 
indicated by the finding of it binding to nNOS, while having no direct influence on 
enzyme  activity  (Rodriguez-Crespo  et  al.,  1998).  CAPON  may  aid  membrane 
association of nNOS via synapsins at synaptic sites. The synapsin family of proteins 
have been identified as binding partners of CAPON, CAPON suggested to serve as an 
intermediate linking nNOS and synapsin. Comparing different subcellular fractions of 
forebrain  obtained  from  mice  lacking  synapsin  I  and  II  revealed  changes  in  the 
subcellular  localisation  of  nNOS  and  CAPON  in  that  both  were  increased  in  the 
soluble  fractions  (Jaffrey  et  al.,  2002).  NOSIP  interaction  with  nNOS  may  act  to 
indirectly reduce nNOS activity by relocating the enzyme away from its site of action 
at the cell membrane as it has been demonstrated to modulate both the localisation 
and activity of nNOS. This hypothesis arose from a number of observations made by 
Dreyer and colleagues (Dreyer et al., 2004). These included co-immunoprecipitation 
of  nNOS  and  NOSIP  from  brain  lysates,  co-localisation  of  NOSIP  and  nNOS  in 
neuronal  synapses  in  various  rat  brain  regions  (including  hippocampus),  reduced 
enzyme  activity  upon  stimulation  with  a  Ca
2+  ionophore  in  a  cell  line  stably 
expressing  nNOS  and  transiently  transfected  with  NOSIP,  and  neuronal  activity-
dependent shuttling of  NOSIP between synaptic, cytosolic  and nuclear subcellular 
location  in  cultured  hippocampal  neurons.  Silencing  of  neuronal  activity  favoured 
nuclear  localisation  of  NOSIP,  while  non-nuclear  localisation  predominated  under 
conditions  of  basal  activity  or  NMDA  receptor-evoked  neuronal  activity.  Finally, 
hsp90  inhibition  has  been  reported  to  reduce  nNOS  activity  in  insect  cells  by 
approximately 75%, suggested to be due to impaired haem insertion (Billecke et al., 
2002). Additionally, studies on purified nNOS have shown hsp90 to enhance enzyme 
activity  directly  and  to  increase  CaM  affinity  for  nNOS  with  resultant  elevated 
catalytic activity (Song et al., 2001).  
 
eNOS: 
 
Just as with phosphorylation, the significance of eNOS interacting with other proteins 
is better established than in the case of nNOS. The most extensively studied proteins 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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that can interact with eNOS, and regulate enzyme activity negatively or positively, 
include caveolin-1, NOSIP, and hsp90. 
 
Caveolin-1 is an integral membrane protein abundant in endothelial cells, and serves 
as  a  structural  scaffold  within  caveolae,  which  are  enriched  with  cholesterol  and 
sphingolipids, which minimise the fluidity of these discrete membrane regions. The 
limited  fluidity  in  caveolae,  which  eNOS  is  localised  to,  draws  together  proteins, 
supporting  protein-protein  interactions.  Studies  on  endothelial  cell  lysates 
demonstrated  eNOS  co-immunoprecipitation  with  caveolin-1  (Feron  et  al.,  1996; 
Garcia-Cardena  et  al.,  1996).  Subsequently,  in  vitro  studies  and  experiments  with 
eNOS and caveolin-1 expressed in cells revealed that both the N- and C-terminal 
domains  of  caveolin-1  interact  directly  with  the  oxygenase  domain  of  eNOS  and 
thereby inhibits enzyme activity (Garcia-Cardena et al., 1997; Ju et al., 1997; Michel 
et  al.,  1997).  Moreover,  in  vitro  manipulations  further  indicated  that  Ca
2+-CaM 
binding to eNOS disrupts the interaction between eNOS and caveolin-1, resulting in 
enhanced catalytic activity (Michel et al., 1997). Later, experiments using particulate 
and soluble cellular fractions indicated that the association and dissociation of eNOS 
and caveolin-1 may be a cyclic event, in which dissociation leads to the mobilisation 
of  eNOS  from  the  particulate  fraction  upon  agonist  stimulation,  followed  by  re-
association of eNOS and caveolin-1 in the particulate fraction (Feron et al., 1998). In 
intact  blood  vessels,  the  caveolin-1  was  shown  to  potently  inhibit  eNOS  in  vivo 
(Bucci et al., 2000). Bucci and colleagues used a membrane-permeable form of the 
caveolin-1 scaffolding domain (amino acids 82-101) and fused it to a cell-permeable 
leader sequence. Exposure of mouse aortas to the peptide resulted in uptake into the 
blood  vessel,  localising  to  endothelial  cells,  and  prevention  of  ACh-mediated 
relaxation, with no effect on relaxation in response to exogenous NO. In aortas from 
mice lacking caveolin-1, on the other hand, the relaxant response to ACh is enhanced, 
attributable to increased basal NO production (Drab et al., 2001).  
NOSIP is another binding partner of eNOS that is proposed to have a negative 
regulatory impact on enzyme activity. Although the true function of NOSIP remains 
to be elucidated, the interaction between NOSIP and eNOS has been shown by co-
immunoprecipitation studies in cells (Dedio et al., 2001). Although NOSIP did not 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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affect eNOS activity when examined by in vitro assays, when co-expressed in cells, 
NO release was reduced, which was suggested, based on immunohistochemical data, 
to  be  caused  by  redistribution  of  eNOS  from  the  plasma  membrane  caveolae  to 
intracellular compartments (Dedio et al., 2001). 
 
In addition to CaM, another positive regulatory protein of eNOS is hsp90. First, hsp90 
was  shown  to  co-precipitate  with  eNOS,  being  associated  with  eNOS  in  resting 
endothelial cells (Garcia-Cardena et al., 1998; Russell et al., 2000). The treatment of 
cells with different stimuli including shear stress and VEGF enhanced hsp90-eNOS 
interaction. Mechanistically, it has been proposed that hsp90 may facilitate the ability 
of CaM to displace caveolin-1 from eNOS, the three constituents having been found 
to be present in the same complex in endothelial cells (Gratton et al., 2000). Also, 
studies on purified enzyme have demonstrated hsp90 to enhance eNOS activity in the 
presence of CaM both at low and high Ca
2+ concentrations, the EC50 values for both 
Ca
2+ and CaM being reduced in the presence of hsp90 (Takahashi & Mendelsohn, 
2003a). More direct evidence supporting the eNOS-hsp90 interaction emerged from 
experiments showing that hsp90 inhibition not only prevents VEGF-stimulated cGMP 
production in cultured endothelial cells, but also the ACh-evoked vasorelaxation of rat 
aortic  rings  (Garcia-Cardena  et  al.,  1998)  as  well  as  flow-induced  dilation  of  rat 
middle cerebral artery to a similar extent as direct NOS inhibition with a non-selective 
NOS inhibitor (Viswanathan et al., 1999).  
Hsp90 may also affect eNOS activity indirectly by acting on the kinase Akt. 
Hsp90 has been shown to bind both the inactive or active Akt and is required for the 
interaction of Akt with eNOS (Garcia-Cardena et al., 1998). Furthermore, it has been 
suggested  that  hsp90  stimulates  eNOS  by  increasing  the  rate  of  Akt-dependent 
phosphorylation of eNOS, and that the kinase Akt and hsp90 synergistically activate 
eNOS at both physiological Ca
2+ concentrations as well as independently of Ca
2+, 
indicating that hsp90-mediated Akt activation and the Akt-unrelated effects of hsp90 
could be occurring simultaneously
 (Takahashi & Mendelsohn, 2003b). A summary of 
the  proposed  mechanism  for  eNOS  activation  via  the  PI3  kinase-Akt  pathway  is 
depicted in Fig. 1.2. 
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Fig. 1.2 Proposed scheme of PI3 kinase-Akt-mediated eNOS phosphorylation. Upon binding to their respective 
receptors, shear stress and various ligands can lead to activation of PI3 kinase. PI3 kinase then catalyses the 
formation of phosphatidylinositol bi- and triphosphates, which are required for the downstream activation of the 
phospholipid-dependent-kinase-1 (PDK-1). Upon activation, the PDK-1 then phosphorylates Akt, which initiates 
the translocation of Akt to the plasma membrane where Akt then phosphorylates eNOS on Ser-1179. Upon eNOS 
phosphorylation, caveolin-1, to which eNOS is bound in its inactive state, dissociates from the enzyme as it is 
displaced by calmodulin (CaM), initiating eNOS activation and NO formation from L-arginine. Adapted from 
Sessa, 2004 
 
 
1.2.4   Pharmacological intervention for NOS inhibition  
 
Inhibitors of NOS have become invaluable tools for investigating the biological roles 
of endogenous NO. The first series of inhibitors developed were derivatives of the 
NOS  substrate  L-arginine,  which  have  a  substituent  on  the  guanidine  nitrogen 
normally used for NO synthesis. The most commonly used of these inhibitors include 
N
G-nitro-L-arginine  (L-NNA),  N-methyl-L-arginine  (L-NMMA),  and  N
G-nitro-L-
arginine  methyl  ester  (L-NAME),  the  latter  being  the  prodrug  of  L-NNA.  These 
compounds exert their inhibitory action non-selectively by competing with L-arginine 
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for  its  binding  site.  All  of  these  broad-spectrum  NOS  inhibitors  have  reasonable 
potencies with Ki values in the low micromolar range (Alderton et al., 2001). Among 
the first evidence for the inhibitory action of L-NNA and L-NMMA at the tissue level 
were results from rabbit aorta, in which both compounds were demonstrated to evoke 
concentration-dependent contractions and to prevent ACh-induced relaxation while 
leaving relaxation in response to exogenous NO intact (Moore et al., 1990).  
  Considerable  effort  has  also  been  dedicated  towards  the  development  of 
isoform-selective  inhibitors.  Compounds  showing  good  selectivity  for  nNOS  over 
eNOS and iNOS include N-propyl-L-arginine (NPA; Zhang et al., 1997; Cooper et 
al., 2000) and N
5-(1-Imino-3-butenyl)-L-ornithine (L-VNIO; Babu & Griffith, 1998). 
To date, L-VNIO is the most potent nNOS-selective inhibitor, with a Ki value in the 
low  nanomolar  range,  being  120-fold  and  600-fold  higher  for  eNOS  and  iNOS 
respectively (Babu & Griffith, 1998). A compound showing good selectivity for iNOS 
over the other two NOS isoforms is [N-(3-aminoethylyl)benzyl]-acetamidine (1400W; 
Garvey et al., 1997; Boer et al., 2000). This inhibitor was found to be approximately 
5000-fold  or  200-fold  more  selective  for  iNOS  over  eNOS  or  nNOS  respectively 
(Garvey et al., 1997). All of these isoform-preferring inhibitors act by targeting the L-
arginine binding site on NOS, competing with L-arginine for binding. No selective 
eNOS inhibitors are known to date. 
 
1.2.5   nNOS and eNOS in the brain 
 
nNOS 
 
In neurons the predominant isoform of NOS is nNOS, which is widely distributed 
throughout  the  brain  and  spinal  cord,  albeit  at  varying  amounts  among  different 
regions. For example, the highest activity and expression of nNOS is found in the 
cerebellum (Bredt et al., 1990; Bredt et al., 1991b), with nNOS localising to virtually 
all neuronal cells. On the other hand, in other areas such as the cerebral cortex and 
striatum,  nNOS  appears  in  a  subpopulation  of  interneurons.  Nevertheless,  dense 
nNOS-containing networks of fibres can be seen throughout the neuropil, including 
areas with relatively sparse numbers of nNOS-bearing neurons, indicating that the 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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majority of neurons receive NO signals (Vincent & Kimura, 1992; Rodrigo et al., 
1994). Potential sites of NO synthesis have largely  been identified in  the past by 
means of immunohistochemistry (Bredt et al., 1990; Rodrigo et al., 1994; de Vente et 
al., 1998; Burette et al., 2002), in situ hybridisation (Keilhoff et al., 1996), and the 
NADPH-diaphorase  staining  methodology  (Vincent  &  Kimura,  1992;  Southam  & 
Garthwaite, 1993; Keilhoff et al., 1996), the latter exploiting NOS activity to reduce 
tetrazolium  salts  to  visible  formazans  in  an  NADPH-dependent  manner,  thereby 
allowing the histochemical visualisation of sites of NOS activity.  
 
In  the  hippocampus  there  have  been  mixed  reports  concerning  nNOS  expression. 
Initially, intense immunoreactivity was described in the dentate gyrus (Bredt et al., 
1990), and also some scattered immunoreactive neurons in the CA1 subfield were 
reported (Bredt et al., 1991b). In both cases, however, pyramidal neurons appeared to 
be  devoid  of  nNOS  staining.  Subsequent  immunohistochemical  studies  suggested 
nNOS to be largely confined to interneurons in the CA1 and CA3 subregions of the 
hippocampus (Valtschanoff et al., 1993; Lumme et al., 2000), which was at odds with 
some of the immunohistochemical evidence finding immunoreactivity in CA1-CA3 
and  subicular  pyramidal  neurons  (Rodrigo  et  al.,  1994),  and  NADPH-diaphorase 
results finding strong pyramidal cell staining in the subiculum (Vincent & Kimura, 
1992) and CA1 region (Southam & Garthwaite, 1993). Eventually, the use of weaker 
fixation  protocols  and  electron  microscopy  in  conjunction  with  light  microscopy 
clearly revealed the presence of nNOS in a number of pyramidal neurons (Endoh et 
al., 1994; Wendland et al., 1994; Blackshaw et al., 2003) and in dendritic spines 
(Burette et al., 2002). Strongly labelled cells were demonstrated to express nNOS 
staining  diffusely  in  the  cytosol,  while  weakly  stained  cells,  or  those  appearing 
unlabelled at the light microscopic level, were revealed to express nNOS localised to 
membranes when examined by means of electron microscopy (Burette et al., 2002). It 
transpired from these studies that not only the method of fixation but also antibody 
incubation times were crucial factors in determining the visibility of nNOS. In order 
to achieve optimal staining in interneurons, the reaction must be terminated before 
any nNOS could be revealed in pyramidal neurons.  
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The membrane localisation of nNOS visualised by Burette et al. (2002) is consistent 
with the known interaction of nNOS with NMDA receptors at synaptic membranes, 
thereby coupling NO formation to NMDA receptor activity, the entry of Ca
2+ in the 
vicinity of the receptor resulting in NOS activation. The association between nNOS 
and the NMDA receptor is provided by the post-synaptic density-95 (PSD-95), which 
acts  as  the  intermediate  interaction  partner.  PSD-95  protein  contains  several  PDZ 
domains,  which  are  protein-protein  interaction  motifs.  nNOS  also  contains  a  PDZ 
domain  in  its  N-terminal  region,  which  interacts  with  the  second  PDZ-domain  of 
PSD-95 (Brenman et al., 1996). The ternary complex is achieved by the second PDZ 
domain  of  PSD-95  also  interacting  with  a  C-terminal  Ser/Thr-X-Val  motif  of  the 
NMDA receptor (Kornau et al., 1995; Christopherson et al., 1999). Disruption of the 
interaction between nNOS and PSD-95 by deletion of the N-terminus of nNOS has 
been demonstrated to prevent membrane association without affecting the catalytic 
activity  of  the  enzyme.  Membrane  association  of  nNOS  with  NMDA  receptors, 
however, is functionally significant in terms of NMDA receptor-dependent synaptic 
activation of NO synthesis. Suppression of PSD-95 in cultured cortical neurons by 
means  of  anti-sense  oligonucleotide  techniques  was  found  to  attenuate  cGMP 
production by more than 60% in response to NMDA receptor-mediated Ca
2+ influx 
but not that in response to Ca
2+ channel activation (Sattler et al., 1999). As mentioned 
earlier, the splice variants nNOSb and nNOSg identified in nNOS mutant mice fail to 
associate with NMDA receptors at synaptic membranes via PSD-95 as they lack the 
PDZ motif, rendering these nNOS isoforms cytosolic (Brenman et al., 1996; Eliasson 
et al., 1997). While nNOSg has been shown to be catalytically inactive, nNOSb has 
been  found  to  retain  catalytic  activity  when  purified  (Brenman  et  al.,  1996). 
Moreover,  in  vivo  examination  of  nNOS  activity  by  visualising  citrulline-
immunoreactivity  in  brain  sections  obtained  from  mice  with  disrupted  nNOSa 
revealed  the  presence  of  active  nNOS,  although  the  type  of  the  splice  variant 
responsible  (nNOSb  or  g)  was  not  identified  (Eliasson  et  al.,  1997).  Overall,  this 
indicates that cytosolic nNOS may be activated by Ca
2+ coming from entry sources 
other than NMDA receptors. 
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eNOS 
 
In  contrast  to  nNOS,  eNOS  expression  is  restricted  to  the  vascular  endothelium. 
Although initially reported to localise in hippocampal pyramidal neurons (Dinerman 
et al., 1994), the same group could not confirm their finding, detecting eNOS mRNA 
exclusively in brain blood vessels (Demas et al., 1999), and attributing their earlier 
observations to poor antibody specificity arising from possible cross-reactivity of the 
antibody with other forms of NOS. The exclusive presence of eNOS in endothelial 
cells lining the brain vasculature, but lacking in neurons or glia, was confirmed by 
other independent in situ hybridisation studies in both mouse and rat brain (Seidel et 
al.,  1997;  Blackshaw  et  al.,  2003),  immunocytochemical  studies  at  the  light-  and 
electronmicroscopic level (Stanarius et al., 1997; Topel et al., 1998), and single-cell 
PCR investigations of eNOS mRNA in single hippocampal neurons (Chiang et al., 
1994). The cell-specific expression of eNOS was later suggested to be down to DNA 
methylation, finding cell-specific methylation patterns in vivo in endothelial cells and 
vascular smooth muscle cells of mouse aorta, and robust expression of eNOS mRNA 
in non-endothelial cell types upon inhibition of DNA methyltransferase activity (Chan 
et al., 2004).  
At  the  subcellular  level,  eNOS  is  localised  to  the  cell  membrane.  The  N-
terminal region of eNOS contains consensus sequences for irreversible myristoylation 
and  reversible  palmitoylation  (Shaul,  2002).  These  modifications  associate  eNOS 
with caveolae in plasma membranes, localising the enzyme to sites of Ca
2+ entry. 
While both myristoylation and palmitoylation firmly anchor eNOS to the caveolar 
lipid bilayer, reversible palmitoylation is thought to be involved in dynamic regulation 
of  eNOS  activity.  Prolonged  stimulation  of  eNOS  has  been  shown  to  induce 
depalmitoylation  with  resultant  translocation  of  eNOS  to  the  cytosol,  a  process 
suggested to serve as an additional mechanism for modulating eNOS activity (Michel 
et al., 1997).  
 
Physiologically, NO produced from endothelial cells, contributes to the maintenance 
of cerebral blood flow via the regulation of small artery and arteriolar tone (Umans & 
Levi,  1995).  The  smallest  vessels  penetrating  the  brain  are  the  capillaries,  the 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
 
  37
capillary endothelial cells releasing NO tonically (Mitchell & Tyml, 1996). While it 
has  been  a  relatively  old  concept  that  neuronal-derived  NO  can  influence  the 
vasculature, emerging evidence suggests that NO from eNOS in blood vessels could 
also  influence  neurons  directly.  Previously,  it  has  been  found  that  application  of 
NMDA to rabbit brain in vivo produces dilatation of the cerebral microcirculation and 
results in an increase in blood flow, which could be prevented by the Na
+ channel 
blocker tetrodotoxin (TTX), a NMDA receptor antagonist, and by nNOS-selective 
inhibition (Faraci & Breese, 1993; Faraci & Brian, 1995). This led to the implication 
that NO released from neurons can signal to the vasculature. On the other hand, at 
least in vitro, it appears now that NO derived from blood vessels may also influence 
neuronal  function.  Vascular-derived  NO  has  been  found  to  modify  the  membrane 
potential  of  rat  optic  nerve  axons  (Garthwaite  et  al.,  2006)  and  the  capacity  for 
synaptic plasticity in the hippocampus (Hopper & Garthwaite, 2006). 
 
1.2.6   The NO signal 
 
The physico-chemical properties of NO distinguish it markedly from conventional 
signalling molecules such as neurotransmitters. Being a small non-polar molecule, 
NO is highly diffusible in both lipid and aqueous environments. Therefore, it can 
readily  cross cell membranes without the need  of specialised release mechanisms, 
thereby  accessing  all  cell  compartments  unhindered.  An  extra,  unpaired  electron 
confers radical status upon NO. Nonetheless, NO is relatively stable at physiological 
concentrations,  which  are  thought  to  be  in  the  low  nanomolar-to-picomolar  range 
(Garthwaite  et  al.,  2005;  Hall  &  Garthwaite,  2009).  One  or  several  simultaneous 
source(s) of NO, such as for example from the microvasculature and a presynaptic 
terminal,  can  influence  neighbouring  cells  within  milliseconds  of  NO  production 
(Garthwaite, 2008). The potential area for signalling will contain a variety of brain 
constituents,  including  neurons  (dendrites,  somata,  and  axons),  glia,  and  the 
vasculature.  While  the  vasculature  may  be  providing  a  tonic  NO  source,  repeated 
activity  of  groups  of  neurons  may  generate  a  ‘cloud’  of  NO.  On  the  other  hand, 
limited neuronal activity may result in a much more localised NO signal (Garthwaite, 
2008).  Taking  a  400-nm-diameter  postsynaptic  density  as  an  example,  containing 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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NMDA receptors associated with nNOS molecules, maximal nNOS activity would 
result in an estimated 2 nM NO at its site of synthesis, reducing to 1 nM NO just on 
the other side of the synaptic cleft, and 0.25 nM at the periphery of the nerve terminal 
where it still would evoke approximately 0.4 mM cGMP (Garthwaite, 2008), enough 
to  trigger  cGMP-dependent  phosphorylation  (Mo  et  al.,  2004).  While  the 
concentration profile of NO based purely on its diffusion away from its source implies 
a high degree of synapse specificity, neighbouring structures close-by would also be 
penetrated by low NO concentrations (Garthwaite, 2008). Considering a tonic NO 
source, such as blood vessels, any point in the brain is at most a typical cell diameter 
(25 mm) away from a capillary (Pawlik et al., 1981), the endothelial cells of which 
release  NO  tonically  (Mitchell  &  Tyml,  1996),  with  the  three-dimensional 
arrangement of the capillary system being as well suited for delivering NO globally to 
the tissue as it is for delivering oxygen (Garthwaite, 2008). 
 
Recently,  it  has  been  proposed  that,  in  addition  to  the  rate  and  pattern  of  NO 
synthesis, active NO inactivation may also be important in shaping the NO signal 
under conditions of multiple-source-NO synthesis (Hall & Garthwaite, 2006). Brain 
tissue actively consumes NO, limiting its half-life at physiological concentrations to 
an estimated 10-millisecond timescale (Hall & Garthwaite, 2006). A high rate of NO 
inactivation was also indicated by the pattern of cGMP immunostaining of sections 
from 400 mm brain slices exposed to different NO concentrations, finding a marked 
gradient. It was revealed that at intermediate bath concentrations of NO (around 100 
nM)  the  edges  of  the  slice  appeared  cGMP-positive,  while  the  centre  did  not, 
indicating  that  NO  failed  to  access  this  region  in  active  concentrations. 
Mechanistically,  NO  consumption  was  found  to  be  independent  of  other  putative 
routes for NO inactivation, such as NO reacting with oxygen. A novel mechanism for 
shaping the NO signal when several sources are active has been uncovered and found 
to  take  place  in  brain  slices,  but  the  identity  of  this  mechanism  remains  to  be 
elucidated. Recent evidence points to a possible involvement of cytochrome P450 
oxidoreductase (Hall et al., 2009). 
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1.2  NO SIGNAL TRANSDUCTION 
 
1.3.1   The NOGC receptor  
 
The key component for translating NO signals into biological messages is the soluble 
guanylyl cyclase (sGC), and to date it is the only well-established physiological signal 
transduction partner for NO. Subsequent to observations in the late 1960s of cGMP-
forming activity being present in mammalian tissues, early work during the 1970s 
established sGC as the principal transducer of NO signals, preceding the identification 
of NO as a biologically important messenger molecule. Shortly after the purification 
of sGC from bovine lung, it was found that NO stimulates sGC activity and increases 
cGMP levels in slices from rat cerebral cortex and cerebellum (Kimura et al., 1975). 
This line of enquiry was crucial for building the hypothesis that EDRF was NO, as the 
smooth muscle relaxation evoked by EDRF was observed to be associated with cGMP 
formation.  The  enzyme  became  initially  known  as  sGC  as  it  was  detected  in  the 
soluble fraction of tissue homogenates. However, based on the present knowledge that 
sGC can also localise to membranes (see below), and it bearing attributes such as the 
presence of a ligand-binding site for NO and a transduction unit, it is preferable to 
refer  to  it  as  the  guanylyl  cyclase-coupled  NO  (NOGC)  receptor  (Bellamy  & 
Garthwaite, 2002). In a nutshell, activation of the NOGC receptor by NO initiates a 
conformational change, which is translated into the fast conversion of GTP to cGMP. 
This event, as well as structural aspects of the NOGC receptor, its pharmacology, and 
its prevalence in the brain will be outlined in more detail in the following section. 
 
General Features 
 
The NOGC receptor has the capacity to capture and communicate very low-level NO 
signals, even when the latter are very transient. The known complement at present is 
two a subunits (a1 and a2) and two b subunits (b1 and b2). The active enzyme exists 
as a heterodimer of one a and one b subunit, the a1b1 heterodimer being the one 
initially purified from bovine lung (Russwurm & Koesling, 2002). Currently, there are 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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two known isoforms of the NOGC receptor, namely a1b1 and a2b1, both of which have 
been detected at the protein level with widespread tissue distribution, and shown to be 
enzymatically active in response to NO (Russwurm & Koesling, 2002). Both isoforms 
share similar kinetic properties with an estimated EC50 value of 10 nM for NO under 
steady-state  conditions  in  cells  (Garthwaite,  2005).  Conflicting  results  exist 
concerning the functioning of heterodimers consisting of a b2 subunit rather than the 
b1 subunit. One study reported that a1b2 dimers have a reduced (30%) activity relative 
to the a1b1 form of the enzyme when expressed in cells (Gupta et al., 1997). However, 
this observation could not be reproduced to date, and no line of enquiry has shown so 
far that the b2-protein exists physiologically (Koesling, 1999; Russwurm & Koesling, 
2002; Gibb et al., 2003).  
The primary structure of the NOGC receptor consists of a C-terminal catalytic 
domain, a dimerisation domain, and a N-terminal regulatory haem-binding domain 
(Fig.  1.3).  Stimulation  of  the  receptor  by  NO  requires  the  presence  of  intact  N-
terminal regions from both subunits, as it is this part of the enzyme that is responsible 
for the incorporation of the ligand-binding site into the receptor (Wedel et al., 1994; 
Foerster et al., 1996). The b2 subunit lacks the initial 63 amino acids of the N-terminal 
region relative to residues of the b1 subunit (Koesling, 1999), and deletion of this 
string of amino acids from b1 leads to the formation of an inactive a1b1 heterodimer 
as a result of its inability to incorporate the haem moiety (Foerster et al., 1996). 
 
The ligand-binding site for NO is a specialised haem moiety (Bellamy & Garthwaite, 
2002),  which  could  potentially  be  targeted  by  other  haemprotein  ligands  that  are 
present in the environment the NOGC receptors function in, such as oxygen and carbon 
monoxide.  However,  it  has  been  established  that  the  haem  moiety  of  the  NOGC 
receptor  selectively  binds  NO,  rigorously  excluding  both  oxygen  and  carbon 
monoxide  (Martin  et  al.,  2006),  allowing  NO  to  associate  and  dissociate  freely 
without oxidising the haem iron and forming nitrate as occurs in the course of the 
NO-oxyhaemoglobin  interaction.  Detailed  structure-function  studies  are  still  being 
awaited  in  order  to  identify  the  determinants  responsible  for  this  high  ligand-
selectivity.  Furthermore,  among  the  different  redox  forms  of  NO  (NO
·,  NO
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NO
+), only the uncharged NO radical (NO
·) has been shown to significantly activate 
the NOGC receptor (Dierks & Burstyn, 1996). Moreover, NO can bind to other haem-
containing proteins such as haemoglobin. The capacity of haemoglobin to bind and 
inactivate  NO  has  been  known  for  long,  in  fact  before  NO  was  recognised  as  a 
biological molecule, and has also been crucial in posing and testing the hypothesis of 
NO being a biological messenger. For instance, early studies demonstrated that the 
endothelium-dependent  ACh-evoked  relaxation  of  rabbit  aortic  rings  and  the 
associated rise in cGMP could be prevented by haemoglobin (Martin et al., 1985a), 
which was subsequently demonstrated to also occur upon exposure to another ferrous 
haemprotein, namely myoglobin (Martin et al., 1985b). However, the binding of NO 
to most haem groups is extremely tight, taking hours or even days for it to dissociate. 
This feature alone would immediately disqualify NO from being a viable dynamic 
signalling molecule. On the contrary, however, despite the NOGC receptor having a 
high  affinity  for  NO  (KD  ~  20  nM;  Garthwaite,  2005),  the  binding  of  NO  to  the 
purified  haem  of  its  receptor  is  a  readily  reversible  process,  with  the  rate  of 
dissociation being 0.04 s
-1. This allows the cyclase to switch off with a half-life of 2-5 
sec under physiological conditions upon removal of NO (Kharitonov et al., 1997). 
While this applies to NO interacting with its purified receptor, in cells the rate of 
deactivation  is  even  faster,  being  on  a  100-millisecond  timescale.  Albeit  at  the 
expense of lowered NO sensitivity, this important attribute of NO-receptor interaction 
allows the NOGC receptor to respond to brief NO transients more faithfully, providing 
a  system  that  detects  NO  with  high  sensitivity  and  allows  efficient  NO  signal 
transduction (Garthwaite, 2005).  
 
The prevailing model for NOGC receptor activation and its structure are summarised in 
Fig. 1.3. As aforementioned, the NOGC receptor exists as a heterodimer comprising a 
and b subunits, ultimately forming the transduction unit the haem moiety is attached 
to. Each heterodimer incorporates a single haem moiety, with the haem binding site 
located in the b1 subunit, where a histidine residue (his-105) forms a covalent link to 
the Fe
2+ centre of the haem group (Wedel et al., 1994). A pivotal requisite for enzyme 
activity is the concurrence of both subunits and the haem group. Homodimers of the 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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receptor could be formed in transfected cells, but were inactive (Zabel et al., 1998). 
Additionally demonstrating the requisite of both complementary subunits were results 
from experiments showing that transfection of different population of cells with a or 
b subunits individually  did not generate enzyme activity (Harteneck  et al., 1990). 
Moreover, change of the his-105 residue to a phenyl in the b1 subunit resulted in a 
receptor species insensitive to NO, which was found to be because of failure of the 
haem to attach to the enzyme (Wedel et al., 1994).  
There  are  three  phases  in  the  NO-receptor  interaction  (Fig.  1.3),  each 
involving the formation of a distinct haem species. This was studied by monitoring 
the  characteristic  absorbance  spectra  for  each  species,  the  absorbance  maximum 
(known as the Soret band) shifting as the receptor moves through the binding and 
activation steps upon NO challenge (Zhao et al., 1999; Friebe & Koesling, 2003). 
Activation of the NOGC receptor commences with the binding of NO to the vacant co-
ordination site on the haem moiety, which is an extremely rapid event that is nearly 
diffusion-limited (Zhao et al., 1999). Additionally, the rate of association of NO with 
its receptor was reported to accelerate with increasing temperatures, while the time for 
NO to dissociate slows down (Zhao et al., 1999). Upon binding of NO to the haem 
group,  within  a  millisecond-timescale  a  6-coordinate  nitrosyl-haem  complex  is 
formed first as an intermediate, which is followed by snapping of the bond between 
the haem-Fe
2+ and the his-105 residue, leading to the formation of a 5-coordinate 
species  (Zhao  et  al.,  1999).  This  bond  cleavage  causes  a  conformational  change, 
thought to be the rate-limiting step for activation, which propagates to the catalytic 
domain of the enzyme, accelerating the conversion of GTP to cGMP by up to 1000-
fold probably by supporting access of GTP to the catalytic site (Garthwaite, 2005; 
Roy et al., 2008). The conversion of GTP to cGMP in the cyclase domain of the 
receptor is a simple displacement reaction constituting no covalent intermediate but 
an inversion of the GTP configuration at the proximal phosphate of GTP, followed by 
direct displacement of pyrophosphate by a 3’-hydroxyl group leading to the formation 
of cGMP (Senter et al., 1983). 
  Catalysis of GTP to cGMP also requires a number of substrate co-factors. The 
divalent cation Mg
2+ is suggested to be a necessity to facilitate the binding of GTP, 
while binding of Ca
2+ to two negative allosteric sites results in inhibition of the NOGC 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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receptor (Kazerounian et al., 2002). Although both subunits that are partnered to form 
the receptor contribute to the catalytic domain, there is only one single active site NO 
binds  to  (Bellamy  et  al.,  2002a;  Roy  &  Garthwaite,  2006).  A  second 
‘pseudosymmetric’ site may have a regulatory function. ATP is an allosteric inhibitor 
of the NOGC receptor. This has been postulated to be via ATP competing with GTP 
for binding at a regulatory site preferring ATP to GTP (Ruiz-Stewart et al., 2004), 
which may be the ‘pseudosymmetric’ site (Roy et al., 2008). Another factor suggested 
to inhibit the NOGC receptor involves the cGMP-dependent kinase (PKG), which is 
among  the  major  downstream  effectors  for  cGMP  (see  later).  It  has  been 
demonstrated  in  smooth  muscle  cells  that  NO  induces  PKG-dependent 
phosphorylation of NOGC receptors, inhibiting enzyme activity and cGMP formation 
(Murthy, 2004). In this way, cGMP appears to provide its own production with a 
negative feedback mechanism.  
 
 
Fig. 1.3 Activation of the NOGC receptor. The resting inactive state of the receptor exists with the Fe
2+ centre of the 
haem moiety bound by his-105 of the β1 subunit (absorption maximum ~ 430 nm). Upon binding of NO, a 6-
coordinated haem is formed (absorption maximum ~ 420 nm), followed by cleavage of the proximal histidine bond 
leading to the formation of a 5-coordinate nitrosyl haem (absorption maximum ~ 400 nm), and a conformational 
change, which is propagated to the catalytic site. Adapted from Bellamy & Garthwaite, 2002 
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Pharmacology of the NOGC receptor 
 
Inhibition of the NOGC receptor: 
 
The most widely used inhibitor of the NOGC receptor, and certainly the most selective 
one, is the compound ODQ. This compound has been well characterised in terms of 
its  potency,  selectivity,  and  mechanism  of  action,  and  is  an  invaluable  tool  in 
differentiating  cGMP-mediated  from  cGMP-independent  effects  of  NO.  ODQ  has 
been shown to inhibit cGMP formation in intact brain slices in response to NMDA 
receptor stimulation or exogenous NO with similar potency (IC50 ~ 20 nM), with no 
effect on NOS in the relevant concentration range for NOGC receptor inhibition, and 
no  effect  on  the  other  type  of  guanylyl  cyclase,  leaving  atrial  natriuretic  peptide 
(ANP)-evoked  cGMP  accumulation  in  endothelial  cells  intact  (Garthwaite  et  al., 
1995). Moreover, probing the inhibitory action of ODQ on purified enzyme revealed 
that  inhibition  occurred  non-competitively  with  respect  to  the  substrate  GTP 
(Garthwaite et al., 1995). ODQ has been shown to work at the haem moiety of the 
NOGC receptor, incubation periods of several minutes (half-time ~ 3 min) leading to 
irreversible inhibition of purified enzyme as a result of oxidation of the ferric centre 
of the haem group from Fe
2+ to Fe
3+ as evaluated by spectroscopic measurements 
finding a characteristic Soret peak shift (Schrammel et al., 1996). Non-specific effects 
of ODQ have been reported, finding inhibition of other haem-containing proteins, 
including NOS (Feelisch et al., 1999). However, non-specificity of ODQ is observed 
only  at  much  higher  concentrations  (>  30  mM)  than  those  required  for  maximal 
inhibition of the NOGC receptor. A benchmark concentration of 10 mM ODQ to be 
used to selectively inhibit NO-cGMP-mediated effects applies accordingly. 
 
In the past other inhibitors had been presented as selective NOGC receptor antagonists, 
which are spuriously still used sometimes nowadays. These include methylene blue 
and  LY83583.  They  are  very  poorly  selective  compounds,  both  being  known  to 
compromise NOS activity (Mayer et al., 1993; Luo et al., 1995) and, in the case of 
methylene  blue,  to  also  generate  superoxide  anions  which  react  rapidly  with  NO, 
thereby inactivating NO (Wolin et al., 1990). Also to mention is that there have been 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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reports of  LY83583 blocking neuronal cyclic nucleotide-gated ion channels in the 
same  concentration  range  (1-10  µM)  required  for  compromising  50%  of  NOGC 
receptor activity in vitro (Leinders-Zufall & Zufall, 1995). These non-selective effects 
make  data  interpretation  difficult,  and  these  compounds  should  not  be  used  to 
evaluate NO-cGMP-mediated effects.   
 
NO donors: 
 
A  number  of  compounds  can  be  used  to  stimulate  NOGC  receptor  activity 
independently  of  NOS-generated  NO,  evoking  an  increase  in  cGMP  levels. 
Originally,  these  comprised  the  so-called  nitrovasodilators,  including  nitroglycerin 
and sodium nitroprusside (SNP; Katsuki et al., 1977). The essential trouble with these 
compounds, however, includes that they do not directly release authentic NO, often 
necessitating metabolism by cellular proteins, and often produce other NO-derivatives 
(Feelisch, 1993). For instance, SNP can generate NO
+ and NO
- additionally to NO
·, as 
well  as  cyanide  ions,  and  its  decomposition  depends  on  light  and  thiols.  Equally 
troublesome  compounds  include  SIN-1,  SNAP,  and  GSNO.  SIN-1  releases 
superoxide (O2
-) alongside NO, thereby generating peroxynitrite (ONOO
-), the latter 
being a highly oxidising species that has a plethora of toxic effects on cells ranging 
from irreversible respiratory inhibition to DNA damage. SNAP and GSNO are S-
nitrosothiols,  also  generating  the  other  two  redox  forms  of  NO,  and  their 
decomposition also being light-sensitive and dependent on the presence of thiols and 
transition metals (Feelisch, 1998). The general consensus is that the interpretation of 
results achieved through the use of these NO-releasing compounds is complicated and 
they should not be used. Unfortunately, however, many of them are still used to the 
present day, often at very high concentrations. 
 
The  pharmacological  solution  to  the  problems  associated  with  earlier  compounds 
came  with  the  development  of  the  so-called  NONOates  (Morley  &  Keefer,  1993; 
Feelisch, 1998). These compounds are invaluable tools to study the actions of NO as 
they deliver authentic NO to tissues. These compounds are a series of nucleophile/NO 
adducts, which are synthesised by exposing a nucleophile in solution to NO gas, and 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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contain a characteristic [N(O)NO
-] functional group. The essential advantages offered 
by  NONOates  include  stability  when  they  are  in  solid  form,  and  spontaneous 
decomposition in aqueous solution, releasing authentic NO with a stoichiometry of 1-
2  mol  NO  per  mol  NONOate.  Moreover,  decomposition  of  these  compounds  is 
exclusively  governed  by  temperature,  pH,  and  the  identity  of  the  nucleophile 
precursor, so that addition of a NONOate compound to a solution at physiological 
temperature and pH will result in the release of authentic NO with predictable kinetics 
which will further only depend on the NO donor concentration and half-life.  
A series of NONOates have been produced and are commercially available, 
with the half-life of degradation ranging from only a couple of seconds to 24 hours. 
Which NO donor with what half-life should be chosen, will depend on the nature of 
the  experiment  and  the  desired  NO  release  profile.  In  parallel  to  this,  once  a 
compound has been chosen with a particular half-life, it is important to select the 
application time sensibly, especially when working with one that has a relatively short 
half-life.  The  meaning  of  this  can  be  illustrated  well  with  the  following  example 
extracted from findings by Bellamy et al. (2002b). Experiments on purified NOGC 
receptors  demonstrated  that  the  concentration  of  NO  produced  by  0.3  mM  of  the 
NONOate DEA/NO (t1/2 = 2.1 min under physiological conditions) peaks at 50 nM 
after 2 min and then falls below detection limit after 5-6 min. The rate at which cGMP 
was accumulating was found to occur maximally  for 3-4 min after NO exposure, 
followed by the rate rapidly falling to zero after approximately 6 min when NO fell 
below 20 nM and eventually disappeared. These results exemplify that it is important 
to measure the response under investigation at the appropriate time points when NO is 
still present at active concentrations. 
 
Allosteric enhancers of NOGC receptors: 
 
A  number  of  compounds  have  been  developed  that  act  as  allosteric  enhancers, 
sensitising  the  NOGC  receptor  towards  NO.  These  pharmacological  tools  are 
particularly  useful  when  measuring  the  cGMP  output  corresponding  to  very  low 
(picomolar) NO concentrations.  
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The first compound earning recognition as an allosteric enhancer of NOGC receptor 
activity was YC-1. This compound was initially found to cause platelet disaggregation 
independently of NO by activating NOGC receptors with ensuing cGMP formation 
(Wu et al., 1995). Later it was revealed that YC-1 inhibits thrombosis in mice in vivo 
(Teng et al., 1997). The novelties of this compound emerged to be that it increased the 
catalytic efficiency of the NOGC receptor alongside increasing the potency of NO for 
its  receptor  by  interacting  with  an  allosteric  site  to  slow  the  rate  at  which  NO 
dissociates from its binding site, thereby stabilising the NOGC receptor in its active 
form (Friebe & Koesling, 1998; Mayer & Koesling, 2001). The finding that YC-1 did 
not  cause  the  characteristic  shift  in  the  Soret  absorption  band  indicated  that  this 
compound was acting not at the haem moiety like NO, but was binding to a distinct 
site (Friebe & Koesling, 1998). Consequently, YC-1 became known as an ‘allosteric’ 
activator of NOGC receptors. The synergistic effect of YC-1 with NO made it unclear 
whether  the  previously  observed  NO-independent  effects  are  real,  or  the  result  of  
YC-1 synergising with trace levels of environmental NO (Friebe et al., 1996a), or, in 
the case of a tissue sample, basal NO levels. Also, stimulation of NOGC receptors by   
YC-1 required the presence of the haem moiety (Friebe et al., 1996b). Later down the 
line, complications started to transpire with YC-1 based on a number of non-selective 
effects. YC-1 has been shown to inhibit a range of phosphodiesterases (PDEs; see 
below), making the aspirations of unravelling the characteristics of the NOGC receptor 
by means of this compound difficult (Friebe et al., 1998). Additionally, the reported 
inhibitory effect of YC-1 on K
+ channels (at concentrations lower than required for 
NOGC receptor stimulation; Wu et al., 2000a), and Na
+ channels (Garthwaite et al., 
2002b) further complicates the use of YC-1 in intact tissues. 
A different compound, also acting as an allosteric enhancer of NOGC receptor 
activity, is available, namely BAY 41-2272. This compound has so far proven to be a 
‘cleaner’ compound compared to its forerunner YC-1, and has been demonstrated to 
reduce  blood  pressure  in  hypertensive  rats  in  vivo  when  administered  orally, 
increasing the survival rate in a low-NO rat model of hypertension (Stasch et al., 
2001). Analogous to YC-1, BAY 41-2272 is proposed to stimulate enzyme activity 
independently of NO, but dependently on the presence of the haem moiety in the 
NOGC receptor (Straub et al., 2001; Stasch et al., 2001). Moreover, like YC-1, the 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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binding of BAY 41-2272 fails to initiate a Soret band change, indicative of it binding 
to a site distinct from the NO binding site (Stasch et al., 2001). Although reported to 
affect  PDE  activity  like  YC-1,  BAY  41-2272  is  approximately  two  orders  of 
magnitude more potent than YC-1 (nanomolar versus micromolar respectively), with 
no inhibitory effect on PDE appearing at concentrations of up to 10 mM (Stasch et al., 
2001; Mullershausen et al., 2004a). Photoaffinity labelling studies have proposed the 
binding site for BAY 41-2272 (and YC-1) to be in the N-terminal region of the a1 
subunit of the receptor, being in close proximity to two cysteine residues (Cys-238 
and Cys-243; Stasch et al., 2001; Becker et al., 2001).  
A  recent  study  has  provided  more  insights  concerning  the  alleged  NO-
independent modulation of enzyme activity by  allosteric NOGC receptor enhancers 
(Roy et al., 2008). As aforementioned, these compounds are thought to act in a NO-
independent manner based on findings that they have residual activity even in the 
absence of added NO or in the presence of NO scavengers such as haemoglobin. New 
data now suggests that when BAY 41-2272 is applied at saturating concentrations, the 
potency of NO for its receptor becomes astonishingly high (EC50 ~ 4 pM) so that trace 
environmental NO levels would be enough to significantly enhance enzyme activity 
(Friebe et al., 1996a; Roy et al., 2008). Additionally, it was found that the allosteric 
site that binds BAY 41-2272 (or YC-1) may be the same site that binds ATP, the 
latter, as mentioned earlier, acting as an allosteric inhibitor of enzyme activity. This 
was  derived  from  the  observation  that  BAY  41-2272  prevents  ATP-mediated 
inhibition of NOGC receptors (Roy et al., 2008).  
 
Localisation of the NOGC receptor in the brain 
 
The NOGC receptor has been visualised in the brain both at its mRNA and protein 
level,  with  both  isoforms  of  the  receptor  being  present,  albeit  with  uneven 
distribution. Some areas show more abundant a1b1, while others express a2b1 more 
prominently.  For  instance,  the  a2  and  b1  subunits  were  shown  to  be  particularly 
notable  in  the  cerebellum  and  the  hippocampus,  with  comparably  weaker  levels 
appearing  for  the  a1  subunit,  while  other  areas  such  as  the  caudate  putamen  and 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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nucleus accumbens appeared  rich in  a1 and b1 but relatively poor in a2  (Gibb & 
Garthwaite, 2001). Overall, however, while the predominating isoform in other tissues 
is the a1b1 heterodimer, the highest occurrence of the a2b1 isoform is found in the 
brain,  with  levels  comparable  to  those  of  a1b1 as  judged  by  the  b1  subunit  being 
present at twice as much as the two a subunits (Mergia et al., 2003). While the a1b1 
isoform is mostly cytosolic, a special attribute of the a2b1 isoform is its ability to 
interact with the third PDZ domain of PSD-95 in vivo (Russwurm et al., 2001), NOGC 
receptors  having  indeed  been  found  to  associate  with  nNOS  at  subpopulations  of 
dendritic spines in the hippocampus (Burette et al., 2002). Also presynaptically in the 
hippocampus, some axon terminals appear to co-localise nNOS, NOGC receptors, and 
the presynaptic protein synaptophysin (Burette et al., 2002). Moreover, while overall 
there appear to be comparable levels of the two NOGC receptor isoforms in the brain, 
the hippocampus (and also cerebellum) is an exception in that it displays much higher 
mRNA levels for a2 than a1 (Gibb & Garthwaite, 2001; Mergia et al., 2003). While 
previously it had been shown that the receptor for NO also localises to pyramidal 
neurons,  appearing  as  a  ‘ring-like’  immunostaining  in  cell  somata  (Burette  et  al., 
2002),  a  recent  study  investigated  the  expression  profile  of  the  two  different 
functional  subunit  compositions  at  high  resolution,  employing  light-  and 
electronmicroscopy, as well as mRNA analysis (Szabadits et al., 2007). Szabadits and 
her  colleagues  demonstrated  that,  at  least  in  the  hippocampus,  the  a1  subunit  is 
restricted to a large number of GABAergic interneurons, being detectable in axon 
terminals  that  establish  synaptic  contacts  on  somata,  dendrites,  and  axon  initial 
segments. On the contrary, the a2 subunit was detected only in pyramidal neurons, 
while the b1 subunit was visualised both in interneurons and pyramidal neurons. The 
authors speculated that the absence of a2 subunits in interneurons might ensure that 
these neurons do not target the NOGC receptor to their afferent excitatory inputs. 
 
The relationship between neuronal NO sources and targets: 
 
Establishment of the relationship between endogenous NO synthesis and its sites of 
action allows insights into the functioning of NO and its effector cGMP as a signal 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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transduction  pathway,  and  is  also  revealing  concerning  the  status  of  NO  as  an 
intercellular  signalling  molecule.  This  is  generally  achieved  by  comparing  the 
distribution of NOS with that of the NOGC receptor. An atlas for the expression profile 
of NOGC receptors in parallel to a map of NOS localisation has been provided by 
means of immunohistochemistry and NADPH diaphorase histochemistry respectively 
in rat brain obtained from animals that had been perfused with an NO donor (Southam 
& Garthwaite, 1993). A good match between the presence of NOGC receptors and 
cGMP formation is apparent in various brain regions, and the general consensus is 
that both proteins, NOS and the NOGC receptor, are functionally expressed in close 
proximity, with the localisation of NOGC receptors appearing complementary to that 
of nNOS. Hence, the direction of signalling by NO in different neuronal circuits can 
be either retrograde or anterograde as it can be synthesised presynaptically in axon 
terminals or postsynaptically in dendrites, accessing its pre- or postsynaptic receptors. 
For  instance,  a  comparatively  small  number  of  NOS-positive  multipolar  neurons 
radiate throughout neocortical layers 2-6, while NO-stimulated cGMP accumulation is 
seen  in  nearly  all  neurons  in  these  layers  (Southam  &  Garthwaite,  1993).  In  the 
cerebellum,  prominent  NOS  staining  is  apparent  throughout  the  neuropil  of  the 
molecular layer  containing the  granule  cell axons, while the downstream Purkinje 
cells lack nNOS (Vincent & Kimura, 1992), but express NOGC receptors (Ariano et 
al., 1982). This juxtaposition of source and target has also been demonstrated at the 
synaptic level (Burette et al., 2002; Szabadits et al., 2007), finding a good match 
where the expression of nNOS and NOGC receptors on the two sides of the synapse 
coincide  (i.e.  NOS-positive  postsynaptic  densities  are  usually  apposed  to  NOGC 
receptor-bearing  presynaptic  axon  terminals).  Additionally,  as  outlined  above,  the 
a2b1 isoform of the NOGC receptor is, via interaction with PSD-95, able to localise to 
postsynaptic membranes where nNOS is, and co-localisation of nNOS and the NOGC 
receptor has also been observed presynaptically (Burette et al., 2002). This expression 
profile would place the NOGC receptor in a convenient position for the transduction of 
localised  nNOS-derived  NO  signals.  Another  feature  to  mention  is  that  a  rich 
expression of nNOS, appearing as a mesh of fibres radiating throughout a particular 
brain region, may correspond to fibres forming synapses and releasing NO elsewhere. 
For instance, a lack of cGMP staining was found around the distinctly nNOS-positive 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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neurons  in  the  pedunculopontine  tegmental  nucleus  of  the  brainstem,  while  clear 
cGMP-staining was apparent in the thalamus whereto these nNOS-positive neurons 
project (Southam & Garthwaite, 1993). This notion is in line with all grey matter 
regions that accumulate cGMP also containing nNOS (Southam & Garthwaite, 1993). 
 
Overall, the remarkable coincidence of NOS and the NOGC receptors also emphasises 
very well the ‘major target-status’ of the NOGC receptor for NO throughout the brain. 
 
1.3.2   Other NO signal transduction routes  
 
S-Nitrosation  
 
One  route  for  NO  signal  transduction,  which  is  independent  of  NOGC  receptor 
activation, and has been perceived to be important, is the chemical modification of 
protein  function  by  the  transfer  of  the  NO  moiety  to  protein  thiol  (-SH)  groups 
(Stamler et al., 2001), a process now termed S-nitrosation (Koppenol, 2002). Within 
the  brain,  modification  of  NMDA  receptors  has  been  reported  to  occur  via  S-
nitrosation of cysteine residues, resulting in down-regulation of NMDA receptors, NO 
being claimed to act in this way as a feedback regulator of NMDA function (Stamler 
et  al.,  2001;  Lipton  et  al.,  2002).  Overall,  however,  a  role  for  S-nitrosation  in 
physiological NO signalling is highly controversial.  
The chemical reactivity of NO is such that it is not able to simply associate 
with thiols directly in a reversible manner. Formation of a S-nitrosothiol first requires 
the formation of an oxidised species of NO such as NO
+ or N2O3 to proceed. A direct 
reaction of NO with thiols would produce a thiol disulphide (not a nitrosothiol), and 
NO from S-nitrosothiols is not released spontaneously. Additionally, the sulphur and 
the nitrogen in a S-nitrosothiol interact by forming a stable covalent link, which is not 
particularly susceptible to bond breakage, unless when exposed to strong irradiation 
(Hogg, 2002). Recently, it has been demonstrated that NMDA receptor inhibition via 
S-nitrosation is a consequence of concomitant exposure to UV light and high, non-
physiological NO concentrations, indicative of artefactual generation of a nitrosating 
species such as NO
+ (Hopper et al., 2004). While high NO concentrations or UV light 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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alone had no significant effect on NMDA receptor activity, pairing of the two factors 
resulted  in  irreversible  depression  of  NMDA  receptor-mediated  fEPSPs  in 
hippocampal slices, as well as depression of NMDA receptor-mediated currents in 
HEK  cells  expressing  NMDA  receptors.  Based  on  the  doubtful  physiological 
relevance of NO-mediated S-nitrosation of proteins, this matter will not be further 
considered here.  
 
Cytochrome c oxidase 
 
Another potential physiological target for NO has previously been suggested to be the 
cytochrome c oxidase of mitochondria. Previously, it has been postulated that NO-
mediated inhibition of cytochrome c oxidase is a physiologically relevant scenario in 
which  NO  presumably  regulates  cellular  oxygen  consumption  by  competing  with 
oxygen for binding, thereby regulating the affinity of mitochondrial respiration for 
oxygen  (Brown,  1995).  However,  following  extensive  revision,  the  physiological 
concentration  of  NO  has  been  revealed  to  be  in  the  low-nanomolar  to  picomolar 
range, most likely not exceeding 10 nM (Garthwaite, 2005; Hall & Garthwaite, 2009). 
Studies in cerebellar cells estimated an IC50 value for NO-mediated cytochrome c 
oxidase inhibition of approximately 120 nM at physiological (30 mM) oxygen and 
steady-state NO delivery (Bellamy et al., 2002b). Additionally, it was found that, in 
order for NO (at concentrations that would maximally engage the NOGC receptor) to 
cause 50% inhibition of cellular respiration, the oxygen concentration would have to 
fall to 5 mM, which is an oxygen level that would be pathological if it prevailed in the 
brain for more than a few seconds (Bellamy,  et al., 2002b). Moreover, very high 
concentrations of NO (~ 10 mM) had to be applied to organotypic hippocampal slices 
in order to kill them by respiratory inhibition (Keynes et al., 2004). Also in the rat 
optic nerve preparation, only a relatively high NO concentration (approximately 100 
nM) was found to kill axons, attributable to metabolic disruption with consequent 
ATP depletion and loss of ionic homeostasis (Garthwaite et al., 2002a). Importantly, 
it has also been demonstrated that the NOGC receptor is not saturated during maximal 
endogenous NO synthase activity, the endogenous NO concentration under maximal 
stimulating conditions rising to an apparent 4 nM in cerebellar brain slices (Bellamy 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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et al., 2002b), which is consistent with the in vivo situation in which cGMP rises to 
only a fraction of the maximally achievable levels even during abnormally elevated 
neuronal activity. Overall, since the interaction of NO with cytochrome c oxidase may 
only  be  relevant  under  pathological  conditions,  it  will  not  be  subjected  to  further 
consideration here. 
 
1.3.3   The cGMP signal – desensitisation and PDEs 
 
The major components regulating the cGMP profile known to date comprise a finely 
controlled balance between cGMP synthesis via NOGC receptor activation and cGMP 
degradation combined with rapid NOGC receptor desensitisation, the ‘switch-on’ and 
‘switch-off’  of  the  receptor  upon  NO  removal  being  a  process  occurring  on  a 
millisecond  timescale.  These  features  render  NOGC  receptors  highly  effective  in 
transducing  NO  signals  into  cGMP  signals  with  good  spatiotemporal  fidelity, 
enabling diverse patterns of cGMP responses to NO to be generated by different cells 
in different subcellular domains. The receptor for NO can activate in response to very 
low NO concentrations (down to the low picomolar range), rapidly convert the NO 
signal into up to 1000-fold higher concentrations of cGMP within a second, and then 
cease activity within a second when NO production stops.  
 
A crucial factor in shaping cGMP signals is the counterbalance to the rate of cGMP 
synthesis  that  is  mainly  provided  by  PDEs.  These  are  enzymes  termed 
phosphohydrolases which selectively catalyse the hydrolysis of cyclic nucleotides to 
the corresponding inactive non-cyclised monophosphate (i.e. 3’,5’-cGMP to 5’-GMP) 
by degrading the 3’ cyclic phosphate bond in the cyclic nucleotide molecule. There 
are  currently  11  PDE  families  known  in  mammals,  comprising  21  different  gene 
products, with additional splice variants that may exhibit different tissue distributions 
and  subcellular  localisations  contributing  to  further  diversity.  The  isoenzymes 
operating in the CNS include PDE5 and 9, which are highly selective for cGMP, and 
subtypes 1, 2, 3, and 10, all of which hydrolyse both cGMP and cAMP (Bender & 
Beavo,  2006).  Also  PDE4  may  be  involved  to  some  extent  in  cGMP degradation 
when cGMP levels rise to very high levels as has been demonstrated in cerebellar 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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astrocytes  (Bellamy  &  Garthwaite,  2001b).  The  vast  diversity  of  the  types  and 
properties  of  PDEs  are  in  stark  contrast  to  the  relatively  limited  molecular 
heterogeneity of NOS and the NOGC receptors. Judging from the level of diversity of 
PDEs, it is not surprising that these enzymes can provide the generation of many 
different  cGMP  signals  which  may  differ  in  amplitude,  duration,  and  localisation, 
where,  depending  on  the  ‘pattern’  of  PDE  expression  in  a  given  cell,  differently 
featured cGMP signals may be at play in the same cell. The presence of two or more 
different  PDEs  in  the  same  cell,  albeit  localising  to  different  subcellular 
compartments, enable PDEs to generate and maintain cGMP-signalling compartments 
within the cell. 
 
The dynamic nature of NOGC receptors is highlighted by very fast activation (within 
20 ms) and rapid deactivation (half-time of 200 ms) on addition and removal of NO 
respectively (Bellamy & Garthwaite, 2001a). This dynamic behaviour goes hand in 
hand with the NOGC receptor also desensitising within seconds (or less) in intact cells 
upon  NO  exposure,  as  has  been  demonstrated  in  cerebellar  astrocytes,  human 
platelets, and striatal neurons, finding a marked decline in enzyme activity with time, 
recovering only slowly (half-time of 16 min) and being more pronounced at higher 
NO  concentrations  with  an  EC50  of  10-20  nM  for  NO  to  cause  desensitisation 
(Bellamy et al., 2000; Wykes et al., 2002; Mo et al., 2004; Halvey et al., 2009). The 
molecular  mechanism  of  NOGC  receptor  desensitisation  remains  to  be  identified, 
although a number of observations have pointed to some unknown, possibly cGMP-
regulated, cellular factor(s) being responsible rather than it being an intrinsic property 
of the NOGC receptor  (Bellamy et al., 2000; Wykes et al., 2002). This latter notion 
was indicated by desensitisation of the NGC receptor not taking place  when in its 
purified form or when studied in lysed cells, which are conditions in which the factor 
would be absent or may be destroyed or diluted, rendering it inactive. An alternative 
explanation  for  the  response  decline  involves  PDE.  It  has  been  proposed  that  in 
platelets the ‘sag’ in the cGMP response with time upon NO exposures is associated 
with  enhanced  PDE5  activity  due  to  PKG-mediated  phosphorylation  of  the  PDE, 
while the desensitisation observed in the presence of PDE inhibitors may be due to 
depletion  of  the  substrate  GTP  (Mullershausen  et  al.,  2001;  Mullershausen  et  al., 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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2003).  However,  not  consistent  with  these  suggestions  were  the  findings  that 
desensitisation in cerebellar cells, which also express PDE5, is unaffected by large 
variations  in  GTP  utilisation,  and  that  the  profile  of  cGMP  accumulation  remains 
unaltered upon inhibition of PKG or phosphatases (Bellamy et al., 2000; Wykes et al., 
2002). Moreover, in rat platelets receptor desensitisation was found to occur over the 
entire range of PDE activities (i.e. PDE activity left intact down to up to 100-fold 
reduction in PDE activity), with 80% of the maximum activity of the NOGC receptor 
being subject to desensitisation (Mo et al., 2004). The general consensus at present is 
that there may be a number of different factors governing desensitisation, which may 
be different among different types of cells. 
How the concerted working of PDEs and desensitisation could be instrumental 
to shaping the cGMP signal is well exemplified by the situation observed in cerebellar 
astrocytes  and  platelets.  In  cerebellar  astrocytes,  the  combination  of  rapid 
desensitisation  but  very  low  PDE  activity  results  in  a  large  increase  in  cGMP 
accumulation and a long-lived plateau in response to NO (Bellamy et al., 2000). On 
the  contrary,  rat  platelets  respond  to  NO  with  a  very  transient  increase  in  cGMP 
(peaking within 2-5 sec) based in part on NOGC receptor desensitisation and partially 
on  PDE5  activation  (Mo  et  al.,  2004;  Halvey  et  al.,  2009).  The  desensitisation 
component  has  been  found  to  predominate,  with  receptor  desensitisation  reverting 
very slowly with a half-time of 16 min, while PDE5 activity subsides much quicker 
upon NO removal with a half-time for recovery of 25 sec (Halvey et al., 2009).  
 
 
1.4    DOWNSTREAM EFFECTORS OF cGMP 
 
1.4.1   cGMP-dependent kinase (PKG)  
 
The cGMP-dependent protein kinase (cGK) or protein kinase G (PKG; as it will be 
referred to here) belongs to a family of Ser/Thr protein kinases, and is activated by 
submicromolar  cGMP  concentrations  (Gamm  et  al.,  1995),  converting  cGMP 
elevations  into  changes  of  cellular  function  via  phosphorylation  of  Ser-  or  Thr-1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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residues  of  a  number  of  substrate  proteins.  In  mammals  there  are  two  genes  that 
encode PKG proteins, generating two isoforms, namely PKGII and PKGI, the latter 
comprising  the  two  variants  PKGIa  and  PKGIb.  The  PKGI  family  are  cytosolic 
proteins, while PKGII is anchored to the plasma membrane via myristoylation at its 
N-terminal glycine residue (Vaandrager et al., 1996).  
 
All PKG isoforms exist as homodimers, being composed of two identical monomers, 
each of which contains an N-terminal domain, a regulatory domain which contains 
two  allosteric  cGMP  binding  sites,  and  a  C-terminal  catalytic  domain,  the  latter 
comprising  binding  sites  for  ATP  and  the  target  protein.  The  N-terminal  region 
contains regulatory sites for dimerisation, auto-inhibition, auto-phosphorylation, and, 
in  the  case  of  PKGII,  myristoylation  (Lohmann  et  al.,  1997).  Activation  of  PKG 
requires the occupation of both cGMP-binding sites to achieve full catalytic activity, 
where the binding of cGMP induces a conformational change, ultimately relieving the 
N-terminal auto-inhibition of the C-terminal catalytic centre (Gamm et al., 1995; Wall 
et al., 2003). Phosphorylation of the target protein involves the transfer of a phosphate 
group from ATP, which is bound in the C-terminal catalytic domain of PKG, to a Ser- 
or Thr-residue of the target protein. As already mentioned, the N-terminal region of 
PKG contains a number of regulatory sites, one of which is the auto-inhibitory site 
which is responsible for the inhibition of kinase activity in the absence of cGMP. 
Among  the  other  N-terminal  regulatory  sites,  one  is  important  for  the 
homodimerisation of the PKG subunits, while another allows auto-phosphorylation of 
this region, leading to more persistent kinase activity which can outlast the timeframe 
of  the  original  stimulus  (Lohmann  et  al.,  1997).  For  example,  PKGIb  auto-
phosphorylation  causes  a  nearly  4-fold  increase  in  basal  kinase  activity,  and  an 
approximately  2-fold  decrease  in  the  EC50  for  cGMP-evoked  phosphorylation  of 
target proteins (Smith et al., 1996). Although being very similar, the different PKG 
isoforms do differ in terms of substrate sensitivity, which is conferred by differences 
in their N-terminal domain. The PKGI isoforms are about 8-fold more sensitive to 
cGMP than PKGII, while the PKGIa isoform is approximately 10-fold more sensitive 
to cGMP activation than the PKGIb isoform (Gamm et al., 1995).  1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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All PKG isoforms have been detected in the brain, with recent analysis of mRNA 
expression (Lein et al., 2007) and immunohistochemical evaluation (El-Husseini et 
al., 1999; Feil et al., 2005) suggesting PKGI to be the predominant isoform. Regions 
in  which  the  PKGI  protein  has  been  detected  include  cerebellar  Purkinje  cells, 
suprachiasmatic nucleus, hypothalamus, medulla, cerebral cortex, amygdala, olfactory 
bulb, the ganglion cell layer of the retina, and the hippocampus. Results from studies 
employing mRNA in situ hybridisation and immunoblotting with isoform-selective 
probes (Geiselhorniger et al., 2004) or antibodies (Feil et al., 2005) suggest that the 
PKGIa is the predominating isoform in the cerebellum and the medulla, while the 
PKGIb  isoform  exists  at  high  levels  in  the  cortex,  the  olfactory  bulb,  the 
hypothalamus, and the hippocampus. Similar levels of the two PKGI variants appear 
to be present in the eye. The expression profile of PKGII has also been studied at the 
mRNA  level,  as  well  as  protein  level  by  means  of  immunohistochemistry  and 
Western blot analysis. A line of such enquiries suggests that PKGII has a widespread 
distribution in the brain, with particular abundance in the cerebral cortex, the olfactory 
bulb, the thalamus, and the superior colliculi (El-Husseini et al., 1999; de Vente et al., 
2001b). 
The  target  proteins  for  the  different  PKG  types  as  well  as  their  discrete 
physiological  involvement  in  PKG-mediated  effects  in  the  CNS  remain  largely 
unexplored.  Among  the  proposed  targets  for  PKGI  is  the  protein  phosphatase-1 
inhibitor  G-substrate,  which  has  been  shown  by  immunoprecipitation  as  well  as 
mRNA- and peptide-mapping techniques to be  concentrated in cerebellar Purkinje 
cells (Detre et al., 1984; Endo et al., 1999; Hall et al., 1999), and is only detected at 
negligible  levels  in  the  cortex  and  hippocampus  (Detre  et  al.,  1984).  Another 
phosphatase inhibitor is DARPP-32, which shares homology with G-substrate, and 
has also been suggested to be a target for PKGI-mediated phosphorylation (Tsou et 
al., 1993). Other proposed targets for PKGI-mediated phosphorylation include the 
PDE5  (see  below),  inositol  1,3,4-triphosphate  (IP3)  receptors,  which  supports 
stimulation of Ca
2+ release from IP3-sensitive stores in the cerebellum and vascular 
smooth muscle (Haug et al., 1999; Wagner et al., 2003), the vasodilator-stimulated 
protein (VASP), which is implicated in vesicle trafficking and the regulation of the 
actin  cytoskeleton  (Butt  et  al.,  1994;  Hauser  et  al.,  1999),  and  the  small  GTPase 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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RhoA, which is implicated in vesicle trafficking (Ellerbroek et al., 2003). A target 
protein for PKGII has been suggested to be the GluRI subunit of AMPA receptors in 
the hippocampus (Serulle et al., 2007; see later). Broadly, cGMP-PKG signalling has 
been implicated in a number of processes, including synaptic plasticity and learning, 
behaviour, development, and nociception (Schlossmann et al., 2005).  
 
1.4.2   cGMP-regulated PDEs 
 
As mentioned earlier, some members of the vast PDE family  degrade  cGMP and 
thereby  affect  cellular  responses  by  shaping  cGMP  signals  derived  from  NOGC 
receptor activity. However, the role of PDEs in cGMP signalling is more sophisticated 
than that as they also act as downstream effectors of cGMP. The activity of some PDE 
isoforms  can  be  modulated  negatively  or  positively  by  cGMP,  either  directly  by 
cGMP binding to a regulatory domain of the PDE, or indirectly via cGMP mediating 
phosphorylation  of  the  PDE.  Additionally,  cross-talk  between  cGMP  and  cAMP 
signalling  cascades  occurs  by  cGMP-dependent  modulation  of  cAMP-preferring 
PDEs (and vice versa). Moreover, different outcomes of cGMP signals may prevail in 
different microdomains of a cell, which is achieved by PDEs being associated with 
different macromolecular complexes, which may comprise regulatory proteins, such 
as kinases, anchoring or scaffolding proteins, and other signalling proteins. This latter 
aspect  is  thought  of  as  a  key  supporter  of  the  specificity  of  cGMP  effects  in  a 
particular tissue (Bender & Beavo, 2006). For ease, Table 1.1 provides a summary of 
PDEs hydrolysing cGMP and/or being regulated by it, outlining the main features. 
The majority of PDEs exist as homodimers, being composed of a catalytic C-terminal 
domain and a regulatory N-terminal domain. The catalytic C-terminal domains are 
highly  homologous  among  the  different  PDE  families,  whereas  the  N-terminal 
domain  is  the  crucial  feature  that  imparts  unique  functional  fingerprints  upon  the 
different  PDEs  based  on  the  incorporation  of  one  or  more  regulatory  segments 
(Bender & Beavo, 2006). 
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cGMP-specific PDEs 
 
PDE5: 
 
PDE5  is  highly  selective  for  cGMP  (Table  1.1)  and  has  the  special  feature  of 
containing  two  so-called  GAF  domains  (GAF-A  and  GAF-B)  in  the  N-terminal 
region, additionally to the catalytic cGMP-binding domain. The name of this motif is 
based on the three classes of proteins in which it was identified, including cGMP-
regulated  PDEs,  the  cyanobacterial  Anabaena  Adenylyl  cyclase,  and  the  E.  coli 
transcription factor Fh1A, hence ‘GAF’. In PDEs, these GAF domains are known to 
exclusively bind cGMP, and serve as non-catalytic allosteric sites (Martinez et al., 
2002). Apart  from cGMP binding to the catalytic site of the  enzyme, these small 
molecule-binding motifs also bind cGMP, usually one cGMP molecule per monomer. 
Binding of cGMP to the GAF-A motif in PDE5 (KD ~ 40 nM), which is more than 
100-fold more selective for cGMP than cAMP (Zoraghi et al., 2005), activates the 
PDE  and  accelerates  the  rate  of  cGMP  hydrolysis.    This  event  of  cGMP-GAF 
interaction  also  makes  PDE5  a  target  for  PKGI,  where  the  PKG-mediated 
phosphorylation of PDE5-Ser-93 enhances the affinity of PDE5 for cGMP and the 
stimulatory effect of cGMP on the rate of hydrolysis further (Thomas et al., 1990; 
Turko et al., 1998; Mullershausen et al., 2001; Rybalkin et al., 2003; Mullershausen 
et  al.,  2003;  Shimizu-Albergine  et  al.,  2003;  Mullershausen  et  al.,  2004b).  In  the 
brain, injection of cGMP analogues into mouse brain has been found to evoke PDE5 
phosphorylation in cerebellar Purkinje neurons  in vivo, which was observed to be 
missing  in  PKGI  knockout  animals  (Shimizu-Albergine  et  al.,  2003).  It  has  been 
suggested  that  phosphorylation  of  PDE5  induces  a  conformational  change,  which 
increases the affinity of the GAF-A domain for cGMP by approximately 10-fold, and 
consequently enhances the catalytic activity of PDE5 by nearly 2-fold (Corbin et al., 
2000; Francis et al., 2002). Overall, this feature of PDE5 is thought to provide a 
negative  regulatory  mechanism  whereby  cGMP  regulates  its  own  accumulation 
negatively. 
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PDE  5  is  characterised  by  being  localised  in  the  cytosol,  and  only  one 
subform, the PDE5A, is known to exist to date, albeit with a number of possible 
variants. It became a famous PDE isoform upon being discovered to be a regulator of 
vascular smooth muscle contraction, and the target for the drug sildenafil (Viagra; 
Turko et al., 1999; Bender & Beavo, 2006). As deduced from mRNA analysis and 
immunohistochemical  results,  PDE5  shows  the  most  abundant  expression  in 
cerebellar Purkinje cells, but is also expressed in the spinal cord, and pyramidal cells 
of the hippocampus as well as granule cells of the dentate gyrus, while it shows only 
little or negligible expression levels in other brain areas (Kotera et al., 1997; Kotera et 
al., 2000; Giordano et al., 2001; van Staveren et al., 2003; Shimizu-Albergine et al., 
2003; Bender & Beavo 2004; van Staveren et al., 2004; de Vente et al., 2006).  
 
PDE9: 
 
The highest affinity to bind cGMP is imparted on PDE9, having by far the lowest Km 
for cGMP, with its Km for cAMP being more than 1000-fold greater, rendering this 
PDE isoform highly cGMP-selective (Table 1.1). To date the only isoform recognised 
is  PDE9A.  However,  as  with  PDE5A,  also  here  a  number  of  variants  have  been 
identified. Unlike PDE5, PDE9 does not contain GAF motifs. Overall, there is not 
much else known concerning the regulation of PDE9 (Bender & Beavo, 2006). The 
high affinity of PDE9 to bind cGMP would predict that cells expressing this PDE 
isoform maintain very low basal cGMP levels, implicating PDE9 to be an important 
constituent in cGMP signalling.  In this respect it is interesting that the pattern of 
PDE9  mRNA  expression  in  the  brain  appears  to  closely  resemble  that  of  NOGC 
receptors,  suggesting  a  potential  functional  association  or  coupling  of  these  two 
constituents in regulating cGMP levels (Andreeva et al., 2001). To tailgate this latter 
aspect, the distribution pattern of PDE9 in the brain appears to be widespread, having 
been  detected  in  neurons  of  the  dentate  gyrus  as  well  as  pyramidal  cells  of  the 
hippocampus,  and  various  other  regions  of  the  brain  including  the  cerebellum  (in 
Purkinje cells), olfactory  system, neocortex, thalamus, and basal  ganglia, with the 
highest mRNA expression levels detected in the dentate gyrus, olfactory bulb, and 
Purkinje neurons (Andreeva et al., 2001; van Staveren et al., 2002; van Staveren et 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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al., 2003; van Staveren et al., 2004). Overall, PDE9 is thought to be predominantly a 
neuronal PDE, but its presence has also been postulated in astrocytes (van Staveren et 
al., 2002). PDE9 enzymes are localised in the cytosol, except the PDE9A1 variant, 
which has been observed to localise to the nucleus (Wang et al., 2003). However, the 
nuclear  expression  has  been  observed  in  HEK  cells  selectively  transfected  with 
PDE9A1, and a possible physiological relevance of this observation remains to be 
determined. One special feature of PDE9 is its resistance to the broad-spectrum PDE 
inhibitor IBMX. 
 
PDE6: 
 
The PDE6 family is highly abundant in the retina and is ultimately best known for its 
role in phototransduction, existing as a membrane-bound enzyme in rod and cone 
photoreceptors,  where  it  mediates  cGMP  breakdown  that  leads  to  the 
hyperpolarisation  of  photoreceptor  cells.  PDE6  comprises  two  catalytically  active 
subunits (a and b in rods, and two a subunits in cones), which are associated with 
two identical inhibitory g subunits and a regulatory d subunit, the latter thought to 
modulate  enzyme  localisation  (Bender  &  Beavo,  2006).  There  are  three  PDE6 
isoforms known to date, termed PDE6A, PDE6B, and PDE6C, where the former two 
are found in rods and PDE6C is expressed in cones. In the dark, PDE6 is kept in an 
inactive state by the presence of the inhibitory g subunits. In common with PDE5, 
PDE6 is not only highly selective for cGMP, but also contains two N-terminal GAF 
domains (GAF-A and GAF-B). It has been suggested that occupation of the GAF-A 
by cGMP enhances the affinity between the inhibitory g subunits and the C-terminal 
catalytic  subunits  (Muradov  et  al.,  2004).  Upon  light  stimulation,  GTP-bound 
transducin-a  displaces  the  inhibitory  g  subunits  from  the  catalytic  core,  thereby 
allowing  activation  of  the  PDE6.  The  result  is  very  rapid  cGMP  degradation, 
supporting phototransduction by leading to the closure of cGMP-gated channels and 
the consequent hyperpolarisation of the photoreceptor cells. A special feature of the 
PDE6 family is that it has the highest catalytic efficiency compared to all other PDEs, 
with more than 3000 cGMP molecules being hydrolysed per molecule of PDE6 per 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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second (Gillespie & Beavo, 1988). The extreme efficiency of PDE6 supports very 
rapid adaptations occurring to changes in light intensity. 
 
PDEs with dual substrate selectivity 
 
PDE 1: 
 
PDE1 can hydrolyse both cGMP and cAMP and thereby provides a mechanism of 
cross-talk  between  the  two  signalling  molecules  in  that  competitive  inhibition  of 
cGMP breakdown can be achieved by elevations in cAMP levels, and vice versa. A 
distinguishing characteristic of the PDE1 family is that its members lack the GAF 
domains,  but  are  instead  regulated  by  Ca
2+/CaM  binding  to  two  N-terminal  CaM 
binding domains, which are structurally followed by the C-terminal catalytic domain. 
At present, there are three isoforms known of PDE1, namely PDE1A, PDE1B, and 
PDE1C, which differ in their substrate preferences (Table 1.1), but are all cytosolic 
proteins (except for the ones expressed in sperm; Bender & Beavo, 2006). A number 
of possible variants have been identified, with the PDE1A having the largest number 
of variants.  
The binding of Ca
2+/CaM to PDE1 has the effect of enhancing the rate of 
catalysis, without much impact upon the Km (Kincaid et al., 1985). The mechanism by 
which CaM binding activates PDE1 is not well understood, but previous biochemical 
studies have suggested that it involves relieve of an inhibition imposed upon enzyme 
activity, where the CaM binding domain spans an inhibitory sequence (Sonnenburg et 
al.,  1995).  Additional  scope  for  regulation  of  enzyme  activity  is  suggested  to  be 
provided by phosphorylation mediated by cAMP-dependent protein kinase (PKA) or, 
in the case of PDE1B, by CaM kinase II, all of which cause a reduction in the affinity 
of the enzyme for CaM binding, thereby compromising enzyme activity (Sharma & 
Wang, 1985; Hashimoto et al., 1989; Ang & Antoni, 2002). What makes the PDE1 
family of particular interest in the NO-cGMP pathway is its activation by Ca
2+/CaM. 
As outlined earlier, NOS activation is also sensitive to Ca
2+. Therefore, the presence 
of two enzymes in the pathway that are sensitive to Ca
2+ levels may have important 
implications  in  that  an  increase  of  Ca
2+  would,  on  the  one  hand,  stimulate  NO-1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
 
  63
mediated cGMP production and, on the other hand, dampen it as a result of activation 
of the cGMP-hydrolysing constituent. Such scenario has been revealed by a study by 
Mayer  and  colleagues  (1992),  in  which  both  NOS  and  PDE1  were  found  in  the 
cytosolic fraction of brain synaptosomes, the two enzymes sharing a common range 
for Ca
2+ sensitivity (EC50 ~ 200-300 nM; Mayer et al., 1992). The authors suggested 
that  the  failure  of  NOGC  receptor-,  NOS-,  and  PDE1-bearing  cells  to  accumulate 
cGMP upon Ca
2+ influx may be explained by the suppression of the cGMP signal 
because of Ca
2+-dependent acceleration of cGMP degradation by PDE1. However, the 
EC50 for activation by Ca
2+ has been found to vary among different PDE1 variants 
(e.g. 0.27 mM for PDE1A1 and 3.2 mM for PDE1C1; Bender & Beavo, 2006). 
In the brain, all three isoforms of PDE1 are expressed in various brain regions, 
including  the  cortex,  hippocampus,  cerebellum,  and  striatum,  albeit  at  differing 
degrees not only among different areas, but also within a neuronal population of the 
same  region.  For  instance,  PDE1A  and  PDE1B  are  expressed  in  neurons  of  the 
neocortex,  striatal  neurons,  and  hippocampal  pyramidal  neurons  (Menniti  et  al., 
2006). The heterogeneity of a neuronal population in terms of PDE1 expression is 
exemplified by the situation in the cerebellum, where PDE1B appears at high levels in 
some  Purkinje  cells  but  not  in  others  (Shimizu-Albergine  et  al.,  2003;  Bender  & 
Beavo, 2004). Functionally, it has been reported that mice lacking PDE1B (the only 
PDE1 knockouts available) suffer deficits in spatial learning in the Morris water maze 
and also exhibit increased locomotor activity (Reed et al., 2002). Overall, there is still 
an  urgent  need  for  potent  and  selective  PDE1  pharmacological  tools,  and  the 
development of mice with disruption of other PDE1 genes would also be beneficial in 
further elucidating the functional roles of the PDE1 family. 
 
PDE2: 
 
Of this PDE family only one isoform is known so far, the PDE2A, of which there are 
three  known  variants,  namely  PDE2A1,  PDE2A2  and  PDE2A3.  PDE2  is 
characterised  by  dual  substrate  selectivity,  hydrolysing  both  cAMP  and  cGMP 
efficiently  with  high  Vmax  and  low  Km  (Table  1.1).  In  terms  of  the  subcellular 
expression  profile,  PDE2A1  is  cytosolic,  and  PDE2A2  and  PDE2A3  are  both 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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membrane-bound  enzymes  (Bender  &  Beavo,  2006).  Similar  to  PDE5 and  PDE6, 
PDE2 also contains regulatory GAF domains, but in this case cGMP binds to the 
GAF-B motif (Martins et al., 1982; Martinez et al., 2002; Bender & Beavo, 2006). 
Exclusive  binding  of  cGMP  to  the  GAF-B  domain  renders  the  affinity  of  PDE2 
greater  for  cGMP,  and  results  in  positive  cooperativity  in  that  hydrolysis  of  both 
cGMP and cAMP is enhanced upon cGMP-GAF interaction. Based on the marked 
increases in the rate of hydrolysis of both cGMP and cAMP that are observed upon 
incubation of the enzyme with cGMP, PDE2 is sometimes referred to as ‘cGMP-
activated PDE’ (Bender & Beavo, 2006). This modulatory effect of cGMP on its own 
breakdown  as  well  as  on  cAMP  levels  highlights  the  potential  cross-talk  between 
these two signalling pathways, and offers a mechanism by which a NO stimulus can 
indirectly affect cAMP signals in cells.  
 
In the brain, PDE2 is found in the cortex, the striatum, and the hippocampus (Wykes 
et al., 2002; Suvarna & O’Donnell, 2002; van Staveren et al., 2003; van Staveren et 
al., 2004; Menniti et al., 2006). The matter of PDE2 in the hippocampus will be a 
subject in Chapters 4 and 5. PDE2 has been proposed to regulate cGMP levels that 
arise  in  response  to  NMDA  receptor  activation  in  rat  neurons  from  cortex  and 
hippocampus  (Suvarna  &  O’Donnell,  2002),  and  also  NO-evoked  cGMP 
accumulation in rat striatal neurons (Wykes et  al., 2002). Functionally, PDE2 has 
been implicated in synaptic plasticity, and learning and memory. Inhibition of PDE2 
has  been  reported  to  enhance  hippocampal  long-term  potentiation  (LTP),  and  to 
improve memory in social and object recognition tasks (Boess et al., 2004; Rutten et 
al., 2007).  
 
PDE3: 
 
This dual-substrate PDE family is also regulated by cGMP like PDE2. However, in 
this case cGMP binding does not limit cyclic nucleotide accumulation by stimulating 
PDE activity, but instead inhibits PDE activity, therefore enhancing cAMP levels. 
This again exemplifies how a NO stimulus may influence the cellular level of cAMP, 
but this time in a positive way. Another difference here is that cGMP does not affect 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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PDE3 activity in an allosteric manner. The catalytic site of PDE3 degrades cAMP 
much more effectively than cGMP (Vmax is ~ 10-fold higher for cAMP than cGMP) 
but yet has a high affinity for cGMP. This latter feature renders cGMP a competitive 
antagonist, where it competes with cAMP for binding to the catalytic site of PDE3 
(Degerman et al., 1997). Furthermore, the activity of PDE3 has been demonstrated to 
be  enhanced  by  approximately  2-fold  via  PKA-  or  PI3  kinase-mediated 
phosphorylation (Manganiello & Degerman, 1999). Currently, there are two known 
isoforms of PDE3, namely PDE3A and PDE3B, where several variants of the former 
have been identified (Bender & Beavo, 2006). The different isofoms can be cytosolic 
or  particulate,  where  residues  in  the  N-terminal  region  have  been  suggested  to 
regulate membrane association (Shakur et al., 2000). Expression of this PDE family 
has been reported in neurons in the striatum and hippocampus, but discrete functional 
roles remain to be elucidated (Menniti et al., 2006). 
 
PDE10: 
 
Also the PDE10 family has the capacity to hydrolyse both cGMP and cAMP, binding 
cAMP with greater affinity than cGMP but hydrolysing cGMP about 5-fold more 
effectively than cAMP (Soderling et al., 1999). The PDE10 family is suggested to be 
a cAMP-inhibited enzyme (analogues to cGMP-inhibited PDE3). There is currently 
one isoform known, the PDE10A, of which there are two recognised variants (Bender 
& Beavo, 2006). Several studies have documented PDE10A to be limited to the testis 
and the brain (Fujishige et al., 1999; Soderling et al., 1999; Seeger et al., 2003). 
Particularly high levels of mRNA transcript are found in striatal neurons, other areas 
including the cerebellum, the hippocampus, the thalamus, and spinal cord. However, 
no  protein  was  detectable  in  the  hippocampus  as  determined  by  Western  blotting 
(Seeger et al., 2003). A possible function of PDE10 in synaptic plasticity has been 
speculated  based  on  the  finding  that  mRNA  levels  for  PDE10A  variants  are 
upregulated following LTP (O’Connor et al., 2004).  
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Isoform 
 
Substrate 
specificity 
 
 
Km – cGMP  
(µM) 
 
Km – cAMP  
(µM) 
 
Vmax – cGMP 
(µmol/min/mg) 
 
Vmax – cAMP 
(µmol/min/mg) 
 
Comments 
PDE1A 
 
cAMP < cGMP  2.6 – 3.5  72.7 – 124  50 – 300  70 – 150  Ca
2+/CaM activated; 
cytosolic 
PDE1B 
 
cAMP < cGMP  1.2 – 5.9  10 – 24  30  10  Ca
2+/CaM activated; 
cytosolic 
PDE1C 
 
cAMP = cGMP  0.6 – 2.2  0.3 – 1.1  -  -  Ca
2+/CaM activated; 
cytosolic 
PDE2A 
 
cAMP = cGMP  10  30  123  120  cGMP-activated; 
membrane-bound (2A2 and 
2A3) or cytosolic (2A1) 
PDE3A 
 
cAMP > cGMP  0.02 – 0.15  0.18  0.34  3 – 6  cGMP-inhibited; 
membrane-bound or 
cytosolic 
PDE3B 
 
cAMP > cGMP  0.28  0.38  2  8.5  cGMP-inhibited; 
membrane-bound 
PDE5A 
 
cAMP < cGMP  2.9 – 6.2  290  1.3  1  cGMP-binding, cGMP-
specific; cytosolic 
PDE6A/B 
 
cAMP < cGMP  15  700  2300  ~ 500  cGMP-binding, cGMP-
specific; membrane-bound 
PDE6C 
 
cAMP < cGMP  17  610  1400  -  cGMP-binding, cGMP-
specific; cytosolic 
PDE9A 
 
cAMP < cGMP  0.07 – 0.17  230  4.9  -  High affinity, cGMP-
specific; cytosolic 
PDE10A 
 
cAMP < cGMP  13 – 14  0.22 – 1.1  3.5  0.74  cGMP-binding; membrane-
bound (10A2) or cytosolic 
(10A1 and 10A3) 
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1.4.3   Cyclic nucleotide-gated (CNG) channels 
 
The ability of cGMP to activate these cation-selective channels was first documented 
in  retinal  rod  photoreceptors  (Fesenko  et  al.,  1985),  followed  by  the  cloning  and 
sequencing  of  rod  photoreceptor  CNG  channels  (Kaupp  et  al.,  1989)  and  the 
discovery of CNG channels in retinal cone cells (Bonigk et al., 1993) and olfactory 
receptor cells (Dhallan et al., 1990), where they are involved in visual and olfactory 
signal  transduction  by  converting  sensory  information  into  changes  in  membrane 
potential. CNG channels are now known to have a more widespread distribution, at 
least at the mRNA level, including the hippocampus (Kingston et al., 1996) and the 
cerebellum (Kingston et al., 1999; Strijbos et al., 1999), and may therefore play a role 
in  the  communication  between  central  neurons.  Characteristic  features  of  CNG 
channels  include  weak  sensitivity  to  voltage,  and  opening  upon  direct  binding  of 
either  cGMP  or  cAMP.  In  the  absence  of  extracellular  Ca
2+,  these  channels  are 
permeable to Na
+ and K
+. However, they have a higher affinity for Ca
2+ so that, at 
physiological extracellular Ca
2+ concentrations (1-2 mM), the pore of the channels is 
blocked  by  the  divalent  cation  excluding  Na
+  and  K
+,  and,  consequently,  Ca
2+ 
becomes the dominant ion permeating the active channels (Kaupp & Seifert, 2002). 
Based on these channels allowing Ca
2+ influx when they open upon cyclic nucleotide 
binding,  it  becomes  apparent  that  these  channels  could  trigger  Ca
2+-dependent 
processes within a cell.  
 
CNG channels closely resemble voltage-gated K
+ channels, and are therefore thought 
to have evolved from these channels. Functional CNG channels exist as a tetrameric 
assembly of a and b subunits arranged around a central pore. Based on hydropathy 
plotting, all subunits are predicted to share a common architecture, comprising a 6-
transmembrane  domain  (S1-6),  an  ion  conducting  pore  region  which  is  located 
between S5 and S6 and carries the inward cationic currents, and an intracellular C-
terminal  cyclic  nucleotide-binding  domain  (CNBD)  which  follows  the  S6  domain 
(Kaupp  et  al.,  1989;  Matulef  &  Zagotta,  2003).  The  pore  region,  which  is  the 
determinant of ion permeation properties of the channel, is very similar to the one in 
K
+ channels except for two residues that are absent in CNG channels but present in K
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channels. Indeed, mutation of these residues has implied that no other regions in the 
channel are required to confer the profoundly different permeation qualities of the two 
channel types (Heginbotham et al., 1992). The CNBD consists of three a-helices and 
an eight-stranded anti-parallel b-roll, and it is the binding of cGMP (or cAMP) to the 
CNBD that evokes the direct opening of the channel (Matulef & Zagotta, 2003).   
 
Molecular cloning has identified two subfamilies of subunits in vertebrates, which are 
termed CNGa(1-4) and CNGb(1,3), where there are two splice variants (b1a and b1b) 
known to exist for the CNGb1. Heterologous expression of subunits has suggested 
subunits CNGa1-3 to be core subunits, which are able to form functional homomeric 
channels. On the contrary, CNGa4 and the b subunits lack this capability, and are 
instead  regarded  to  have  regulatory  roles  influencing  channel  properties  such  as 
ligand sensitivity and gating properties (Kaupp & Seifert, 2002; Craven & Zagotta, 
2006).  
The CNGa1 and CNGb1a subunits are primarily found in rod photoreceptors, 
the rod CNG channels thought to be made of three CNGa1 subunits and one CNGb1a 
subunit (Weitz et al., 2002). Cone photoreceptors appear to express mainly CNGa3 
and CNGb3, where two CNGa3 subunits are thought to pair up with two CNGb3 
subunits to form the native channel (Peng et al., 2004). The CNGa2, CNGa4, and 
CNGb1b subunits are found in olfactory receptors, the native channel being thought 
to comprise a tetramer of two core CNGa2 subunits and two regulatory subunits – 
one CNGa4 and one CNGb1b (Zheng & Zagotta, 2004). The rod and cone CNG 
channels prefer cGMP as their ligand, while the olfactory-type channels are relatively 
non-selective between cGMP and cAMP (Kaupp & Seifert, 2002). 
 
Functionally, much remains to be learned about these channels and how they may be 
participating  in  the  NO-cGMP  signal  transduction  cascade,  which  has  been  made 
difficult by the lack of good pharmacological tools. Based on the features of these 
channels, it is plausible to suggest that membrane potential and Ca
2+ influx may be 
modulated  through  NO-cGMP-mediated  activation  of  CNG  channels  (Biel  et  al., 
1998). For instance, based on defined NADPH-diaphorase activity in amacrine cells 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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and NO-activated CNG channel currents in cultured retinal ganglion cells, which were 
occluded upon pre-exposure to cGMP, it has been suggested that NO from nearby 
amacrine cells could elevate cGMP levels in retinal ganglion cells, thereby enhancing 
CNG  channel  activity  (Ahmad  et  al.,  1994).  Another  suggested  role  for  the  NO-
cGMP-CNG channel pathway is the modulation of neurotransmitter release. In retinas 
isolated  from  lizards,  it  has  been  demonstrated  that  NO-cGMP-mediated  CNG 
channel activation promotes neurotransmitter release from cone presynaptic terminals, 
which was sensitive to NOGC receptor inhibition, culminating in enhanced neuronal 
firing  of  the  postsynaptic  horizontal  cells  (Savchenko  et  al.,  1997).  In  the 
hippocampus, in situ hybridisation studies and patch clamp-recordings from cultured 
neurons demonstrated the presence of both olfactory- and rod-type CNG channels in 
this  brain  region,  being  localised  in  neuronal  somata  and  dendrites  of  pyramidal 
neurons, as well as in granule cells of the dentate gyrus (Leinders-Zufall et al., 1995; 
Kingston et al., 1996). Consistent with the expression profile of CNG channels in the 
hippocampus, it has been suggested that the olfactory-type CNG channels support 
LTP in the Schaffer collateral/CA1 synapse recorded from hippocampal slices, based 
on  the  finding  that  theta-burst-evoked  LTP  in  mice  lacking  the  a  subunit  of  the 
channel  was  reduced  (Parent  et  al.,  1998).  Also  NOGC  receptor-sensitive 
depolarisation of the membrane potential of rat hippocampal CA1 pyramidal neurons 
in slices has been reported, that was, however, insensitive to NOS inhibition and the 
ODQ  concentration  used  was  twice  the  ‘bench-mark’  concentration,  therefore 
questioning the physiological relevance of this observation (Kuzmiski & MacVicar, 
2001).  
 
1.4.4   Hyperpolarisation-activated cyclic nucleotide-modulated 
(HCN) channels 
 
General features 
 
HCN  channels  have  only  relatively  recently  emerged  as  a  potential  player  in 
transducing  NO-cGMP  signals.  Similar  to  CNG  channels,  also  HCN  channels  are 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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modulated by cyclic nucleotide binding. However, while CNG channels are virtually 
voltage-insensitive and open directly upon cyclic nucleotide binding, HCN channels 
are quite different in that their binding of cyclic nucleotides modulates their voltage 
dependence for activation. HCN channels have long puzzled scientists due to their 
‘unorthodox’ behaviour compared to other voltage-gated channels in that they activate 
at  more  hyperpolarised  membrane  potentials  negative  to  or  close  to  the  resting 
membrane potential. This unique characteristic  has led to the nicknaming of their 
current as ‘funny’ (If) or ‘queer’ (Iq), alongside the more ‘conservative’ nomenclature 
of ‘hyperpolarisation-activated’ (Ih). While CNG channels carry an inward current 
dominated by Ca
2+, but also to a lesser extent by monovalent cations such as K
+, Na
+, 
Li
+, and Cs
+ (Kaupp & Seifert, 2002), the inward current conducted by HCN channels 
is a mixed cation current of both K
+ and Na
+ at an average permeability ratio of 4:1 
(Robinson & Siegelbaum, 2003; Wahl-Schott & Biel, 2009). There is some evidence 
suggesting that HCN channels expressed in HEK293 cells also conduct Ca
2+ ions to a 
small  extent  (Yu  et  al.,  2004),  but  the  functional  relevance  of  this  remains  to  be 
elucidated, and, unlike CNG channels, HCN channels are not blocked by divalent 
cations (Kaupp & Seifert, 2002). The binding of cyclic nucleotides has the effect of 
causing a depolarising shift in the voltage dependence of HCN channel activation. 
HCN channels are found in a variety of excitable cells, including neurons, cardiac 
pacemaker cells, and photoreceptors (Pape, 1996; Wahl-Schott & Biel, 2009), their 
function being best established in the heart where Ih controls heart rate and rhythm by 
acting  as  a  ‘pacemaker  current’  in  the  sinoatrial  (SA)  node  (Accili  et  al.,  2002; 
Barbuti & DiFrancesco, 2008). 
 
HCN channels have a proposed structure (Fig. 1.4) as described for CNG channels. 
Four  isoforms  have  been  cloned  in  mammals,  termed  HCN  1-4,  homomeric 
expression  of  the  different  subtypes  revealing  differences  in  terms  of  activation 
kinetics,  gating  properties,  and  cyclic  nucleotide  sensitivity  (Accili  et  al.,  2002; 
Robinson & Siegelbaum, 2003; Wahl-Schott & Biel, 2009). These subunits combine 
to  form  tetrameric  channels,  arranged  around  a  central  pore,  but  the  subunit 
stoichiometry  of  native  channels  remains  largely  unknown.  The  different  subunits 
share  an  unifying  structure,  each  comprising  a  cytosolic  N-terminus,  which  is 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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important for subunit association (Proenza et al., 2002), six transmembrane domains 
(S1-S6) of which the S4 is the positively charged voltage sensor that moves inwards 
on hyperpolarisation to produce channel opening, a pore-forming region between S5 
and S6, which determines ion selectivity, and a cytosolic C-terminal CNBD, which is 
preceded by a C-linker region and to which cyclic nucleotides bind. The difference in 
activation polarity compared to other voltage-dependent channels is suggested to be 
determined by the downstream coupling mechanism between the voltage sensor and 
the gate (Rosenbaum & Gordon, 2004). Binding of cGMP or cAMP to the CNBD 
speeds  up  channel  opening  and  causes  a  shift  in  activation  to  more  depolarised 
potentials and an increase in current amplitude by initiating the removal of a tonic 
inhibition of the channel (Robinson & Siegelbaum, 2003; Wahl-Schott & Biel, 2009).  
The determination of the crystal structure of part of the HCN2, beginning just 
after  the  end  of  S6  and  extending  through  the  C-linker  and  CNBD,  has  provided 
insights into cyclic nucleotide-dependent channel modulation (Zagotta et al., 2003). 
The CNBD is made of an eight-stranded anti-parallel b-roll, which is connected to the 
pore by the C-linker region consisting of six a-helices. The construction of truncation 
mutants has shown that, during the inactivated state, the channel is inhibited by the 
CNBD at its core transmembrane domain region S1-S6 (Wainger et al., 2001). The 
same study suggested that differences in the efficacy of CNBD, exerting different 
levels  of  tonic  inhibition,  are  the  cause  of  varying  activation  gating  and  cyclic 
nucleotide-dependent  modulation,  where  cyclic  nucleotide  binding  relieves  this 
inhibition. Indeed, the deletion of the CNBD was found to mimic the effect of cAMP 
by moving the voltage dependence of channel gating to more depolarised potentials to 
a similar level as cAMP. Subsequently, chimeric subunit studies demonstrated that the 
difference in cAMP efficacy also depends on the interaction of the CNBD with the 80 
amino acid C-linker, which itself has no intrinsic inhibitory influence, but accounts 
for  the  differences  in  basal  gating  and  cAMP  modulation  by  interacting  with  the 
CNBD (Wang et al., 2001). 
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Fig. 1.4 The proposed topology and structure for HCN channel subunits. A single subunit comprises six α-helical 
membrane-spanning segments (S1-S6), a positively charged S4 domain, and cytoplasmic N- and C- termini. The 
putative pore region between S5 and S6 extends into the membrane, and the cyclic nucleotide binding domain 
(CNBD) is located in the C-terminal region. Adapted from Robinson & Siegelbaum, 2003 
 
 
As aforementioned, the HCN subtypes exhibit marked differences in their biophysical 
properties, including voltage-dependence, activation kinetics, and cyclic nucleotide 
sensitivity. Homotetramers of HCN1 show the fastest activation kinetics, falling on a 
hundred-millisecond timescale, while HCN4 is the slowest channel, taking several 
seconds to activate at resting membrane potential but gradually becoming faster at 
more  hyperpolarised  potentials.  HCN2  and  HCN3  show  activation  kinetics 
intermediate  to  that  of  HCN1  and  HCN4.  Estimated  values  for  the  half-maximal 
voltages for activation are -70 mV for HCN1, -95 mV for HCN2, -85 mV for HCN3, 
and -100 mV for HCN4 (Wahl-Schott & Biel, 2009). In terms of cyclic nucleotide 
sensitivity, HCN1 and HCN3 homotetramers are the least sensitive, while HCN2 have 
greater  sensitivity,  followed  by  HCN4,  which  are  strongly  regulated  by  cyclic 
nucleotides. Although much remains to be learned about native channel compositions, 
HCN channels have been shown to co-assemble to form heteromers. A construct of 
HCN1  and  HCN2  subunits  has  been  found  to  exhibit  modulation  by  cAMP  and 
activation kinetics intermediate to those of HCN1 and HCN2 homomers (Ulens & 
Tytgat, 2001). Both native and heterologously expressed channels are activated by 
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cAMP and cGMP with similar efficacy, albeit with different sensitivity. Based on 
apparent dissociation constants, the channels appear to be about 30-fold less sensitive 
to cGMP as compared to cAMP, resulting in cAMP being often considered as the 
‘natural’ ligand, showing approximately 10-fold greater potency to activate channels 
(DiFrancesco & Tortora, 1991; Ludwig et al., 1998; Zagotta et al., 2003). However, 
there have been instances where cAMP and cGMP were demonstrated to exhibit quite 
similar concentration-effect profiles (Ingram & Williams; 1996).  
 
Initially, it had been proposed that Ih gating is directly regulated by cyclic nucleotide 
binding to the cytoplasmic CNBD, not involving other modulatory factors such as 
protein phosphorylation (Pape, 1996; Robinson & Siegelbaum, 2003). However, it has 
now  emerged  that  also  HCN  channels  may  be  modulated  by  other  factors 
independently  of  cyclic  nucleotides.  The  membrane  lipid  phosphatidylinositol-4,5-
bisphosphate  (PIP2)  apparently  acts  as  an  allosteric  ligand,  shifting  the  voltage-
dependence of HCN channel activation to more depolarised values by about 20 mV 
(Zolles et al., 2006; Pian et al., 2006). A possible physiological significance for this 
has  been  proposed  on  the  grounds  of  enzymatic  degradation  of  phospholipids 
reducing  channel  activation  and  slowing  neuronal  firing  frequency  (Zolles  et  al., 
2006). How PIP2 exerts this effect mechanistically is still unknown. Other proposed 
factors include the non-receptor tyrosine kinase c-Src and the Ser/Thr-kinase mitogen 
activated protein kinase p38-MAP, where c-Src has been found to enhance activation 
kinetics  of  the  channels  via  C-linker  domain  phosphorylation,  and  p38-MAP  is 
suggested  to  shift  voltage-dependent  activation  to  more  positive  potentials  (Wahl-
Schott & Biel, 2009). An involvement of PKA in channel modulation has so far only 
been reported in rat olfactory receptor neurons, where infusion of the PKA catalytic 
subunit was found to shift the activation voltage to more positive potentials (Vargas & 
Lucero, 2002). Furthermore, like with many other signalling components, it appears 
that  there  are  ‘context-dependent’  mechanisms  also  at  work  in  the  case  of  HCN 
channels. A number of interacting proteins that may influence the coupling of HCN 
channels  to  signalling  pathways  and  the  trafficking  of  the  channels  to  different 
cellular  compartments  have  been  identified,  including  the  TPR-containing  Rab8b-
interacting protein (TRIP8b), which had no previously ascribed function, the mink-1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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related  peptide  1  (MiRP1),  and  the  cytoplasmic  scaffold  protein  filamin  A.  Their 
functional implications in native tissue remain to be determined (Wahl-Schott & Biel, 
2009).  
 
Pharmacological manipulation of Ih 
 
HCN channels can be blocked with Cs
+ and various organic compounds, including 
ZD 7288, zatebradine, and ivabradine. The two most commonly used inhibitors are 
caesium  (Cs
+)  and  ZD  7288  (Harris  &  Constanti,  1995;  Takigawa  et  al.,  1998; 
Ghamari-Langroudi & Bourque, 2001).  
The compound ZD 7288 has been suggested to adapt properties of a lipophilic 
quaternary cation that can readily cross the cell membrane when applied externally, 
which  is  consistent  with  intracellular  application  of  ZD  7288  also  inhibiting  Ih. 
Moreover, it has been proposed that ZD 7288 exerts its Ih-blocking effect in a non-use 
dependent manner, with an approximate half-maximal blocking concentration of 2 
 M (Harris & Constanti, 1995). Inhibition of Ih by ZD 7288 occurs in a time- and 
concentration-dependent manner and is irreversible, its action being relatively slow (~ 
10-15 min; Harris & Constanti, 1995; Takigawa et al., 1998; Chevaleyre & Castillo, 
2002). ZD 7288 has been reported to have also non-selective effects at high (> 30 
mM) concentrations. At these higher concentrations, ZD 7288 has been observed to 
depress basal synaptic transmission, which did not occur upon Cs
+ application and 
was also not occluded by Cs
+ and therefore assumed to be Ih-independent (Chevaleyre 
& Castillo, 2002). 
In contrast to ZD 7288, while also exerting its effect in a non-use dependent 
manner, Cs
+ induces block much more rapidly in a reversible manner, and has no 
effect  on  Ih  when  loaded  into  the  cell  interior,  indicating  that  it  acts  on  the 
extracellular site (Harris & Constanti, 1995). However, Cs
+ has the shortcoming of 
also blocking K
+ inward rectifier (IKir) channels (Pape, 1996; Ghamari-Langroudi & 
Bourque, 2001). Inhibition of IKir results in extracellular K
+ accumulation, leading to 
membrane  depolarisation,  which  is  indeed  observed  when  using  Cs
+  (Ghamari-
Langroudi & Bourque, 2001). This may have great importance when using Cs
+ to 
block Ih, as the conductance of HCN channels is highly sensitive to external K
+ levels, 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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where a reduction below normal levels (2-4 mM) leads to a marked decrease in Ih 
magnitude and vice versa (Robinson & Siegelbaum, 2003). 
 
Expression of HCN in the CNS and proposed functions 
 
While in the heart HCN3 is absent (Shi et al., 1999; Moosmang et al., 2001), all four 
subtypes of HCN are found in the mammalian brain as determined by their expression 
pattern at protein and mRNA levels. HCN1 is found in the neocortex, hippocampus, 
brainstem,  cerebellum,  olfactory  bulb,  and  spinal  cord  (Moosmang  et  al.,  1999; 
Santoro et al., 2000; Notomi & Shigemoto, 2004; Milligan et al., 2006). HCN2 has 
been reported to have widespread distribution, with highest expression levels detected 
in the thalamus, brainstem, hippocampus, and olfactory bulb (Moosmang et al., 1999; 
Santoro et al., 2000; Notomi & Shigemoto, 2004). In contrast, HCN3 is seen in the 
CNS at very low levels, appearing to be mainly restricted to the olfactory bulb and 
hypothalamus,  whereas  HCN4  is  predominantly  expressed  in  the  thalamus  and 
olfactory bulb (Moosmang et al., 1999; Santoro et al., 2000; Notomi & Shigemoto, 
2004).  
 
An  emerging  general  consensus  is  that  Ih  plays  an  important  role  in  influencing 
intrinsic  neuronal  excitability.  Tonic  activation  of  Ih  sets  the  resting  membrane 
potential  at  a  depolarised  level,  and  also  reduces  the  input  resistance  so  that  the 
influence of any current on the membrane potential is reduced according to V = I x R. 
These basic properties can lead to opposing  effects of  Ih on neuronal excitability, 
depending on the HCN isoform and the type of input reaching the cell. Dendritic Ih 
can  reduce  neuronal  excitability  on  the  basis  of  reducing  membrane  resistance, 
ultimately  causing  a  decrease  in  dendritic  summation  in  response  to  a  dendritic 
depolarising input. In other words, Ih influences the cable properties of dendrites and 
in turn shapes the time course of the EPSP as it is propagated to the soma. On the 
other hand, by depolarising the resting membrane potential, Ih can enhance neuronal 
excitability by driving the neuron closer to firing threshold of action potentials. Based 
on these features, the physiological roles ascribed to HCN channels include control of 
oscillatory activity of neurons, maintenance of reliable conduction by counteracting 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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hyperpolarisation  occurring  during  high-frequency  activity,  control  of  resting 
membrane potential, and modulation of membrane resistance and dendritic integration 
(Robinson & Siegelbaum, 2003; Wahl-Schott & Biel, 2009).  
 
Evidence supporting the presence of a NO-cGMP-HCN pathway in the brain 
 
It has been demonstrated in vitro that rhythmic oscillations of thalamic neurons are 
generated by the interplay between Ih and a low threshold Ca
2+ current, termed ‘IT’, 
that arises from T-type Ca
2+ channels. It is proposed that Ih slowly depolarises the 
membrane,  which  in  turn  evokes  a  low-threshold  Ca
2+  spike  via  activation  of  IT. 
These spikes are depolarising and last tens of milliseconds and therefore cause the 
generation of a series of Na
+ spikes. The prolonged depolarisation then leads up to the 
inactivation  of  T-type  Ca
2+  channels,  terminating  the  low-threshold  Ca
2+  spike. 
During  the  spike,  HCN  channels  are  deactivated,  therefore  generating  a 
hyperpolarising overshoot upon termination of the Ca
2+ spike. This hyperpolarising 
overshoot removes the inactivation of the T-type Ca
2+ channels and activates Ih again, 
initiating a new cycle. This ‘burst mode’ of thalamic neurons is characteristic for non-
REM sleep and is thought to reduce sensory information transfer to the cortex during 
this sleep state (McCormick & Bal, 1997).  One of the first reported observations 
suggesting NO as a potential regulator of Ih came from studies in guinea-pig and cat 
thalamocortical relay neurons maintained in vitro in slices (Pape & Mager, 1992). 
Using  intracellular  recordings  it  was  found  that  both  NO  and  a  cGMP  analogue 
depolarise  the  membrane  potential  of  these  neurons  by  1-3  mV  and  reduce  their 
membrane resistance. The target for the NO-cGMP pathway being Ih was deduced 
from the current-voltage relationship that suggested NO to have a greater effect at 
hyperpolarised potentials, the rate of rise and amplitude of Ih found to be enhanced by 
NO or cGMP. This work by Pape & Mager (1992) found NO to shift the voltage for 
half-maximal activation of the channels to a more depolarised value by approximately 
5  mV.  In  this  way,  NO  was  demonstrated  to  potently  and  reversibly  block  the 
oscillatory activity in these spontaneously active neurons by causing a reduction in 
rebound depolarisation because of less de-inactivation of IT, consequently reducing 
rebound action potentials (Pape & Mager, 1992).  1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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During wakefulness and REM sleep, thalamocortical neurons are depolarised 
by afferent inputs and switch to a ‘transmission’ or ‘single spike’ mode, as opposed to 
the  situation  during  non-REM  sleep  (McCormick  &  Bal,  1997).  Fibres  of  the 
cholinergic tegmental neurons innervate the thalamus, and contain nNOS (Vincent & 
Kimura, 1992). These neurons are thought to increase their firing rate just before the 
transition from sleep to wakefulness (McCormick & Bal, 1997), which in turn would 
presumably facilitate the release of NO into the thalamus. Taken together, it appears 
that there is the possibility that NO regulates the switch between the two distinct 
firing  modes  of  thalamic  relay  neurons,  regulating  the  transition  from  the  ‘burst 
mode’ associated with non-REM sleep to the ‘transmission mode’ prevailing during 
REM sleep and wakefulness, thereby supporting the increase in the transfer of sensory 
information to the cortex (Pape & Mager, 1992). 
 
The  above  evidence  suggesting  the  NO-cGMP  pathway  as  a  modulator  of  HCN 
channels  was  supported  by  a  number  of  subsequent  studies.  Exogenously  applied 
cGMP  was  demonstrated  to  enhance  Ih  in  dissociated  guinea-pig  nodose  and 
trigeminal neurons, finding the cGMP analogue to have a very similar concentration-
effect profile to the related analogue for cAMP, where both analogues applied at 1 
mM caused a shift in the half-maximal activation voltage of about 4 mV to more 
depolarised  potentials  (Ingram  &  Williams,  1996).  This  indicated  that  NO-cGMP 
signalling could play a role in nociceptive processing, which was further implied by a 
recent study  by Kim  and colleagues (2005), finding NO and exogenously applied 
cGMP to augment Ih in rat substantia gelatinosa neurons in spinal cord slices, the 
effect of the former being prevented by NOGC receptor inhibition. Additionally, they 
reported NO to evoke depolarisation of the neurons by approximately 5 mV, which 
was sensitive to Ih block by Cs
+. Based on these findings a possible role of NO in 
central sensitisation was suggested (Kim et al., 2005).  
  Exogenously applied cGMP or NO has also been demonstrated to increase Ih 
in  guinea-pig  trigeminal  motor  pool  and  rat  mesencephalic  neurons  maintained  in 
vitro in slices (Abudara et al., 2002; Pose et al., 2003). In these studies, NO (in an 
ODQ-sensitive manner) and exogenous cGMP reversibly depolarised the membrane 
potential by approximately 3-7 mV and reduced the threshold for firing so that the 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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enhanced Ih had an excitatory effect, suggested to have an importance in various jaw 
reflexes  and  movements.  In  both  papers,  these  neurons  were  demonstrated,  by 
immunohistochemical  analysis,  to  be  innervated  by  nNOS-bearing  fibres, 
underscoring a possible physiological relevance of modulation of these neurons by 
NO. 
 
Recently,  it  has  been  discovered  that  in  vitro  in  the  rat  optic  nerve,  tonic  eNOS-
derived  NO  depolarises  axons,  this  being  transduced  by  cGMP  engaging  HCN 
channels. The prevailing tone of the NO-cGMP-HCN-maintained membrane potential 
was found to lie around the midpoint, indicating that the system is well balanced to 
respond to changes in eNOS activity (Garthwaite et al., 2006). 
 
 
1.5   OVERVIEW OF THE PHYSIOLOGICAL FUNCTIONS OF 
NO IN THE CNS 
 
1.5.1   Development 
 
There are three distinct steps NO has been suggested to play a role in during CNS 
development.  These  are  inhibition  of  proliferation  and  promotion  of  cell 
differentiation, influence over the direction of neurite growth, and the refinement of 
topographical projections.  
 
The indication of NO regulating neurogenesis in the developing embryo brain and in 
neurogenic areas in the adult brain came from studies demonstrating an inhibitory 
effect of NO on the rate of proliferation of undifferentiated neuronal precursors, and 
an accelerating effect on the neuronal differentiation process, NO thereby presumably 
acting as a switch between proliferation and differentiation. Inhibition of endogenous 
NO  production  by  means  of  NOS  inhibitors  or  application  of  haemoglobin  to 
scavenge NO was found to increase the proliferation of cultured embryonic mouse 
brain  neuronal  progenitor  cells  or  postnatal  subventricular  zone  progenitors  as 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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quantified  by  the  expression  of  markers  of  proliferating  cells  such  as  nestin  and 
bromodeoxyuridine (BrdU). Exogenous NO, on the other hand, was found to have the 
opposite effect (Cheng et al., 2003; Matarredona et al., 2004). Analogous results were 
obtained  in  studies  investigating  the  role  of  NO  in  cell  proliferation  of  neuronal 
progenitor cells in the adult mammalian brain (Park et al., 2003; Packer et al., 2003; 
Moreno-Lopez et al., 2004).  
Consistent  with  NO  facilitating  cell  differentiation  is  the  finding  that  the 
expression of neuronal phenotypic markers is delayed upon NOS inhibition or NO 
scavenging by haemoglobin, but increased upon NO application, which are the very 
same  treatments  that  promote  or  suppress  proliferation  respectively  (Cheng  et  al., 
2003;  Moreno-Lopez  et  al.,  2004;  Matarredona  et  al.,  2004).  The  spatiotemporal 
pattern  of  nNOS  expression  appears  to  correlate  with  NO  acting  as  an  anti-
proliferative, pro-differentiation molecule. In the developing rodent CNS, transient 
increases in nNOS expression parallel cessation of proliferation and the beginning of 
differentiation, while in the adult brain NOS-bearing neurons are adjacent rather than 
within areas of adult neurogenesis (Moreno-Lopez et al., 2000; Packer et al., 2003; 
Moreno-Lopez et al., 2004). Moreover, the growth factor brain-derived neurotrophic 
factor (BDNF) was shown to reduce cell proliferation and to augment nNOS levels in 
post-mitotic neurons nearby proliferating cells in the developing cortex, executing a 
stimulatory effect on neuronal differentiation that was sensitive to NOS inhibition or 
NO scavenging (Cheng et al., 2003).  
Additional evidence supporting the role of NO in these early developmental 
processes has been provided by studies using mice lacking nNOS, which were found 
to exhibit an increase in the number of proliferating cells, albeit to a lesser extent as 
compared to the effect observed upon non-selective NOS inhibition, indicating that 
NO sources other than the deleted NOS form may be involved in the regulation of 
proliferation and differentiation (Packer et al., 2003). Overall, it appears that NO acts 
in  a  paracrine  fashion  during  these  early  stages  of  neuronal  development,  being 
released from nearby differentiating neurons to stop neuronal precursors from further 
proliferation and to initiate differentiation into neuronal phenotypes. However, as the 
involvement of the NOGC receptor and ensuing cGMP production has not been tested, 
the mechanism(s) through which NO exerts these actions remain elusive. The absence 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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of  NOGC  receptors  and  cGMP  in  neurons  prior  to  differentiation,  as  evaluated  by 
means  of  immunohistochemistry,  as  well  as  the  lack  of  effect  of  allosteric  NOGC 
enhancers  on  proliferation,  have  indicated  that  an  alternative,  as  yet  unidentified, 
signalling process may be at play (Arnhold et al., 2002). 
 
Several studies have proposed a role for NO in the control of neurite outgrowth. In the 
developing visual system of the ferret, based on a disruptive effect of NOS inhibition, 
NO has been suggested to be involved in directing retinal axons to the appropriate 
locations in the lateral geniculate nucleus of the thalamus (Cramer et al., 1996). This 
finding parallels the proposed role of cyclic nucleotides in regulating neuronal growth 
cones, where it was observed that varying levels of cyclic nucleotides change the 
turning  behaviour  of  isolated  growth  cones  of  Xenopus  spinal  neurons,  NO-
stimulation  of  cGMP  formation  or  application  of  a  cGMP  analogue  converting 
repulsion  to  attraction  (Song  et  al.,  1998).  There  are  a  number  of  contradictory 
observations,  however,  showing  either  collapse  and  retraction  of  growth  cones  in 
response to NO (Ernst et al., 2000; Gallo et al., 2002; He et al., 2002), or NO-cGMP-
mediated attraction of growth cones and protection from collapse (Campbell et al., 
2001; Schmidt et al., 2002; Xiang et al., 2002; Steinbach et al., 2002). Overall, the 
opposing observations appear to be related to the concentration of NO that is applied. 
Growth cone collapse occurs in studies applying NO donors at high micromolar to 
millimolar  concentrations,  while  attraction  and  protection  is  observed  in  studies 
applying  lower  NO  donor  concentrations  or  cGMP  analogues.  Also,  for  instance, 
semaphorin-3A-mediated attraction of rat cortical pyramidal cell dendrites to the pial 
surface was demonstrated to depend on NOGC receptors and PKG, localising NOGC 
receptors to the region of the cells where apical dendrites are generated, and finding 
that inhibition of these two constituents disrupts oriented dendritic growth. However, 
pharmacological  inhibition  of  these  constituents  did  not  cause  the  dendrites  to  be 
repelled by semaphorin-3A, implying that NOGC receptor activity does not simply act 
as a polarity switch. Additionally, the repellent effect of semaphorin-3A on pyramidal 
cell  axons  was  found  to  be  independent  of  this  pathway  (Polleux  et  al.,  2000). 
Another study, although not identifying the site of action of cGMP (i.e. growth cones 
vs. their target cells), reported that reducing cGMP levels impairs synapse formation 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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between mossy fibres and CA3 pyramidal cell apical dendrites in the stratum lucidum, 
leading  to  random  orientation  of  mossy  fibres  (Mizuhashi  et  al.,  2001).  Evidence 
coming  from  studies  documenting  effects  of  exogenously  applied  NO  or  cGMP 
analogues  therefore  suggests  a  role  for  NO  in  regulating  the  direction  of  neurite 
outgrowth. The involvement of endogenous NO was first indicated in retinal axon 
path finding (Cramer et al., 1996), and by a study on PC12h cells (Yamazaki et al., 
2001),  showing  prevention  of  nerve  growth  factor-mediated  neurite  outgrowth 
following NOGC receptor inhibition or upon inhibition of endogenous NO production 
by  means  of  broad-spectrum  NOS  inhibition  or  NO  scavenging.  Additionally, 
Yamazaki  and  colleagues  found  enhanced  NADPH-diaphorase  activity  and  nNOS 
protein  in  cells  prior  to  neurite  outgrowth.  Recently,  a  study  in  organotypic 
hippocampal slice cultures from postnatal rats using electronmicroscopy demonstrated 
that  the  postsynaptic  site  promotes  synapse  formation  with  nearby  axons  via  NO 
derived from the nNOS-PSD-95 interaction site (Nikonenko et al., 2008). The key 
findings  leading  to  this  proposal  included  prevention  of  synapse  formation  upon 
deletion of the second PDZ domain of PSD-95, or through small interfering RNA-
induced down-regulation of nNOS or pharmacological broad-spectrum inhibition of 
NOS.  Interestingly, knockdown of nNOS had only a partial effect in this respect, 
while non-selective NOS inhibition caused complete inhibition of synapse formation. 
This could point towards another NO source (e.g. eNOS) contributing. Conversely, 
application  of  a  cGMP  analogue  or  slow-releasing  NO  donor  enhanced  synapse 
formation. Finally, the notion that NO is acting downstream of PSD-95 was indicated 
by the result that NO donor treatment also increased synapse formation in slices with 
deleted PDZ, which was prevented upon NOGC receptor inhibition (Nikonenko et al., 
2008).  
Overall,  however,  it  appears  difficult  to  propose  a  general  model  for  NO-
regulated  neurite  growth,  as  this  may  differ  among  species,  and  also  may  vary 
depending  on  the  extracellular  cue  communicating  with  the  NO-cGMP  signalling 
cascade in a given brain region, as well as the cGMP effector engaged. For example, 
in postnatal dissociated dorsal root ganglion neurons, inhibition of endogenous NO 
synthesis by means of broad-spectrum NOS inhibition or a NO scavenger revealed a 
repulsive action of endogenous NO on axon guidance, the extracellular cue being the 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
 
  82
neurotrophic factor neurotrophin-4. Additionally, NO scavenging or NOGC receptor 
inhibition were both found to convert the neurotrophin-4-induced repulsion of the 
growth cones to attraction (Tojima et al., 2009). 
 
NO  has  also  been  implicated  in  mediating  activity-dependent  refinement  of 
topographical projections after a coarse map has been laid down by guidance cues. 
However,  this  seems  to  be  restricted  to  only  a  few  specific  areas.  Inhibition  of 
endogenous  NO  production  has  been  demonstrated  to  cause  disorganisation  of 
refinement of ipsilateral retinotectal or retinocollicular projections in the chick and rat 
in vivo (Campello-Costa et al., 2000; Wu et al., 2001). In the rat, projections undergo 
topographical refinement within the first two postnatal weeks, and the role of NO in 
this process was compatible with the spatiotemporal expression profile of NOS in the 
tectum and colliculus during the period of refinement. Maximal NOS activity in tissue 
homogenates or NADPH-diaphorase levels were measured towards the end of the first 
postnatal week, followed by a slight decrease by the end of the third postnatal week, 
which  is  the  time  point  marking  the  end  of  topographical  fine-tuning,  and  an 
approximately  two-third  reduction  in  adulthood  (Campello-Costa  et  al.,  2000). 
Overall, these findings are in line with double-knockout mice that lack eNOS and 
nNOS  exhibiting  delayed  refinement  with  more  diffuse  ipsilateral  retinocollicular 
projections that eventually become more refined with age presumably due to residual 
NOS  activity  in  the  knockouts  (Wu  et  al.,  2000b).  Additionally,  the  refinement 
process  in  normal  mice  or  nNOS  or  eNOS  knockouts  is  in  progress  before  eye 
opening,  but  significantly  delayed  in  double  knockouts  (Wu  et  al.,  2000c).  Also, 
during  visual  system  development,  the  terminals  of  retinal  ganglion  cell  axons 
segregate  first  into  eye-specific  layers  within  the  dorsal  lateral  geniculate  nucleus 
(dLGN), which is followed by a process of sublamination during which the ON- and 
OFF-inputs  from  retinal  ganglion  cells  are  organised  into  sublayers.  It  has  been 
demonstrated in ferret kittens that the period of retinogeniculate axon sublamination 
within the dLGN requires activity of the incoming fibres, NMDA receptor-mediated 
NO  synthesis,  and  ensuing  NOGC  receptor-dependent  cGMP  formation.  This  was 
accompanied  by  the  finding  that  the  period  of  connection  refinement  in  the 
retinogeniculate  pathway  overlaps  with  transient  upregulation  of  NOGC  receptor 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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activity in pre- and postsynaptic elements, as revealed by particularly strong cGMP 
staining  during  the  second  to  third  postnatal  week  (Leamey  et  al.,  2001).  Also 
continuous infusion of ferrets with ODQ by means of osmotic mini-pumps led to 
impaired normal sublamination, indicating that the activity of the NO-cGMP pathway 
may be required for normal ON- OFF-sublamination in vivo (Leamey et al., 2001).  
  The organisation of other sensory projections appears to be unrelated to the 
NO-cGMP  transduction  pathway.  The  lack  of  large  scale  neuroanatomical, 
neurochemical,  or  behavioural  changes  in  adults  following  chronic  neonatal  NOS 
inhibition  in  vivo  suggests  that  NO  may  not  be  a  necessity  in  the  formation  and 
refinement of cortical neuronal maps during late development (Contestabile, 2000). 
 
1.5.2   Acute effects on neuronal function 
 
Neuronal function can be modulated by NO in an acute manner via influences upon 
neuronal  excitability,  firing  rate,  and  neurotransmitter  release.  This  section  will 
outline the possibilities by a number of examples. 
 
In a study in rat hypothalamic slices, NO was reported to reduce the firing rate of 
spinally  projecting  paraventricular  nucleus  (PVN)  neurons  by  enhancing  GABA 
release through a cGMP-PKG-dependent mechanism (Li et al., 2002; Li et al., 2004). 
In this case, L-arginine, a cGMP analogue or NO donor enhanced the frequency of 
GABAergic miniature IPSCs and reduced the discharge activity of PVN neurons, the 
NO-mediated effect being prevented by inhibiting GABAA receptors, scavenging NO, 
inhibiting  NOGC  receptors  or  PKG,  or  selectively  inhibiting  nNOS.  Furthermore, 
inhibition of NOS activity or scavenging of basal NO was found to have no effect, 
suggesting that the NO-mediated effect is stimulus-evoked rather than tonic. On the 
contrary, a subpopulation of PVN neurons in the hypothalamus that project to the 
rostral  ventrolateral  medulla  have  been  found  to  increase  their  discharge  rate  in 
response  to  nNOS  inhibition,  demonstrating  a  tonic  inhibitory  function  of  NO, 
exogenous  NO  having  the  opposite  effect  (Stern  et  al.,  2003).  Other  proposed 
mechanisms via which the NO-cGMP signalling pathway could exert postsynaptic 
inhibitory effects on excitability include hyperpolarisation by activating various types 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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of K
+ channels as has been observed for delayed-rectifier K
+ channels in cultured 
mouse neocortical neurons (Han et al., 2006), leak K
+ channels in basal forebrain 
neurons  maintained  in  vitro  in  slices  (Kang  et  al.,  2007),  and  ATP-sensitive  K
+ 
channels in brainstem neurons maintained in vitro in slices (Mironov  &  Langohr, 
2007).  While  the  former  two  studies  investigated  this  at  the  level  of  NO  donors, 
cGMP analogues, and NOGC receptor inhibition only, Mironov & Langohr (2007) also 
tested the effect of two different NO scavengers and a broad-spectrum NOS inhibitor. 
They found that exogenous NO suppressed spontaneous synaptic currents, activated 
K
+  channels,  and  inhibited  L-type  Ca
2+  channels,  inhibition  of  endogenous  NO 
synthesis having the opposite effect. An in vivo example of NO acting in an inhibitory 
manner is derived from work in the cat visual cortex, where inhibition of endogenous 
NO  levels  caused  an  increase  in  the  responses  to  visual  stimuli  in  a  small  (5%) 
population of cells (Cudeiro et al., 1997). 
 
NO has also been shown to dis-inhibit by reducing GABAergic transmission, thereby 
acting in an excitatory manner indirectly. For example, in the cerebellum, endogenous 
NO appears to reduce GABA release from Golgi cells by tonically hyperpolarising 
them, possibly through mediating the opening of large conductance Ca
2+-activated K
+ 
channels (Wall, 2003). Also, GABAA-mediated currents in cerebellar granule cells, 
which are innervated by GABAergic Golgi cells, appear to be tonically suppressed by 
NO through a PKG-dependent mechanism (Robello et al., 1996). The overall result of 
this NO-mediated effect is dis-inhibition of granule cell activity due to the negative 
effect on GABAergic tone.  
 
In the rat ventrobasal and lateral geniculate nucleus of the thalamus, exogenous NO or 
application of a cGMP analogue were found to depolarise neurons in vitro, and to 
enhance neuronal responses to whisker or light stimulation respectively, as well as to 
ionotropic glutamate receptor activation in vivo, indicating that NO enhances sensory 
transmission through the thalamus (Shaw et al., 1999). An enhancing effect of NO has 
also been observed in the visual cortex, where inhibition of endogenous NO levels 
was found to lead to decreases in the responses to visual stimuli in a population (38%) 
of cells, while protocols enhancing NO levels endogenously or exogenously caused an 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
 
  85
increase in the number of action potentials in response to visual stimuli (Cudeiro et 
al.,  1997;  Kara  &  Friedlander,  1999).  In  rat  medial  vestibular  nucleus  neurons 
maintained in vitro in brain stem slices, the NO-cGMP pathway was shown to cause 
depolarisation and increase their spontaneous discharge rate via activation of CNG 
channels  (Podda  et  al.,  2004;  Podda  et  al.,  2008).  Nitric  oxide-cGMP-mediated 
depolarisation has also been observed in vitro in a number of different central neurons 
via HCN channel modulation (see above). Another possible route for NO to modulate 
excitation in a facilitating manner has been proposed to be via suppression of K
+ 
conductances. For instance, intracellular recordings from rat striatal neurons in vivo 
revealed NO, perhaps derived from local nNOS-bearing interneurons, to modulate the 
spontaneous up- and down-state membrane activity and synaptic responses (West & 
Grace,  2004).  This  study  demonstrated  that  NO  causes  membrane  depolarisation 
probably by cGMP-mediated suppression of K
+ currents, with the ultimate net effect 
of enhanced EPSPs. Pharmacological disruption of NO-NOGC receptor signalling by 
means of infusion of a NO scavenger, nNOS inhibitor, or ODQ, on the other hand, 
was  found  to  reduce  neuronal  responsiveness  associated  with  membrane 
hyperpolarisation.  
 
Direct excitatory effects of NO on synaptic transmission could also be based on NO-
cGMP-PKG-dependent augmentation of glutamate release by potentiating Ca
2+ entry 
through  presynaptic  N-type  Ca
2+  channels,  as  has  been  demonstrated  in  rostral 
ventrolateral  medulla  neurons  in  brainstem  slices  (Huang  et  al.,  2003).  Another 
potential  mechanism  in  NO-modulated  transmitter  release  has  been  suggested  to 
involve  inhibition  of  presynaptic  voltage-gated  K
+  channels,  including  Kv1.1  and 
Kv1.2 subtypes, a mechanism reported to be involved in potentiating GABA release 
to  PVN  neurons  (Yang  et  al.,  2007).  Paradoxically,  also  NO-cGMP-mediated 
activation  of  K
+  channels  has  been  found  to  facilitate  neurotransmitter  release.  In 
peptidergic  nerve  terminals  of  the  posterior  pituitary,  NO-cGMP-PKG-mediated 
enhancement of Ca
2+-activated K
+-channels activity at depolarised potentials has been 
found  to  facilitate  transmitter  release.  This  is  suggested  to  be  associated  with 
increased action potential afterhyperpolarisation, which in turn facilitates the recovery 
of Na
+ channels from their inactivated state, ultimately reducing the rate of action 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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potential  failure.  This  in  turn  would  allow  more  Ca
2+  influx  and  consequently 
increased neuropeptide release (Klyachko et al., 2001). 
 
1.5.3   Long-term modulation of neuronal function 
 
The  function  of  NO  in  the  CNS  that  has  been  studied  most  extensively  is  its 
involvement  in  synaptic  plasticity.  This  is  an  activity-dependent  process  in  which 
neurons undergo long-term adjustments in the strength of their synaptic connections 
either in the ‘upward’ or ‘downward’ direction in response to brief periods of altered 
input.  These  processes  are  known  as  long-term  potentiation  (LTP)  and  long-term 
depression (LTD) respectively, and are commonly proposed to be a cellular correlate 
of learning and memory (Bliss & Collingridge, 1993; Neves et al., 2008; Nader & 
Hardt, 2009). In LTP, the correlated firing of the pre- and postsynaptic neuron leads 
to  an  increase  in  the  efficiency  of  synaptic  transmission  as  such  that  subsequent 
presynaptic  activity  is  able  to  exert  a  stronger  influence  on  the  firing  of  the 
postsynaptic neuron. Since the first observation of LTP at the perforant path/granule 
cell synapse in the rabbit hippocampus following brief high frequency stimulation 
(Bliss & Lomo, 1973), this structure in the medial temporal lobe became the dominant 
model  of  this  process,  with  intense  research  aiming  to  elucidate  the  molecular 
mechanisms of synaptic plasticity. Nonetheless, LTP is not a phenomenon restricted 
to that brain region, but has – just as the reciprocal phenomenon to LTP, namely LTD, 
which has been most extensively described in the cerebellum – also been observed in 
other brain regions. The NO-cGMP pathway has been proposed to be involved in LTP 
in the hippocampus, cerebral cortex, cerebellum, amygdala, and the spinal cord, as 
well as in LTD in the cerebellum and the striatum. There has been much controversy 
in  the  vast  research  field  of  NO  in  synaptic  plasticity,  but  one  well-accepted 
hypothesis is that NO may act pre- and/or postsynaptically. This section will outline 
features of NO in LTP and LTD in the light of the hippocampus and the cerebellum 
respectively. 
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NO and LTP 
 
The  involvement  of  NO  in  LTP  has  been  extensively  studied  at  the  Schaffer 
collateral/CA1  synapse  in  the  hippocampus.  Following  the  establishment  that  this 
involved postsynaptic NMDA receptors, in combination with NO’s properties (i.e. 
association with NMDA receptor activation and diffusibility), NO became implicated 
in a scheme where NMDA receptor-mediated Ca
2+ influx activates nNOS leading to 
postsynaptic NO formation, which then diffuses as a retrograde messenger across the 
synaptic cleft to activate its receptor in the presynaptic terminal, ultimately thought to 
converge on changes in neurotransmitter release (Garthwaite & Boulton, 1995).  
Initial evidence showing that NO can augment neurotransmitter release came 
from experiments on cultured hippocampal neurons, finding that a low nanomolar 
concentration  of  exogenous  NO  increases  the  frequency  of  spontaneous  miniature 
EPSPs,  while  bath  application  of  the  membrane-impermeable  haemoglobin  to 
scavenge NO, or postsynaptic injection of a NOS inhibitor, prevented LTP (O’Dell et 
al.,  1991).  A  number  of  subsequent  studies  have  supported  the  proposition  that 
presynaptic NO signalling involves NOGC receptor activation, cGMP accumulation, 
and  PKG  activation.  Evidence  supporting  a  presynaptic  localisation  of  the  cGMP 
response  came  from  studies  on  NMDA  receptor-dependent  LTP  between  pairs  of 
cultured hippocampal pyramidal neurons, finding that injection of cGMP only into the 
presynaptic  neuron  is  sufficient  to  facilitate  activity-dependent  LTP  alongside  an 
increase in miniature EPSPs, while inhibition of NOGC receptors or PKG prevented 
the induction of LTP (Arancio et al., 1995). This paralleled further experiments, using 
the same preparation, showing that tetanus-evoked LTP is prevented by injection of a 
NO  scavenger  into  pre-  or  postsynaptic  neurons,  while  under  conditions  of 
simultaneous  NO  application  and  tetanic  stimulation  the  LTP  was  only  prevented 
when the scavenger was injected into the presynaptic neuron. Additionally, tetanus-
induced LTP was prevented upon injection of a NOS inhibitor into the postsynaptic 
neuron,  but  not  the  presynaptic  neuron  (Arancio  et  al.,  1996).  A  predominant 
involvement  of  PKG  in  presynaptic  signalling  was  first  proposed  based  on  the 
detection  of  PKGI  in  presynaptic  terminals,  demonstrated  to  co-localise  with  the 
vesicle  protein  synaptophysin  (Arancio  et  al.,  2001).  Studying  NMDA  receptor-1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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dependent  LTP  between  pairs  of  cultured  hippocampal  neurons,  the  same  study 
reinforced the concept of presynaptic NO-cGMP signalling via PKG based on the 
observation  that  injection  of  purified  PKGIa  protein  or  a  PKG  inhibitor  into  the 
presynaptic  neuron  respectively  facilitates  or  prevents  LTP  induced  by  a  weak 
tetanus. At odds with these findings are results from studies in hippocampus-specific 
PKGI knockout mice, reporting not only normal LTP in juvenile animals (4-6 weeks) 
and  reduced  LTP  in  older  animals  (12  weeks),  but  also  normal  hippocampus-
dependent  learning  of  the  older  mice  in  contextual  fear  conditioning  and  spatial 
learning in a water maze (Kleppisch et al., 2003).  
 
There are a number of mechanisms suggested to underlie NO-mediated modulation of 
transmitter release, including changes in the mode of vesicle fusion, the number of 
vesicles  released  in  response  to  afferent  stimulation,  and  vesicle  recycling.  PKG 
targets  suggested  to  link  the  cGMP  signal  to  vesicle  function  include  the 
Ca
2+/calmodulin-dependent protein kinase II (CaMKII) and the vasodilator-stimulated 
phosphoprotein  (VASP).  The  possible  presynaptic  function  of  CaMKII  in  this 
scenario was provided by a study in cultured hippocampal neurons, demonstrating 
that  presynaptic  injection  of  a  membrane-impermeable  CaMKII  inhibitor  peptide 
prevented LTP in response to weak tetanic stimulation, glutamate, an NO donor, or 
PKG  activator,  while  presynaptic  injection  of  CaMKII  itself  paired  with  tetanic 
stimulation  evoked  LTP  in  the  presence  of  a  NOS  or  PKG  inhibitor  (Ninan  & 
Arancio, 2004). However, this is at great odds with a study investigating hippocampal 
slices  from  mutant  mice  lacking  the  dominant  CaMKII  a  isoform  selectively  in 
presynaptic CA3 neurons of the Schaffer collateral pathway, reporting an inhibitory 
rather than stimulatory function of CaMKII in activity-dependent transmitter release 
(Hinds et al., 2003).  
It  is  suggested  that  activity-dependent  potentiation  is  accompanied  by 
cytoskeletal changes at the presynaptic site, comprising a rapid increase in clusters of 
the vesicular proteins synaptophysin and synapsin I (Antonova et al., 2001; Wang et 
al., 2005). In these latter studies, at synapses between pairs of cultured hippocampal 
neurons, application of glutamate was shown to induce NO-dependent clustering of 
both pre- and postsynaptic proteins. A regulator of actin dynamics, namely VASP, has 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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been implicated as a downstream target of cGMP-PKG signalling, suggested to be a 
critical component in activity-dependent changes in transmitter release. It has been 
found in cultured hippocampal neurons that VASP appears to be an endogenous PKG-
substrate and that PKG-dependent VASP-Ser-239 phosphorylation is important in the 
induction of LTP, all necessary components (i.e. NOGC receptors, PKGI, and VASP) 
being expressed in presynaptic terminals (Arancio et al., 2001; Wang et al., 2005). 
Finally, a different set of work in cultured hippocampal neurons that monitored exo- 
and endocytosis in the neurons by means of fluorescence imaging suggested that NO 
promotes  synaptic  vesicle  recycling  in  an  activity-dependent  manner,  the  NMDA 
receptor-dependent production of NO accelerating vesicle endocytosis in a cGMP-
dependent manner (Micheva et al., 2001; Micheva et al., 2003).  
There  is  also  evidence  suggesting  routes  for  enhanced  transmitter  release 
independent  of  PKG.  Experiments  on  cone/horizontal  cell  synapses  in  culture 
indicated that exocytosis can also be triggered by cGMP-evoked Ca
2+ influx through 
CNG  channels  (Savchenko  et  al.,  1997).  CNG  channels  are  expressed  in  the 
hippocampus in cell bodies and processes of CA1 and CA3 neurons, and therefore 
they may serve as transducers that link activity-dependent generation of cGMP in the 
presynaptic terminal to increases in transmitter release (Kingston et al., 1996; Bradley 
et al., 1997). In support of this latter notion is the finding of reduced LTP in the 
Schaffer collateral pathway recorded in hippocampal slices from mice with disrupted 
CNG channels (Parent et al., 1998). 
 
In  addition  to  its  presynaptic  action,  NO  may  also  act  postsynaptically.  While 
postsynaptic NMDA receptor activation requires glutamate release into the synaptic 
cleft and membrane depolarisation in order to be relieved of their Mg
2+ block, fast 
excitatory transmission in the CNS is mediated by AMPA receptors. It has emerged 
that activity-regulated AMPA receptor trafficking represents an additional mechanism 
for  the  modification  of  synaptic  strength.  Initial  evidence  came  from  studies  in 
cultured hippocampal neurons, reporting an increase in the amplitude of EPSPs in 
response to brief applications of glutamate, associated with an increase in the number 
of  postsynaptic  protein  clusters  containing  the  GluR1  subunit  of  AMPA  receptors 
(Antonova et al., 2001), which was later demonstrated to be replicable upon exposure 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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to a cGMP analogue and dependent on PKG (Wang et al., 2005). A recent study in 
cultured  hippocampal  neurons  and  adult  mouse  hippocampal  slices  suggested  that 
cGMP  regulates  AMPA  receptor  trafficking  and  subunit  composition  via  PKGII 
(Serulle et al., 2007). These authors reported PKGII and GluRI to co-localise and 
interact in a cGMP-dependent manner, resulting in the phosphorylation of the Ser-845 
residue of the GluRI, ultimately leading to an increase of AMPA receptor surface 
expression at extrasynaptic sites. Impediment of phosphorylation by mutating the Ser-
845 residue prevented the surface increase. Serulle and colleagues (2007) found the 
increase in AMPA receptors and the associated enhancement in synaptic strength to 
occur in response to exogenous NO as well as NMDA receptor activation in a NOS-, 
NOGC receptor-, and PKG-dependent manner. Also, additionally to the data obtained 
in  cultured  neurons,  the  authors  demonstrated  a  reduction  in  LTP  in  slices  upon 
PKGII inhibition by a PKGII inhibitor peptide. 
  There is also evidence in terms of postsynaptic NO-cGMP actions regarding 
the regulation of gene expression. It has been reported that transcription via cAMP-
response-element-binding protein (CREB) can be activated in a NO-cGMP-dependent 
manner in the hippocampus (Lu et al., 1999;  Lu  & Hawkins, 2002;  Chien et al., 
2003). These studies, employing protein analysis by means of Western blotting and 
immunofluorescence in slice preparations, showed that CREB in postsynaptic CA1 
cell  somata  is  phosphorylated  via  the  NO-cGMP-PKG  pathway.  The  complete 
signalling  cascade  for  cGMP-mediated  activation  of  CREB-regulated  gene 
transcription remains to be clarified, but a mechanism involving Ca
2+ release from 
ryanodine-sensitive stores has been proposed (Lu & Hawkins, 2002). Additionally, 
the possibility has been put forward that the cognitive decline in Alzheimer’s disease 
might,  at  least  partially,  result  from  inhibition  of  hippocampal  cGMP-CREB-
interaction by amyloid-b peptide (Puzzo et al., 2005). Puzzo and co-workers found in 
their experiments on hippocampal slices that application of low micromolar NO donor 
concentrations, a cGMP analogue, or an allosteric NOGC receptor activator, protects 
against the impairment of LTP that is caused by exposure to amyloid-b in a PKG-
dependent manner. Additionally, the authors demonstrated that amyloid-b prevents 
tetanus-induced  phosphorylation  of  CREB  in  CA1  cell  somata,  which  could  be 
rescued  by  NO  in  a  cGMP-dependent  manner,  as  well  as  by  PKG  activation,  the 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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amyloid-b possibly directly interfering with the NO-cGMP pathway as it prevented 
tetanus-evoked cGMP elevation.  
 
Investigations using genetic approaches to study the importance of endogenous NO in 
LTP have yielded incoherent results. For example, mice lacking eNOS or nNOS were 
demonstrated to exhibit normal hippocampal LTP, while double knockouts lacking 
both NOS isoforms showed impaired LTP in the stratum radiatum containing CA1 
pyramidal apical dendrite/CA3 axon synapses with no gross anatomical abnormalities 
and the reduction in LTP being quantitatively similar to that observed upon exposure 
to a broad-spectrum NOS inhibitor in wild-type mice (Son et al., 1996). Others found 
impaired  LTP  in  eNOS  knockouts  (Kantor  et  al.,  1996;  Wilson  et  al.,  1999).  An 
important role of eNOS was suggested as disrupting the localisation of eNOS to the 
cell membrane impaired LTP, which could be overcome by expressing a chimeric 
form of the eNOS constitutively targeted to the cell membrane (Kantor et al., 1996). 
Complications may arise in nNOS knockouts due to the upregulation of active splice 
variants of the enzyme (Eliasson et al., 1997; and see above). In eNOS knockout 
mice, disruptions in other second messenger pathways may make data interpretation 
difficult,  as  indicated  by  studies  of  the  mossy  fibre  synapse  in  the  dentate  gyrus 
(Doreulee et al., 2001). On the other hand, there is the implication that endogenous 
NO generated from both nNOS and eNOS play their part in LTP. NO appears to 
function not only as an acute signalling molecule that is evoked during the triggering 
of LTP, but also a tonic one (Bon & Garthwaite, 2003). Recently, it has been revealed 
that LTP induction at the Schaffer collateral/CA1 synapse requires both a tonic, low 
level  eNOS-derived  NO  as  well  as  activity-evoked  phasic  nNOS-generated  NO 
(Hopper & Garthwaite, 2006). However, the precise roles of these two distinct NO 
signals remain to be uncovered.  
Recent studies using genetic approaches have also explored the endogenous 
pathway at the level of NOGC receptors. Mice lacking either the a1 or a2 subunit of 
the NOGC receptor were shown to have reduced LTP in visual cortical slices, which 
could be restored in both strains by exposure to a cGMP analogue (Haghikia et al., 
2007). Also hippocampal LTP, recorded in slices from mice lacking either the a1 or 
a2 subunit of the NOGC receptor, is abolished in both knockout strains (Taqatqeh et 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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al., 2009). Taqatqeh and colleagues (2009) also provided indication for a presynaptic 
role of the a1b1 isoform of the NOGC receptor in neurotransmitter release, observing 
increased paired-pulse ratios in mice lacking the a1 subunit. 
 
NO and LTD 
 
LTD has been best characterised in the cerebellum, where the large dendritic tree of 
an individual Purkinje cell in the molecular layer of the cerebellar cortex receives 
excitatory inputs from a single climbing fibre and many parallel fibres originating 
from the granule cells in the granular layer. This form of plasticity is evoked when the 
parallel fibres are repeatedly activated simultaneously with the climbing fibre that 
converges onto the same Purkinje neuron, leading to postsynaptic Ca
2+ rises, and is 
thought  to  underlie  specific  forms  of  motor  learning  such  as  adaptation  of  the 
vestibulo-ocular  reflex,  which  keeps  images  stable  on  the  retina  during  head 
movements (Ito, 2001).  
 
A  string  of  studies  have  implicated  NO-cGMP  signalling  in  this  process.  The 
prevention  of  LTD  induction  was  demonstrated  in  cerebellar  slices  upon  NOS  or 
NOGC receptor inhibition, substituting NO or applying cGMP analogues restoring it 
(Boxall & Garthwaite, 1996; Lev-Ram et al., 1997). Here, NO is thought to act as an 
anterograde  messenger  that  is  produced  upon  repetitive  activity-evoked  NMDA 
receptor  activation  on  presynaptic  parallel  fibres  or  liberated  from  interneurons 
(Casado et al., 2002; Shin & Linden, 2005), and then evokes postsynaptic LTD via 
stimulating a cGMP-dependent signalling pathway in the postsynaptic cell (Boxall & 
Garthwaite, 1996; Ito, 2001). As mentioned earlier, Purkinje cells are rich in PKGIa, 
and  it  is  this  downstream  effector  of  cGMP  that  is  thought  to  play  a  key  role  in 
cerebellar  LTD.  Inhibition of PKG was shown  to impair  LTD in cerebellar slices 
(Hartell, 1994; Lev-Ram et al., 1997), which was consistent with the later finding that 
mice with a Purkinje neuron-specific disruption of the PKGI gene exhibit abolished 
LTD  recorded  in  acute  slice  preparations  (Feil  et  al.,  2003).  Additionally,  these 
mutants were found to show marked deficits in their adaptation of the vestibulo-ocular 
reflex, while exhibiting normal general motor performance as assessed by foot print 1 1 1            G G Ge e en n ne e er r ra a al l l    i i in n nt t tr r ro o od d du u uc c ct t ti i io o on n n    
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patterns and the runway tests. The possibility of this specific phenotype arising due to 
structural  or  physiological  abnormalities  has  been  ruled  out  based  on  the 
demonstration that the Purkinje neurons in these mutants have normal climbing fibre 
innervations as revealed by normal dendritic Ca
2+ signals in the Purkinje cells upon 
climbing  fibre  stimulation,  without  any  notable  morphological  changes  of  the 
cerebellar cortex in general (Feil et al., 2003). 
 
Reciprocally to what has been suggested in LTP, in LTD the rapid internalisation of 
AMPA receptors has been proposed to contribute to the expression of cerebellar LTD 
(Wang  &  Linden,  2000).  LTD  induction  is  thought  to  comprise  an  increase  in 
postsynaptic  endocytosis  of  GluR2-containing  AMPA  receptors,  a  process  that  is 
proposed to involve phosphorylation of the Ser-880 residue of the GluR2 by protein 
kinase C (Wang & Linden, 2000; Chung et al., 2003). A central role of the GluR2 
subunit in this respect was highlighted by the finding that LTD is absent in cultured 
cerebellar Purkinje neurons from mice lacking this AMPA receptor subunit, which 
could, however, be rescued by transiently transfecting the cells with the wild-type 
GluR2  subunit  (Chung  et  al.,  2003).  An  alternative  mechanism  suggested  for 
enhanced  AMPA  receptor  phosphorylation  and  consequent  removal  from  the 
postsynaptic membrane is reduced phosphatase activity. Cerebellar Purkinje cells are 
rich in the PKG-target protein G-substrate, which is a phosphatase inhibitor (Detre et 
al., 1984; Hall et al., 1999; Endo et al., 1999). Phosphorylation of G-substrate via the 
cGMP-PKGI  cascade  has  been  shown  to  suppress  the  activity  of  the  protein 
phosphatases 1C and 2A (Hall et al., 1999), inhibition of the latter having been found 
to lead to enhanced AMPA-GluR2 phosphorylation in cultured cerebellar neurons, in 
turn causing endocytosis of the receptors and reduced synaptic currents in a manner 
that occludes subsequent induction of LTD (Launey et al., 2004). 
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1.6   GENERAL AIMS OF THIS WORK 
 
Previous data obtained in the optic nerve pointed to a potential mechanism of vasculo-
neuronal communication involving eNOS (Garthwaite et al., 2006). The aim was to 
further test the involvement of eNOS and to investigate the underlying mechanism for 
the maintenance of tonic NO synthesis in the rat optic nerve, assessing the role of the 
PI3 kinase-Akt pathway, which is thought to be one of the key mechanisms for tonic 
eNOS  stimulation.  Previous  work  has  indicated  tonic  eNOS-derived  NO  to  be  a 
requisite for LTP induction in the hippocampus (Hopper & Garthwaite, 2006). The 
subsequent aim was to determine if blood vessel-neuron communication may be more 
widespread, investigating further if a PI3 kinase-dependent mechanism also accounts 
for basal NO production in the rat hippocampus.  
Taking advantage of the now available pharmacological tools, the following 
objective  was  to  re-investigate  the  targets  for  NO  in  the  hippocampus  based  on 
inconsistencies regarding NOGC receptor expression versus cGMP accumulation and 
functional implications in this brain region.  
The lack of information about endogenous NO and cGMP signals is a major 
deficit in the current understanding of this signalling pathway. A final objective of the 
present work was to begin to analyse NO transduction in cells in real-time combined 
with  steady-state  delivery  of  NO  at  physiological  concentrations,  using  a  newly 
developed fluorescent cGMP sensor (Nausch et al., 2008) transfected into cell lines 
expressing various levels the NOGC receptor and phosphodiesterase. 
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2.1   MATERIALS 
 
2.1.1   Reagents 
 
Pharmacological agents 
 
Table 2.1: Overview of pharmacological compounds utilised 
 
 
Compound 
 
 
Abbreviation 
 
Action  
 
Solubility 
 
Source 
Acetylcholine chloride  ACh   Cholinergic agonist  10 mM Stock in 
dH2O 
Sigma 
D-(-)-2-Amino-5-
phosphonopentanoic acid 
D-AP5  NMDA receptor 
antagonist 
20 mM Stock in 
dH2O 
Tocris 
(Z)-1-[N-(3-Ammoniopropyl)-
N-(n-propyl)-amino]/NO 
PAPA/NO  NO donor  10 mM Stock in  
10 mM NaOH 
Axxora 
[R-(R*,S*)]-5-(6,8-Dihydro-8-
oxofuro[3,4-e]-1,3-benzodioxol-
6-yl)-5,6,7,8-tetrahydro-6,6-
dimethyl-1,3-dioxolo[4,5-
g]isoquinolinium chloride 
Bicuculline 
 
GABAA receptor 
antagonist 
100 mM Stock in 
DMSO 
Tocris 
Bradykinin acetate  BK  Bradykinin receptor 
agonist 
1 mM Stock in dH2O  Sigma 
Cadmium sulfate 8/3-hydrate  Cd
2+  Non-selective Ca
2+ 
channel blocker 
20 mM Stock in 
dH2O 
Sigma 
2-(4-Carboxyphenyl)-4,4,5,5-
tetramethylimidazoline-1-oxyl-
3-oxide . potassium salt 
CPTIO  NO scavenger  100 mM Stock in  
dH2O 
Axxora 
(2S)-3-[[(1S)-1-(3,4-
Dichlorophenyl)ethyl]amino-2-
hydro 
xypropyl](phenylmethyl)phosphi
nic acid 
CGP 55845  GABAB receptor 
antagonist 
10 mM Stock in 
DMSO 
Tocris 
6-Cyano-7-nitroquinoxaline-2,3-
dione 
CNQX  AMPA/Kainate 
receptor antagonist 
10 mM Stock in 
DMSO 
Tocris 
2-(N,N-Diethylamino)-
diazenolate-2-oxide 
diethylammonium salt 
DEA/NO  NO donor  10 mM Stock in  
10 mM NaOH 
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[2-(3,4-dimethoxybenzyl)-7-
[(1R)-1-[(1R)-1-hydroxyethyl]-
4-phenylbutyl]-5-
methylimidazo[5,1-
f][1,2,4]triazin-4(3H)-one 
BAY 60-7550  PDE2 inhibitor  1 mM Stock in 
DMSO  
Axxora 
4-Ethylphenyl-amino-1,2-
dimethyl-6-
methylaminopyrimidinium 
chloride 
ZD 7288  HCN channel blocker  10 mM Stock in 
dH2O 
Tocris 
Forskolin  -  AC activator  10 mM Stock in 
DMSO 
Tocris 
Gadolinium(III) chloride 
hexahydrate 
Gd
3+  TRP channel blocker  10 mM Stock in 
DMSO 
Sigma 
HOE-140  -  Bradykinin B2 receptor 
antagonist 
1 mM Stock in dH2O  Sigma 
1-Hydroxy-2-oxo-3-(N-ethyl-2-
aminoethyl)-3-ethyl-1-triazene 
NOC-12  NO donor  10 mM Stock in  
10 mM NaOH 
Axxora 
3-Isobutyl-1-methylxanthine  IBMX  Non-selective PDE 
inhibitor  
(except PDE 9) 
1 mM final 
concentration 
dissolved in aCSF 
Sigma 
Lanthanum(III) chloride 
heptahydrate 
La
3+  TRP channel blocker  20 mM Stock in 
DMSO 
Sigma 
N-Methyl-D-aspartic acid  NMDA  NMDA receptor agonist  10 mM Stock in 
dH2O 
Tocris 
N
G-Monomethyl-L-arginine 
acetate 
L-MeArg  Non-selective NOS 
inhibitor 
10 mM Stock in 
dH2O 
Tocris 
2-(4-Morpholinyl)-8-phenyl-4H-
1benzopyran-4-one 
hydrochloride 
LY 294002  PI3K inhibitor  20 mM Stock in 
DMSO 
Tocris 
N
G-Nitro-L-arginine  L-NNA  Non-selective NOS 
inhibitor 
10 mM Stock in 10 
mM HCl 
Tocris 
1H-[1,2,4]Oxadiazolo[4,3-
a]quinoxalin-1-one 
ODQ  NOGC receptor inhibitor  10 mM Stock in 
DMSO 
Sigma 
Phenylmethanesulphonylfluoride 
or phenylmethylsulphonyl 
fluoride 
PMSF  Protease inhibitor  100x Stock made in 
DMSO 
 
N-Propyl-L-arginine  NPA  nNOS inhibitor  10 mM Stock in 
DMSO 
Axoora 
SKF 96365 hydrochloride  -  TRP channel blocker  10 mM Stock in 
dH2O 
Tocris 
Superoxide dismutase (from 
bovine erythrocytes) 
SOD  Catalyses the 
dismutation of 
100K U/ml Stock in 
dH2O 
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superoxide radicals to 
hydrogen peroxide and 
molecular oxygen 
Tetrodotoxin  TTX  Na
+ channel blocker  Soluble in acetic acid   Latoxan 
Uric acid  -  Endogenous 
antioxidant; converts 
NO2 into NO2
-
 
30 mM Stock in  
60 mM NaOH 
Sigma 
Vinyl-N-5-(1-imino-3-butenyl)-
L-ornithine 
L-VNIO  nNOS inhibitor  10 mM Stock in 
dH2O 
Axxora 
Wortmannin   -  PI3K inhibitor  1 mM Stock in 
DMSO 
Sigma 
 
Other reagents 
 
Table 2.2: Overview of other reagents used 
 
 
Compound 
 
 
Abbreviation 
 
Source 
Bicinchoninic acid Protein assay kit  BCA kit  Perbio 
Bovine serum albumin (fraction V)  BSA  Sigma 
Cyclic adenosine monophosphate (
3H) 
biotrak assay  
3H-cAMP kit  GEHealth-
care 
Chromium potassium sulfate   -  Sigma 
3,3’-Diaminobenzadine tablets  DAB  Sigma 
Dimethyldichlorosilane solution (for coating)  DMDS  Sigma 
Dimethyl sulfoxide   DMSO  Sigma 
Donkey serum  -  Chemicon 
DPX mounting medium  -  VWR 
Dulbecco’s Modified Eagle Medium (1x), 
High Glucose 
DMEM, high glucose  Invitrogen 
Dulbecco’s Phosphate Buffered Saline (1x)  D-PBS  Invitrogen 
Ethylenediaminetetraacetic acid disodium  EDTA  Sigma 
Ethylene glycol-bis(2-aminoethylether)-
N,N,N’,N’-tetra-acetic acid  
EGTA  Sigma 
Foetal Bovine Serum (Heat inactivated)  FBS  Invitrogen 
Gelatine powder (for coating)  Gelatine  Sigma 
Geneticin Selective Antibiotic (G-418 
Sulfate) 
G-418  Invitrogen 
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Glycine  -  Sigma 
Hygromycin B  -  Invitrogen 
Hydrogen peroxide   H2O2  Sigma 
Magermilchpulver (dried milk)   -  VWR 
MEM Non Essential Amino Acids  MEM-NEAAs  Invitrogen 
OCT embedding medium  OCT  Lamb 
Paraformaldehyde  PFA  Sigma 
Peroxidase suppressor   PS  Perbio 
Poly-D-Lysine  PDL  Sigma 
Sodium bisulfite  -  Sigma 
Sodium dodecyl sulphate  SDS  VWR 
Tris-hydrochloric acid   Tris-HCl  Calbio-
chem 
Tritiated cyclic guanosine monophosphate 
3H-cGMP  Amers-ham 
(GEHealthc
are) 
Trizma base   Tris base  Sigma 
Triton X-100  Triton  Sigma 
Trypsin, 0.05% with EDTA  Trypsin  Invitrogen 
Tween 20  Tween  Sigma 
Vectashield mounting medium with 4’,6’-
diamidino-2-phenylindole 
DAPI  Vector 
Vectastain Elite ABC complex  ABC reagent  Vector 
Zeocin Selection Reagent  Zeocin  Invitrogen 
 
Note: All standard reagents (including salts used for aCSF and other solutions) were 
obtained from BDH (VWR) unless otherwise stated. 
 
Antibodies 
 
Table 2.3: Overview of antibodies:  
 
Primary Antibodies 
Antigen  Host  Dilution  Source 
cGMP  Sheep  1 : 40 000  Gift from Dr. J. de Vente 
(Maastrich, Netherlands) 
CNPase  Mouse  1 : 2000  Chemicon 
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GCβ1  Rabbit  1 : 500  Cayman 
GFAP  Rabbit  1 : 1000  Chemicon 
NeuN  Mouse  1 : 1200  Chemicon 
NF 200  Mouse  1 : 500  Chemicon 
nNOS  Rabbit  1 : 500  Zymed 
eNOS (for Western blot)  Rabbit  1 : 1000  BD Biosciences 
Phospho-eNOS (Ser1179) 
(for Western blot) 
Rabbit  1 : 2000  New England Biolabs 
Secondary Antibodies 
Antigen  Host  Tag  Dilution  Source 
Mouse   Donkey  Alexa 594  1 : 600  Invitrogen 
Rabbit  Donkey  Alexa 594  1 : 1500  Invitrogen 
Rabbit   Donkey  Biotin  1 : 200  Chemicon 
Sheep  Donkey  Alexa 488  1 : 1000  Invitrogen 
Rabbit 
(for Western blot) 
Goat  Horseradish 
peroxidase 
conjugated 
1 : 25 000  Perbio 
 
Suppliers key 
 
Axxora      Axxora  Ltd  (Alexis  Biochemicals),  Nottingham,  UK 
Calbiochem      Calbiochem (Merck Chemicals Ltd), Nottingham, UK 
Cayman      IDS Ltd (Cayman Chemical), Tyne & Wear, UK 
Chemicon      Chemicon Europe Ltd, Hampshire, UK 
GEHealthcare     GE Healthcare (Amersham Bioscience), Bucks, UK 
Invitrogen      Invitrogen Ltd, Paisley, UK 
Lamb        Raymond A Lamb Ltd, Eastbourne, UK 
Latoxan      Latoxan Laboratories, Rosans, France 
New England Biolabs   New England Biolabs (Cell signalling technology, Inc.) 
        3 Trask Lane, Danvers, MA 01923, USA 
Perbio       Perbio Science UK Ltd, Northumberland, UK 
Sigma       Sigma-Aldrich Company Ltd, Poole, Dorset, UK 
Tocris        Tocris Cooksen Ltd, Avonmouth, Bristol, UK 
Transduction  BD  Transduction  Laboratories  (BD  Biosciences), 
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Vector       Vector Labs Ltd, Peterborough UK 
VWR        VWR International, Dorset, UK   
Zymed       Zymed Laboratories Inc, San Francisco, CA, USA 
 
2.1.2   NO donors 
 
Stock solutions at 10 mM were prepared freshly each day of experimentation in 10 
mM NaOH, and kept on ice until use. The NO donors used are members of the 1-
substituted  diazen-1-ium-1,2-diolate  (NONOate)  class  of  compounds  that  generate 
authentic  NO  at  predictable  rates  (Keefer  et  al.,  1996).  These  compounds  have 
different half-lives and were chosen according to the timeframe requirements of the 
experiment.  
 
Table 2.4: NO donor compounds 
 
Donor            Structure                  Half-life (pH 7.4; 37ºC) 
 
 
PAPA/NONOate                 15 mins 
                                        
 
 
 
DEA/NONOate                  2 mins 
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NOC-12                  100 mins 
       
 
 
 
2.2   GENERAL SOLUTIONS 
 
2.2.1   Artificial cerebral spinal fluid (aCSF) 
 
Was  composed  of  the  following  (in  mM):  NaCl  (120),  KCl  (2.0),  MgSO4  7H2O 
(1.19), NaHCO3 (26.0), KH2PO4 (1.18), CaCl2 (2.0) and glucose (11.0); the aCSF was 
equilibrated with 95% O2 / 5% CO2; pH (37ºC) = 7.4. 
 
2.2.2   Reagents used in cGMP radioimmunoassay 
 
Inactivation buffer 
 
Was  composed  of  Tris-HCl  (50  mM)  and  EDTA  disodium  salt  (4  mM);  pH  was 
adjusted to 7.4 (solution kept at 4°C). 
 
cGMP Standard stock solution (80 nM) 
 
Stocks of 80 µM cGMP (sodium salt) were prepared in inactivation buffer (aliquots 
were kept at -20 ºC); for a working solution the 80 µM stock was diluted 1: 1000 in 
inactivation buffer to give a 80 nM cGMP solution (kept at 4ºC) which was used to 
prepare the standards (standards were diluted down from the 80 nM stock solution in 
inactivation buffer). 
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cGMP blank 
 
Cyclic GMP at 10 µM was prepared in inactivation buffer (aliquots were kept at  
-20ºC and working stock was kept at 4ºC). 
 
[
3H]-cGMP solution 
 
Stock  solutions,  later  diluted  in  inactivation  buffer,  were  prepared  by  diluting  the 
original [
3H]-cGMP supply 1: 1000 in 50% ethanol (aliquots were kept at -20ºC). 
 
cGMP antibody (raised in rabbit; made by Giti Garthwaite) 
 
Antibody  (freeze-dried  kept  at  -80ºC;  reconstituted  in  dH2O)  was  prepared  in 
inactivation buffer containing γ-globulin (132 mg per 17.5 ml inactivation buffer; for 
precipitation purposes). 
 
Ammonium sulphate solution ([NH4]2SO4; saturated) 
 
One litre of dH2O to 390 g ammonium sulphate; stored at 4ºC. 
 
2.2.3   Solutions used for immunohistochemistry 
 
Phosphate buffer (PB) 
 
Stock ‘A’ and stock ‘B’ solutions were prepared; ‘A’ contained 31.2 g NaH2PO4 . 2 
H2O dissolved in 1 L dH2O; ‘B’ contained 35.6 g Na2HPO4 . 2 H2O dissolved in 1 L 
dH2O; a 0.2 M stock of PB solution was prepared adding 95 ml of ‘A’ to 405 ml of 
‘B’; pH was adjusted to 7.4; a 0.1 M stock of PB solution was prepared diluting the 
0.2 M PB solution 1: 2 in dH2O. 
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Tris-buffered saline (TBS) 
 
5.85 g of Tris base (Trizma) was dissolved in 250 ml dH2O; 3.4 ml HCl (37%) was 
added to 200 ml dH2O; 250 ml Tris solution, 192 ml HCl solution and 8.77 g added 
NaCl were combined and topped up to a final volume of 1 L with dH2O; pH was 
adjusted to 7.4. 
 
Tris-buffered saline with Triton (TBST) 
 
TBS with added Triton at 0.1%. 
 
Paraformaldehyde (PFA) fixative (in 0.1 M PB) 
 
To make 4% or 1% fixative, 4 g or 1 g PFA were added to 40 ml dH2O; heated with 
stirrer  to  65ºC;  added  1-2  drops  of  5  M  NaOH  to  clear  the  solution  (filtered  if 
necessary); allowed to cool and made up to 50 ml with dH2O; added 50 ml of 0.2 M 
PB solution to final volume of 100 ml; adjusted pH to 7.4 (stored at 4ºC; never kept 
for longer than a week). 
 
Sucrose solutions 
 
Prepared in 0.1 M PB. 
 
Coating slides for immunohistochemistry 
 
Dissolved 5 g of gelatine in 1 L of hot dH2O; let cool while continuously stirring; 
added 0.5 g chromium potassium sulphate; dipped slides several times in the solution; 
drained and let dry in a dust free warm oven (37-40ºC). 
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2.2.4   Extracellular solutions used for the imaging experiments 
 
Imaging buffer 
 
Was  composed  of  the  following  (in  mM):  NaCl  (136),  KCl  (2.0),  MgSO4  (1.19), 
KH2PO4 (1.18), CaCl2 (1.5) and glucose (5.5), HEPES (10); the pH was adjusted to 
7.4 at 37ºC by adding 5 M NaOH solution (1-1.5 ml). The osmolality was adjusted to 
285 mOsm (± 2).  
 
Clamp buffer 
 
To achieve a constant concentration of NO over a given period of time (Griffiths et 
al., 2003), the following was added to the imaging buffer: CPTIO (100 µM), SOD 
(100 U/ml) and uric acid (300 µM). The broad-spectrum NOS inhibitor L-NNA (30 
µM) was added to inhibit any endogenous NO production. To complete the attainment 
of a clamped NO profile, an NO donor with a long half-life was chosen (in this case 
NOC-12; see below). 
 
2.2.5   Solutions used for Western blotting 
 
SDS PAGE buffer (“Running buffer”) 
 
In a final volume of 1 L dissolved: 3 g Tris-base, 14 g glycine and 1 g SDS in dH2O; 
stored at room temperature. 
 
Transfer buffer (“Blotting buffer”) 
 
In a final volume of 2 L dissolved: 12 g Tris-base and 56 g glycine. Dissolved these in 
just under 2 L of dH2O and add 50 ml methanol. Removed 500 ml to a fresh bottle for 
gel treatments and stored the remainder at 4ºC. Note: this buffer was used for soaking 
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Equilibration buffer 
 
For each gel to be shaken, took 100 ml of transfer buffer and added 0.5 ml triton and  
100 µl of antioxidant (see below). 
 
1000x Antioxidant 
 
Prepared a 10% solution of N’N’-dimethylformamide (DMF) in 5 ml dH2O; dissolved  
1 g of sodium bisulfite in this solution. Frozen in 1 ml aliquots and kept one working 
tube at 4ºC.  
 
10x TBS (diluted to 1x TBS for use) 
 
In a final volume of 1 L dissolved: 24 g Tris-base and 88 g NaCl in dH2O. Added 
approximately 16.5 ml of concentrated HCl for pH 7.2-7.4 (adjusted if necessary). 
 
TBS with detergents (“Washing buffer”) 
 
To 500 ml of 1x TBS added 1 ml of 10% Triton and 2.5 ml of 10% Tween. Note: This 
solution was used to wash the membranes in blotting experiments following antibody 
incubations and in some instances also to dilute antibodies.  
 
Blocking and antibody dilution buffers 
 
5% milk dissolved in 1x TBS were used to block the membranes to prevent non-
specific background binding of the antibodies. The primary antibodies were diluted to 
their  final  concentration  in  1x  TBS  containing 5%  BSA  and  0.075%  Tween.  The 
secondary antibody was diluted to its final concentration in 1x TBS containing 5% 
milk and 0.05% Tween. 
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2.3   METHODS 
 
2.3.1   Protein measurement 
 
Following  homogenisation  of  the  tissue  by  means  of  sonication,  the  protein 
concentrations  of  each  sample  were  determined  by  comparison  to  bovine  serum 
albumin (BSA) standards using the BCA Protein Assay Kit, which is based on the 
reduction of Cu
2+ to Cu
+ in the presence of protein under alkaline conditions. Briefly, 
10 µl of sample or BSA standards (0-100 µg/ml made up from a 1 mg/ml BSA stock; 
all prepared in inactivation buffer) in triplicates was dispensed into a 96-well plate to 
which 200 µl of the BCA reagent was added. The plates were incubated for 30 min at 
37°C, allowed to cool to room temperature followed by measuring the absorbance at 
562 nm using a Spectra Max 250 spectrometer (Molecular devices, California, USA). 
The absorbance over the standard concentration range was linear, from which the 
unknown protein content of the samples was calculated. The remainder of the samples 
was centrifuged at 800 rpm for 10 min at 4°C to pellet the debris, the supernatant used 
for cGMP quantification by means of radioimmunoassay (see below). Samples not 
assayed immediately were kept at -20°C. 
 
2.3.2   Quantitative evaluation of cGMP accumulation –  
radioimmunoassay (RIA) 
 
The  principle  of  RIA  is  based  on  competitive  binding  to  an  antibody  raised 
specifically for cGMP. The test tube will contain a fixed quantity of tritium (
3H)-
labelled cGMP, a fixed amount of antibody for cGMP and an aliquot of unlabelled 
cGMP  (in  this  case  the  supernatant  form  the  tissue  suspension).  The  two  cGMP 
‘species’ will compete for the binding to the antibody and the more cGMP the tissue 
sample contains the less radioactively labelled cGMP will be bound to the antibody, 
which appears as a lower dpm count when reading the samples in the scintillation 
counter (and vice versa). The abbreviation ‘dpm’ stands for disintegrations per minute 2 2 2            G G Ge e en n ne e er r ra a al l l    m m ma a at t te e er r ri i ia a al l ls s s    a a an n nd d d    m m me e et t th h ho o od d ds s s    
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and is the measure for the number of atoms in a quantity of radioactivity that decay 
per minute. Below is an overview of the RIA procedure. 
 
RIA procedure in detail 
 
Standard curve: 
 
Standards were tested in duplicates (18 microfuge tubes required). To 6 (‘A-F’) tubes 
250 µl inactivation buffer were added. To tube ‘A’ 250 µl of cGMP standard stock 
solution was added. From tube ‘A’ it was double diluted down to tube ‘F’ (i.e. 250 µl 
from ‘A’ to ‘B’ containing 250 µl inactivation buffer, 250 µl from tube ‘B’ to ‘C’ 
containing 250 µl inactivation buffer, etc). This series of dilutions gave the following 
amounts of cGMP (pmol/assay tube): 
 
‘A’ = 4 pmol 
‘B’= 2 pmol 
‘C’ = 1 pmol 
‘D’ = 0.5 pmol 
‘E’ = 0.25 pmol 
‘F’ = 0.125 pmol 
   
Tubes 1 + 2 contained inactivation buffer only, tubes 15 + 16 contained the 80 nM 
cGMP standard stock solution (giving 8 pmol cGMP/assay tube) and tubes 17 + 18 
contained the cGMP blank. The tubes in between contained the standard dilutions in 
ascending order, producing a sigmoidal standard curve (see below). 
   
The following quantities were added to the microfuge tubes: 
 
Unknown Sample / Standard (µl)  [3H]-cGMP (µl)  Rabbit-anti-cGMP (µl) 
100  50  50 
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Samples were incubated at 4ºC, placed on ice for a minimum of 2 hours or left under 
these conditions overnight.  
 
Protocol following incubation period: 
 
Ammonium  sulphate  solution  (1  ml)  was  added  to  each  tube  to  precipitate  the 
antibody-bound  complex  and  left  for  5  min  on  ice,  followed  by  centrifugation  at 
12500 rpm for 5 min at 4ºC to pellet the antibody-bound complex. The supernatant 
was removed by vacuum suction to separate the antibody-bound complex from the 
unbound cGMP and 1 ml of dH2O was added to each tube to dissolve the pellet (left 
for 20-30 min or until dissolved). A volume of 0.95 ml was transferred to scintillation 
vials  containing  5  ml  scintillant.  Vials  were  shaken  vigorously  to  mix  well  and 
counted for 5 min per vial using a scintillation counter (LS6500 – 
137Cs; Beckman 
Coulter Ltd). 
 
RIA analysis 
 
The radioactivity in each sample is determined as disintegrations per minute (dpm). 
The dpm data was entered in and analysed with OriginPro 7.5 Client to obtain the 
amount of cGMP in a sample given as pmol cGMP per mg protein. First, the standard 
curve data was entered, plotting the dpm counts as a function of pmol cGMP per tube 
on a logarithmic scale. The data was fitted using the following logistic function: 
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Where y is dpm, A1 and A2 are the mean zero cGMP (i.e. top of the standard curve) 
and mean blank (i.e. bottom of the standard curve) respectively, p is the slope (that 
should approximate 1), x is pmol cGMP/assay tube and x0 is the amount of cGMP at 
which half of the displacement has occurred. Below, in Fig. 2.1, an example of a 
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Fig. 2.1. Typical standard curve obtained for RIA 
 
 
Having obtained the values for A1, A2 and x0, it is possible to calculate the amount of 
cGMP in pmol normalised to ‘per mg tissue protein’, using OriginPro 8. This was 
achieved by the following series of steps: 
 
·  Spread sheet in Origin 
·  Enter dpm of unknown samples into column(A) 
·  Set column(B) equal to x 
i.e. x = x0 * (((A1 – A2) / (column(A) – A2))-1), where x = pmol cGMP per 
assay tube 
·  Set column(C) equal to 10 * column(B), giving the amount of cGMP in pmol 
per ml 
·  Set column(D) equal to the dilution factor for each sample (e.g. 2 for 1:2 
dilution, 5 for 1:5 dilution etc) 
·  Set column(E) equal to column(C) * column(D), giving pmol cGMP per ml of 
the original sample 
·  Enter the concentration of protein (mg protein/ml) of the brain slice that where 
obtained by means of the protein assay for each sample into column(F) 
1E-9 1E-8 1E-7 1E-6 1E-5 1E-4 1E-3 0.01 0.1 1 10 100 1000 10000
0
1000
2000
3000
4000
5000
A1 4113.28437 ±34.16359
A2 117.35981 ±35.0423
x0 1.06109 ±0.03789
p 0.99488 ±0.02743
d
p
m
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·  Set column(G) equal to column(E)/column(F), giving the amount of cGMP in 
pmol per mg of tissue protein 
 
All data are presented as means ± SEM obtained from a minimum of three samples in 
duplicates  derived  from  three  different  animals.  Statistical  evaluation  of  cGMP 
measurements  was  carried  out  in  GraphPad  InStat  version  3  (GraphPad  Software, 
Inc., San Diego, CA, USA) using ANOVA with Dunnett’s test, statistical significance 
being accepted at P < 0.05. 
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3.1   INTRODUCTION 
 
The  characteristics  of  NO  set  it  apart  from  ‘classical’  neurotransmitters. 
Firstly, NO is not produced in advance or stored; additionally, it is freely diffusible 
and able to cross membranes rapidly. The unique nature of NO is highlighted by its 
ability to spread out in a three-dimensional fashion. Based on these properties, NO 
may  act  on  different  tissue  elements  within  the  brain,  irrespective  of  anatomical 
connection (Garthwaite & Boulton, 1995; Garthwaite 2008). 
Central axons have been proposed as a target for NO (de Vente et al., 1998), 
but the functional changes it induces are largely unexplored. The optic nerve provides 
a good model to study white matter function as it consists solely of axons, blood 
vessels, and glial cells (Waxman et al., 1991; Bolton & Butt, 2005). The NO-cGMP 
pathway has been shown to play an intriguing role in this tissue (Garthwaite et al., 
1999a;  Garthwaite  et  al.,  1999b).  Stimulation  of  optic  nerves  with  NO  has  been 
demonstrated to induce the generation of cGMP in axons only (Garthwaite et al., 
1999b),  followed  by  the  finding  that  NO  at  high  concentrations  kills  axons 
(Garthwaite et al., 2002a). In association with the latter finding, it was shown that 
high concentrations of NO cause a biphasic depolarisation of optic nerve axons, the 
second large phase being associated with pathological actions of NO (Garthwaite et 
al., 2002a). The second phase of the depolarisation was found to be blocked by the 
Na
+ channel blocker TTX, reflecting the Na
+-dependent toxicity under conditions of 
impaired cellular respiration and ATP loss. In contrast, the earlier small phase of the 
depolarising response persisted (Garthwaite et al., 2002a). Based on these previous 
findings, initial work (Garthwaite et al., 2006) was aimed at elucidating the cellular 
mechanism through which axons depolarise in response to a low concentration of NO. 
Garthwaite et al. (2006) discovered that the depolarising response induced by low 
concentrations  of  exogenous  NO  was  cGMP-dependent,  and  that  the  underlying 
mechanism for this voltage response involved the direct modulation of HCN channels 
by cGMP, these channels being a potential downstream target for cGMP (see Chapter 
1) and having been proposed to reside in the rat optic nerve previously (Eng et al., 
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of NO in the optic nerve that kept optic nerve axons in a depolarised state under basal 
conditions, the endogenous NO acting through the same mechanism as exogenous NO 
(Garthwaite et al., 2006).  
After setting out to identify the source of this continuous NO release, it was 
found that it was NO coming from the capillaries permeating the optic nerve that 
influences the membrane potential of optic nerve axons (Garthwaite et al., 2006). 
While NO is usually considered a key player purely in terms of vascular function, 
communication  between  neurons  and  vascular  elements  is  taking  place  during 
development, where it has been found that blood vessels send out signals via certain 
growth factors to aid axonal guidance (Carmeliet & Tessier-Lavigne, 2005). In terms 
of vascular function, NO is able to reach underlying smooth muscle cells to raise 
cGMP levels and, consequently, to induce vessel dilatation in large blood vessels over 
distances of several 100 µm (Martin et al., 1985a; Gold et al., 1990). In contrast, any 
point in the brain is at most a cell diameter (25 µm) away from a capillary (Pawlik et 
al., 1981), the endothelial cells of which release NO tonically from the endothelial 
isoform of NOS (Mitchell & Tyml, 1996). The global levels of NO produced may 
depend on the geometrical arrangement of capillaries within the tissue (Tsoukias & 
Popel, 2003), and the three-dimensional arrangement of the capillary network around 
axons would be able to deliver NO just as well as it distributes O2 (Garthwaite, 2008). 
Concerning the expression pattern of endothelial (e)NOS in the brain there have been 
disagreements in the past. Previous immunohistochemical studies claimed eNOS to be 
also expressed in some neurons (Dinerman et al., 1994) or in astrocytes (Lin et al., 
2007). However, concerning the latter, the specificity and credibility of the staining 
has not yet been confirmed, and no astrocytic eNOS or neuronal (n)NOS was detected 
in the rat optic nerve (Garthwaite et al., 2006). For instance in the work by Lin et al. 
(2007), only a very small number of structures appeared to be positive for both eNOS 
and the astrocytic marker GFAP, and, judging by the nature of the staining, the minor 
degree  of  co-localisation  is  likely  to  be  arising  from  astrocytic  endfeet  contacting 
blood  vessels.  Additionally,  the  observations  made  in  terms  of  eNOS  residing  in 
neurons has been disputed (Chiang et al., 1994; Demas et al., 1999) and based on 
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in endothelial cells (Seidel et al., 1997; Stanarius et al., 1997; Topel et al., 1998; 
Demas et al., 1999; Blackshaw et al., 2003; Chan et al., 2004). Taking these aspects 
and  the  unique  characteristics  of  NO  compared  with  other  neurotransmitters  into 
consideration,  the  possibility  of  components  of  the  vascular  system  actively 
influencing neuronal function becomes readily conceivable.  
 
 
3.2   AIM OVERVIEW 
 
The  overall  evidence  from  preceding  work  led  to  the  suggestion  that  the 
endothelial cells of the capillary network within the optic nerve persistently signal to 
axons, causing depolarisation by releasing NO from eNOS (Garthwaite et al., 2006). 
Although direct communication between neurons and the vascular system has been 
implied, this has only been noted for ‘neuron-to-blood vessel’ rather than the opposite 
way  around.  Fergus  &  Lee  (1997),  for  example,  found  that  NMDA-evoked 
vasodilatation  of  microvessels  monitored  in  a  hippocampal  slice  preparation  is 
diminished  upon  nNOS  inhibition,  implicating  NO  derived  from  local  neurons  in 
close apposition to blood vessels directly participating in the regulation of vascular 
tone. Foregoing work found expression of both nNOS and eNOS in rat optic nerves, 
but a lack of iNOS (Garthwaite et al., 2006). However, nNOS was only detected in 
large blood vessels on the surface of the nerve, frequently co-localising with eNOS, as 
has been observed in pial blood vessels (Seidel et al., 1997). This was in contrast to 
the  restricted  and  rich  expression  pattern  of  eNOS  throughout  the  microvascular 
network  that  runs  within  the  optic  nerve  (Garthwaite  et  al.,  2006).  A  number  of 
questions  remained  to  be  answered,  which  would  help  to  further  validate  the 
hypothesis  of  blood  vessels  directly  signalling  to  axons,  and  if  it  merited  further 
examination.  Additional  experimental  evidence  was  sought  to  further  test  the 
hypothesis that eNOS is indeed the chief endogenous source of NO in the optic nerve. 
Moreover, the electrophysiological technique used is not a direct readout of the actual 
changes  in  membrane  potential.  Hence,  to  further  evaluate  the  significance  of  the 
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membrane  potential,  correlating  to  the  DC  potential  detected  by  the  extracellular 
recordings. Finally, it was of interest to elucidate the underlying cause of tonic NO 
release under basal conditions. Production of NO from endothelial cells is stimulated 
by  a  variety  of  factors,  such  as  shear  stress,  which  blood  vessels  are  constantly 
exposed to, as well as a number of humoral factors, including acetylcholine, vascular 
endothelial growth factor (VEGF), bradykinin, and oestrogen (Dudzinski et al., 2006). 
One of the key regulatory mechanisms of eNOS activity at basal level is thought to be 
the  PI3  kinase-Akt  phosphorylation  pathway,  which  can  mediate  a  15-  to  20-fold 
increase in eNOS activity, enabling the enzyme to function even at resting levels of 
cytosolic  Ca
2+  (Dimmeler  et  al.,  1999;  Fulton  et  al.,  1999;  Michell  et  al.,  1999; 
Dudzinski et al., 2006). The present study aimed at investigating whether it is this 
mechanism prevailing in the rat optic nerve, thereby governing ongoing NO release. 
The rationale for testing this is not only to follow the mechanism upstream, but also to 
obtain more evidence that would test further the suggested involvement of eNOS in 
the  proposed  scenario.  Some  of  the  data  that  will  be  presented  here  have  been 
published in conjunction with data that originated from preceding work (Garthwaite et 
al., 2006). 
 
 
3.3   METHODS 
 
3.3.1   Optic nerve preparation and in vitro maintenance 
 
Optic nerves (Fig. 3.1) from 10- to 11-day-old Sprague Dawley rats were used. All 
animals were purchased from Charles River UK Ltd. The animals were sacrificed by 
cervical dislocation followed by decapitation as approved by the UK Home Office 
Schedule 1 regulations. Following transection of the optic nerves immediately behind 
the eye, the cranium was cut along the hemisphere-midline and removed. The brain 
was then gently retracted, which has the effect of pulling the optic nerves through the 
optic canals, and placed into pre-oxygenated, ice-cold aCSF. Optic nerves were then 
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chiasm attached, and were then separated by cutting along the midline of the chiasm. 
A piece of thread was tied to the retinal end, to allow the nerves to be physically 
manipulated into the chamber. Nerves were then transferred into a flask containing 
continuously oxygenated cold aCSF, and were left at room temperature to recover for 
at least 30-60 min before installing the tissue in the recording chamber. 
 
Solutions for K
+ calibration experiments 
 
Nerves were perfused and allowed to stabilise in aCSF composed of the following (in 
mM): NaCl (120), KCl (2.0), MgSO4 7H2O (1.19), NaHCO3 (26.0), KH2PO4 (1.18), 
CaCl2 (2.0) and glucose (11.0); the aCSF was equilibrated with 95% O2 / 5% CO2; pH 
(37ºC) = 7.4. Taking into account that the aCSF contained 3.18 mM K
+, appropriate 
volumes  of  a  4  mM  KCl  stock  solution  were  added  to  the  aCSF  (Na
+  replaced 
isotonically with K
+) to expose the nerve to 15, 40, and 130 mM K
+, the depolarising 
responses to which were recorded.  
  
3.3.2   The grease-gap technique 
 
Principle and method procedure 
 
The isolated optic nerve was mounted in a three-compartment grease-gap recording 
chamber (Fig. 3.1), similar to the one designed and described in detail by Garthwaite 
and Batchelor (1996). The principle of the grease-gap method is the imposition of an 
extracellular  resistance  formed  by  a  greased  barrier  separating  two  chambers  of  a 
tissue bath. A voltage change in the middle chamber (where the main body of the 
nerve lies) leads to intra- and extracellular current flow. The extracellular component 
of the current generates a voltage between the two sides of the barrier as it flows 
across the resistance. This voltage change is monitored using Ag/AgCl electrodes. 
The observed voltage deflection corresponds to voltage changes in the population of 
axons that cross the barrier, where the amplitude will depend on the quality of the 
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grease-gap technique provides a number of advantages such as stable responses over 
long  periods  of  time  (usually  several  hours)  and  a  low  noise  level  with  a  good 
baseline stability, which allows small potential changes to be detected. In addition, it 
is  a  relatively  non-invasive  method,  therefore  avoiding  tissue  damage  due  to 
experimental procedure.  
 
The central chamber (0.5 ml capacity) was connected to a pump, allowing continuous 
perfusion with aCSF with or without test compounds at a rate of 1.5-2 ml/min, and the 
perfusate was removed by a suction arm in the middle chamber. The recording bath 
was separated into a three-compartment unit by two pairs of Perspex slats that would 
be placed on top of each other. The Perspex slats that would be positioned on top of 
the nerve had a groove so that the nerve would not be crushed. The regions that come 
into  contact  with  the  sides  of  the  recording  bath,  as  well  as  the  grooves  of  the 
partitions  were  greased  with  Dow  Corning  High-Vacuum  Grease  (Cole-Parmer 
Instrument Company Ltd, London, UK) in order to obtain a good seal that provided 
the resistance between the chambers. The main body of the nerve was contained in the 
middle  compartment.  Once  the  nerve  was  installed,  the  central  compartment  was 
immediately perfused with aCSF and the two side-chambers were filled with aCSF to 
a suitable level but were not perfused. Nerves were left for further recovery until a 
stable  recording  baseline  was  obtained  (normally  for  approximately  1  hour).  The 
whole chamber and the perfusates were kept at 37 ± 0.5°C throughout the experiments 
and all perfusates were continuously equilibrated with 95% O2 / 5% CO2. Experiments 
were started once a stable baseline had been obtained. Potential changes in response 
to pharmacological agents were recorded using Ag/AgCl electrodes embedded in agar 
(see below) and monitored on a personal computer using Clampex 8.0 (Molecular 
Devices, Palo Alto, CA) for data collection. To check the stability of the recordings 
and nerve viability, control responses to the NO donor PAPA/NO (1 µM) and/or K
+ 
(1-3 mM, added as KCl) were obtained before the start and after completion of each 
recording. Changes in DC potential provided the readout of changes in membrane 
potential.  
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Fig. 3.1. Schematic showing the grease-gap set up 
 
 
Ingredients and method for Ag/AgCl electrodes: 
 
2 x 2 mm sockets  
2 x 20 cm lengths of silver wire (AG10-W 2 m 0.25 mm dia.; Harvard apparatus Ltd) 
Rapid Araldite  
2 x pipette tips (size P20/P200) 
2 x 1 ml syringes  
Agar 
NaCl solution 0.9%  
Chloriding setup (battery and NaCl solution slightly acidified with HCl) 
Storage vessels for electrodes 
Shorting wire (5 cm wire with 2 mm plug either end) 
 
The silver wire was soldered to the sockets. Two trimmed and bent tips were glued to 
the  end  of  the  syringes  with  Araldite  and  left  to  set.  The  silver  wires  were  then 
cleaned with acetone and wound around a metal stick to give a spiral that would fit in 
the syringes. This was followed by careful cleaning to remove grease, and coating 
with chloride until the wires had turned black-red-coloured. Subsequently, 100 ml of 
4% agar made up in 0.9% NaCl solution was heated in a Pyrex beaker. Once the agar 
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was dissolved, it was left for a few minutes until the solution was clear and free of air 
bubbles. The hot agar was sucked up into the syringes to a level that would cover the 
spiral portion of the wires. With finger over the syringe tip, the spiral was inserted and 
the socket pushed in firmly. When the agar had cooled enough to stop it from flowing 
back out, the syringes were returned to the beaker containing agar. This was then left 
at 4°C allowing it to set completely before removing the electrodes. The electrodes 
were stored in 0.9% NaCl solution at 4°C. Before starting an experiment the recording 
electrodes were allowed to equilibrate at room temperature and returned to 4°C after 
the experiment. A pair of electrodes was usually used for approximately 2-3 months, 
if their quality was very good. Running down of the quality of the electrodes was 
normally judged by drifts during the recordings and/or variable control responses in 
successive experiments.  
 
3.3.3   Western blot 
 
Following  isolation  (see  above  for  details),  optic  nerves  from  10-  to  11-  day  old 
Sprague Dawley rat pups were kept in 50 ml Erlenmeyer flasks containing 20 ml pre-
oxygenated,  ice-cold  aCSF.  Flasks  were  transferred  to  a  shaking  water  bath  for  a 
recovery period of 1-2 hours at 37°C with a constant stream of carbogen flowing 
through the inlet stopper, mimicking the recovery period optic nerves were normally 
given before commencing electrophysiological experiments. Subsequent to recovery, 
the PI3 kinase inhibitors LY 294002 and wortmannin were added to their respective 
flasks  for  an  incubation  period  of  20  min.  In  the  meantime,  control  nerves  not 
receiving pharmacological treatment, were snap-frozen over dry ice / iso-pentane into 
an  Eppendorf  tube.  The  same  was  carried  out  for  the  other  nerves  that  had  been 
exposed to PI3 kinase inhibitors following the exposure period. For each condition, at 
least ten nerves were pooled into one Eppendorf tube in order to obtain plenty of 
protein  for  the  Western  blot.  The  frozen  optic  nerves  were  stored  at  -80ºC  until 
Western blotting.  
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Sample preparation 
 
Eppendorf tubes containing the frozen optic nerves were placed on ice and left to 
thaw (samples were kept cold at all times). Lysis buffer was then added at 100 µl to 
each tube, followed by addition of PMSF at 1% final concentration. Samples were 
sonicated,  and  10%  Triton  at  1%  final  concentration  was  added  to  the  protein 
suspension. Samples were spun for 5 min at 6000 rpm at 4ºC, the supernatant placed 
into a fresh Eppendorf tube (discarding the pellet), and protein contents determined 
using  the  BCA  Protein  Assay  kit.  4x  loading  buffer  was  added  to  an  appropriate 
amount of sample (e.g. 12 µl of 4x loading buffer to 36 µl protein sample) followed 
by loading the samples into the gel pockets (see below). The protein / loading buffer 
mix was not denatured by boiling at 95ºC before loading the sample onto the gel 
(when done so, no staining was obtained).  
 
Western blotting 
 
Proteins were separated by means of SDS-polyacrylamid gel electrophoresis loading 
crude protein homogenate (70 µg) plus loading buffer onto a 4-15% Tris-HCl ready 
gel (Bio-Rad), loading a total of 40 µl into each well. The gel was then left for 30 min 
gently shaking in equilibration buffer before proceeding to the protein transfer onto a 
PVDF membrane. Using electrophoresis, the protein bands were blotted onto a piece 
of PVDF membrane that had previously been hydrated by soaking it in methanol 
followed by dH2O and then equilibration buffer. To achieve the protein transfer, the 
negative charge was on the side of the gel and the positive charge on the side of the 
PVDF membrane, so that the negatively charged proteins would be driven over onto 
the PVDF membrane. Following the blot, the side of the membrane that had been 
facing down on the gel was marked and the membrane dried at 37ºC. The membrane 
was stored at 4ºC until proceeding for staining the protein of interest. 
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Probing for phospho-eNOS (Ser1179) and total eNOS protein 
 
Note: Where not specified, steps were carried out at room temperature. 
 
The PVDF membrane was first re-hydrated by placing it in methanol (shaking) for a 
couple of minutes followed by a couple of rinses with dH2O. The membrane was then 
placed  into  1x  TBS  for  5  min  (shaking).  Non-specific  background  binding  was 
blocked by immersing the membrane in 5% dried milk emulsion (made in 1x TBS) 
for 1-2 hours (shaking). Following blocking, the membrane was washed in 1x TBS 
(no detergents) for 5 min (shaking). Primary antibody was added made up to its final 
concentration in 1x TBS containing 5% BSA and 0.075% Tween and left incubating 
overnight at 4ºC (gently shaking). The final concentrations for the primary antibodies 
used were 1: 2000 and 1: 1000 for phospho-eNOS and eNOS protein respectively. To 
prevent protein degradation the preservative sodium azide was added to the antibody 
dilutions (50 µl of 10% sodium azide per 10 ml). Primary antibody incubation was 
followed by 3x 5 min washes with washing buffer. Secondary antibody (horseradish 
peroxidase anti-rabbit) was applied to the membrane at 1: 25 000 made in 1x TBS 
containing 5% dried milk and 0.05% Tween and left incubating at room temperature 
for approximately 2 hours (shaking), which was followed by 3x 5 min washes with 
washing buffer. The membrane was rinsed several times with dH2O to get rid of any 
residual detergent contained in the washing buffer. Finally, the membrane was placed 
into  developer  solution  (1:  1  ratio  of  SuperSignal  West  Pico  Luminol/  Enhancer 
solution:  SuperSignal  West  Pico  Stable  Peroxide  solution;  Thermo  Scientific, 
Rockford,  IL, USA)  for 5 min (shaking) and put into the developer cassette. The 
stained protein blot was developed in the dark room by placing a piece of film into the 
cassette  onto  the  membrane,  which  was  then  developed  utilising  the  X-Ograph 
Compact  X2  film  processor  (Xograph  Imaging  systems,  Tetbury,  Gloucestershire, 
UK). Following developing, the PVDF membrane was prepared for re-probing with a 
different  primary  antibody  by  leaving  it  in  Restore  Western  Blot  Stripping  buffer 
(Thermo Scientific, Rockford, IL, USA) for 10-20 min at 37ºC, followed by a few 
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filter paper and, if not immediately re-probed, stored at 4ºC. To re-probe the PVDF 
membrane with a different primary antibody, the above steps were repeated exclusive 
of the blocking procedure. 
 
3.3.4   Analysis 
 
Electrophysiology 
 
Response  amplitudes,  when  reversible,  were  measured  relative  to  the  interpolated 
baseline,  obtained  by  fitting  a  linear  regression  to  5  min  periods  on  either  side. 
Otherwise, measurements were made relative to the mean voltage during a 5 min 
period of preceding baseline. The data were analysed using Clampfit 8.0 (Molecular 
Devices, Palo Alto, CA) and OriginPro 7.5 Client. All data are presented as means ± 
SEM  of  a  minimum  of  three  experiments  obtained  from  three  different  animals. 
Statistical  evaluation  was  carried  out  in  OriginPro  7.5  using  Student’s  t-test  and 
statistical significance was accepted at P < 0.05. 
 
Western blot 
 
Time  of  antibody  incubations  (primary  and  secondary),  washing  intervals,  and 
exposure time in developer solution were kept the same between the phospho-eNOS 
and total eNOS blots. Western blots were captured and then analysed by means of 
densitometry using the Gel Analysis Software GeneTools (Syngene, Cambridge, UK). 
This was performed for the bands stained for the phospho-eNOS and total eNOS, the 
latter  serving  as  the  reference  which  was  used  for  correcting  for  uneven  protein 
loading. The ratios of the densities of the bands corresponding to phospho-eNOS over 
the  density  of  the  respective  bands  corresponding  to  total  eNOS  protein  were 
determined in arbitrary units and expressed as percentage of controls (i.e. protein from 
untreated optic nerves). For each condition tested, at least ten nerves were pooled into 
one Eppendorf tube in order to obtain plenty of protein for the Western blot, and each 
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carried  out  in  OriginPro  8.  Statistical  analysis  was  performed  in  GraphPad  InStat 
version  3  (GraphPad  Software,  Inc.,  San  Diego,  CA,  USA)  using  ANOVA  with 
Dunnett’s test, statistical significance being accepted at P < 0.05. 
 
 
3.4   RESULTS 
 
3.4.1   NOS isoforms responsible for tonic NO production in  
            the optic nerve 
 
Effect of bradykinin, an eNOS stimulator 
 
To test further the hypothesis that eNOS is the endogenous source of NO in 
the optic nerve by which blood vessels signal to axons, experiments were conducted 
that investigated the action of bradykinin, a well established stimulator of eNOS in 
endothelial  cells,  where  the  receptors  for  this  endogenous  eNOS  activator,  the 
bradykinin B2 receptors, exist in a complex with eNOS (Ju et al., 1998; Marrero et al., 
1999; Prado et al., 2002).  
Exposure  of  rat  optic  nerves  to  bradykinin  (300  nM)  evoked  reproducible 
depolarisations (Fig. 3.2a), peaking after 2-3 min and reversing on washing out the 
agonist. Both the general NOS inhibitor L-NNA (100 µM) and the NOGC receptor 
antagonist ODQ (10 µM) caused hyperpolarisations (-0.451 ± 0.074 mV, n = 4 for L-
NNA; -0.233 ± 0.034 mV, n = 4 for ODQ) signifying the loss of basal, tonic NO, and 
inhibited the bradykinin-evoked depolarisation (Fig. 3.2b,c,f). The depolarisation in 
response  to  bradykinin  was  also  significantly  prevented  in  the  presence  of  the 
bradykinin B2 receptor antagonist HOE-140 (1 µM; Fig. 3.2d,f). However, the lack of 
an obvious hyperpolarising effect of HOE-140 on the basal membrane potential (Fig. 
3.2d) indicates that endogenous bradykinin is unlikely to contribute to the tonic NO 
release in rat optic nerve measurably. Measurements were made on random stretches 
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peaks averaged 0.045 ± 0.009 mV (n = 5) and negative peaks averaged -0.060 ± 0.006 
mV (n = 7), with the average of both in the same records being 0.019 ± 0.002 mV (n = 
8). The average effect of HOE-140 on the baseline (-0.067 ± 0.0028 mV; n = 3) was 
not significantly different from average fluctuations in the baseline.  
To  further  test  if  bradykinin  is  acting  through  the  cellular  mechanism 
suggested for NO-induced depolarisation (Garthwaite et al., 2006), the role of HCN 
channels was explored. Perfusion of the HCN channel inhibitor ZD 7288 (10 µM) 
elicited  a  marked  hyperpolarisation  (-1.6  ±  0.27  mV,  n  =  4)  and  prevented  the 
response to bradykinin (Fig. 3.2e,f), implying that HCN channels are mediating the 
bradykinin-induced depolarisation. Overall, if NO synthesised by eNOS in endothelial 
cells signals persistently to axons, as indicated by preceding data (Garthwaite et al., 
2006), it would be predicted that an agonist that selectively increases eNOS activity 
evokes a NO-dependent depolarisation through HCN channels that is associated with 
cGMP formation. The data presented here are consistent with these predictions. 
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FIG. 3.2. Effect of the eNOS stimulator bradykinin (BK) on rat optic nerve. A: BK evokes reproducible 
depolarisation of optic nerves (n = 4). B-E: Inhibition of BK-induced depolarisation by L-NNA (B, n = 4), ODQ 
(C; n = 3), HOE-140 (D; n = 3) and ZD 7288 (E; n = 4). F: Summary data for experiments illustrated in B-E (n = 
3-4; **p < 0.009, *p < 0.002, 
++p < 0.001, 
+p < 0.00001). Note: Applications of compounds in A-E were for the 
duration shown by the horizontal bars. The scaling in E applies to all scale bars. 
 
 
Possible involvement of NOS isoforms other than eNOS 
 
Although foregoing data (Garthwaite et al., 2006) as well as data presented 
here  strongly  imply  eNOS  as  the  main  source  responsible  for  the  ongoing  NO 
synthesis  in  optic  nerves,  more  evidence  was  sought  to  exclude  the  possible 
involvement  of  other  NOS  isoforms  in  the  rat  optic  nerve.  One  way  to  test  the 
involvement of nNOS more directly would be the use of mice lacking the gene for 
nNOS.  However,  such  knock-out  mice  are  problematic  due  to  remaining 
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compensatory  active  splice  variants  (see  Chapter  1).  Therefore,  instead,  a 
pharmacological  approach  was  adopted  to  investigate  this  issue,  utilising  three 
inhibitors (NPA, L-VNIO and 1400W) that have been shown to have good selectivity 
for nNOS over eNOS in enzymatic studies (Babu & Griffith, 1998; Bretscher et al., 
2003; Erdal et al., 2005) and in whole tissue (Hopper & Garthwaite, 2006). This also 
provided a way of testing for the involvement of iNOS, as one of the compounds 
(1400W) also inhibits iNOS more potently than eNOS (and nNOS; Garvey et al., 
1997).  
Perfusion of the nerves with the nNOS/iNOS inhibitor 1400W (1 µM), or the 
nNOS inhibitors L-VNIO (100 nM) or NPA (1 µM) had no significant antagonistic 
effect on the bradykinin-evoked depolarisation, the hyperpolarisation caused by L-
NNA (100 µM) being retained (Fig. 3.3a-d). Also, no significant effect was observed 
on  the  baseline  under  basal  conditions  during  pre-incubation  of  these  inhibitors          
(-0.056 ± 0.0043 mV, n = 5 for 1400W; -0.085 ± 0.0093 mV, n = 4 for L-VNIO; -
0.062 ± 0.007 mV, n = 3 for NPA) as compared to fluctuations in the baseline (see 
above). These data suggest that there is no measurable contribution of the other NOS 
isoforms to the tonic level of NO in the optic nerve, or to the increase in NO in  
response to bradykinin. Taken together, these data further strengthen the implication 
that eNOS as is the principal endogenous NO source. 
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FIG. 3.3. Testing for the role of nNOS and iNOS in tonic NO production in the rat optic nerve. A-C: Compounds 
inhibiting nNOS (NPA, A; L-VNIO, B; 1400 W, C) and iNOS (1400W, C) had no significant antagonistic effect on 
the depolarisation elicited by bradykinin (BK) and, unlike L-NNA, did not cause a noticeable hyperpolarisation. In 
the presence of the nNOS/iNOS inhibitors, L-NNA retained its hyperpolarising action of the usual magnitude that 
was observed in experiments discussed and illustrated earlier. D: Summary data for experiments illustrated in A-C 
(n = 3-5). Note: Applications of compounds in A-C were for the duration shown by the horizontal bars. The scaling 
in A applies to all scale bars. 
 
 
3.4.2   Estimation of the true magnitude of membrane potential  
changes that occur using the grease-gap technique 
 
To estimate the true magnitude of the membrane potential changes obtained 
from recordings using the grease-gap method, calibration experiments were carried 
out that were based on a previously adopted approach (Stys et al., 1993; Leppanen & 
Stys, 1997). Voltage responses to PAPA/NO (1 µM) were recorded at the beginning 
of each experiment (0.44 ± 0.13 mV; n = 4), serving as a control for nerve viability 
and  recording  stability.  This  was  followed  by  perfusing  the  nerve  with  ascending 
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concentrations of K
+ (15 mM, 40 mM and 130 mM; added as KCl), correcting for 
junction  potentials  before  each  application  and  during  the  plateau  phase  of  the 
depolarisation  evoked  by  K
+.  Sufficient  wash-out  time  was  allowed  after  each 
application until the response had returned to baseline. Presuming an intracellular K
+ 
concentration of 130 mM in the rat optic nerve (Stys et al., 1993; Leppanen & Stys, 
1997; Stys et al., 1997), the application of 130 mM K
+ should drive the membrane 
potential to near zero. The mean recorded depolarisation under these conditions at 
steady state were 18.9 ± 2.4 mV (n = 4; Fig. 3.4). Mean depolarisation at steady-state 
in response to 15 and 40 mM K
+ solution were 4.4 ± 0.64 mV and 11.7 ± 1.9 mV, 
respectively (n = 4; Fig. 3.4). The ratios of the responses to isotonic (130 mM) K
+ 
solution and to PAPA/NO were very similar in the different nerves, ranging from 39 
to 46 (mean: 43 ± 1.7, n = 4). The mean magnitude of depolarisation in response to 
each  of  the  tested  K
+  concentrations  was  obtained,  and  a  value  of  -80  mV  was 
assumed for the resting membrane potential of the optic nerve (Stys et al., 1997). 
From these data it was possible to estimate (from the Goldman equation) the actual 
membrane potential at each of the respective K
+ concentrations  (Fig 3.4). Having 
determined that a mean depolarisation of 18.9 mV in response to isotonic K
+ solution 
corresponds  to  a  shift  in  membrane  potential  from  -80  to  0  mV  (Fig.  3.4),  it  is 
possible to estimate the true magnitude of membrane potential changes occurring in 
the experiments in response to pharmacological agents. The results obtained from 
these calibration experiments imply that the actual mean depolarisation produced by 1 
µM  PAPA/NO  is  approximately  2  mV,  while  the  size  of  the  ZD  7288-evoked 
hyperpolarisation corresponds to an actual change of about 6-8 mV (Garthwaite et al., 
2006). The overall scope of NO for altering the membrane potential in optic nerve 
axons is approximately 6 mV. 
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FIG. 3.4. Calibration experiments for estimation of the true value of membrane potential changes in rat optic 
nerve, recorded by means of the grease-gap recording method. The magnitude of the depolarisations in response to 
ascending K
+ concentrations were in close relation with the changes in membrane potential that would be predicted 
by the Goldman equation, assuming the same extracellular K
+ concentrations. 
 
The above was determined from the Goldman equation as follows: 
 
Goldman equation is given as 
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As estimated previously (Stys et al., 1993; Leppanen & Stys, 1997; Stys et al., 1997), 
in the rat optic nerve [K
+]i is 130 mM ([K
+]o = 3 mM), [Na
+]i is 25 mM ([Na
+]o = 146 
mM), and [Cl
-]i is 55 mM ([Cl
-]o = 122 mM), the permeability ratios being 35:1:0.1 
for PK:PNa:PCl (Stys et al., 1993; Leppanen & Stys, 1997). Incorporating these ion 
concentrations that have been estimated to prevail in the rat optic nerve (Stys et al., 
1993; Leppanen & Stys, 1997; Stys et al., 1997) into the Goldman equation predicts a 
resting  potential  of  -77  mV,  a  value  consistent  with  previous  experimental 
determinations of the resting membrane potential (Stys et al., 1997). The respective 
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concentrations  of  K
+  applied  in  the  experiments  (i.e.  15,  40  and  130  mM)  were 
incorporated into the Goldman equation, giving a number of values for the resting 
membrane  potential  that  would  exist  at  these  respective  extracellular  K
+ 
concentrations. This ultimately provided the calibration curve against which it would 
be possible to estimate the magnitude of change in the membrane potential (Fig. 3.4).  
 
 
3.4.3   Underlying cause of tonic NO synthesis – role of PI3 kinase 
 
One of the key mechanisms for maintaining tonic eNOS activity in endothelial 
cells is phosphorylation of the enzyme, in part through the PI3 kinase-Akt pathway 
(Dimmeler et al., 1999; Fulton et al., 1999; Michell et al., 1999; Dudzinski et al., 
2006). The following sets of experiments investigated whether this mechanism is also 
responsible  for  the  continuous  NO  release  from  eNOS  in  optic  nerves.  If  the 
endogenous NO level in rat optic nerves is sustained through this phosphorylation 
pathway, inhibition of the PI3 kinase should occlude the hyperpolarising response to a 
general NOS inhibitor, and vice versa. Inhibition of PI3 kinase would be expected to 
cause  hyperpolarisation  in  itself,  which  should  be  prevented  upon  NOGC  receptor 
inhibition presuming that the NO is acting via its receptors and cGMP accumulation. 
To test these assumptions, the general NOS inhibitor L-MeArg (100 µM) was used. In 
contrast to the previously used inhibitor L-NNA, L-MeArg is reversible, which was a 
requisite  in  this  set  of  experiments.  It  has  been  shown  in  earlier  work  that  this 
reversible  NOS  inhibitor  causes  hyperpolarisation  repeatedly,  given  that  sufficient 
time is allowed for wash-out of the compound (Garthwaite et al., 2006).  
Two different PI3 kinase inhibitors, wortmannin (1 µM) and LY 294002 (30 
µM), both induced comparable hyperpolarisations which were, however, of slightly 
smaller  magnitude  than  that  seen  in  response  to  the  general  NOS  inhibitor 
(wortmannin vs. L-MeArg: 0.24 ± 0.03 vs. 0.37 ± 0.07 mV; LY 294002 vs. L-MeArg: 
0.25  ±  0.01  vs.  0.34  ± 0.03  mV;  n  =  4-6;  Figs.  3.5c  and  3.6c).  Both  PI3  kinase 
inhibitors partly prevented the hyperpolarisation caused by L-MeArg (Fig. 3.5a,b,c), 
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when L-MeArg was added beforehand (Fig. 3.6a,b,c). Upon inhibition of the NOGC 
receptors  by  ODQ  (10  µM)  the  hyperpolarisations  to  both  wortmannin  and  LY 
294002 were prevented (Fig. 3.7a,b,c), confirming that the PI3 kinase inhibitors act 
through inhibition of NO which acts via its guanylyl cyclase-coupled receptors. In all 
experiments, control voltage responses to PAPA/NO (1 µM) were recorded which 
were of the usual magnitudes found in previous experiments (Garthwaite et al., 2006), 
and were unaffected in the presence of PI3 kinase or general NOS inhibitors (0.34 ± 
0.03  vs.  0.39  ±  0.04  mV  in  the  presence  of  inhibitors).  However,  as  would  be 
expected, the response to PAPA/NO was prevented in the presence of ODQ (Fig. 
3.7a,b,c). In summary, these data suggest that the tonic NO release from eNOS in the 
rat optic nerves is, at least partly, maintained by PI3 kinase-mediated phosphorylation. 
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FIG. 3.5. Effect of PI3 kinase inhibition on the response to a general NOS inhibitor. A-B: The hyperpolarising 
action of L-MeArg was partially prevented by both PI3 kinase inhibitors, wortmannin (A; n = 6) and LY 294002 
(B; n = 4), while the PI3 kinase inhibitors alone produced a hyperpolarising response. The PAPA/NO-evoked 
depolarisation was not different from what is usually observed under normal conditions. C: Summary data for 
experiments depicted in A and B. The mean hyperpolarising effect of L-MeArg was greater as compared to that in 
response to wortmannin or LY 294002, and was partially prevented by both PI3 kinase inhibitors (n = 4-6; *p < 
0.03, **p < 0.002). Note: Applications of compounds in A and B were for the duration indicated by the horizontal 
bars. The scaling in A applies to all scale bars. 
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FIG. 3.6. Effect of NOS inhibition on the response to PI3 kinase inhibitors. A-B: The hyperpolarising effect of 
both, wortmannin (C; n = 4) and LY 294002 (D; n = 4), was near to completely occluded in the presence of L-
MeArg, the latter having the usual hyperpolarising effect under control conditions. The voltage responses to 
PAPA/NO remained unaffected, as compared to what is usually observed under control conditions. C: Summary 
data for experiments shown in A and B (n = 4; 
+p < 0.008, 
++p < 0.001). Note: Applications of compounds in A 
and B were for the duration indicated by the horizontal bars. The scaling in A applies to all scale bars. 
 
 
 
 
 
 
 
100 mM L-MeArg
30 mM LY 294002
1 mM PAPA/NO B 
100 mM L-MeArg
1 mM Wortmannin
0.25 mV
250 s
A 
-0.4
-0.2
0.0
0.2
0.4
0.6
+
 
L
Y
 
2
9
4
0
0
2
L-MeArg
+
 
W
o
r
t
m
a
n
n
i
n
PAPA/NO
+ PI3K inhibitor
and L-MeArg
m
V
L-MeArg
W
o
r
t
m
a
n
n
i
n
L
Y
 
2
9
4
0
0
2
77%
++
90%
+
C 3 3 3                M M Me e ec c ch h ha a an n ni i is s sm m m    o o of f f    v v va a as s sc c cu u ul l lo o o- - -n n ne e eu u ur r ro o on n na a al l l    c c co o om m mm m mu u un n ni i ic c ca a at t ti i io o on n n    t t th h hr r ro o ou u ug g gh h h                
n n ni i it t tr r ri i ic c c    o o ox x xi i id d de e e    i i in n n    o o op p pt t ti i ic c c    n n ne e er r rv v ve e e    
    
 
  135
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 3.7. Role of the PI3 kinase phosphorylation pathway in the maintenance of tonic NO release from eNOS in 
rat optic nerve – cGMP dependence. A-B: The hyperpolarisation induced by wortmannin (E; n = 4) or LY 294002 
(F; n = 4) was prevented by ODQ, as was, expectedly, the PAPA/NO-evoked depolarisation. C: Summary data for 
experiments illustrated in A and B (n = 4; *p < 0.004, **p < 0.001). Note: Applications of compounds in A and B 
were for the duration indicated by the horizontal bars. The scaling in A applies to all scale bars. 
 
 
Quantitative evaluation of eNOS phosphorylation by means of Western blotting 
 
As the data derived from the electrophysiological experiments only provide 
circumstantial evidence with regard to the involvement of the PI3 kinase pathway in 
eNOS phosphorylation, Western blotting was employed in order to investigate this 
more directly. Optic nerves were exposed in vitro to either LY 294002 (30 µM) or 
1 mM PAPA/NO
1 mM PAPA/NO
1 mM Wortmannin
10 mM ODQ
0.25 mV
250 s A 
1 mM PAPA/NO
1 mM PAPA/NO
10 mM ODQ
30 mM LY 294002
B 
-0.3
-0.2
-0.1
0.0
0.1
0.2
0.3
0.4
+
 
L
Y
 
2
9
4
0
0
2
ODQ
+
 
W
o
r
t
m
a
n
n
i
n
PAPA/NO
+ PI3K inhibitor
and ODQ
 
m
V
ODQ
W
o
r
t
m
a
n
n
i
n
L
Y
 
2
9
4
0
0
2
71%
**
87%
*
P
A
P
A
/
N
O
C 3 3 3                M M Me e ec c ch h ha a an n ni i is s sm m m    o o of f f    v v va a as s sc c cu u ul l lo o o- - -n n ne e eu u ur r ro o on n na a al l l    c c co o om m mm m mu u un n ni i ic c ca a at t ti i io o on n n    t t th h hr r ro o ou u ug g gh h h                
n n ni i it t tr r ri i ic c c    o o ox x xi i id d de e e    i i in n n    o o op p pt t ti i ic c c    n n ne e er r rv v ve e e    
    
 
  136
wortmannin  (1  µM)  and  then  snap  frozen  before  proceeding  to  perform  Western 
blotting. Control nerves were treated in the same way except for the exposure to PI3 
kinase  inhibitors.  Antibodies  directed  against  phosphorylated  eNOS  at  the  residue 
serine 1179 (S1179) or to total eNOS protein were used. This provided the possibility 
to try evaluating, first, the amount of phosphorylated eNOS protein relative to total 
eNOS protein, and, secondly, whether the amount of basal phosphorylated eNOS was 
reduced after optic nerves had been exposed to the PI3 kinase inhibitors LY 294002 
or wortmannin. As determined by means of densitometry, and normalised to total 
eNOS  protein  to  correct  for  uneven  protein  loading,  neither  of  the  PI3  kinase 
inhibitors led to a detectable decline in the degree of phosphorylation of native eNOS 
at S1179 (Fig. 3.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 3.8. Effect of PI3 kinase inhibition on eNOS phosphorylation as determined by means of Western blotting. A: 
Representative Western immunoblots of phospho-eNOS-S1179 (top row) and total eNOS (bottom row) in the 
absence or presence of LY 294002 (30 µM) or wortmannin (1 µM). B: Summary data for experiments illustrated 
in A (n = 3; 
nsp > 0.05). The ratio of the densities of phophorylated-eNOS-S1177 bands to their respective total 
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eNOS bands was determined in arbitrary units. Each bar represents the mean ± SEM of phospho-eNOS / total 
eNOS expressed relative to the results obtained from untreated control optic nerves. C, control (i.e. untreated optic 
nerves); LY, LY 294002-treated nerves; W, wortmannin-treated nerves; P-eNOS S1179, phospho-eNOS-Ser-1179 
 
 
3.5   DISCUSSION 
 
Data from foregoing work (Garthwaite et al., 2006) pointed to an intriguing 
concept, in which two distinct structures, namely blood vessels and axons, display an 
unexpected sequence of communication. These data suggested a scenario in which 
endothelial  cells  of  the  microvasculature  permeating  the  optic  nerve  persistently 
signal to optic nerve axons by releasing NO derived from eNOS. The ultimate result 
of  the  NO  signal  was  axonal  depolarisation,  the  underlying  transduction  pathway 
engaging  cGMP-mediated  HCN  channel  modulation.  The  results  presented  here 
address several questions, which required answering to further confirm the proposed 
hypothesis of blood vessels actively influencing axonal function. The current work 
provides further evidence indicating that eNOS is the chief contributor to tonic NO 
synthesis in the rat optic nerve, and suggests that basal eNOS activity is partially 
maintained by a PI3 kinase-mediated mechanism. 
 
Direct signalling from blood vessels to neurons is a relatively unusual concept, 
and further evidence was sought that would test whether eNOS is indeed the principal 
source  of  NO  in  the  optic  nerve  that  influences  the  axonal  membrane  potential 
(Garthwaite et al., 2006). Display of the right characteristics upon eNOS stimulation 
with  bradykinin  provided  further  indication  concerning  eNOS  being  the  tonic  NO 
source, including bradykinin-evoked depolarisation that is prevented upon NOS and 
NOGC  receptor  inhibition  and  mediated  by  HCN  channels.  Moreover,  the  lack  of 
effect of pharmacological tools that exhibit selective inhibition of nNOS (and iNOS) 
over eNOS further argues against the participation of NOS isoforms other than eNOS 
in the proposed scenario, which is in support of foregoing findings (Garthwaite et al., 
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in  line  with  previous  work  (Garthwaite  et  al.,  2006).  HCN  channels  have  been 
implicated in the control of pacemaker and oscillatory activity in the heart and brain 
respectively (see Chapter 1), setting of the resting membrane potential, as well as 
control  of  membrane  resistance,  dendritic  integration  and  regulation  of  synaptic 
transmission  (Robinson  &  Siegelbaum,  2003;  Wahl-Schott  &  Biel,  2009).  Central 
axons  express  HCN  channels  (Notomi  &  Shigemoto,  2004),  and  the  current 
conducted  by  these  channels  has  been  proposed  to  be  important  in  maintaining 
reliable  conduction  by  counteracting  membrane  hyperpolarisation  during  high-
frequency  activity  in  axons.  It  has  been  proposed  that  activity-dependent 
hyperpolarisation as a result of the high activity of the electrogenic Na
+/K
+ pump 
during repetitive action potential firing, Na
+ being extruded out of the cell to oppose 
the  large  net-influx  of  Na
+  that  results  from  high-frequency  neuronal  activity,  is 
counteracted by Ih (Grafe et al., 1997; Soleng et al., 2003; Robinson & Siegelbaum, 
2003). This is suggested to be related to Ih conducting a Na
+ inward current into the 
axoplasm,  resulting  in  depolarisation.  This  in  turn  would  drive  the  membrane 
potential back to its resting level, assisting the cell to reach threshold for triggering 
the  next  action  potential.  The  finding  that  inhibition  of  HCN  channels  leads  to 
membrane  hyperpolarisation  indicates  that  Ih  is  active  at  the  resting  membrane 
potential of the rat optic nerve, NO apparently setting the resting membrane potential, 
and,  possibly,  influencing  excitability  and  reliable  conduction  via  cGMP-mediated 
HCN  channel  modulation.  The  Ih  conducted  by  HCN  channels  has  also  been 
demonstrated in retinal ganglion cells (Tabata & Ishida, 1996), where Ih is proposed 
to  be  activated  during  and  following  hyperpolarising  light  responses,  transiently 
enhancing excitability after termination of light stimuli. A mechanism engaging NO-
cGMP-mediated modulation of HCN channels may help explain why block of NOS 
activity inhibits light-evoked compound action potentials in the optic nerve (Maynard 
et al., 1995), while modulation of dendritic or somatic HCN channels by the NO-
cGMP signalling pathway may affect neuronal firing threshold or pattern (Pape & 
Mager, 1992; Abudara et al., 2002). 
The  reason  for  using  the  isolated  rat  optic  nerve  preparation  is  its  well 
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measurements of white matter function in vitro (Waxman et al., 1991; Bolton & Butt, 
2005).  The  cellular  population  of  the  optic  nerve  comprises  axons  of  the  retinal 
ganglion cells, glial cells and capillaries (Forrester & Peters, 1967; Butt & Ransom, 
1993). Myelination begins around the sixth postnatal day and proceeds rapidly so that 
at the end-point of development the entire axonal population is fully myelinated. Also, 
there is an increase in size as maturation of the optic nerve ensues. Neonatal optic 
nerve axons have a diameter of about 0.14 µm, in contrast to a diameter of about 0.8 
µm in the case of adult optic nerve axons (Forrester & Peters, 1967; Foster et al., 
1982). This study uses 10- to 11-day-old rat optic nerves which have been shown to 
have  an  average  axonal  diameter  of  approximately  0.4  µm,  containing  mixed 
populations of axons with respect to the degree of myelination and diameter (Foster et 
al., 1982). The electrophysiological method used here is a standard extracellular gap 
technique, advantages of which include stable recordings over long periods of time, 
allowing  repeatable  drug  wash-in  and  wash-out,  as  well  as  the  monitoring  of  the 
average  membrane  potential  of  all  axons  of  the  optic  nerve.  In  common  with  all 
extracellular recording methods, however, the grease-gap technique does not give the 
real value of membrane potential. Hypothetically, one could carry out intracellular 
patch-clamp recordings from axons. However, such an approach to record directly 
from optic nerve axons is not practical due to the small axonal diameter compared to 
the  diameters  of  patch  or  sharp  electrodes  and  would  be  highly  unlikely  to  yield 
stable, long duration recordings. Since the electrophysiological technique used is not a 
direct  readout  of  the  actual  changes  in  membrane  potential,  it  was  necessary  to 
quantify these findings further. Calibration experiments estimated an actual shift in 
membrane potential of 2 mV in response to the NO donor PAPA/NO, and 6 mV for 
the overall scope of NO altering the membrane potential in optic nerve axons. Studies 
that looked at HCN channel modulation by NO-cGMP signalling in neurons (Pape & 
Mager, 1992; Ingram & Williams, 1996; Abudara et al., 2002; Pose et al., 2003; Kim 
et al., 2005) observed effects on the membrane potential that are comparable with that 
observed  on  optic  nerves.  In  addition,  a  small  depolarisation  of  the  presynaptic 
membrane  potential  has  been  shown  to  lead  to  enhanced  probability  of 
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analogous  modulation  of  membrane  properties  by  tonic  endogenous  NO-cGMP 
signalling has been observed on rat striatal neurons in vivo (West & Grace, 2004).  
 
Although  a  Ca
2+-dependent  enzyme,  eNOS  is  subjected  to  additional 
regulation through multiple phosphorylation sites, the tonic activity achieved also at 
resting levels of cytosolic Ca
2+ being mainly attributable to PI3 kinase-Akt-mediated 
phosphorylation (Dudzinski et al., 2006). The present study investigated whether it is 
this  mechanism  prevailing  in  the  rat  optic  nerve,  thereby  governing  ongoing  NO 
release.  The  observation  about  NO  tonically  depolarising  optic  nerve  axons  is 
revealed as a membrane hyperpolarisation upon NOS inhibition. If NO maintains a 
constant depolarisation via PI3 kinase-mediated eNOS phosphorylation, exposure of 
the optic nerve to a PI3 kinase inhibitor should also evoke a hyperpolarisation, which 
in  itself  should  be  prevented  in  the  presence  of  a  broad  spectrum  NOS  inhibitor. 
Moreover, the hyperpolarisation in response to the general NOS inhibitor should also 
be reduced in the presence of a PI3 kinase inhibitor. Moreover, the action of the PI3 
kinase inhibitor would be sensitive to inhibition of the relevant mechanism, namely 
NO  acting  via  its  guanylyl  cyclase-coupled  receptors  in  axons  (Garthwaite  et  al., 
2006).  The  results  presented  here  are  in  line  with  these  predictions,  indicating  a 
participation of the PI3 kinase pathway in sustaining tonic NO release from eNOS 
under resting conditions. However, while the hyperpolarisations in response to either 
of the used PI3 kinase inhibitors (wortmannin and LY 294002) were occluded in the 
presence of the general NOS inhibitor L-MeArg, only partial inhibition was observed 
vice versa (57% inhibition of L-MeArg-evoked hyperpolarisation by LY 294002 vs. 
49%  by  wortmannin).  This  indicates  only  partial  involvement  of  the  PI3  kinase 
pathway,  which  is  consistent  with  the  PI3  kinase  inhibitors  evoking  smaller 
hyperpolarisations than the broad-spectrum NOS inhibitor. One may ask why a broad-
spectrum NOS inhibitor occludes the response observed upon application of the PI3 
kinase inhibitors but not vice versa. This could possibly be answered by considering 
the point of the signalling pathway at which these inhibitors act. Applying the broad-
spectrum inhibitor blocks the activity of NOS overall as it prevents the binding of L-
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applying PI3 kinase inhibitors will only block that aspect of NOS activity regulation, 
meaning  that  any  other  factor,  such  as  for  example  small  fluctuations  in  the 
intracellular  Ca
2+  concentration,  could  still  contribute  to  keeping  eNOS  to  some 
degree active. Furthermore, from these types of experiments it is not possible to know 
whether the total eNOS population is in a phosphorylated state. It is likely that only a 
partial eNOS population is under the control of PI3 kinase-mediated phosphorylation, 
while  the  remaining  population  maintains  tonic  activity  via  a  different  regulatory 
mechanism.  
There are proteins, for example, that may interact with eNOS and regulate its 
activity positively (Fulton et al., 2001; Fleming & Busse, 2003). These include hsp90, 
which  generally  exists  in  association  with  eNOS  within  endothelial  cells  (Garcia-
Cardena  et  al.,  1998).  Furthermore,  multiple  phosphorylation  sites  on  eNOS  have 
been recognised, and it is suggested that there may still be more, as yet unidentified, 
sites (Boo & Jo, 2003; Mount et al., 2007). Additionally, phosphorylation of eNOS at 
different sites can be regulated not only by PI3 kinase or its downstream kinase Akt, 
but also by various other protein kinases, such as PKA (Butt et al., 2000; Boo et al., 
2002a; Boo et al., 2002b; Michell et al., 2002), PKG (Butt et al., 2000), AMPK (Chen 
et  al.,  1999;  Thors  et  al.,  2004)  and  CaMKII  (Fleming  et  al.,  2001).  A  further 
complication is the regulation of eNOS phosphorylation by different phosphatases, 
including  PP2A,  PP1  and  calcineurin  (Boo  &  Jo,  2003;  Fleming  &  Busse,  2003; 
Mount  et  al.,  2007).  In  summary,  the  above  demonstrates  the  complexity  that 
underlies eNOS regulation. The main site of eNOS phosphorylation is considered to 
be the Ser-1179 (Dudzinski et al., 2006). In the light of this, it has been shown, for 
example, that this residue on eNOS may be phosphorylated by at least five different 
protein kinases, including Akt (e.g. Butt et al., 2000; Fleming et al., 2001; Thors et 
al.,  2004).  Moreover,  different  protein  kinases  may  phosphorylate  a  number  of 
different sites on eNOS (e.g. Chen et al., 1999; Butt et al., 2000; Michell et al., 2002). 
Taken as a whole, which site on eNOS is phosphorylated or dephosphorylated by 
which protein kinase or phosphatase may depend on factors such as vascular type or 
origin, and on the general cellular context as well as on the given stimuli (Michel & 
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factors could account for the only partial contribution of PI3 kinase in the optic nerve 
with regard to tonic NO synthesis from eNOS. 
Investigating  the  effects  of  PI3  kinase  inhibitors  on  basal  eNOS 
phosphorylation  by  means  of  Western  blotting  resulted  in  a  discrepancy  with  the 
foregoing electrophysiological data. There was no detectable decline in the degree of 
basal eNOS phosphorylation in rat optic nerves that had been treated with LY 294002 
or wortmannin as compared to control nerves. One possibility is that the effects of the 
inhibitors observed in the electrophysiological experiments are due to these inhibitors 
acting  on  some  other  unknown  factor  which  ultimately  contributes  to  tonic  NO-
mediated cGMP synthesis in the rat optic nerve. Alternatively, it can be argued that 
Western blotting is too insensitive to detect a change in basal eNOS phosphorylation 
upon PI3 kinase inhibition at the whole tissue level that may nevertheless be enough 
to  bring  about  a  change  in  eNOS  output  seen  as  hyperpolarisations  in  the 
electrophysiological  experiments.  Although  this  methodology  is  popularly  used  to 
establish the presence of a  given protein, it is not suitable for detecting changing 
levels  for  all  proteins  –  especially  not  relatively  small  changes.  Large,  obvious 
changes may be easily detectable as against a background of small variations caused 
by possible artefacts. However, the present work is investigating basal, unstimulated 
eNOS phosphorylation and several aspects of this method may make the detection of 
smaller  changes  problematic.  Given  that  the  bands  appearing  for  S1179-
phosphorylated eNOS are already fairly weak and undefined this may indicate that 
one is already at the verge of the detection limit. It should be taken into consideration 
that aspects such as differences in the background intensity are not taken into account, 
as the measurements obtained from the densitometry analysis do not correspond to 
absolute  peak  values  from  which  the  respective  background  densities  had  been 
subtracted. Additionally, the slightest variation in band density brought about perhaps 
artefactually, such as for example uneven film exposure or the slightest smearing of 
the bands at the edges of the blot, could make substantial differences to the values 
obtained later in the analysis, especially  when  dealing with relatively  weak bands 
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possibility arose especially after comparing the raw numbers from one experiment to 
the other, as demonstrated below (see also Fig. 3.8): 
 
 
Experiment # 
 
 
P-eNOS/total 
eNOS 
Controls 
 
P-eNOS/total eNOS 
LY 294002 
 
P-eNOS/total eNOS 
Wortmannin 
 
% of control 
LY 294002 
* 
 
% of control 
Wortmannin 
* 
1  0.131  0.224  0.189  171  144 
2  0.268  0.242  0.217  90  81 
3  0.312  0.240  0.285  77  91 
* Control = 100% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Looking at the results from the individual experiments depicted above it appears that 
in  two  experiments  PI3  kinase  inhibition  caused  some  reduction  in  the  level  of 
phosphorylation  ranging  between  10  to  20%.  However  in  another  experiment  the 
values suggest that there was in fact an increase in phosphorylation. This result is 
difficult to interpret. Nevertheless, if the lanes corresponding to experiment #1 were 
in fact ambiguous, it could be suggested that, although fairly small, there appears to 
be a trend in the other two experiments revealing some degree of reduction in the 
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basal  level  of  eNOS-S1179  phosphorylation.  Moreover,  although  statistically  not 
significant,  this  extent  of  decline  in  the  degree  of  eNOS  phosphorylation  may  be 
sufficient to bring about a change in eNOS output that is revealed as small membrane 
hyperpolarisation in the electrophysiological recordings corresponding to some loss of 
ongoing endogenous NO synthesis in the whole nerve. Overall, perhaps increasing the 
n number of independent experiments may lead to the emergence of a clearer result. It 
is true that previous studies have successfully employed the same pharmacological 
and  methodological  approach  in  order  to  evaluate  the  impact  of  blocking  the  PI3 
kinase on eNOS phosphorylation and activity. However, earlier studies establishing 
the  importance  of  this  phosphorylation  pathway  in  regulating  eNOS  activity  have 
compared  the  degree  of  inhibition  to  situations  of  selective  stimulation  and 
enhancement of eNOS phosphorylation, using agonists or applying shear stress. The 
scope of detection is most likely to be much greater in these cases as the signal is first 
increased before comparing it to the reduction brought about by preventing the action 
of the PI3 kinase. Furthermore, much of the published work has been carried out 
using cultured aortic smooth muscle cells, for example, or isolated endothelial cells, 
rather than a whole tissue. Previous work studying the role of the PI3 kinase pathway 
at  the  whole  tissue  level  had  to  use  large  amounts  of  protein  (0.4  mg  or  more) 
combined with subsequent protein purification to eliminate everything that does not 
bind  NADPH  (as  eNOS  does)  in  order  to  detect  a  clear,  single  band  for 
phosphorylated eNOS (Hurt et al., 2002). Looking at the result obtained in the present 
study,  one  can  notice  that  the  bands  for  phosphorylated  eNOS  are  very  weak 
compared to those corresponding to total eNOS, and non-specific bands were visible 
when  probing  against  phosphorylated  eNOS.  The  antibody  directed  against  eNOS 
would detect all eNOS protein rather than only the S1179-phosphorylated population 
and  the  result  may  imply  that  only  a  small  population  of  eNOS  is  in the  S1179-
phosphorylated state, enough to contribute to tonic eNOS activity. This idea would tie 
in  with  some  of  the  suggestions  brought  forward  above  on  the  basis  of  the 
electrophysiological  data.  On  the  other  hand,  however,  the  weakness  of  the  band 
corresponding  to  S1179-phosphorylated  eNOS  may  solely  be  based  on  the  anti-
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purification would enhance the signal that is detected for phosphorylated eNOS at 
basal level also in this case. However, also here the question may yet arise whether 
normalisation of the relatively weak population of S1179-phosphorylated eNOS to 
total eNOS protein could possibly introduce some error to the final result.  
 
In summary, the lack of a detectable effect of nNOS/iNOS inhibitors and the 
characteristics of bradykinin-evoked depolarisation further strengthens the implication 
of vascular eNOS as the principal source of the endogenous tonic NO level in the 
optic nerve that actively influences the axonal membrane potential. The role of eNOS 
is further underpinned by the finding that one of the key regulatory mechanisms for 
basal eNOS activity, namely the PI3 kinase phosphorylation pathway, appears to be at 
least partially contributing to ongoing NO synthesis. This notion is supported by the 
electrophysiological data. However, a discrepancy was revealed when investigating 
the role of PI3 kinase-mediated eNOS phosphorylation by means of Western blotting, 
seeing  no  measurable,  significant  reduction  in  eNOS-S1179-phosphorylation.  It  is 
most likely that this is due to this methodology being not sensitive enough to detect 
small changes in the signal under investigation. 
A partial contribution of the PI3 kinase pathway to tonic eNOS-derived NO is 
consistent  with  findings  in  rat  hippocampal  slices  (Hopper  &  Garthwaite,  2006), 
wherein it has been demonstrated that a basal eNOS-derived NO level is partially 
dependent on a PI3 kinase-mediated mechanism and is required for LTP (Hopper & 
Garthwaite, 2006). Deletion of eNOS has been reported to impair synaptic plasticity 
in the hippocampus (Wilson et al., 1999), the cerebral cortex (Haul et al., 1999), and 
striatum (Doreulee et al., 2003). One of the main physiological stimulators for PI3 
kinase-mediated eNOS phosphorylation is shear stress, the force imposed on blood 
vessel walls by blood flowing across them. This force would ultimately increase as 
blood  flow  increases  (as  would  occur  for  instance  during  exercising),  therefore 
boosting NO production in the vasculature. The finding of increases and decreases in 
eNOS  activity  changing  cGMP  levels  and  the  membrane  potential  in  opposite 
directions may provide a possible mechanism through which changes in blood flow 
and eNOS activity are coupled to changes in neuronal function, providing a possible 3 3 3                M M Me e ec c ch h ha a an n ni i is s sm m m    o o of f f    v v va a as s sc c cu u ul l lo o o- - -n n ne e eu u ur r ro o on n na a al l l    c c co o om m mm m mu u un n ni i ic c ca a at t ti i io o on n n    t t th h hr r ro o ou u ug g gh h h                
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hypothesis  for  how  factors  that  change  eNOS  activity  in  vivo,  such  as  physical 
exercise (Green et al., 2004), alter brain activity. In relation to this, physical exercise 
is also indicated to boost brain function and improve synaptic plasticity, to increase 
learning, and to enhance cognitive function (van Praag, 2009). 
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4.1   INTRODUCTION 
 
The study presented in this chapter stemmed from work showing that there is a 
tonic  level  of  NO  continuously  synthesised  by  eNOS  in  the  rat  optic  nerve 
(Garthwaite  et  al.,  2006).  Chapter  3  addressed  the  underlying  mechanism  for  this 
tonic  NO  release,  finding  a  partial  involvement  of  PI3  kinase,  phosphorylation  of 
eNOS via the PI3 kinase-Akt pathway being among the key regulators of basal eNOS 
activity (Dimmeler et al., 1999; Fulton et al., 1999; Michell et al., 1999; Dudzinski et 
al., 2006). Founded on the data obtained from electrophysiological recordings (see 
Chapter 3) it was intended to determine the level of basal eNOS phosphorylation in 
rat  optic  nerves  by  means  of  a  more  direct  approach.  One  option  was  to  employ 
Western blotting, which would give a more direct read out in terms of the level of 
basal eNOS phosphorylation relative to the amount of total protein. Additionally, this 
would test whether the PI3 kinase inhibitors, LY 294002 and wortmannin, are acting 
through  the  alleged  mechanism  in  a  more  direct  way.  Previous  work  from  this 
laboratory  has  shown  that  there  is  also  a  tonic  level  of  NO  in  the  adult  rat 
hippocampus under basal conditions, the source being eNOS in blood vessels, finding 
this  tonic  NO  level  to  be  partly  sensitive  to  PI3  kinase  inhibition  (Hopper  & 
Garthwaite, 2006). Moreover, while in the optic nerve the eNOS-derived tonic NO 
appeared to modify the axonal membrane potential (Garthwaite et al., 2006), in the 
adult  rat  hippocampus  this  basal  level  of  NO  was  found  to  be  a  requisite  for 
hippocampal LTP (Bon & Garthwaite, 2003; Hopper & Garthwaite, 2006). Based on 
these findings, the aim was to use the hippocampal slice preparation as the control 
tissue in the Western blot experiments in the rat optic nerve. As the forgoing work 
(Bon & Garthwaite, 2003; Hopper & Garthwaite, 2006) used adult rat hippocampus, 
to allow a more direct comparison with what had been found in immature rat optic 
nerves (Chapter 3), the  primary aim was to determine the significance  of the PI3 
kinase pathway in maintaining tonic NO release in the immature rat hippocampus, 
replicating some of the experiments performed in Hopper and Garthwaite (2006).  
The  most  sensitive  and  reliable  method  available  at  the  time  to  monitor 
existing  endogenous  NO  levels  was  the  measurement  of  cGMP  levels  that  are 
sensitive to NOS inhibition (Griffiths et al., 2002). However, this method has a limit 4 4 4            M M Me e ec c ch h ha a an n ni i is s sm m m    f f fo o or r r    t t to o on n ni i ic c c    N N NO O O    s s sy y yn n nt t th h he e es s si i is s s    i i in n n    t t th h he e e    h h hi i ip p pp p po o oc c ca a am m mp p pu u us s s        
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of detection when looking at very low cGMP levels and/or changes of the cGMP 
signal  upon  pharmacological  manipulation.  One  important  hallmark  of  the 
hippocampus  is  very  high  activity  of  the  cyclic  nucleotide  degrading  enzyme 
phosphodiesterase (PDE), which contributes to the difficulty to measure detectable 
GMP levels. Therefore, in order to study endogenous NO production in unstimulated 
hippocampal slices, using cGMP as an index, it is necessary to firstly prevent cGMP 
breakdown and, secondly, to amplify the activity of the NOGC receptors. Fortunately, 
there are good pharmacological tools available to date to do just this.  
 
Several isoforms of PDE have been demonstrated to be localised in the rat 
hippocampus by means of in situ hybridisation and immunohistochemical approaches. 
These include PDE1, 2, 3 and 4 (Ludvig et al., 1991; Repaske et al., 1993; Furuyama 
et al., 1994; Reinhardt & Bondy, 1996), as well as PDE9 and, to a weaker extent, 
PDE5  (van  Staveren  et  al.,  2004).  However,  the  principal  PDE  iso-enzyme 
responsible for cGMP hydrolysis in the hippocampus appears to be PDE2 (Repaske et 
al., 1993; van Staveren et al., 2001; Suvarna & O’Donnell, 2002), being expressed 
throughout  postnatal  development  up  until  adulthood  alongside  PDE5  and  9  (van 
Staveren et al., 2003; van Staveren et al., 2004). The major role of PDE2 in cGMP 
hydrolysis in the hippocampus is emphasised by studies finding no detectable effect 
of  PDE1  and  PDE3  inhibition  on  cGMP  accumulation  in  the  hippocampus  (van 
Staveren et al., 2001; Suvarna & O’Donnell, 2002) and the fact that PDE4 is a cAMP-
specific PDE (Bender & Beavo, 2006) the inhibition of which would be of no benefit 
to the current study. Intuitively, the first approach would be to use a general PDE 
inhibitor such as IBMX in order to prevent any given PDE activity that could be 
governing the profile of the cGMP signal. However, this could impose a number of 
possible complications. First of all, the one PDE isoform not affected by IBMX is 
PDE9, so that a combination of PDE inhibitors would be required if one wanted to 
ensure the inhibition of this PDE isoform (e.g. IBMX and BAY 73-6691; Wunder et 
al.,  2005;  Bender  &  Beavo,  2006).  Also,  IBMX  is  not  a  ‘very  clean’  compound, 
antagonising adenosine receptors (Choi et al., 1988), which may modulate synaptic 
transmission  and  neuronal  excitability  (Dunwiddie  &  Fredholm,  1989;  Greene  & 
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neuronal firing, which is suggested to be the result of suppressed glutamate release 
(Mitchell  et  al.,  1993;  Wu  &  Saggau,  1994;  Fowler  et  al.,  1999).  Conversely, 
inhibition  of  adenosine  receptors  can  lead  to  an  increase  in  neuronal  firing.  An 
additional problem that may arise is related to the fact that IBMX would also prevent 
the  breakdown  of  cAMP,  so  that  crosstalk  between  cAMP  and  cGMP  signalling 
pathways may ensue (Vigne et al., 1994; Pelligrino & Wang, 1998; Bender & Beavo, 
2006)  making  the  interpretation  of  the  data  difficult.  As  mentioned  above,  the 
prevalent PDE isoform in the hippocampus appears to be the PDE2, which is not only 
strongly  expressed  in  hippocampal  neurons  (Repaske  et  al.,  1993)  but  also  in 
endothelial cells (Sadhu et al., 1999). Despite it being able to degrade both cAMP and 
cGMP with similar Km and Vmax in vitro (Martins et al., 1982; Bender & Beavo, 
2006),  evidence  coming  from  studies  on  cortical  neurons  and  hippocampal  slices 
indicates  that  cGMP  primarily  is  elevated  upon  PDE2  inhibition  (Suvarna  & 
O’Donnell, 2002; Boess et al., 2004). This could be explained by the presence of PDE 
isoforms  specifically  degrading  cAMP,  binding  this  cyclic  nucleotide  with  greater 
affinity than PDE2 (Bender & Beavo, 2006). A compound previously used as a PDE2 
inhibitor is EHNA. However, not only does this compound exhibit a poor potency 
towards PDE2, it also potently inhibits adenosine deaminase (Sattin & Rall, 1970; 
Vargeese  et  al.,  1994;  Caiolfa  et  al.,  1998),  therefore  potentially  increasing 
extracellular adenosine levels (Cunha et al., 1998).  
 
The cGMP signal of main interest in this study corresponds to a low tonic NO 
level  prevailing  in  unstimulated  hippocampal  slices.  Therefore,  to  achieve  an 
improvement in the signal-to-noise ratio, the compounds BAY 60-7550 and BAY 41-
2272  were  used.  The  former  is  a  recently  developed,  highly  selective  and  potent 
PDE2 inhibitor devoid of the other actions seen in the case of EHNA (Boess et al., 
2004). BAY 41-2272, is used to further amplify the cGMP signal, being an allosteric 
enhancer  of  NOGC  receptor  activity  sensitising  NOGC  receptors  towards  very  low 
(picomolar) concentrations of NO (Stasch et al., 2001; Garthwaite, 2005; Roy et al., 
2008). 
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4.2   AIM 
 
The initial aim of this study was to test the hypothesis that tonic NO release under 
basal  conditions  in  immature  rat  hippocampal  slices  is  mediated  via  PI3  kinase-
dependent phosphorylation of eNOS, further evaluating that it is this NOS isoform 
that is the principal source of endogenous tonic NO levels.  
 
 
4.3   METHODS 
 
4.3.1   Hippocampal slice preparation and in vitro maintenance 
 
Ten-day-old Sprague Dawley rats from Charles River UK Ltd were used. The animals 
were sacrificed by cervical dislocation followed by decapitation as approved by the 
UK Home Office Schedule 1 regulations. The cranium was cut along the midline and 
gently peeled away, followed by removal and placement of the brain into ice-cold, 
pre-oxygenated  aCSF.  Brains  were  first  severed  through  the  hemisphere-midline 
before the hippocampus of each hemisphere was isolated and carefully cleaned of 
adhering brain tissue. Transverse slices (400 µm; Fig. 4.1) were cut from the central 
portion of the hippocampus using a McIlwain tissue chopper (The Mickle Laboratory 
Engineering Co. Ltd). The slices from each hippocampus were kept in separate 50 ml 
Erlenmeyer  flasks  containing  20  ml  pre-oxygenated,  cold  aCSF.  Flasks  were 
transferred to a shaking water bath for a recovery period of 1-2 hours at 37°C with a 
constant stream of 95% O2 / 5% CO2 flowing through the inlet stopper. 
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Fig. 4.1 Transverse hippocampal section, including a schematic outline of the basic anatomy of the 
hippocampus (Source: Neves et al., 2008) 
 
 
4.3.2   Aortic ring preparation 
 
Aortic  rings  were  prepared  from  10-day-old  Sprague  Dawley  rats  (Charles  River, 
Margate,  UK).  The  animals  were  sacrificed  humanely  according  to  Home  office 
regulations by cervical dislocation. Upon exposure of the aorta, adhering perivascular 
connective tissue was gently cleaned away, and the thoracic portions rapidly removed 
and immediately immersed in cold aCSF that had been pre-equilibrated with 95% O2 / 
5% CO2. Subsequent to gently flushing out the remaining blood from the aortas, 2-3 
mm aortic ring segments were cut using a razor blade. On average 6 to 8 rings were 
obtained  per  aorta.  Aortic  rings  were  transferred  into  50  ml  Erlenmeyer  flasks 
containing 20 ml pre-oxygenated, cold aCSF, and left to recover in a shaking water 
bath for 1-2 hours at 37ºC with a constant stream of 95% O2 / 5%  CO2 flowing 
through the inlet stopper.  
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4.3.3   Experimental treatment of slices and cGMP measurements by  
means of radioimmunoassay (RIA) 
 
Subsequent to the recovery period at 37ºC in the shaking water bath, rat hippocampal 
slices  (or  aortic  rings)  were  randomised,  transferring  them  to  fresh  aCSF  before 
starting the pharmacological treatments. Equilibration with 95% O2 / 5% CO2 at 37°C 
occurred throughout the experiment. Except for the slices providing the measurements 
for  ‘basal’  cGMP  levels,  hippocampal  slices  were  pre-incubated  with  the  PDE2 
inhibitor BAY 60-7550 for 15 min before adding any agonists and left to be present 
throughout the experiment. Aortic rings were incubated for the same interval with the 
general PDE inhibitor IBMX. All antagonists to be tested were applied for a certain 
interval prior to BAY 60-7550 and then continued to be present for the remainder of 
the experiment. Except for LY 294002 and wortmannin, which were applied 20 min 
prior to BAY 60-7550, all other inhibitors tested were incubated for 10 min prior to 
BAY 60-7550 exposure. Exposure of hippocampal slices to PAPA/NO, NMDA and 
BAY 41-2272 were for 5 min, 2 min and 5 min respectively, and ACh was applied for 
1  min  in  the  case  of  aortic  rings.  To  inactivate  the  biological  reaction  within  the 
tissue, each of the slices or aortic rings were transferred into a separate Eppendorf 
tube containing 250 µl of boiling inactivation buffer at the appropriate time, and left 
to boil for at least 15 min. Tissue samples were then left to cool to room temperature 
and homogenised by sonication, and the protein content measured using the BCA 
Protein  Assay  Kit.  Afterwards,  samples  were  centrifuged  at  800  rpm  for  10  min, 
discarding the debris. The supernatant was used to determine the cGMP amount by 
means of RIA as described in detail in Chapter 2. The level of cAMP was quantified 
using the 
3H-cAMP kit (GE Healthcare, Amersham Bioscience, Bucks, UK). 
 
 
4.3.4   Analysis 
 
The procedure for determining cGMP content normalised to protein amount has been 
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from  at  least  two  different  slices  per  animal,  testing  at  least  three  rats.  Statistical 
evaluation was carried out using ANOVA with Dunnett’s test in GraphPad  InStat 
version 3 (GraphPad Software, Inc., San Diego, CA, USA), statistical significance 
being accepted at P < 0.05. 
 
 
4.4   RESULTS 
 
4.4.1   Identification of suitable concentrations of BAY 41-2272 and the  
PDE2 inhibitor BAY 60-7550 
 
The aim of this part of this study was to evaluate the basal NO synthesis under resting 
conditions in the immature rat hippocampus alongside examining hippocampal slice 
viability. To assess hippocampal slice viability first, the amount of cGMP formation in 
response to NMDA was determined. The rise in cGMP in response to NMDA depends 
on nNOS, therefore providing an index for neuronal NO formation within the slices. 
NMDA (1-300 µM) in the presence of BAY 60-7550 (1 mM) gave rise to concentration-
dependent cGMP accumulation (Fig. 4.2a), as did the NO donor PAPA/NO (Fig. 4.2b).  
Despite the presence of the PDE2 inhibitor BAY 60-7550 (1 µM), basal cGMP 
levels in hippocampal slices were near to being undetectable (Fig. 4.2d,e). However, it 
is this basal level of cGMP that is related to the tonic endogenous NO level, the main 
subject of the study presented in this chapter. A pharmacological approach provides a 
solution to this problem. The compound BAY 41-2272 acts allosterically to sensitise 
NOGC receptors to NO, pulling the equilibrium over to the active species of the NOGC 
receptor (Roy  et al., 2008). The net result in  general is enhanced  activity of NOGC 
receptors in the presence of low NO levels, where it has been suggested that in the 
presence of BAY 41-2272 the NOGC receptors would exhibit low picomolar sensitivity 
for NO (Garthwaite, 2005; Roy et al., 2008). Exposures of slices to BAY 41-2272 (0.3-
30 µM) in the presence of BAY 60-7550 (1 mM) resulted in a concentration-dependent 
increase in cGMP levels (Fig. 4.2c), which was inhibited by the broad-spectrum NOS 
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Fig. 4.2e). This confirmed that the response to BAY 41-2272 is NO-dependent and 
corresponds to a boost in NOGC receptor activity.  
 
 
 
 
                 
 
 
                 
 
 
 
 
 
 
 
 
 
 
FIG. 4.2 Concentration-response curves for NMDA,                                                                                    
PAPA/NO, and BAY 41-2272 in rat hippocampal slices.                                                                                            
A-B: Concentration-dependent increase in cGMP in                                                                                                
response to ascending concentrations of NMDA (A) or                                                                                       
PAPA/NO (B) in the presence of the PDE2 inhibitor                                                                                                  
BAY 60-7550 at its maximal concentration of 1 µM, an                                                                                              
index for brain slice viability (n = 5-6). C: Concentration-                                                                                   
dependent increase in cGMP in response to ascending                                                                                     
concentrations of BAY 41-2272 in the presence of the                                                                                              
PDE2 inhibitor BAY 60-7550 at its maximal concentration                                                                                             
of 1 µM (n = 6-12). D: Concentration-response curve for                                                                                           
BAY 41-2272 in hippocampal slices incubated with the                                                                                              
PDE2 inhibitor BAY 60-7550 in the absence and presence of L-NNA, verifying the dependence of the BAY 41- 
2272 effect on endogenous NO. The cGMP signal in response to all tested BAY 41-2272 concentrations was 
prevented  by  L-NNA  (n  =  4-6).  E:  Concentration-response  curve  for  BAY  41-2272  in  hippocampal  slices 
incubated with the PDE2 inhibitor BAY 60-7550 in the absence and presence of ODQ, further verifying the NO-
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dependence of the cGMP response evoked by BAY 41-2272. The cGMP signal in response to all tested BAY 41-
2272 concentrations was prevented by ODQ (n = 5-6). 
 
 
The present study uses the recently developed PDE2 inhibitor BAY 60-7550. 
In adult rat hippocampal slices this compound raised cAMP levels as well as cGMP, 
significant  cAMP  levels  being  detected  when  the  concentration  of  BAY  60-7550 
exceeded 1 µM (Boess et al., 2004). Although, according to the observations made in 
adult  hippocampal  slices,  1  µM  of  BAY  60-7550  should  be  a  reasonable 
concentration to use, it is yet possible that the potency of BAY 60-7550 to increase 
cAMP formation in young hippocampal slices differs, as appears to be the case for 
NMDA-  and  BAY  41-2272-evoked  responses  (compare  Boess  et  al.,  2004  and 
Hopper  &  Garthwaite,  2006  with  the  present  data).  It  has  been  reported  that  NO 
release from eNOS and its phosphorylation via the PI3 kinase-Akt pathway may also 
be stimulated directly by cAMP (Zhang & Hintze, 2006). Also PKA has been found 
to stimulate eNOS, but in this case in a PI3 kinase-independent manner (Boo et al., 
2002a; Boo et al., 2002b). It has been implied that PKA does not necessarily act in 
association with cAMP in this respect. For example, among the cAMP-independent 
mechanisms proposed is direct activation of PKA by vasoactive peptides including 
endothelin-1  and  angiotensin  II  (Dulin  et  al.,  2001).  Nonetheless,  a  factor  which 
directly increases cAMP in endothelial cells would also stimulate PKA. Additionally, 
it has been reported that the kinase Akt may be activated in a PI3 kinase-independent 
manner by cAMP (Sable et al., 1997). For this to occur in the preparation investigated 
in the present study, cAMP would need to be raised within the blood vessels. The 
finding of PDE2 expression in a variety of microvessels, including within the brain 
(Sadhu et al., 1999), makes the odds of cAMP interfering with the response under 
investigation  more  likely.  Furthermore,  BAY  60-7550  has  been  found  to  have 
inhibitory actions on purified PDE1 and PDE5 (Boess et al., 2004). PDE5 inhibition 
(van Staveren et al., 2003; van Staveren et al., 2004; Rutten et al., 2005), but not 
PDE1 inhibition (van Staveren et al., 2001), has been shown to raise cGMP levels in 
the hippocampus marginally. To address the concentration of BAY 60-7550 required 
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slices were tested for cAMP accumulation in the presence of different BAY 60-7550 
concentrations. The previously reported effects of BAY 60-7550 on PDE1 and PDE5 
were examined on purified enzyme (Boess et al., 2004). Based on aspects such as 
diffusion  properties  of  a  compound  in  a  whole  tissue,  it  is  likely  that  higher 
concentrations  of  BAY  60-7550  would  be  required  in  order  to  exhibit  actions 
observed on purified PDEs. Nonetheless, the concentrations of BAY 60-7550 tested 
in the cAMP assays in the current work were kept below the ones which had been 
shown to inhibit PDE isoforms other than PDE2. One more aspect to consider is the 
potential crosstalk between cyclic nucleotides such as the ability of cGMP to inhibit 
cAMP-specific PDEs, which would in turn lead to enhanced cAMP levels (Bender & 
Beavo, 2006). Overall, the aim in this section was to identify a concentration of BAY 
60-7550  that  would  not  only  be  devoid  of  interfering  actions,  but  would  also 
nonetheless result in a good window of cGMP formation when applied in conjunction 
with BAY 41-2272. A good window of cGMP level was considered to be submaximal 
but large enough so that the signal-to-noise ratio would not impose a problem when 
looking at inhibition of the response.  
Exposure of hippocampal slices to different concentrations of BAY 60-7550 
(0.001-1 µM) in the presence of a set concentration of BAY 41-2272 (1 µM; Fig. 
4.3a, or 3 µM; Fig. 4.3b) led to concentration-dependent increase in cGMP, which 
was prevented by L-NNA (100 µM) and ODQ (10 µM), the basal level of cGMP 
(with or without added BAY 60-7550) again being near to undetectable when BAY 
41-2272 had not been applied (Fig. 4.3a,b).  
To test whether cAMP was capable of evoking an increase in basal cGMP 
levels in the presence of the PDE2 inhibitor, the two highest concentrations of BAY 
60-7550 tested (0.1 and 1 µM) were probed in the presence of the adenylyl cyclase 
activator forskolin (10 µM). Incubation of slices with these two test concentrations of 
BAY 60-7750, followed by exposure to forskolin, failed to evoke a significant rise in 
cGMP as  compared to the basal level  with or  without added  BAY 60-7550 (Fig. 
4.3b). The lowest concentration of BAY 60-7550 that still resulted in an adequate 
window  of  cGMP  accumulation,  and  should  be  devoid  of  interfering  actions  as 
outlined above, was found to be in the 10 nM range, combined with 3 µM BAY 41-
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general PDE inhibitor IBMX in the presence of either forskolin (1 and 10 µM) or 
BAY  41-2272  (3  µM),  the  latter  determining  whether  cGMP  accumulation  under 
these conditions can raise cAMP levels. IBMX caused a greater increase in cAMP 
compared to the basal level with or without added BAY 60-7550 (Fig. 4.4; given in 
pmol cGMP/mg protein: ‘IBMX only’ vs. ‘basal’, ’10 nM BAY 60-7550 only’ and 
‘30 nM BAY 60-7550 only’ was 13.38 ± 0.73 vs. 3.47 ± 0.75, p < 0.001, 4.69 ± 0.67, 
p < 0.001, and 3.94 ± 0.39, p < 0.001 respectively), as would be expected when many 
different PDE isoforms are inhibited. Inhibition of PDE2 with 10 or 30 nM BAY 60-
7550 also evoked an increase in cAMP when the adenylyl cyclase was activated by 
forskolin,  albeit  to  lesser  extent  than  IBMX  (Fig.  4.4;  given  in  pmol  cGMP/mg 
protein: ‘IBMX + 1 µM forskolin’ vs. ’10 nM BAY 60-7550/forskolin’ and ‘30 nM 
BAY  60-7550/forskolin’  was  75.79  ±  1.9  vs.  8.19  ±  1.77  and  13.04  ±  1.09 
respectively,  p  <  0.001;  ‘IBMX  +  10  µM  forskolin’  vs.  ‘10  nM  BAY  60-
7550/forskolin’ and ‘30 nM BAY 60-7550/forskolin’ was 165.4 ± 6.4 vs. 55.5 ± 0.3 
and 62.1 ± 10.4 respectively, p < 0.001). This is consistent with PDE2 being a dual 
substrate enzyme that hydrolyses both cAMP and cGMP (Bender & Beavo, 2006). 
However, stimulating cGMP synthesis by applying BAY 41-2272 failed to induce a 
significant rise in cAMP levels when the PDE2 inhibitor BAY 60-7550 was present, 
being not significantly different from cAMP levels measured under basal conditions 
in the absence or presence of BAY 60-7550 (Fig. 4.4), suggesting that there is no 
crosstalk occurring between the two cyclic nucleotides under these conditions. Direct 
stimulation of cAMP accumulation by  forskolin (1µM) in the presence of 10 nM 
BAY 60-7550 failed to raise cAMP levels significantly compared to the basal level 
with or without added BAY 60-7550, while in the presence of 30 nM BAY 60-7550 
and  forskolin  (1  µM)  this  resulted  in  a  significant  difference  in  cAMP  levels  as 
compared to the basal level with or without added BAY 60-7550 (Fig. 4.4; given in 
pmol cGMP/mg protein: 30 nM BAY 60-7550 + forskolin vs. ‘basal’, ‘10 nM BAY 
60-7550 only’, and ‘30 nM BAY 60-7550 only’ was 13.04 ± 1.09 vs. 3.47 ± 0.75, p < 
0.001, 4.69 ± 0.67, p < 0.001, and 3.94 ± 0.39, p < 0.001 respectively). The levels of 
cAMP measured under conditions where only BAY 60-7550 was present at 10 or 30 
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In summary, 10 nM of the PDE2 inhibitor BAY 60-7550 was chosen for all 
subsequent  experiments.  This  concentration  resulted  in  a  good  window  of  cGMP 
accumulation  when  slices  were  exposed  to  BAY  41-2272  (3  mM),  and  does  not 
enhance cAMP formation or inhibit PDE isoforms other than PDE2, as described 
above.  Moreover,  at  10  nM  BAY  60-7550,  no  crosstalk  between  the  two  cyclic 
nucleotides was apparent as forskolin failed to raise cGMP significantly and BAY 41-
2272  did  not  evoke  a  significant  increase  in  cAMP.  As  to  the  BAY  41-2272 
concentration, 3 µM was chosen to be used in conjunction with the PDE2 inhibitor, a 
concentration at which BAY 41-2272 lacks PDE inhibitory activity (Stasch et al., 
2001; Mullershausen et al., 2004a). 
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FIG. 4.3 Concentration profile of the PDE2 inhibitor BAY 60-7550 on cGMP accumulation. A: cGMP 
accumulation in response to 1 µM BAY 41-2272 in the presence of ascending concentrations of BAY 60-7550. 
The cGMP signal was prevented by both L-NNA and ODQ, confirming NO- and cGMP-dependence respectively 
(n = 3). B: cGMP accumulation in response to 3 µM BAY 41-2272 in the presence of ascending concentrations of 
BAY 60-7550. The cGMP signal was prevented by both L-NNA and ODQ, confirming NO- and cGMP-
dependence respectively. Also, the adenylyl cyclase activator forskolin failed to evoke an increase in cGMP 
synthesis (n = 3). Note the low cGMP signal detectable under basal conditions in the absence or presence of BAY 
60-7550. 
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FIG. 4.4 Concentration profile of the PDE2 inhibitor BAY 60-7550 on cAMP accumulation. The adenylyl cyclase 
activator forskolin evoked a concentration-dependent increase in cAMP accumulation in the presence of the non-
specific PDE inhibitor IBMX and the PDE2 inhibitor BAY 60-7550. The guanylyl cyclase sensitizer BAY 41-
2272 failed to evoke a significant increase in cAMP synthesis (n = 3). Note: Except in the case of IBMX, the 
cAMP level detected under conditions of BAY 60-7550 application alone was not significantly different from that 
measured under basal conditions. 
 
 
4.4.2   Underlying cause of tonic NO synthesis – the role of PI3 kinase 
 
As described earlier, one of the key mechanisms thought to be responsible for 
tonic eNOS activity is the PI3 kinase-Akt pathway, which was found to be partially 
contributing  to  basal  eNOS-derived  NO  synthesis  in  the immature  rat  optic  nerve 
(Chapter 3) and in the adult rat hippocampus (Hopper & Garthwaite, 2006).  
In immature rat hippocampal slices, the PI3 kinase inhibitors LY 294002 (100 
µM) and wortmannin (1 µM) were tested against the cGMP accumulation in response 
to 3 µM BAY 41-2272 and 10 nM of the PDE2 inhibitor BAY 60-7550, a condition 
that gave a good window to work with in terms of the cGMP signal (see above). 
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(Fig. 4.5), questioning the involvement of the PI3 kinase pathway in the maintenance 
of basal eNOS activity in the developing rat hippocampus as opposed to the rat optic 
nerve (Chapter 3) and the adult rat hippocampus (Hopper & Garthwaite, 2006). In 
contrast, exposing the slices to the broad-spectrum NOS inhibitor L-NNA, inhibiting 
the  enzyme  more  directly  by  preventing  the  substrate  for  NO  synthesis  (i.e.  L-
arginine) to bind to the enzyme, prevented the cGMP signal down to basal levels (Fig. 
4.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 4.5 Role of the PI3 kinase in the maintenance of basal NO release. Two different PI3 kinase inhibitors, LY 
294002 and wortmannin, both failed to significantly affect the cGMP levels that were measured in the presence of 
BAY 41-2272 and PDE2 inhibitor (n = 6-9; 
nsp > 0.05). In contrast, consistent with previous results, the NOS 
inhibitor L-NNA prevented the cGMP signal, in line with the response being dependent on endogenous NO. Also, 
as previously observed, only a very low cGMP signal could be detected both under basal conditions or when BAY 
60-7550 was applied exclusively. 
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contributing to or being responsible for the level of tonic NO in the immature rat 
hippocampus, one alternative explanation for the lack of inhibitory effect of the PI3 
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receptor enhancer BAY 41-2272. It is suggested that in the presence of BAY 41-2272, 
NOGC receptors would exhibit low picomolar NO sensitivity (Garthwaite, 2005; Roy 
et al., 2008). Such NO levels may persist in the hippocampal slices even following 
PI3 kinase inhibition. If this were the case, long enough application of BAY 41-2272 
would  more  slowly,  but  yet  eventually,  drive  the  cGMP  signal  to  a  level  that 
approaches  that  seen  in  the  absence  of  a  PI3  kinase  inhibitor.  Related  to  this 
argument, the scope of inhibition may depend on whether at 5 min application of 
BAY 41-2272 the cGMP response has reached steady-state or is still in its rising 
phase. A greater antagonistic effect would be expected during the rising phase of the 
agonist-evoked  response.  This  has  been  shown,  for  example,  in  the  case  of  the 
inhibitory action of ODQ on NO-induced cGMP increases (Mo et al., 2004). To test 
this idea in the light of the present investigation, experiments were performed to look 
at the responses to BAY 41-2272 at different time points in the absence and presence 
of a PI3 kinase inhibitor. If the above arguments hold, one would predict a greater 
degree of inhibition by the PI3 kinase inhibitor at the early time points.  
The level of cGMP was determined in response to BAY 41-2272 (1 µM) and 
the PDE2 inhibitor BAY 60-7550 (10 nM) at the time points 30 s, 1 min, 2 min and 5 
min in the absence and presence of wortmannin (1 µM). No difference in the degree 
of inhibition was found among the different time points (Fig. 4.6), further disputing 
the participation of the PI3 kinase pathway in preserving basal NO synthesis in the 
immature hippocampus. 
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FIG. 4.6 Role of the PI3 kinase in the maintenance of tonic NO release – dependence on the application time of 
BAY 41-2272. In comparison with the respective controls, the PI3 kinase inhibitor wortmannin failed to reduce the 
cGMP accumulation significantly in response to BAY 41-2272, irrespective of the time BAY 41-2272 had been 
applied for (n = 3; 
nsp > 0.05). 
 
 
4.4.3   Identification of NOS isoforms responsible for tonic NO     
synthesis 
 
Since the PI3 kinase pathway is apparently not involved in the maintenance of 
tonic  NO  release  in  the  immature  rat  hippocampus,  the  mechanism(s)  and  the 
source(s) of basal tonic NO synthesis remained to be determined. Firstly, the aim was 
to try to dissect out which isoform(s) of NOS the tonic NO is coming from – eNOS 
and/or nNOS. To test the involvement of nNOS, two different nNOS inhibitors (L-
VNIO and NPA) and an inhibitor that exerts greater inhibitory potency for iNOS than 
nNOS (1400W; Garvey et al., 1997; Boer et al., 2000; Young et al., 2000) were 
employed. 
The cGMP signal was measured in hippocampal slices that had been treated 
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one of the nNOS inhibitors, L-VNIO (100 nM) or NPA (1 µM), or the nNOS/iNOS 
inhibitor  1400W  (1  µM;  Fig.  4.7).  All  of  the  inhibitors  used  were  applied  at  a 
concentration effective in the adult hippocampus (Hopper & Garthwaite, 2006). The 
cGMP  response  to  BAY  41-2272,  which  corresponds  to  endogenous  basal  NO 
production, was unaffected by these inhibitors (Fig. 4.7). This would immediately 
point  to  eNOS  as  being  the  major  source  for  tonic  NO  synthesis.  However, 
puzzlingly, control responses to NMDA (100 µM), which depend on nNOS, were also 
not affected significantly by the nNOS/iNOS inhibitors in the same experiments (Fig. 
4.7), making the interpretation of these data difficult. Overall, this result makes it 
impossible at this stage to conclude anything about the involvement of NOS isoforms 
other than eNOS as contributors to the ongoing basal NO synthesis. In contrast, L-
NNA, which inhibits all NOS isoforms, prevented both the NMDA-induced and the 
BAY 41-2272-evoked cGMP accumulation accordingly (Fig. 4.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 4.7 Source of basal endogenous NO – nNOS/iNOS. The nNOS inhibitors NPA and L-VNIO, as well as the 
nNOS/iNOS inhibitor 1400W, at their usual working concentrations, all failed to reduce cGMP levels in the 
presence of BAY 41-2272 and the PDE2 inhibitor BAY 60-7550 as compared with their respective control (n = 6; 
nsp > 0.05) . This would be indicative of NOS isoforms other than eNOS not being significant contributors to 
ongoing NO synthesis under basal conditions. However, unexpectedly, the same inhibitors also fell short in 
preventing the cGMP signal significantly in response to NMDA, making the interpretation of this data problematic 
(n = 6; 
nsp > 0.05). 
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One reason for the above result shown in Fig. 4.7 may be that the applied 
concentrations of the nNOS/iNOS inhibitors are not maximal for inhibition in the 
immature hippocampus, despite showing clear inhibitory activity against the cGMP 
signal in response to NMDA in the adult hippocampus (Hopper & Garthwaite, 2006). 
This possibility can be extended based on comparison of the data presented here to 
those obtained from adult hippocampal slices (Hopper & Garthwaite, 2006). In the 
forgoing study by Hopper & Garthwaite (2006), the nNOS/iNOS inhibitors, used at 
the same concentrations as here, prevented the control responses to NMDA. However, 
30 µM BAY 41-2272 was required to increase cGMP to levels that were only about a 
fifth of what is observed here in immature hippocampal slices exposed to only 3 µM 
of this compound. Also, 100 µM NMDA, the same concentration used here, produced 
cGMP  levels  in  adult  hippocampal  slices  that  were  only  about  a  third  of  what  is 
yielded here from immature hippocampal slices. These differences may indicate why 
higher concentrations of the nNOS/iNOS inhibitors may be required to accomplish 
significant inhibition of the cGMP signal in response to NMDA. To test this idea, the 
aim  of  the  following  set  of  experiments  was  to  look  at  concentration-dependent 
inhibition of the NMDA-evoked cGMP signal by these inhibitors. As nNOS is of the 
main  interest  here,  iNOS  being  usually  only  induced  under  certain  pathological 
conditions over a course of several hours (Iadecola et al., 1995; Iadecola et al., 1996; 
Moro et al., 1998; Yamada et al., 2003 and is absent in hippocampal slices subjected 
to  standard  treatment  and  incubation  (Hopper  &  Garthwaite,  2006),  only  the 
inhibitory  actions  of  L-VNIO  and  NPA  were  examined  in  the  following  set  of 
experiments.  
First, the concentrations of these inhibitors required to prevent the response to 
NMDA  were  established  by  producing  concentration-inhibition  curves  (Fig.  4.8). 
Surprisingly,  approximately  10-fold  higher  concentrations  of  both  inhibitors  were 
necessary in order to achieve efficient inhibition (80-90%) of the response to NMDA 
(Fig.  4.8)  and  that  was  similar  to  the  degree  of  inhibition  observed  in  adult 
hippocampal slices (Hopper & Garthwaite. 2006).  
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FIG. 4.8 Effect of nNOS inhibitors on NMDA-stimulated cGMP accumulation. A-B: Concentration-effect curve 
for NPA (n = 6; IC50 = 1.4 ± 0.43 µM). C-D: Concentration-effect curve for L-VNIO (n = 6; IC50 = 0.28 ± 0.08 
µM). Note, for both inhibitors a concentration-dependent decrease in cGMP levels was observed in the presence 
of increasing concentrations of nNOS inhibitor. Furthermore, cGMP accumulation was prevented in the presence 
of  L-NNA, providing confirmation of the NMDA-induced response entailing NO. 
 
 
Having  identified  the  profile  of  inhibition  of  the  nNOS  inhibitors  in  the 
immature hippocampus, the question now was whether the concentration at which the 
response to NMDA was prevented would also inhibit the cGMP signal upon BAY 41-
2272 exposure. The prediction is that if eNOS is the solitary contributor to basal NO 
levels the response to BAY 41-2272 should not be prevented by inhibition of nNOS.  
Exposure of hippocampal slices to BAY 41-2272 (3 µM) and BAY 60-7550 
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led to significant inhibition of the cGMP signals (Fig. 4.9a,b). Lower concentrations 
of  nNOS  inhibitor  failed  to  reduce  the  cGMP  level  in  response  to  BAY  41-2272 
markedly (Fig. 4.9a), as was the case for NMDA-evoked responses (Fig. 4.9a), the 
latter  implying  only  partial  inhibition  of  nNOS.  As  the  cGMP  response  was  only 
reduced by approximately 50%, these data indicate that both eNOS and nNOS may 
partially be involved in keeping up the NO production at basal level. As there are no 
inhibitors available for eNOS, it was not possible to test whether the remainder of the 
response could be prevented when both nNOS and eNOS were selectively inhibited. 
Also,  there  is  still  the  likelihood  that  the  degree  of  inhibition  observed  at  higher 
concentrations of nNOS inhibitors is because they affect eNOS also. Therefore, a way 
was sought to find out whether the degree of inhibition observed was due to nNOS 
inhibition  only  (see  Fig.  4.10).  If  this  were  the  case,  it  would  provide  reason  to 
hypothesise that both nNOS and eNOS may partially be responsible for tonic NO 
synthesis.  
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FIG. 4.9 Effect of nNOS inhibitors on NMDA-stimulated and BAY 41-2272-evoked cGMP accumulation A: The 
NMDA-induced cGMP response was concentration-dependently reduced in the presence of increasing 
concentrations of L-VNIO. In contrast, in the case of BAY 41-2272, only the maximal concentration of nNOS 
inhibitor tested (i.e. concentration of nNOS inhibitor required to prevent the cGMP level in response to NMDA) 
resulted in a significant decrease in the cGMP level (n = 3; **p < 0.01). B: The cGMP increase in response to 
BAY 41-2272 was only significantly reduced at the concentration of NPA that was required to prevent the cGMP 
level in response to NMDA (n = 3; 
‡p < 0.002). 
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It is well known that stimulation of NO synthesis in blood vessels by ACh 
occurs  via  eNOS  activation  (Furchgott  &  Zawadzki,  1980)  and  aortas  from  mice 
lacking eNOS have been shown to lack a dilating response to ACh (Huang et al., 
1995). This standard way  of generating NO from eNOS was exploited to test the 
selectivity of the nNOS inhibitors. The question was whether the concentrations of L-
VNIO and NPA that significantly reduced the cGMP level in response to BAY 41-
2272 (see Fig. 4.9a,b) were only due to nNOS inhibition or were also affecting the 
activity of eNOS.  
Aortic rings cut from 10-day-old rat aortas were stimulated with ACh (10 µM) 
in the absence or presence of ascending concentrations of the two nNOS inhibitors 
(Fig. 4.10). Concentrations that led to partial inhibition of the response to BAY 41-
2272 (Fig. 4.9a,b) and prevention of the NMDA-evoked signal as well (Fig. 4.8a,c 
and Fig. 4.9a), also resulted in partial reduction of the cGMP level evoked by ACh in 
the rat aorta (Fig. 4.10).  
From this it can be concluded that, at least in the immature rat hippocampus, 
the allegedly selective nNOS inhibitors L-VNIO and NPA, do not seem to be suitable 
tools for identifying the isoform of NOS involved in the biological response under 
investigation. From these data, showing a clear overlap of selectivity of these nNOS 
inhibitors  between  eNOS  and  nNOS,  in  conjunction  with  a  lack  of  good  eNOS 
inhibitors, it is impossible to determine whether only one or both of the two NOS 
isoforms are responsible for the persistent NO release under basal conditions in the 
immature rat hippocampus.  
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FIG. 4.10 Rat aorta control – effect of nNOS inhibitors on ACh-stimulated eNOS-dependent cGMP accumulation. 
Note, concentrations of both L-VNIO and NPA, which were previously found to significantly affect the cGMP 
increase in response to BAY 41-2272 in hippocampal slices, also reduced the ACh-evoked cGMP response in rat 
aortas (n = 4; *p < 0.05, **p < 0.01, 
‡p < 0.001). 
 
 
4.4.4   What maintains tonic NO?  
 
Possible involvement of glutamate receptors, Na
+
 channels and GABA 
 
The  cGMP  response  seen  upon  NMDA  receptor  activation  is  related  to 
glutamate-evoked, Ca
2+-dependent activation of nNOS in neurons (Garthwaite et al., 
1988; Garthwaite, 1991). There is a possibility that basal neuronal activity sustains 
neurons in a depolarised state, which may result from basal glutamate release and 
some glutamate receptor activation. This could ultimately aid in establishing tonic 
nNOS  activity.  A  further  test  for  the  involvement  of  nNOS  in  the  basal  NO 
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production was to determine whether the cGMP response associated with endogenous 
NO could be prevented when NMDA receptors were inhibited. Additionally, AMPA 
receptors and voltage-dependent Na
+ channels can also participate in the activation of 
nNOS  (Southam  et  al.,  1991).  Moreover,  during  certain  stages  of  postnatal 
development the neurotransmitter GABA is excitatory before adopting its inhibitory 
nature (Ben-Ari, 2002; Ben-Ari et al., 2007). This is the result of an initially high 
intracellular chloride concentration based on the delayed expression of the K
+ - Cl
- co-
transporter.  An  interesting  feature  of  the  excitatory  nature  of  GABA  during 
development is the occurrence of so-called giant depolarising potentials (GDPs). This 
is a network-driven pattern of electrical activity in developing circuits which leads to 
the generation of large intracellular Ca
2+ oscillations (Ben-Ari, 2001). In addition, the 
switch from an excitatory to an inhibitory nature of GABA during development is 
suggested  to  take  place  during  the  second  postnatal  week  in  the  hippocampus 
(Khazipov et al., 2004; Ben-Ari et al., 2007). Noting that the present work is carried 
out on 10-day-old hippocampal slices, there is the possibility of GABA evoking Ca
2+ 
oscillations that could ultimately lead to NO synthesis. Using pharmacological agents, 
the  aim  of  the  following  set  of  experiments  was  to  examine  if  any  of  the  above 
neurotransmitters are linked to the tonic NO formation in the immature hippocampal 
slices. 
The responses to BAY 41-2272 (3 µM), in the presence of PDE2 inhibitor, 
remained  unaffected  by  the  NMDA-R  antagonist  D-AP5  (100  µM),  the  AMPA-
R/kainate-R antagonist CNQX (30 µM), and the Na
+ channel blocker TTX (1 µM; 
Fig. 4.11a), the inhibition of the responses to NMDA and veratrine by the respective 
antagonists  serving  as  positive  controls  (Fig.  4.11a).  Also  the  GABAA  receptor 
antagonist bicuculline (50 µM) and the GABAB receptor antagonist CGP 55845 (3 
µM) failed to exhibit an effect on the cGMP signal (Fig. 4.11b). The non-selective 
NOS  inhibitor  L-NNA  prevented  cGMP  accumulation  as  expected  (Fig.  4.11a,b). 
These data suggest that, although cGMP levels in unstimulated hippocampal slices are 
NO-dependent, it is unlikely that any of the above systems are linked to tonic NO 
production. 
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FIG. 4.11 Effect of pharmacological agents inhibiting GABA receptors, Na
+ channels, or glutamate receptors on 
cGMP levels. A: Effect of pharmacological agents, blocking Na
+ or GluRs, on cGMP levels. Incubation of 
hippocampal slices in aCSF containing the PDE2 inhibitor BAY 60-7550 and BAY 41-2272 in the absence or 
presence of APV to block NMDA receptors, CNQX to block AMPA receptors and TTX to block Na
+ channels. 
While causing clear inhibition when tested against the agonist, none of the agents produced significant inhibition 
of the cGMP level in response to BAY 41-2272, while L-NNA did, the latter being in line with the BAY 41-2272-
evoked response being endogenous NO-dependent (n = 6-9; 
‡p < 0.001). B: Effect of GABA receptor inhibition. 
Incubation of hippocampal slices in aCSF containing the PDE2 inhibitor BAY 60-7550 and BAY 41-2272 in the 
absence or presence of bicuculline or CGP 55845 to block GABAA or GABAB receptors respectively. No 
significant inhibition of the cGMP response to BAY 41-2272 occurred, while L-NNA abolished the cGMP signal 
as expected (n = 3-6; 
nsp > 0.05). 
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Calcium dependence  
 
As described in the main introduction (Chapter 1), both constitutive isoforms 
of NOS (eNOS and nNOS) are Ca
2+-dependent enzymes. One route for Ca
2+ entry and 
consequent  nNOS-dependent  NO  formation  would  be  following  NMDA  receptor 
activation. However, as this study is looking at unstimulated hippocampal slices, this 
would mean that there is circuit activity occurring with neurons being in a depolarised 
state.  Since  inhibition  of  glutamate  receptors,  Na
+  channels,  and  GABA  receptors 
failed  to  affect  the  cGMP  levels  in  response  to  BAY  41-2272  (Fig.  4.11a),  the 
scenario outlined above is highly unlikely. Other potential routes for Ca
2+ entry into 
cells are via voltage-gated Ca
2+ channels.  
To investigate the Ca
2+-dependence of endogenous basal NO release in the 
immature  hippocampus,  slices  were  exposed  to  the  general  Ca
2+  channel  blocker 
cadmium (Cd
2+, 200 µM). This led to significant reduction of the BAY 41-2272-
evoked cGMP signal (Fig. 4.12a). To evaluate the total contribution of Ca
2+, slices 
were incubated in Ca
2+-free aCSF containing the Ca
2+ chelator EGTA (1 mM). While 
Cd
2+ caused approximately 60% inhibition, omission of any Ca
2+ at all resulted in 
further  reduction  of  the  cGMP  signal,  producing  a  total  of  approximately  90% 
inhibition as compared to the control response (Fig. 4.12a). Consistent with forgoing 
results, also ODQ and L-NNA prevented cGMP accumulation in response to BAY 
41-2272 (Fig. 4.12a). 
To ensure that the conditions used so far for establishing the Ca
2+ dependence 
were not causing inhibition of the response due to some direct action on the NOGC 
receptors,  control  experiments  were  performed  in  which  the  responses  to  the  NO 
donor PAPA/NO were assessed in the absence and presence of the same conditions 
tested  above.  The  response  to  PAPA/NO  remained  unaffected  by  the  presence  of 
Cd
2+,  while  Ca
2+-free  conditions  led  to  a  small,  but  yet  statistically  significant, 
increase in the cGMP level (Fig. 4.12b). The latter may be due to relief of a small 
degree of inhibition, which the NOGC receptors are experiencing in the presence of 
Ca
2+ (Kazerounian et al., 2002). As expected, ODQ fully prevented the response to 
exogenous NO (Fig. 4.12b). 
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FIG. 4.12 Ca
2+-dependence of BAY 41-2272-evoked cGMP accumulation. A: Exposure of slices to the general 
Ca
2+ channel inhibitor cadmium or incubation of slices in zero Ca
2+/ EGTA both significantly reduced the cGMP 
accumulation that is caused by BAY 41-2272 (n = 9; 
‡p < 0.001). B: The same conditions now tested against 
cGMP accumulation that is caused by the NO donor PAPA/NO. No inhibitory effect was observed, excluding the 
possibility of these conditions directly interfering with cGMP production by affecting the NOGC receptor. Under 
Ca
2+-free condition there appeared to be a slight increase in the cGMP response (n = 6; *p < 0.05). 
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The next question was whether it would be possible to isolate the subtype(s) of 
Ca
2+  channels  involved.  Previous  experiments  discussed  and  illustrated  above 
revealed  that  there  is  no  spontaneous  circuit  activity  occurring  in  the  immature 
hippocampal slices and that the basal NO level is independent of glutamate receptors. 
Based on this, it is unlikely that the high-voltage activated Ca
2+ channels (including 
L-, N-, P-, Q- and R-type Ca
2+ channels, (Catterall et al., 2005) are involved as their 
activation would require neurons to be in a depolarised state. Therefore, Ca
2+ channel 
types were tested which could facilitate Ca
2+ entry also under resting conditions. Low-
voltage activated Ca
2+ channels, which include the T-type Ca
2+ channels, can activate 
at relatively negative membrane potentials (-50 mV to -70 mV; Catterall, 2000). An 
interesting feature of T-type channels is their exhibiting a so-called window current, 
which means that a fraction of these channels can maintain a current tonically under 
resting  steady-state  conditions  as  their  inactivation  and  activation  profiles  overlap 
(Hughes et al., 1999; Jones, 2003; Iftinca & Zamponi, 2009). This could provide a 
level of basal Ca
2+ entry, which could in turn stimulate NOS activity. Importantly, 
these  channels  have  also  been  shown  to  be  expressed  in  hippocampal  pyramidal 
neurons somato-dendritically (Talley et al., 1999; McKay et al., 2006), as well as in 
microvascular endothelial cells of the bovine adrenal medulla (Bossu et al., 1989; 
Vinet & Vargas, 1999) and rat brain (Delpiano & Altura, 1996).  
Hippocampal slices incubated in the presence of nickel (Ni
2+; 50 µM), at this 
concentration reported to be a selective R-/T-type Ca
2+ channel inhibitor (Soong et 
al., 1993; Zamponi et al., 1996; Tottene et al., 1996), revealed a marked reduction in 
BAY 41-2272-evoked cGMP accumulation (Fig. 4.13a). 
Another potential candidate was the large family of channels referred to as 
transient receptor potential (TRP) channels, of  which numerous different subtypes 
exist, some of which are thermosensitive (Pedersen et al., 2005). Entry of Ca
2+ via 
this putative route has been suggested to occur in the case of both neurons (Moran et 
al., 2004; Talavera et al., 2008) and endothelial cells (Wissenbach et al., 2000; Güler 
et  al.,  2002;  Nilius  et  al.,  2003;  Yao  &  Garland,  2005;  Kwan  et  al.,  2007).  In 
endothelial cells, for example, they are proposed to be constitutively open at body 
temperature, thereby providing a way for Ca
2+ to enter cells under resting steady-state 
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Three different inhibitors, lanthanum (La
3+; 100 µM), gadolinium (Gd
3+; 30 
µM) and SKF96365 (10 µM), suggested to generally block TRP channels (Leung & 
Kwan, 1999; Halaszovich et al., 2000; Pinilla et al., 2005), were examined. All three 
inhibitors produced significant inhibition of the cGMP signal induced by BAY 41-
2272 (Fig. 4.13a). Combining TRP channel inhibitors with the T-type channel blocker 
Ni
2+ caused an additive degree of inhibition, which was comparable to that produced 
by the general Ca
2+ channel blocker Cd
2+ (Fig. 4.13a). Taken all together, these data 
indicate  that  at  least  one  or  more  subtypes  of  TRP  channels,  and  T-type  Ca
2+ 
channels, appear to be likely routes for Ca
2+ entry under resting conditions which 
allows for tonic NO synthesis to be sustained under basal conditions.  
To certify that the inhibition seen under the above tested conditions is not due 
to  a  direct  effect  on  the  NOGC  receptors,  control  experiments  were  carried  out  in 
which they were tested against the response evoked by the NO donor PAPA/NO. 
None  of  the  inhibitors  on  their  own  or  combinations  of  inhibitors  used  in  the 
foregoing  experiments  affected  the  cGMP  signal  in  response  to  the  NO  donor 
significantly, while this was prevented upon inhibition of the NOGC receptor by ODQ 
(Fig. 4.13b).  
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FIG. 4.13 Effect of subtype-selective Ca
2+ - channel inhibitors on the BAY 41-2272-evoked cGMP response A: 
Exposure of slices to the R-/T-type Ca
2+ channel blocker nickel or to three different TRP channel inhibitors 
(lanthanum, gadolinium and SKF96365) caused a significant reduction in the cGMP level. Additive inhibition 
occurred when a TRP channel inhibitor was applied in the presence of nickel, the overall extent of inhibition 
approximating the one seen in the presence of the general Ca
2+ channel blocker cadmium (n = 5; 
‡p < 0.001, **p < 
0.01, *p < 0.05). Note: Statistical analysis shown in red employed ANOVA with Tukey’s. B: The same Ca
2+ 
channel blockers now tested against cGMP accumulation that is caused by the NO donor PAPA/NO. No inhibitory 
effect was observed, excluding the possibility of these conditions directly interfering with cGMP production by 
affecting the NOGC receptor (n = 3; 
nsp > 0.05). 
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4.5   DISCUSSION 
 
Stemming  from  foregoing  findings  in  the  adult  hippocampus  (Hopper  & 
Garthwaite, 2006), the initial objective of the present study was to investigate the 
involvement of the PI3 kinase pathway in the maintenance of basal NO production 
from  eNOS  in  the  immature  hippocampus.  This  was  intended  to  then  serve  as  a 
comparison to what had been found in the immature rat optic nerve (Garthwaite et al., 
2006 and Chapter 3). Unexpectedly, this work took a new direction upon realisation 
that there appear to be marked differences in NO signalling – at least in the aspects 
investigated here – between the immature and adult rat hippocampus.  
 
The measurement of a robust cGMP signal in immature hippocampal slices 
upon  PDE2  inhibition  with  BAY  60-7550  in  conjunction  with  BAY  41-2272  to 
amplify the NOGC receptor output confirmed the presence of biologically active NO in 
the unstimulated tissue. Also, pharmacological tests using the general NOS inhibitor 
L-NNA and the NOGC receptor inhibitor ODQ at concentrations that would ensure 
maximal inhibition (East & Garthwaite, 1991; Garthwaite et al., 1995) confirmed that 
the cGMP signal resulting from PDE2 inhibition and NOGC receptor sensitisation is 
indeed dependent on endogenous NO and corresponds to activity of NOGC receptors. 
Suitable concentrations of both BAY 60-7550 and BAY 41-2272 in order to achieve a 
good working window in terms of the cGMP level and also a ‘clean’ cGMP response 
devoid  of  possible  interferences  (such  as  cAMP  accumulation),  as  well  as 
hippocampal  slice  viability  were  established.  Subsequently,  when  moving  on  to 
investigating  whether  the  tonic  NO  production  in  the  unstimulated  immature 
hippocampus  was  governed  by  the  PI3  kinase  pathway,  the  data  disputed  an 
involvement of this mechanism. Both PI3 kinase inhibitors tested (LY 294002 and 
wortmannin),  shown  previously  to  affect  endogenous  tonic  NO-mediated  cGMP 
production in the adult rat hippocampus (Hopper & Garthwaite, 2006), and indicated 
to at least partly sustain tonic NO levels in the immature rat optic nerve (Chapter 3), 
failed to affect the amount of cGMP accumulation in response to BAY 41-2272 in the 
immature hippocampus investigated here. The difference between the immature and 
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of basal NO synthesis may be differently controlled during development. In contrast, 
optic nerves were from rats of the same age as the immature hippocampal slices (i.e. 
10- to 11-day old). This indicates that, in terms of sustenance of basal endogenous NO 
levels in an unstimulated tissue, the same mechanisms may not be common among 
different brain regions. A divergence could be related to the fact that, while the optic 
nerve is a white matter tract exclusively composed of axons, blood vessels and glial 
cells, the hippocampus consists of not only vascular elements and glial cells, but also 
a complex circuitry with synaptic connections and abundant expression of both eNOS 
and nNOS. There is the likelihood of not only different mechanisms being at play in 
maintaining a basal NO level, but also of this tonic NO production playing different 
roles at different developmental stages. This speculative possibility will be explored 
in more detail later. 
 
Subsequently to the initial findings suggesting that the PI3 kinase pathway is 
not involved in controlling basal NO synthesis in the immature hippocampus, one of 
the first questions that arose concerned the isoforms of NOS at play. While evidence 
obtained from immature optic nerves and adult hippocampi pointed to eNOS as the 
primary source of basal NO with undetectable contribution of nNOS (Garthwaite et 
al., 2006; Hopper & Garthwaite, 2006), this may not be the case in the immature 
hippocampus. To investigate a possible contribution of nNOS to basal NO levels in 
the immature hippocampus, the effect of nNOS inhibitors on the endogenous NO-
dependent  cGMP  level  was  assessed.  Concentrations  of  these  inhibitors  were 
employed  that  were  previously  shown  to  prevent  the  NMDA-evoked  cGMP 
accumulation but not cGMP levels that depend on basal endogenous  NO (East & 
Garthwaite, 1991; Hopper & Garthwaite, 2006). One of the inhibitors (1400W) also 
provided a way of testing the involvement of iNOS, exhibiting a greater inhibitory 
potency for iNOS than nNOS (Garvey et al., 1997; Boer et al., 2000; Young et al., 
2000). Inhibition of nNOS, or iNOS, failed to reduce the cGMP level in response to 
BAY  41-2272,  the  latter  being  consistent  with  iNOS  being  an  unlikely  candidate 
based  on  its  principal  involvement  in  pathological  situations,  its  induction  being 
initiated over the course of several hours (Iadecola et al., 1995; Moro et al., 1998; 
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subjected to standard treatment and incubation (Hopper & Garthwaite, 2006). The 
lack of effect of nNOS inhibition would initially imply that there is no detectable 
constituent  of  neuronal  NO  release.  Surprisingly,  however,  at  the  concentrations 
tested, the nNOS inhibitors also fell short in reducing the NMDA-evoked response 
significantly,  indicating  an  inadequate  degree  of  nNOS  inhibition  at  these 
concentrations in immature hippocampal slices.  One explanation for the failure of 
nNOS  inhibitors  to  reduce  the  NMDA-induced  cGMP  signal  may  be  insufficient 
concentrations used. Determining the potency of the nNOS inhibitors in the immature 
hippocampus  led  to  the  discovery  that10-fold  higher  concentrations  of  the  nNOS 
inhibitors were required to prevent NMDA-evoked cGMP accumulation compared to 
findings in adult hippocampi (Hopper & Garthwaite, 2006). Also worth mention is the 
observation that immature hippocampal slices were producing about three times as 
much cGMP in response to the same concentration of NMDA upon PDE2 inhibition 
as  compared  to  findings  in  adult  hippocampal  slices.  Moreover,  also  the  cGMP 
response to BAY 41-2272 was noticeably greater in the immature hippocampal slices 
despite exposure to a 10-fold lower concentration of BAY 41-2272 than that applied 
to  adult  hippocampal  slices  (Hopper  &  Garthwaite,  2006),  indicating  that  higher 
endogenous NO levels may prevail in the immature hippocampus.  
An  early  study  observed  smaller  cGMP  responses  to  NMDA  in  adult 
hippocampal  slices  compared  with  immature  tissue  (East  &  Garthwaite,  1991), 
indicative  of  developmental  differences.  In  the  same  study,  it  was  found  that 
supplementation of L-arginine, the substrate for NO synthesis, markedly enhanced the 
response to  NMDA in the adult tissue. These  findings indicate that there may  be 
higher endogenous L-arginine levels in developing hippocampal slices. Moreover, the 
nNOS inhibitors that were used in the present study compete with L-arginine to exert 
their inhibitory action (Erdal et al., 2005). Taken together, a difference in the amount 
of endogenous L-arginine may be an underlying reason for the necessity of higher 
concentrations of nNOS inhibitors to achieve the extent of inhibition of the response 
to NMDA as is observed in adult hippocampal slices. This is in concert with findings 
coming from studies investigating the potencies of inhibitors towards nNOS directly. 
The use of different concentrations of L-arginine has led to variations in the IC50 
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When  probing  the  concentrations  of  the  nNOS  inhibitors  that  efficiently 
prevented NMDA-induced cGMP accumulation against BAY 41-2272-evoked cGMP 
levels, a partial reduction of the latter occurred. However, also this result failed to 
give any indications concerning the NOS isoforms involved in maintaining basal NO 
levels. Much higher concentrations of nNOS inhibitors were required to reduce the 
cGMP  response  to  BAY  41-2272,  and  although  with  lower  potency,  the  nNOS 
inhibitors have the potential to also compromise eNOS activity (Zhang et al., 1997; 
Boer et al., 2000). Selectivity towards nNOS at the higher concentrations of nNOS 
inhibitors required in the present study to efficiently inhibit nNOS was not preserved. 
Compromise of eNOS activity by the higher concentrations of nNOS inhibitors was 
evident by ACh-mediated eNOS-dependent cGMP production in rat aortas also being 
significantly reduced. Because of this overlap in potencies of the nNOS inhibitors, it 
is not possible to come to a clear conclusion regarding the source of basal NO in the 
immature hippocampus. 
Arguably, the lack of reduction of the cGMP signal in response to BAY 41-
2272 upon indirect inhibition of eNOS activity by means of preventing PI3 kinase 
activity could point to eNOS not being involved. However, the Ca
2+-dependence of 
eNOS activity should be taken into consideration. Preventing PI3 kinase-mediated 
phosphorylation  of  eNOS  will  reduce  the  sensitivity  of  the  enzyme  towards  Ca
2+ 
(Dudzinski  et  al.,  2006)  but  will  not  in  itself  entirely  enable  eNOS  from  being 
activated by other factors (see Chapter 3). Therefore, if there is sufficient Ca
2+ present 
to preserve a basal state of eNOS activity, this could amount to enough basal NO 
output that would be detected upon sensitisation of the NOGC receptors to very low 
NO levels by means of BAY 41-2272 (Garthwaite, 2005; Roy et al., 2008). Equally, 
none of the data presented in the present study allows a firm conclusion to be made 
with regard to the contribution of nNOS. The possibility remains that both or only one 
of  the  isoforms  may  be  at  play  to  preserve  ongoing  NO  formation  under  basal 
conditions. One issue these data reveal, however, concerns the questionable reliance 
on the selectivity of these nNOS inhibitors. Numerous studies use these compounds – 
as  well-established  nNOS  antagonist  –  and  interpret  data  for  or  against  an 
involvement of nNOS based on the effects observed with these inhibitors. In addition, 
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the observations made in studies that have investigated the potency and selectivity of 
nNOS inhibitors on isolated enzymes show clearly that results are sensitive to aspects 
such as different assay conditions (e.g. L-arginine concentration used) and species 
(Nakane et al., 1995; Wolff et al., 1998). This sensitivity will probably be aggravated 
when working on a whole tissue. Potencies of these inhibitors at the cellular level 
could be influenced by several factors. Permeability and/or intracellular metabolism 
of  the  compound  may  vary  among  different  preparations,  possibly  depending  on 
species, age and/or brain region investigated. Also, even if membrane permeability 
may not impose a problem for access per se, differences in the cellular context of the 
enzyme may impinge on the interaction between the inhibitor and its binding site. 
Considering the physical association of NMDA receptors and nNOS (Brenman et al., 
1996; Christopherson et al., 1999; Valtschanoff & Weinberg, 2001), the presence of 
other proteins that may be targeted to the site of nNOS may shield the enzyme from 
an easy access of the inhibitor. For example, nNOS activity or its location may be 
influenced by interactions with various proteins such as synapsin and hsp90 (Billecke 
et al., 2002; Jaffrey et al., 2002; Dreyer et al., 2004). As already mentioned above, 
another potential influence upon enzyme-inhibitor interaction may be differences in 
the concentration of endogenous L-arginine. As it appears to be a possibility in terms 
of the hippocampus, this may vary according to the age of the animal. While in the 
adult hippocampus the nNOS inhibitors were found to have higher potencies towards 
nNOS inhibiton compared with previous studies (Boer et al., 2000; Cooper et al., 
2000; Hopper & Garthwaite, 2006), the results in the present study reveal that much 
higher concentrations need to be employed to achieve inhibition of the bulk nNOS 
activity. Moreover, different endogenous L-arginine levels may prevail in different 
brain areas. Overall, the data obtained in the present study, showing that at least in the 
hippocampus the inhibitory profile of the nNOS inhibitors differs between immature 
and  adult  tissue  (Hopper  &  Garthwaite,  2006),  underline  the  importance  of  the 
inclusion of appropriate controls when using these compounds. Failure to do so may 
lead to either nNOS being wrongly assumed to be a participant in the response under 
investigation or to eNOS being overlooked as a contributor.  
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To further test a possible contribution of a neuronal component to endogenous 
NO production, a number of neurotransmitter systems were investigated that could be 
involved in nNOS stimulation. It has been estimated that the presence of BAY 41-
2272 shifts the potency of NO for its receptor to low picomolar concentrations (EC50 
~ 4 pM; Roy et al., 2008). Spontaneous NO oscillations in the picomolar range have 
been measured in hippocampal neurons grown in culture (Sato et al., 2006). Sato and 
colleagues observed periodic spontaneous NO release, which was NMDA receptor-
dependent and relied on spontaneous neurotransmission, as revealed by its sensitivity 
to  Na
+  channel  block  by  TTX,  as  well  as  coincident  with  neuronal  Ca
2+  spikes. 
Spontaneous circuit activity in the hippocampal slices could lead to a basal level of 
glutamate  being  released,  which  could  ultimately  lead  to  activation  of  AMPA 
receptors  and/or,  given  a  sufficient  degree  of  neuronal  depolarisation,  NMDA 
receptors. Both AMPA and NMDA receptors are permeable to Ca
2+, which in turn 
could  stimulate  NO  formation  from  nNOS  which  is  coupled  to  NMDA  receptors 
(Brenman et al., 1996; Christopherson et al., 1999; Valtschanoff & Weinberg, 2001) 
and  is  expressed  in  pyramidal  neurons  at  the  protein  level  (Endoh  et  al.,  1994; 
Wendland et al., 1994; Burette et al., 2002; Blackshaw et al., 2003). Block of neither 
glutamate receptors nor Na
+ channels revealed any significant change in the cGMP 
response  evoked  by  BAY  41-2272.  This  implies  that  the  tonic  NO  production  in 
immature  hippocampal  slices  is  unlikely  to  be  dependent  on  spontaneous 
neurotransmission.  This  is  consistent  with  findings  in  adult  hippocampal  slices 
(Hopper & Garthwaite, 2006). Additionally, tonic NO generation from NOS that is 
independent of NMDA receptor activation and maintains a basal cGMP level – as 
revealed upon PDE inhibition – has been demonstrated previously in hippocampal 
and striatal slices (Chetkovich et al., 1993; Griffiths et al., 2002), On the other hand, 
the  evidence  taken  together  reveals  a  possible  discrepancy  between  hippocampal 
neurons in their native environment and neurons that are grown and maintained in 
culture, perhaps arising from a different balance between excitation and inhibition. 
Overall,  the  finding  that  pharmacological  manipulation  of  either  of  the  above 
examined  systems  did  not  show  a  detectable  impact  on  the  cGMP  signal  that 
corresponds  to  the  tonic  NO  level  makes  the  involvement  of  nNOS  even  more 
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basal NO synthesis. However, based solely on  the data obtained here,  this is still 
speculative,  bearing  in  mind  that  there  are  other  potential  routes  by  which  nNOS 
could be stimulated in neurons such as, for example, Ca
2+ entry via Ca
2+ channels.  
 
Both eNOS and nNOS are Ca
2+-dependent, another potential route of Ca
2+ 
entry into cells being voltage-gated Ca
2+ channels. Incubation of hippocampal slices 
with the general Ca
2+ channel blocker cadmium markedly reduced the cGMP response 
to  BAY  41-2272,  while  incubation  of  slices  in  Ca
2+-free  aCSF  prevented  cGMP 
accumulation to a level approaching that measured in the absence of pharmacological 
treatment or upon NOS or NOGC receptor inhibition. This result strongly indicates that 
in the immature hippocampus basal NO levels are chiefly Ca
2+-dependent. As to the 
Ca
2+ channel types involved, the data obtained in the present study suggests T-type 
Ca
2+ channels and TRP channels as possible contributors. 
There  are  three  isoforms  of  T-type  Ca
2+  channels  (Perez-Reyes,  2003),  all 
three having been found to be expressed in hippocampal pyramidal neurons (Talley et 
al.,  1999).  Additionally,  T-type  channels  have  also  been  demonstrated  on 
microvascular  endothelial  cells  from  rat  brain  (Delpiano  &  Altura;  1996).  These 
channels exhibit a window current; that is they display an overlap between the curves 
describing their inactivation and activation, effectively allowing them to support a 
maintained current under steady-state conditions (Hughes et al., 1999; Jones, 2003; 
Iftinca & Zamponi, 2009). The level of cGMP was significantly inhibited by nickel at 
concentrations reported to inhibit T-type (and R-type) Ca
2+ channels (Soong et al., 
1993; Zamponi et al., 1996; Tottene et al., 1996), indicating a likely involvement of 
T-type  channels  in  Ca
2+-dependent  NOS  activation.  The  involvement  of  the  high-
voltage activated R-type Ca
2+ channels can probably be discounted, as their activation 
would  require  neurons  to  be  depolarised.  However,  to  ascertain  that  the  effect  of 
nickel is not due to R-type channel inhibition, further experiments should have been 
conducted,  employing  a  selective  R-type  channel  inhibitor  such  as  SNX-482 
(Newcomb et al., 1998). T-type Ca
2+ channels have been demonstrated to provide a 
route for sustained Ca
2+ entry in the adrenal cortex (Cohen et al., 1988) and in the 
heart  (Nilius,  1985;  Hagiwara  et  al.,  1988),  regulating  secretion  from  adrenal 
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Also, mice lacking T-type channels were found to exhibit constitutively constricted 
coronary  arterioles  and  focal  myocardial  fibrosis,  displaying  normal  contractile 
responses but defective NO-mediated relaxation to ACh (Chen et al., 2003). Chen and 
colleagues (2003) also demonstrated prevention of relaxation of coronary arteries by a 
low concentration of nickel.  
The other possible contributor to Ca
2+ entry under basal conditions that was 
assessed were TRP channels, which are permeable to Ca
2+ and also can be open at the 
resting membrane potential (Clapham et al., 2001) or be stimulated by extracellular 
signals such as the brain-derived neurotrophic factor (BDNF; Li et al., 2005). The 
TRP channel family is one of the largest among the different groups of ion channels, 
comprising at least 28 genes that are subcategorised into six different protein families 
(Pedersen et al., 2005). TRP channels  are intimately involved in the  processes of 
sensing and responding to environmental changes such as temperature, mechanical 
forces and taste (Damann et al., 2008). With relevance to the present work, members 
of the TRP channel family have also been found to be expressed in endothelial cells 
(Wissenbach et al., 2000; Güler et al., 2002; Nilius et al., 2003; Yao & Garland, 
2005;  Kwan  et  al.,  2007)  and  in  neurons  in  various  brain  regions  including  the 
hippocampus (Moran et al., 2004; Talavera et al., 2008). Among the 28 different TRP 
channel isoforms, at least 19 are found in vascular endothelial cells. Some are open 
constitutively  while  others  are  activated  by  circulating  vasoactive  agents  released 
from vascular cells (Yao & Garland, 2005; Kwan et al., 2007). Either way, opening of 
these channels elicits a rise in Ca
2+ in the endothelial cells, leading to the release of a 
number of vasodilating agents such as NO. For instance, the TRPV4 has been found 
to  be  highly  expressed  in  endothelial  cells  (Wissenbach  et  al.,  2000)  and  to  be 
constitutively  open  at  body  temperature,  thereby  potentially  contributing  to  the 
maintenance  of  a  steady-state  Ca
2+  level  (Güler  et  al.,  2002;  Nilius  et  al.,  2003). 
Additionally,  mice  lacking  TRPV4  are  devoid  of  NO-dependent  vasorelaxation  to 
ACh (Freichel et al., 2001). TRP channels that have been found to be expressed in the 
hippocampus include TRPV1 and TRPV4, as well as subtypes 1, 3, 4, 5 and 6 of 
TRPC (Moran et al., 2004; Talavera et al., 2008). For example, TRPV4 channels have 
been  demonstrated  to  allow  basal  Ca
2+  influx  at  37ºC  in  hippocampal  neurons, 
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obtained in the present study together with the other evidence outlined above, it is 
possible that T-type channels and TRP channels are at least partly responsible for the 
Ca
2+-dependent basal NO production in the immature hippocampal slices, the NO 
possibly originating from blood vessels (eNOS) and/or neurons (nNOS). 
 
The overall picture of the present study reveals one major difference between 
the adult and the immature hippocampi. While in the adult hippocampus tonic NO 
release  was  found  to  be  partly  mediated  by  the  PI3  kinase  pathway  (Hopper  & 
Garthwaite, 2006), the basal NO production in the immature hippocampus appears to 
be mainly controlled in a Ca
2+-dependent manner, with no detectable contribution of 
the PI3 kinase pathway. Moreover, while pharmacological approaches in the adult 
hippocampus  allowed  differentiation  between  eNOS  and  nNOS,  in  the  immature 
hippocampus  overlap  in  potencies  of  available  inhibitors  prevented  such  a  clear 
distinction  between  NOS  isoforms. Several  important  issues  arise  from  this  work. 
What  could  be  the  significance  of  activity-independent,  Ca
2+-mediated  tonic  NO 
synthesis in the immature hippocampus? What role may be served by possibly both 
eNOS and nNOS being locked into a state of basal activity? Is it possible that the 
readout  obtained  in  these  experiments  corresponds  to  tonic  NO  release  initiated 
artefactually in the unstimulated hippocampal slices?  
Calcium is a ubiquitous intracellular signalling molecule that is involved in a 
vast  array  of  different  cellular  processes.  There  is  an  impressive  universality  to 
calcium  signalling,  including  its  involvement  in  development.  In  the  rat  brain, 
angiogenesis, the formation of new vessels, is not complete until about postnatal day 
20 (Plate, 1999). Endothelial cells play an important role in this process, and TRP 
channels,  for  instance,  have  been  proposed  to  affect  angiogenesis  through  several 
mechanisms  such  as  activation  by  angiogenic  growth  factors  including  vascular-
derived endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF; 
Nilius et al., 2003; Yao & Garland, 2005). Moreover, NO has also been implicated to 
play a role in angiogenesis (Ziche & Morbidelli, 2000; Donnini & Ziche, 2002), as 
has VEGF both in the developing and adult brain (Ment et al., 1997; Plate, 1999; 
Greenberg & Jin, 2005). On the other hand, however, to date there is no evidence 
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development  or  repair.  Also  in  neurons,  Ca
2+  oscillations  may  have  a  purpose  in 
development.  For  example,  neuronal  spontaneous  Ca
2+  signals  that  appear  to  be 
independent of synaptic activity have been observed in cultured immature spinal cord 
neurons  by  means  of  Ca
2+  imaging  (Fabbro  et  al.,  2007).  The  authors  described 
mitochondrial Ca
2+ uptake and release mechanisms to be a source for cytoplasmic 
repetitive Ca
2+ transients in the neurons. Developmental processes such as neurite 
growth and neuronal differentiation are thought to be dependent on different patterns 
of Ca
2+ transients (Gu & Spitzer, 1995; Gu & Spitzer, 1997; Gomez & Zheng, 2006). 
Interesting in this respect is the finding that, for example, types of the TRPC channel 
appear to be implicated in neurite outgrowth and axonal pathfinding (Greka et al., 
2003; Moran et al., 2004; Talavera et al., 2008). Spontaneous glial Ca
2+ oscillations in 
acute brain slices have also been observed (Parri et al., 2001; Nett et al., 2002). Glial 
cells are known to release a number of substances including growth factors (Martin, 
1992). Could there be a complex interplay among blood vessels, neurons and glia 
during development? For instance; could spontaneous Ca
2+ activity in glia promote 
the  release  of  substances  which  in  turn  could  act  on  their  receptors  that  my  be 
expressed  by  neurons  and/or  endothelial  cells,  in  turn  causing  spread  of  Ca
2+ 
fluctuations  (by,  for  example  TRP  channels)  to  these  structures  and  ultimately 
stimulating  tonic  NO  synthesis?  Could  it  be  possible  that  during  postnatal 
development both neurons and blood vessels exhibit a basal level of continuous NO 
production, either being involved in their own maturation (e.g. angiogenesis, neurite 
growth) or influencing each other? Finally, to try to put this idea into context, NO has 
been shown to be involved in various processes during neuronal development in both 
vertebrates and invertebrates (Bicker, 2005; Bicker, 2007), NO being implicated in 
the  granule  cell  migration  in  the  rat  cerebellum,  for  instance,  and  cGMP  being 
proposed  to  play  a  role  in  growth  cone  behaviour.  In  snail  neurons,  growth  cone 
morphology and neuronal pathfinding have been reported to be influenced in a NO-
mediated,  cGMP-dependent  manner  (van  Wagenen  &  Rehder,  2001;  Tornieri  & 
Rehder, 2007). Here, the authors provided evidence that NO released from a given 
neuron  can  affect  growth  cone  dynamics  on  neighbouring  cells.  Also  in  cultured 
hippocampal  slices,  for  example,  cGMP  has  been  proposed  to  be  a  participant  in 
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of the hippocampal formation (Mizuhashi et al., 2001). However, the latter study on 
hippocampus  claimed  to  have  not  observed  evidence  for  NO  involvement, 
unfortunately  not  showing  the  data  and  not  describing  the  types  of  experiments 
executed to investigate the role of NO. Alternatively, it is likely that the effects the 
authors  observed  were  related  to  cGMP  production  by  the  particulate  natriuretic 
peptide-stimulated guanylyl cyclase, which is insensitive to NO. Although uncertain, 
this line of evidence could point to cGMP playing a role in aspects of hippocampal 
development, some of which may or may not be NO-mediated. Another purpose of 
basal  NO-mediated  cGMP  production  during  development  may  be  to  engage  the 
regulation  of  gene  expression  and  protein  synthesis,  which  could  be  mediated  by 
phosphorylation  of  some  transcription  factors  such  as  CREB  by  cGMP-dependent 
protein kinase (PKG; Pilz & Broderick, 2005). 
 
To summarise, it is very tempting to reason and speculate that there may be a 
dual  contribution  of  eNOS  and  nNOS  to  tonic  NO  levels  in  the  immature 
hippocampus. However, from the present work the source(s) of NO remain unknown. 
The lack of good pharmacological tools makes it impossible to identify the origin of 
the  endogenous  basal  NO  in  the  immature  hippocampus.  Better  pharmacology  is 
crucial  to  build  a  new  hypothesis  concerning  the  role  of  tonic  NO  release  in  the 
immature  hippocampus.  Also,  regarding  the  underlying  mechanism  for  tonic  NO 
release,  this  work  only  provides  circumstantial  evidence  and  more  detailed 
investigation is required to clarify the components involved. It is also possible that the 
persistent NO production and corresponding cGMP levels were induced artefactually. 
Preventing normal degradation of cGMP greatly amplifies and prolongs the cGMP 
signal, which is an experimental way to detect the NO-mediated cGMP accumulation 
but is highly un-physiological. Hippocampal slices were pre-exposed to the PDE2 
inhibitor BAY 60-7550 for at least 15 minutes before any further pharmacological 
manipulation. Since cGMP can modulate many downstream effectors, this prolonged 
cGMP accumulation may have led to continuous NO synthesis. For instance, both 
nNOS and eNOS may be phosphorylated by PKG, increasing enzyme activity (Butt et 
al., 2000; Garthwaite, 2008), and the finding that the cGMP response corresponding 
to basal NO levels was prevented under Ca
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Ca
2+-dependence of constitutive NOS isoforms. Overall, many aspects of the present 
work remain inconclusive.  
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5.1   INTRODUCTION 
 
As  described  in  more  detail  in  Chapter  1,  NO  exerts  its  actions  via  a 
mechanism  which  commences  with  its  synthesis  by  the  NO  synthase  (NOS),  the 
constitutive  isoforms  of  this  enzyme  being  neuronal  (n)NOS,  which  is  found  in 
neurons  (Bredt  et  al.,  1991b;  Vincent  &  Kimura,  1992),  and  endothelial  (e)NOS, 
which is expressed in blood vessels (Chiang et al., 1994; Seidel et al., 1997; Stanarius 
et al., 1997; Topel et al., 1998; Demas et al., 1999; Blackshaw et al., 2003; Chan et 
al.,  2004).  This  is  followed  by  NO  binding  to  its  receptor,  the  guanylyl  cyclase, 
generating the second messenger cGMP, which can then interact with a number of 
downstream  targets,  including  ion  channels,  protein  kinase  G  (PKG)  and 
phosphodiesterases (PDEs; see Chapter 1). Nitric oxide can be produced in various 
brain constituents, including neurons and the vascular system, and is able to diffuse 
from its site of synthesis in a three-dimensional manner to target structures in its 
vicinity such as astrocytes, neurons, and blood vessels (Garthwaite & Boulton, 1995, 
Garthwaite,  2008).  Since  the  discovery  that  NO  is  the  missing  transmitter  that  is 
generated  in  response  to  NMDA  receptor  activation  (Garthwaite  et  al.,  1988; 
Garthwaite,  1991),  the  list  on  how  NO  may  affect  neuronal  function  has  grown, 
including its implication in the long-term regulation of neuronal function (see Chapter 
1) where neurons can undergo long-term changes in the efficacy of their synaptic 
connections.  This  event,  referred  to  as  long-term  potentiation  (LTP),  has  been 
observed  in  different  brain  regions,  the  most  extensively  studied  being  the 
hippocampus,  and  is  considered  to  model  the  cellular  events  that  underlie  the 
acquisition  and  storage  of  information  (Bliss  &  Collingridge,  1993;  Neves  et  al., 
2008; Nader & Hardt, 2009). Nitric oxide via cGMP generation has been implicated 
in both pre- and postsynaptic changes such as modulation of neurotransmitter release 
(O’Dell et al., 1991; Arancio et al., 1995; Arancio et al., 2001) or increase in AMPA 
receptor density respectively (Wang et al., 2005; Serulle et al., 2007), these changes 
being  implicated  in  LTP  (Garthwaite  &  Boulton,  1995;  Prast  &  Philippu,  2001; 
Collingridge  et  al.,  2004;  Kerchner  &  Nicoll,  2008).  For  example,  Serulle  et  al. 
(2007) demonstrated cGMP-dependent PKG-mediated phosphorylation of GluR1 (the 
AMPA receptor subunit required for NMDA-dependent LTP), in this way apparently 5 5 5            T T Ta a ar r rg g ge e et t ts s s    f f fo o or r r    N N NO O O    i i in n n    t t th h he e e    h h hi i ip p pp p po o oc c ca a am m mp p pu u us s s    
 
  193
facilitating the delivery of the GluRI subunit to extrasynaptic sites. Moreover, cGMP-
mediated PKG-dependent phosphorylation of the transcription factor CREB has been 
reported  to  occur  in  the  hippocampus,  suggesting  an  involvement  of  the  NO-
signalling cascade in the component of LTP that relies on RNA and protein synthesis 
in the postsynaptic neuron (Lu et al., 1999). Additionally, direct removal of NO from 
the postsynaptic neuron by means of injection of the NO scavenger CPTIO has been 
found to impair tetanus-evoked synaptic potentiation (Ko & Kelly, 1999). 
Intuitively, based on the implications stemming from functional studies, one 
would expect to see cGMP accumulation in the appropriate structures upon NOGC 
receptor  activation,  such  as  axons  and  neuronal  somata.  Unexpectedly,  however, 
previous studies found no detectable cGMP formation in the principal neurons of the 
hippocampus, the pyramidal cells, despite the expression of the NOGC receptor both at 
its mRNA and protein level (Matsuoka et al., 1992; Teunissen et al., 2001; Burette et 
al.,  2002;  Gibb  &  Garthwaite,  2001;  Ding  et  al.,  2004;  Szabadits  et  al.,  2007). 
Conditions employed in previous studies found no cGMP accumulation in neuronal 
cell bodies of the hippocampus but predominant cGMP immunoreactivity (cGMP-IR) 
in astrocytes, particularly around the CA1 region. This was accompanied by cGMP 
staining  in  some  interneurons  and  varicose  fibres  in  different  sub-regions  of  the 
hippocampus (de Vente et al., 1988; de Vente et al., 1996; van Staveren et al., 2001; 
Teunissen et al., 2001; van Staveren et al., 2004; van Staveren et al., 2005). Thus, it 
appears  that  there  is  a  clear  mismatch  between  anatomical  and  functional  studies 
concerning the involvement of the NO-cGMP signalling pathway in neuronal function 
that can be either at the pre- or postsynaptic level, as discussed above.  
 
One very important component of the NO-cGMP signalling pathway is PDE 
(see Chapter 1), as it provides great spatiotemporal control over the cGMP signal, 
rapidly  breaking  cGMP  down  to  the  inactive  derivative  GMP  (Bender  &  Beavo, 
2006). Therefore, the amount and duration of cGMP formation will highly depend not 
only on its rate of synthesis but also the presence and activity of PDE (Garthwaite, 
2005). Moreover, the shape of the cGMP signal may also determine the downstream 
target  and  ensuing  biological  effect.  For  example,  the  concentration  of  cGMP 
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downstream target is an ion channel or PKG, the two having different affinities for 
cGMP binding (Garthwaite, 2005). In the hippocampus, the presence and high activity 
of PDE is an important hallmark (see Chapter 4 – Introduction). Currently there are 
11 PDE families known, the main ones found in the hippocampal formation being 
PDE2, 5 and 9 throughout various embryonic and postnatal developmental stages up 
until adulthood (van Staveren et al., 2003). Previous evidence implicates PDE2 as the 
major PDE that shapes cGMP accumulation in the hippocampus (see Chapter 4 – 
Introduction).  
In  order  to  characterise  signalling  cascades  and  their  impact  on  functional 
aspects, the availability  of selective pharmacological tools is invaluable. Although 
there have been inhibitors available, the low potency and non-selectivity of available 
inhibitors could have confounded studies into the role of these enzymes. For PDE2, a 
commonly used inhibitor in the past has been the compound EHNA, which, however, 
not only has poor potency but is also used as a potent adenosine deaminase inhibitor 
(see Chapter 4 – Introduction). More recently, a highly selective and more potent 
PDE2 inhibitor, known as BAY 60-7550, has been developed and shown to enhance 
LTP of synaptic transmission and to improve the performance of rats in a number of 
memory tasks (Boess et al., 2004). Other tools for manipulating the NO signalling 
pathway  include  the  so-called  NO  donors.  The  NOGC  receptor  can  be  activated 
independently of NOS-generated endogenous NO by these compounds. The choice of 
NO donor and the conditions they are used under are vital in terms of the outcome of 
the cGMP signal as both of these aspects will determine how NO is released (Morley 
& Keefer, 1993; Keefer et al., 1996; Schmidt et al., 1997; Feelisch, 1998). Another 
aspect to consider is the signal-to-noise ratio of the cGMP signal. Depending on the 
methodology utilised, a cGMP signal could remain undetected. Thus, additionally to 
inhibiting PDE, it is possible to further amplify the signal by using compounds such 
as  BAY  41-2272,  which  sensitises  the  NOGC  receptors  to  NO,  with  the  effect  of 
shifting the potency of NO for its receptor from low nanomolar to low picomolar 
concentrations (Stasch et al., 2001; Garthwaite, 2005; Roy et al., 2008).  
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5.2   AIM 
 
Taking advantage of the now available pharmacological tools, the aim of this study 
was to re-investigate the targets for NO in the hippocampus.  
 
 
5.3   METHODS 
 
5.3.1   Hippocampal tissue preparation 
 
Hippocampi were isolated and sliced at 400 µm as described in detail in Chapter 4, 
and left to recover in a shaking water bath for 1-2 hours at 37°C with a constant 
stream of 95% O2 / 5% CO2 flowing through the inlet stopper.  Brain  slices were 
transferred to fresh aCSF before exposure to pharmacological treatment. For  each 
experiment, a number of slices were processed for quantitative cGMP evaluation by 
means of radioimmunoassay, while the remaining slices were further processed for 
immunohistochemistry.  
 
5.3.2   Quantitative analysis of cGMP accumulation 
 
A number of hippocampal slices were processed for cGMP immunohistochemistry 
(see  below)  while  some  were  treated  for  cGMP  quantification  by  means  of 
radioimmunoassay  (RIA).  Following  a  recovery  period  of  1-2  hours  at  37ºC  in  a 
shaking water bath, rat hippocampal slices were transferred into fresh aCSF before 
starting  the  pharmacological  treatments.  Except  for  the  slices  providing  the 
measurements for ‘basal’ cGMP levels, hippocampal slices were pre-incubated with 
the PDE2 inhibitor BAY 60-7550 for 15 min before adding any agonists, the PDE2 
inhibitor  being  present  throughout  the  experiment.  Inhibitors  such  as  L-NNA  and 
ODQ were applied for a 10 min interval prior to BAY 60-7550 and were present for 
the remainder of the experiment. Exposure of hippocampal slices to DEA/NO and 
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sensitise the NOGC receptors before adding the NO donor. To inactivate the biological 
reaction within the tissue at the appropriate time, each of the slices was transferred 
into  a  separate  Eppendorf  tube  containing  250  µl  of  boiling  inactivation  buffer, 
leaving it to boil for a minimum of 15 min. In parallel, hippocampal slices for the 
immunohistochemical analysis were transferred into fixative (see below). After tissue 
inactivation,  samples  were  left  to  cool  to  room  temperature,  homogenised  by 
sonication,  and  the  protein  content  measured  using  the  BCA  Protein  Assay  Kit. 
Following  this,  samples  were  centrifuged  at  800  rpm  for  10  min,  discarding  the 
debris. The supernatant was used to determine the cGMP amount by means of RIA as 
described in detail in Chapter 2. 
 
5.3.3   Fluorescence immunohistochemistry 
 
The  antibody  against  cGMP  was  kindly  given  to  us  by  Jan  de  Vente,  Maastricht 
University.  Following  pharmacological  treatment,  the  slices  used  for  histological 
evaluation of cGMP accumulation were placed onto a piece of filter paper and then 
transferred into 4% fresh depolymerised PFA fixative. Slices were fixed for 2 hours at 
4ºC under constant motion, subsequent to which they were washed 4-5 times with 0.1 
M PB (15-20 min each) and then placed into 5% sucrose for 2 hours standing at 4ºC. 
Subsequently, slices were transferred to 20% sucrose and left overnight standing at 
4ºC. This was followed by placing the slices first into a 1: 1 mixture of OCT and 50% 
sucrose for 1 hour at room temperature and then into neat OCT for approximately 30 
min before embedding in OCT in the appropriate embedding mould over dry ice / iso-
pentane. Slices were then cryosectioned at 10 µm sections, mounted onto gelatine-
coated slides, which were left to dry at room temperature overnight before storing 
them at -20ºC. Frozen tissue/OCT blocks that were not cryosectioned immediately 
were stored at -80ºC.  
 
Staining procedure 
 
Slides were allowed to thaw and were then re-hydrated with TBST at 2x 5 min. Non-
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the secondary antibody (in this case donkey) for 1 hour at room temperature, followed 
by applying primary antibody made up in TBST containing 1% serum, leaving it to 
incubate  overnight  for  approximately  20  hours  at  4ºC  (negative  controls  were 
incubated  with  TBST-1%  serum).  Primary  antibodies  were  used  at  the  following 
dilutions: 1: 40 000 sheep-anti-cGMP, 1: 2000 mouse-anti-CNPase, 1: 1000 rabbit-
anti-GFAP,  1:  1200  mouse-anti-NeuN,  and  1:  500  mouse-anti-NF  200.  Primary 
antibody incubation was followed by washing with TBST at 4-5x 10-15 min before 
applying the secondary antibody (made up in TBST) for 1 hour at room temperature 
in  the  dark.  Secondary  antibodies  were  used  at  the  following  dilutions:  1:  1000 
donkey-anti-sheep-Alexa  488,  1:  1500  donkey-anti-rabbit-Alexa  594,  and  1:  600 
donkey-anti-mouse-Alexa 594. Slides were washed with TBST at 4-5x 10-15 min and 
then mounted and coverslipped in mounting medium (containing DAPI to stain the 
nuclei). Slides were stored at 4ºC in the dark.  
 
5.3.4   Immunohistochemistry for GCβ1 
 
For the GCβ1 immunohistochemistry, animals were deeply anaesthetised with 200 µl 
i/p  of  Pentoject  (Pentobarbitone  sodium  –  200  mg/ml)  per  animal,  followed  by 
intracardial  in  situ  fixation  (this  procedure  was  kindly  carried  out  by  Mr.  Nick 
Davies). The in situ fixation consisted of one flush with cold PBS (0.1 M; sterile), to 
avoid blood contamination, followed by perfusion with cold, fresh depolymerised 1% 
PFA fixative. Whole hippocampi were transferred into 1% cold PFA and left for 3 
hours at room temperature under continuous motion. Following fixation, hippocampi 
were washed 5 times with 0.1 M PB (20-30 min each), placed into 5% sucrose for 2-3 
hours standing at 4ºC, transferred to 10% sucrose for 2 hours standing at 4ºC, and 
finally  added  to  25%  sucrose  in  which  they  were  left  overnight  standing  at  4ºC. 
Subsequently, whole hippocampi were incubated for 1-2 hours in 1: 1 OCT and 50% 
sucrose, followed by approximately 30 min neat OCT. The hippocampi were then 
embedded in OCT in the appropriate mould over card ice / iso-pentane, dipping the 
bottom  of  the  embedding  mould  into  a  plastic  dish  resting  on  the  card  ice  and 
containing  iso-pentane  to  ensure  rapid  freezing  of  the  tissue.  Slices  were  then 
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to dry at room temperature overnight before storing them at -20ºC. Frozen tissue/OCT 
blocks that were not cryosectioned immediately were stored at -80ºC.  
 
Staining procedure 
 
Slides were allowed to thaw and were then re-hydrated with TBS (no triton) at 2x 5 
min. Tissue was permeabilised with neat acetone for 5 min, continuously dropping 
some onto the slide, followed by 3x 5 min washes with TBS. Peroxidase suppressor 
was then applied for 15 min at room temperature, followed by 3x 5 min washes with 
TBS. Non-specific binding was blocked by adding 10% serum (made in TBS) from 
the  host  of  the  secondary  antibody  (in  this  case  donkey)  for  1  hour  at  room 
temperature. Primary antibody (rabbit-anti-GCβ1; 1: 500) made up in TBS containing 
1% serum was then applied and incubated overnight for approximately 20 hours at 
4ºC (negative controls were incubated with TBS-1% serum), followed by 4x 10-15 
min  washes  with  TBS.  Sections  were  then  incubated  with  secondary  antibody 
(donkey-anti-rabbit-biotin;  made  up  in  TBS  at  1:  200)  for  1-2  hours  at  room 
temperature, followed by 4x 10-15 min washes with TBS. Subsequently, ABC reagent 
was applied for 45 min at room temperature, followed by 4x 10-15 min washes with 
TBS, and DAB was then applied in excess for 4-5 min at room temperature. Slides 
were then rinsed with plenty dH2O, counter-stained with haemalum (applying it for 
20-25 seconds at room temperature and immediately rinsing it off with tap water), 
washed once with dH2O, and finally allowed to air-dry overnight at room temperature. 
Slides were then mounted and coverslipped in DPX and allowed to dry overnight 
before taking pictures, storing them at room temperature. 
 
5.3.5   Analysis 
 
cGMP quantification by means of RIA 
 
The procedure for determining cGMP content normalised to protein amount has been 
dealt with in detail in Chapter 2. All data are presented as means ± SEM obtained 
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Immunohistochemistry 
 
Images were taken, using a communal Leica TCS SP confocal microscope, running 
Leica  LCS  SP2  software  (Leica  Microsystems,  Heidelberg,  Germany).  The  Leica 
TCS SP confocal microscope is equipped with four lasers giving 5 selectable lines; 
Argon ion giving 458nm (blue) and 488nm (cyan), Krypton 568nm (green/yellow), 
HeNe 633nm (red) and a water-cooled Argon ion producing UV with lines at 351 and 
364 nm. The Leica DM-R upright fluorescence microscope is fitted with standard 
FITC/TRITC filters. In the saved settings box of the Leica software, the appropriate 
filter was selected – e.g. DAPI (UV laser; blue emission, e.g. Hoechst and other UV 
dyes excited by 351 and 364 nm such as DAPI used in the present study),  FITC 
(Argon  laser;  green  emission,  e.g.  FITC,  fluorescein,  GFP  and  other  green  dyes 
excited by 488, 512 and 476 nm such as Alexa-488 used in the present study) or 
TRITC (HeNe laser; red emission, e.g. TRITC, rhodamine red, Texas red, Cy5 and 
other red dyes excited by 568-633 nm such as Alexa-594 used in the present study). 
For 10 µm tissue sections, 6 optical sections were taken and each was averaged 4-6 
times. When comparing cGMP staining in different parts of the same tissue section, 
the same parameters were applied. Negative controls were also imaged in parallel 
with the same parameters. The images were then processed and merged in Leica LCS 
Lite. To determine cGMP-positive structures, the appropriate markers were stained 
and  co-localisation  was  evaluated.  Images  presented  here  are  qualitative 
representatives of at least three observations from different rats.  
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5.4   RESULTS 
 
5.4.1   Localisation and characterisation of cGMP-positive structures 
 
Stimulation of NOGC receptors – in the absence of NO donor 
 
cGMP signal corresponding to endogenous NO: 
 
Incubation  of  hippocampal  slices  in  the  presence  of  PDE  inhibitor  only, 
resulted in barely detectable cGMP accumulation, as did incubation of slices under 
basal  conditions  without  pharmacological  treatment  (Fig.  5.4).  In  the  presence  of 
submaximal concentrations of both BAY 60-7550 (10 nM) and BAY 41-2272 (3 µM), 
cGMP levels were measured by RIA to be 151 ± 14 pmol/mg protein (Fig. 5.4). 
Under these conditions, cGMP signals were observed mainly in astrocytes, especially 
around the CA1 region, a few interneurons, and blood vessels (Fig. 5.1b and Fig. 
5.2). A similar staining pattern was found when slices were incubated in the presence 
of the broad-spectrum PDE inhibitor IBMX (1 mM) and BAY 41-2272 (3 µM; Fig. 
5.1a and Fig. 5.2), a condition investigated previously in rat and mouse hippocampi, 
with a prominent cGMP signal in astrocytes (especially around the CA1 area) and 
varicose fibres (van Staveren et al., 2004). Moreover, the similarity of the staining 
pattern  that  is  obtained  using  either  IBMX  or  BAY  60-7550  at  a  submaximal 
concentration echoes findings concerning the similarity observed when using IBMX 
and  the  PDE2  inhibitor  EHNA  in  the  absence  or  presence  of  an  NO  donor  (van 
Staveren et al., 2001).  
 
In order to maximise the signal in response to endogenous NO the effects of 
maximal concentrations of these agents were investigated. When tested on purified 
PDE2, BAY 60-7550 showed maximal inhibition of enzyme  activity  at 0.1-1 µM 
(Boess et al., 2004). Only the activity of PDE1 was noticeably affected by BAY 60-
7550, while PDE5 activity was marginally enhanced. Bearing in mind, however, that 
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a higher concentration would be required for these actions to occur when looking at 
the  whole  tissue  level.  A  lower  potency  of  inhibitors  in  slices  is  based  on  cell 
permeability  or  possible  intracellular  metabolism  of  the  compound.  For  example, 
differences in potency were found for the PDE5 inhibitor DMPPO when comparing 
the inhibitory effect in an enzymatic assay to a cell model (Coste & Grondin, 1995). 
Furthermore, while inhibition of PDE5 has been shown to elevate cGMP to some 
extent, no increase in cGMP has been found to occur upon PDE1 inhibition in the 
hippocampus (de Vente et al., 1996; van Staveren et al., 2001). As it is well known, 
cyclic  nucleotides  can  modulate  each  others’  signal  profile  by,  for  example,  one 
acting on a PDE affecting the breakdown of the other such as is the case with cGMP 
inhibition of PDE3 that may ultimately lead to enhanced cAMP levels (Vigne et al., 
1994;  Pelligrino  &  Wang,  1997;  Bender  &  Beavo,  2006).  This  could  ultimately 
interfere with the signal of interest. The levels of cAMP in the presence of different 
BAY  60-7550  concentrations  have  been  assessed  previously  in  adult  hippocampal 
slices, significant cAMP elevation being obtained when the concentration of BAY 60-
7550 exceeded 1 µM (Boess et al., 2004). Taken together, a maximal concentration of 
1 µM was chosen for BAY 60-7550 in conjunction with a maximal concentration of 
10 µM BAY 41-2272, the latter being devoid of non-selective effects such as PDE 
inhibition  (Stasch  et  al.,  2001;  Mullershausen  et  al.,  2004a).  It  should  be  noted, 
however, that even if cross talk occurred between the two cyclic nucleotides under 
these chosen conditions, or any other cGMP-hydrolysing PDE isoform were inhibited, 
this would not interfere with the primary aim of the present study, namely to evaluate 
structures  in  the  hippocampus  that  are  potential  NO  targets,  being  capable  of 
synthesising cGMP. Moreover, direct  elevation  of cAMP via PDE4 inhibition has 
been reported to result in weak cGMP-IR in some astrocytes only (van Staveren et al., 
2001).  
Under these chosen conditions in the present study (i.e. 1 µM BAY 60-7550 
and 10 µM BAY 41-2272), the level of cGMP was found to be enhanced to 578 ± 53 
pmol/mg  protein  (Fig.  5.4)  and  a  quite  distinct  staining  pattern  revealed  itself 
compared to previously tested conditions. In addition to broad astrocytic cGMP-IR 
throughout the hippocampal formation, a greater proportion of interneurons appeared 
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cluster  of  unidentified  cells,  most  likely  pyramidal  cells  (as  verified  later  by  co-
localisation with the neuronal marker NeuN), was apparent in the subiculum, as well 
as faintly stained pyramidal cells in the CA4 region (Fig. 5.1c). In addition, cGMP-IR 
was  noticeable  throughout  the  neuropil  of  the  slice  (Fig.  5.1c).  The  cGMP-IR 
resulting from incubation of slices with these maximal concentrations of BAY 60-
7550  and  BAY  41-2272  was  absent  in  slices  that  had  been  exposed  to  the  same 
treatment but in the presence of the broad-spectrum NOS inhibitor L-NNA or the 
NOGC  receptor  inhibitor  ODQ,  confirming  mediation  by  endogenous  NO  and 
specificity to NOGC receptor activity respectively (Fig. 5.1d-f).  
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FIG. 5.1 cGMP-IR (green) in whole sections of rat hippocampal slices incubated in vitro under the 
conditions indicated in the upper right corner of each panel. (A, B) Predominant cGMP-IR in astrocytes 
surrounding the CA1, with a few interneurons throughout the hippocampal formation also stained for cGMP. (C) 
Onset of detectable cGMP-IR in the neuropil as well as in pyramidal cell bodies in CA4 and more strongly in the 
subiculum. (D-F) Representative controls for the treatment condition shown in (C). cGMP-IR was abolished in L-
NNA and ODQ-incubated slices, confirming the NO-dependence of the signal and the specificity of the staining 
respectively. Nuclei are stained with DAPI (blue); Sub, subiculum; scale bar, 200 µm (A-C), 50 µm (D-F). 
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FIG. 5.2. Confocal images taken at a higher magnification, showing cGMP-IR (green) in astrocytes which 
are double immunostained for their marker GFAP (red). Photographs illustrating cGMP-IR in astrocytes 
around the CA1 region in sections of hippocampal slices incubated with submaximal concentrations of the PDE2 
inhibitor BAY 60-7550 (10 nM) and Bay 41-2272 (3 µM) (A-C), or the broad-spectrum PDE inhibitor IBMX (1 
mM) and BAY 41-2272 (3 µM) (D-F) Note: indicated by the arrows are cGMP-positive cell bodies outside the 
pyramidal cell layer, most likely being interneurons. Nuclei are stained with DAPI (blue); so, stratum oriens; sp, 
stratum pyramidale; sr, stratum radiatum; scale bar in C, 30 µm; scale bar in F, 50 µm. 
 
 
Stimulation of NOGC receptors – in the presence of NO donor 
 
Effect of BAY 60-7550 and BAY 41-2272 at maximal concentrations in the presence of 
an NO donor: 
 
The  cGMP  signal  presented  in  the  foregoing  data  corresponded  solely  to 
endogenous NO. Therefore, the capacity for cGMP accumulation upon addition of an 
NO donor remained to be investigated. Thus, in addition to inhibiting PDE2 by means 
of BAY 60-7550 at the maximal concentration of 1 µM and sensitising the NOGC 
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DEA/NO (10 µM), this concentration of DEA/NO causing maximal cGMP elevation 
in  rat  hippocampal  slices  (Bon  &  Garthwaite,  2001).  Under  these  conditions,  the 
cGMP signal was pushed to a remarkable 1741 ± 45 pmol/mg protein as determined 
by RIA (Fig. 5.4). This corresponded to a quite different staining pattern from that 
observed previously. Clear cGMP-IR was apparent throughout the neuropil, as well as 
in pyramidal cells of the subiculum, CA1, CA3 and CA4 (Fig. 5.3a), recognisable by 
the  distinct,  compact  arrangement  of  the  cell  bodies  in  the  band  of  the  stratum 
pyramidale. This staining for cGMP was entirely absent in sections from slices that 
were  incubated  in  the  presence  of  ODQ  (Fig.  5.3b).  No  staining  appeared  in  the 
granule cell layer of the dentate gyrus (Fig. 5.3a).  
 
 
 
 
FIG. 5.3. cGMP-IR (green) in whole sections of rat hippocampal slices incubated in vitro under the 
conditions indicated in the upper right corner of each panel. (A) Marked cGMP-IR in the neuropil throughout 
the hippocampal formation with noticeable staining in pyramidal cell bodies in CA4, CA3, CA1 and subiculum. 
(B) No detectable cGMP-IR in sections from slices that were incubated in the presence of ODQ, confirming the 
specificity of the staining. Nuclei are stained with DAPI (blue); scale bar, 200 µm. 
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FIG. 5.4. Quantification of the cGMP signal by means of radioimmunoassay. For each animal tested, some of 
the hippocampal slices were processed for the quantitative evaluation of the cGMP-IR observed. Respective 
conditions are colour coded, showing the amount of cGMP accumulation that resulted when slices where incubated 
in aCSF containing the PDE2 inhibitor BAY 60-7550 and BAY 41-2272, with or without added NO donor, in the 
absence or presence of L-NNA or ODQ. Note, only in the ‘red group’ did L-NNA fail to prevent the cGMP 
response, which is consistent with exogenous NO being applied (n = 3-6). 
 
 
Sections  were  counterstained  for  a  number  of  cellular  markers  in  order  to 
localise cGMP accumulation. To look at the cGMP-IR in pyramidal cells, sections 
were co-stained with NeuN, a neuron-specific marker that stains the cytoplasm and 
nucleus of cell somata as well as dendrites in some cases (Mullen et al., 1992; Weyer 
& Schillilng, 2003). Confocal images taken at higher magnification revealed a clear 
co-localisation of cGMP in the cell bodies of pyramidal cells in the region of the CA1, 
CA3, CA4 and subiculum (Fig. 5.5). The most intense staining for cGMP appeared to 
be  in  the  CA4  (Fig.  5.5g-l)  and  the  subiculum  (Fig.  5.5j-l),  followed  by  slightly 
weaker cGMP-IR in the CA3 and CA1 (Fig. 5.5d-f). Among these regions, the CA1 
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immuno-positive for cGMP as compared to the other regions investigated (Fig. 5.5a-
c). In the case of the CA3 region, an interesting feature was the stratum lucidum – the 
area in which the pyramidal cells receive their synaptic inputs from the mossy fibres 
originating from the granule cells in the dentate gyrus – appearing dark (Fig. 5.5d-f). 
This implies that the presynaptic component of this synapse may be devoid of cGMP 
accumulation under these conditions. In contrast, there was evident cGMP-IR in the 
apical dendrites of CA3 pyramidal cells (Fig. 5.5d-f). In all four hippocampal regions 
illustrated, there are some brightly stained cell bodies outside the stratum pyramidale 
on either side which are most likely interneurons as judged by co-staining with NeuN 
(Fig. 5.5). Furthermore, in the subiculum, in which a distinct cluster of cells appears 
to be positive for cGMP, clearly co-localise with the neuronal marker NeuN. Yet, a 
number  of  cells  stained  for  NeuN  in  this  hippocampal  sub-region  evidently  lack 
cGMP-IR (Fig. 5.5j-l). Cell counts of neurons for Fig. 5.5 estimated 37% of neurons 
stained for cGMP in CA1 (43 cells out of 117), 76% in CA3 (35 out of 46), 48% in 
CA4 (33 out of 69), and 62% in subiculum (45 out of 73).  
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FIG. 5.5. Confocal images taken at a higher magnification, showing cGMP-IR (green) in pyramidal cell 
bodies which are double immunostained for NeuN (red) in hippocampal slices incubated with 1 µ BAY 60-
7550, 10 µM Bay 41-2272, and 10 µM DEA/NO. Photographs show cGMP-IR in pyramidal cell bodies in CA1 
(A-C), CA3 (D-F), CA4 (G-I) and subiculum (J-L). Note the clear dendritic staining for cGMP in CA3. Nuclei are 
stained with DAPI (blue); Sub, subiculum; so, stratum oriens; sp, stratum pyramidale; sr, stratum radiatum; sl, 
stratum lucidum; gcl, granule cell layer; h, hilus; scale bar, 50 µm. 
 
 
 5 5 5            T T Ta a ar r rg g ge e et t ts s s    f f fo o or r r    N N NO O O    i i in n n    t t th h he e e    h h hi i ip p pp p po o oc c ca a am m mp p pu u us s s    
 
  209
To investigate cGMP-accumulation in axons, sections were co-stained with 
the  marker  NF200,  an  intermediate  filament  protein  expressed  abundantly  along 
axons.  Axons  positively  immunolabelled  for  cGMP  were  found  in  all  regions 
examined, namely CA1, CA3, CA4 and the subiculum (Fig. 5.6). Axons appeared to 
be more heavily stained for cGMP in the CA1 (Fig. 5.6a-c), CA3 (Fig. 5.6d-f) and the 
subiculum (Fig. 5.6j-l), while less intense cGMP-IR showed in the CA4 (Fig. 5.6g-i). 
Clear axonal staining was revealed both in the stratum oriens and stratum radiatum 
around the CA1 and CA3 regions (Fig. 5.6a-f). Around the CA4 region, most axons 
stained for cGMP were found to be in the polymorphic cell layer (or hilus) of the 
dentate  gyrus  (Fig.  5.6g-i).  Also  noticeable  are  some  fibre-like  structures  that  are 
clearly cGMP-positive but are not stained for NF200. These are most likely astrocyte 
processes or possibly dendrites (Fig. 5.6). 
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FIG. 5.6. Confocal images taken at a higher magnification, showing cGMP-IR (green) in axons which are 
double immunostained for NF200 (red) in hippocampal slices incubated with 1 µ BAY 60-7550, 10 µM Bay 
41-2272, and 10 µM DEA/NO. Photographs show cGMP-IR in axons in CA1 (A-C), CA3 (D-F), CA4 (G-I) and 
subiculum (J-L). Nuclei are stained with DAPI (blue); Sub, subiculum; so, stratum oriens; sp, stratum pyramidale; 
sr, stratum radiatum; sl, stratum lucidum; gcl, granule cell layer; h, hilus; scale bar, 50 µm. 
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Pronounced  cGMP-IR  was  also  found  in  astrocytes  throughout  the 
hippocampal formation (Fig. 5.7a-c), co-localising with the astrocytic marker GFAP, 
which is a type of cytoskeletal intermediate filament protein abundant in this type of 
glial cell. No cGMP-IR was detected in oligodendrocytes (Fig. 5.7d-f), perceptible as 
a lack of co-localisation of cGMP-IR with the staining for the enzyme CNPase which 
is prominent in oligodendrocytes. These data apply to all regions investigated, the 
illustrations of the CA3 being representative for observations made in the subiculum 
as  well  as  the  CA1  and  CA4  regions  of  the  hippocampus,  and  throughout  the 
hippocampal section as a whole.  
 
 
 
 
FIG. 5.7. Confocal images taken at a higher magnification, showing cGMP-IR (green) in glial cells which 
are double immunostained for their respective markers in hippocampal slices incubated with 1 µ BAY 60-
7550, 10 µM Bay 41-2272, and 10 µM DEA/NO. (A-C) Photographs illustrating examples of cGMP-IR in 
astrocytes, here showing astrocytes in the CA3 double immunostained for GFAP (red). (D-F) Photographs 
illustrating examples of cGMP-IR in oligodendrocytes, here depicting these cells in the CA3 double-
immunostained for CNPase (red). Nuclei are stained with DAPI (blue); so, stratum oriens; sp, stratum pyramidale; 
sr, stratum radiatum; sl, stratum lucidum; scale bar, 50 µm. 
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5.4.2   Localisation of the NOGC receptor in the immature 
hippocampus 
 
Previous results suggested that optimal protein staining for the NOGC receptor 
was achieved only after a weak fixation paradigm (Burette et al., 2002). The method 
optimised and applied by these authors was adopted in the present study, resulting in a 
staining pattern resembling the one demonstrated previously in the adult hippocampus 
(Burette et al., 2002), as well as that of mRNA expression of the receptor in the 
immature hippocampus (Gibb & Garthwaite, 2001). Immunostaining for GCβ1 protein 
was evident in the pyramidal cell bodies of the CA1 area, the CA3 region, and also in 
neurons in the CA4 area and the subiculum (Fig. 5.8a-d). Prominent staining was also 
recognised in the granule cell layer of the dentate gyrus (Fig. 5.8e). Throughout the 
different sub-regions, intense immunostaining was also detected in cell bodies outside 
the  defined  neuronal  cell  layers,  most  likely  being  interneurons,  which  have  been 
shown previously to express GCβ1 abundantly (Burette et al., 2002; Szabadits et al., 
2007).  Also  striking  was  the  prominent  fibrous,  punctate  staining  throughout  the 
neuropil,  which  could  be  presynaptic,  postsynaptic  and/or  astrocytic  elements, 
consistent with their ability to synthesise cGMP.  
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FIG. 5.8. Immunostaining for GCβ1 in immature rat hippocampal slices. Photographs showing CA1 (A), CA3 
(B), CA4 (C), subiculum (D), dentate gyrus (E) and a representative image of the negative control in which 
primary antibody was omitted, lacking GCβ1 immunoreactivity (F). So, stratum oriens; sp, stratum pyramidale; sr, 
stratum radiatum; sl, stratum lucidum; gcl, granule cell layer; h, hilus; scale bar, 100 µm. 
 
 
5.5   DISCUSSION 
 
In terms of NO sources in the hippocampus it is well known that these could 
be neurons and/or blood vessels. Less clear, however, has been the matter concerning 
the targets for NO in this brain region. The work presented here demonstrates that 
NO,  via  activation  of  its  receptor,  the  guanylyl  cyclase,  initiates  the  formation  of 
cGMP not only predominantly in astrocytes as observed in previous studies, but also 
in cell bodies of pyramidal neurons in the different sub-regions of the hippocampus, 
as well as in some dendrites and, possibly, axons. This concurred with the expression 
pattern of the NOGC receptor found in the present study in immature hippocampal 
slices. The high specificity of the cGMP-directed antibody used in the present study 
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has been evaluated extensively in previous studies (de Vente et al., 1987; Tanaka et 
al., 1997), showing no cross-reactivity with cAMP, cyclic nucleotide monophosphate 
or  triphosphates,  or  guanosine,  indicating  that  the  staining  revealed  in  the  present 
work exclusively reflects NO-responsive, cGMP-synthesising structures. This is also 
in harmony with the lack of staining for cGMP upon inhibition of NOGC receptors, 
demonstrated in the present work. 
 
Up until now, as visualised by means of immunohistochemistry, the general 
notion concerning cGMP-producing structures in the rat hippocampus either under 
basal conditions or exposed to exogenous NO in the absence or presence of PDE 
inhibitor,  has  been  that  the  targets  expressing  functional  NOGC  receptors  are  only 
astrocytes,  a  dense  network  of  unidentified  varicose  fibres  throughout  this  brain 
region,  and  blood  vessel  walls,  with  the  occasional  interneuron  also  displaying 
cGMP-IR (de Vente et al., 1988; de Vente et al., 1996; van Staveren et al., 2001; 
Teunissen et al., 2001; van Staveren et al., 2004; van Staveren et al., 2005). However, 
none has been detected in postsynaptic structures, including pyramidal or granule cell 
somata  and  dendrites.  In  contrast,  functional  studies  have  provided  evidence  that 
points  to  NO-mediated  cGMP  signal  transduction  taking  place  both  pre-  and 
postsynaptically in hippocampal neurons, a clear mismatch with anatomical studies 
(see Introduction). This mismatch is further highlighted by the clear expression of 
NOGC receptors in pyramidal and granule neurons at the mRNA and protein level 
(Matsuoka  et  al.,  1992;  Teunissen  et  al.,  2001;  Burette  et  al.,  2002;  Gibb  & 
Garthwaite, 2001; Ding et al., 2004; Szabadits et al., 2007), not agreeing with the 
failure  to  detect  cGMP  accumulation  in  these  structures  upon  NO  challenge.  The 
present  study  found  clear  expression  of  the  GCβ1  subunit  throughout  the 
hippocampus, with prominent localisation in pyramidal cell bodies of the subiculum, 
CA1, CA3, and CA4, as well as neurons in the granule cell layer. Additionally, a 
dense, punctate staining was observed throughout the neuropil. This corroborates the 
previous  demonstration  of  all  three  subunits  being  present  in  the  immature 
hippocampus at their mRNA level (Gibb & Garthwaite, 2001).  
The pattern revealed for the GCβ1 subunit largely complements the pattern of 
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Successful activation of the NOGC receptor requires the α-subunit (α1 or α2) linked to 
the β1-subunit, and the prosthetic haem (Harteneck et al., 1990; Zabel et al., 1998). A 
simple explanation for why no cGMP accumulation has been observed so far in all 
NOGC receptor-bearing structures could be that not all structures in which the receptor 
has been detected contain receptors that are in this function-determining form. This is 
emphasised by the fact that only antibodies directed against one or the other subunit 
have  been  employed,  the  presence  of  one  subunit  not  giving  any  information 
regarding  the  functional  state  of  the  receptor.  Immature  granule  cells  in  the 
developing cerebellum, for instance, appear to express the α2 subunit, as demonstrated 
by  in  situ  hybridisation,  but  lack  any  other  subunits  (Gibb  &  Garthwaite,  2001). 
Alternatively, the receptors may be rendered inactive by some other factor(s). The 
idea of NOGC receptors in cell somata being inhibited by some endogenous factor or 
by  the  absence  of  some  vital  cofactor  has  been  put  forward  previously  (Domek-
Lopacinska  et  al.,  2005).  In  analogy,  a  mismatch  between  receptor-bearing  and 
ligand-responding structures has also been observed in various regions of the rat brain 
upon  exposure  to  atrial  natriuretic  peptide  (ANP),  the  resulting  response 
corresponding to cGMP output from the NO-insensitive form of the guanylyl cyclase 
(Saavedra, 1987; de Vente et al., 1989; de Vente et al., 1990a). For example, despite 
it revealing the highest density of ANP receptors (Saavedra, 1987), the supraoptic 
nucleus was found to not show ANP-responsive, cGMP-producing cells (de Vente et 
al., 1990a). Moreover, cholinergic somata in the caudate putamen of adult rats were 
found to express NOGC receptors, but, when exposed to NO, only fibres but not cell 
bodies  appeared  to  accumulate  cGMP  (de  Vente  et  al.,  2001a).  Also  in  cerebella 
Purkinje cells no detectable cGMP accumulates (de Vente et al., 1990b; de Vente et 
al., 1998) despite the presence of NOGC receptor subunits in these cells (Zwiller et al., 
1981; Nakane et al., 1983; Ding et al., 2004), mirroring the unexplained mismatch 
found in the hippocampus. Even in the presence of BAY 41-2272, to sensitise the 
NOGC  receptor  to  NO,  and  PDE  inhibitor,  no  cGMP  immunostaining  has  been 
observed in postsynaptic hippocampal structures (van Staveren et al., 2004). The lack 
of cGMP accumulation in hippocampal pyramidal cell bodies, despite the presence of 
the NOGC receptor, as indicated by GCβ1 expression, has also been demonstrated in 
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At this point two things should be considered. Firstly, immunohistochemistry 
allows to locate a given receptor and to investigate its functional activity by locating 
cells exhibiting immunostaining for the relevant signal. However, there is a limit to 
the sensitivity of immunohistochemistry, which could likely be the reason for why 
clear  axonal  cGMP-IR,  for  instance,  was  only  observed  under  conditions  of 
maximally  evoked  cGMP  production  (i.e.  PDE2  inhibitor,  BAY  41-2272  and  NO 
donor). On the other hand, the presence of some brightly stained structures may mask 
very weakly stained structures. Overall, the absence of cGMP-IR is not an absolute 
indication for the non-existence of cGMP-producing structures in the region under 
investigation.  Even  complete  failure  to  detect  cyclic  nucleotides  by  means  of 
immunohistochemistry has been reported in the early days (Cumming et al., 1977; 
Cumming et al., 1980), in this case the paradigm of fixation appearing to be a crucial 
factor,  with  long  fixation  times  found  to  destroy  all  cyclic  nucleotide 
immunoreactivity (Rall & Lehne, 1982; de Vente et al., 1987). Secondly, although not 
an aspect looked into experimentally in the present work, the age of the animal at 
which cGMP accumulation is investigated may be important in determining the scope 
of the detection limit of the cGMP-IR, as related to the amount of cGMP produced in 
the  given  tissue.  Different  patterns  of  cGMP-responding  structures  may  reflect 
variations in the NO-cGMP signalling cascade at different developmental stages.  
One of the key findings in the current study was the remarkable capacity of the 
immature  tissue  to  produce  cGMP.  Purely  corresponding  to  endogenous  NO, 
incubation of the 10-day-old hippocampal slices with maximum concentrations of the 
PDE2  inhibitor  and  BAY  41-2272  to  sensitise  the  NOGC  receptors  produced 
approximately  600  pmol  of  cGMP  per  mg  protein.  Addition  of  the  NO  donor 
DEA/NO to this condition amounted in remarkable amounts of cGMP accumulation 
in the whole tissue, approaching 1800 pmol of cGMP per mg protein. These data 
reflect a cGMP-producing capacity never observed before in the hippocampus. While 
this  work  utilised  immature  hippocampal  slices,  the  majority  of  previous  work 
evaluated cGMP localisation in adult hippocampal tissue, finding the characteristic 
cGMP-IR mainly in varicose fibres, astrocytes, blood vessel walls, and the occasional 
interneuron, with a clear absence in postsynaptic elements as discussed above. In the 
rat cerebellum, for instance, there is an increase in cGMP content in astrocytes upon 5 5 5            T T Ta a ar r rg g ge e et t ts s s    f f fo o or r r    N N NO O O    i i in n n    t t th h he e e    h h hi i ip p pp p po o oc c ca a am m mp p pu u us s s    
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maturation  but  a  decreased  responsiveness  of  the  NOGC  receptor  to  NMDA 
(Garthwaite, 1982). A significant decrease in basal cGMP levels has been found in the 
olfactory bulb and the hippocampus of aged animals when compared to adult rats (de 
Vente et al., 1990a), and in vitro slice studies have revealed changes in the functional 
activity  of  the  NOGC  receptor  during  development  (Markerink-van  Ittersum  et  al., 
1997), noting that cGMP synthesis in cerebral neuronal somata in response to NO is 
more  widespread  during  postnatal  development  than  in  adult  and  aged  animals. 
Subsequent to the linkage of NO and cGMP production to NMDA receptor activation 
(Morris et al., 1994), also in the spinal cord NOS-mediated cGMP synthesis has been 
proposed to be reduced upon maturation, NMDA-induced, NO-mediated cGMP-IR 
occurring in 2-week-old rats but none in adult (3-month-old) animals (Vles et al., 
2000). In the same study the authors described apparent ongoing NO synthesis in 
neonatal spinal cord slices which was, however, undetectable in the adult tissue slices. 
Furthermore, cholinergic neurons of the rat basal forebrain and the caudate putamen 
apparently lose the greater part of their capacity to synthesise cGMP in response to 
NO upon maturation, a marked reduction beginning during the second postnatal week 
(Domek-Lopacinska  et  al.,  2005).  These  age-dependent  changes  with  regard  to 
detectable cGMP accumulation may, however, be region-differentiated. Cholinergic 
fibres  in  the  neocortex,  for  instance,  retain  their  capacity  to  synthesise  cGMP  in 
response to NO throughout life (de Vente et al., 2001a), whereas there is apparent loss 
of  NO-responsiveness  in  the  cholinergic  fibres  of  the  hippocampus  during 
development (Domek-Lopacinska et al., 2005). As to the reason for why there are 
higher  levels  of  cGMP  in  the  brain  in  general  during  postnatal  development,  this 
could be related to the proposed function of cGMP during maturation of neuronal 
networks  both  in  vertebrates  and  invertebrates  (Bicker,  2005;  Bicker,  2007).  For 
example, in the rat cortex, cGMP has been suggested to determine the direction of 
dendritic outgrowth during development (Polleux et al., 2000), where inhibition of 
cGMP  production  or  PKG  was  demonstrated  to  result  in  random  orientation  of 
dendrites. The indications concerning lower detectable levels of cGMP in the adult 
CNS parallels the finding of higher PDE activity in the aged brain of rats, resulting in 
more active cGMP degradation (Chalimoniuk & Strosznajder, 1998). Other studies 
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protein  expression  of  some  PDE  isoforms  such  as  PDE1  and  PDE3  during  brain 
development (Billingsley et al., 1990; Reinhardt & Bondy, 1996). Additionally, more 
directly related to the present work, it appears that also the expression of PDE2, PDE5 
and  PDE9  increases  during  maturation  of  the  hippocampus  (van  Staveren  et  al., 
2003).  
 
In the present study, incubation of immature hippocampal slices with either 
the  general  PDE  inhibitor  IBMX  or  the  PDE2  inhibitor  BAY  60-7550  at  its 
submaximal concentration in the presence of a submaximal concentration of BAY 41-
2272  resulted  in  a  similar  distribution  of  cGMP-IR  predominantly  in  astrocytes 
around the CA1 region, a few interneurons and blood vessels, which is in agreement 
with  previous  evidence  cited  above.  However,  upon  exposure  to  maximal 
concentrations  of  BAY  60-7550  and  BAY  41-2272,  astrocytic  cGMP-IR  became 
more  apparent  throughout  the  different  hippocampal  regions  and  marked  cGMP-
immunofluorescence started to clearly appear in a cluster of neuronal cell bodies in 
the subiculum alongside diffuse neuropil staining and weak cGMP-IR in some cell 
bodies in the CA4. More pronounced staining throughout the neuropil as well as in 
pyramidal  cell  bodies  of  the  subiculum,  CA4,  CA3  and,  to  a  lesser  extent,  CA1 
occurred only following the addition of the NO donor. Under conditions of added 
exogenous NO, granule cells still lacked cGMP-IR, which could be related to weaker 
expression of PDE2 in this region but greater abundance of PDE9 (van Staveren et al., 
2003; van Staveren et al., 2004). On the other hand, clear cGMP accumulation was 
now  evident  in  dendrites  of  pyramidal  cells  in  the  CA3  region,  as  well  as  axons 
surrounding or transecting the regions investigated. In terms of the axonal staining, 
however, the extent of investigation carried out in the present study does not allow 
further conclusions to be made concerning the identity of the cGMP-accumulating 
axons. The mere presence of NO-reactive axons in the different sub-regions of the 
hippocampus does not imply that these axons terminate in a particular region or make 
a particular functional contact within the hippocampus. Moreover, there is also the 
likelihood that some (if not the majority) of the cGMP-stained axons are interneuronal 
or are part of a pathway travelling through the hippocampus. Cholinergic neurons of 
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hippocampus,  the  varicose  cholinergic  fibres  of  these  areas  that  innervate  the 
hippocampus having been demonstrated to synthesise cGMP (Domek-Lopacinska et 
al., 2005). Additionally, upon addition of DEA/NO, the cGMP-immunofluorescence 
seemed now to be brighter in the cell bodies of the subiculum and the CA4 area 
compared to when no NO donor was added.  
The different conditions revealing a sequence of emergence of NO-responding 
targets, immunofluorescence intensity seemingly being brighter as cGMP levels are 
raised more, could reflect different profiles of PDE activity contained in cells in a 
given region. While PDE2, alongside PDE5 and PDE9, have been demonstrated at the 
mRNA  level  primarily  in  neuronal  cell  bodies  (van  Staveren  et  al.,  2003;  van 
Staveren et al., 2004), a different balance among these PDE isoforms in terms of their 
activity  and/or  abundance  could  be  responsible  for  varying  cGMP  signals  in  the 
different hippocampal subregions. This possibility is strengthened by the lack of these 
PDE  isoforms  in  astrocytes  (van  Staveren  et  al.,  2004)  and  the  profile  of  cGMP 
accumulation in these cells, for example.  
The  identification  of  cGMP  in  astrocytes  even  in  the  presence  of  PDE 
inhibitor alone (van Staveren et al., 2001) and cGMP appearing in blood vessel walls 
even in the absence of PDE inhibitor (de Vente et al., 1996), is a good indication that 
PDE activity is a key determinant of detectable cGMP signals. Also, in the present 
study under all conditions tested, in the absence or presence of the NO donor, cGMP-
immunofluorescence was obvious in astrocytes.  It should be noted, however, that, 
while astrocytes in the CA1 region appeared cGMP-positive even under ‘endogenous 
NO  conditions’,  cGMP  accumulation  in  astrocytes  in  the  other  areas  investigated 
appeared clearly upon addition of exogenous NO by means of DEA/NO, or when 
maximal concentrations of BAY 60-7550 and BAY 41-2272 were applied. This could 
reflect  different  subpopulations  of  astroglia  exhibiting  different  PDE  activity.  In 
analogy,  a  subregional  heterogeneity  of  astroglia  has  been  suggested  previously, 
demonstrating that populations of these glial cells may contain either ANP-responding 
guanylyl cyclase or NOGC receptors only, or both (de Vente et al., 1989; de Vente et 
al., 1990a; Teunissen et al., 2001). In contrast, no cGMP-immunofluorescence was 
detectable  in  the  oligodendrocytes  with  only  a  sparse  number  of  these  glial  cells 
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oligodendrocytes and is thought to be involved in myelin formation. For example, in 
multiple sclerosis, where the main hallmark is the degeneration of myelin, plaque 
regions where myelin is lost also exhibit reduced levels of CNPase (Johnson et al., 
1986).  Immunohistochemically,  in  the  corpus  callosum  of  the  rat  forebrain, 
oligodendrocytes  have  been  demonstrated  to  have  cGMP-producing  capacity  in 
response to NO (Tanaka et al., 1997), using the same antibodies as the present study. 
Tanaka and colleagues found that the number of cGMP-producing oligodendrocytes 
decreases during maturation and appears to be absent in the adult brain, suggesting 
that the cGMP-dependent signalling pathway could be involved in the regulation of 
myelin formation. Tanaka et al. also showed that there is no cross-reactivity between 
the cGMP antibody, also used in the present study, and the 2’3’-analogues contained 
in oligodendrocytes. The limited number of CNPase-stained oligodendrocytes in the 
immature  hippocampal  slices  could  be  explained  by  the  expression  profile  of  this 
oligodendrocyte  marker  in  this  brain  region.  Up  to  postnatal  day  10  (the  age  of 
animals used in the current study), CNPase expression is very low, being nearly non-
existent during the first 8 days of rat life, but sharply increases and approaches its 
peak around the fourth postnatal week (Virgili et al., 1990). This trend of CNPase 
activity  concurs  with  the  beginning  of  myelination,  myelinated  fibres  in  the 
hippocampus being first seen between postnatal days 15 and 17 and progressively 
increasing until postnatal day 25 (Savaskan et al., 1999; Meier et al., 2004). Immature 
oligodendrocytes  in  the  rat  brain  are  suggested  to  express  a  number  of  different 
markers  sequentially  (Virgili  et  al.,  1990)  and,  although  the  few  CNPase-positive 
oligodendrocytes did not reveal any cGMP accumulation in response to NO, it could 
be argued that there may be populations of oligodendrocytes at this developmental 
stage that may be targets for NO but could only be localised by means of a different 
marker. On the other hand there is no evidence of PDE2 in these glial cells, the only 
PDE subtype inhibited in the current work. Hence, it also becomes conceivable that, if 
there was any cGMP synthesis occurring in oligodendrocytes, one or more isoforms 
of PDE other than PDE2 could be degrading it, making it untraceable.  
 
Another question remaining is as to why previous studies failed to observe 
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indication that cGMP may rise in dendrites derived from a previous study that also 
employed BAY 60-7550 (Boess et al., 2004). Exposing hippocampal slices to similar 
conditions (i.e. maximal BAY 60-7550 concentration plus NO donor), the authors 
demonstrated  diffuse,  punctate  neuropil  staining  for  cGMP.  This  is  similar  to  the 
observation made in the present study following incubation of the slices with maximal 
concentrations of BAY 60-7550 and BAY 41-2272 in the absence or presence of NO 
donor. However, Boess et al. found only minimal co-localisation of cGMP with the 
presynaptic  marker  synaptophysin,  leading  the  authors  to  the  conclusion  that, 
although cGMP levels may be increased in a subset of presynaptic terminals, the main 
rise in cGMP may occur in postsynaptic parts of the neuron. However, also Boess and 
colleagues failed to detect cGMP-IR in pyramidal cell bodies, which could be related 
to the absence of BAY 41-2272 as compared to the present study. Moreover, the data 
presented here clearly show cGMP accumulation in dendrites emerging from CA3 
pyramidal cell bodies, as evaluated by the co-localisation with the neuronal marker 
NeuN,  which  can  also  stain  dendrites  (Mullen  et  al.,  1992).  While  the  study 
conducted by Boess et al. employed BAY 60-7550 just as the present work, a likely 
explanation  for  the  absence  of  cGMP-IR  in  pyramidal  cell  bodies  may  be  the 
pharmacological paradigm employed. Perhaps addition of a compound sensitising the 
NOGC  receptors  so  that  the  signal  would  be  even  further  amplified  would  have 
revealed positive cGMP staining in the neuronal somata. Another aspect worthwhile 
considering, however, is the possibility of different splice variants of PDE occurring 
in  a  given  tissue  or  cell.  Different  splice  variants  have  been  reported  for  PDE2, 
PDE2A1 being a cytosolic form, and PDE2A2 and PDE2A3 being membrane-bound 
variants (Bender & Beavo, 2006), where PDE2 in the hippocampus has been shown to 
appear ‘ring-like’ mainly around the plasma membrane of pyramidal neurons (van 
Staveren et al., 2003). Studies that have investigated PDE2 in the hippocampus have 
focussed on mRNA expression, which does not necessarily give an accurate account 
concerning protein abundance. Also, the published work does not distinguish among 
different  PDE2  splice  variants.  Therefore,  previous  tools  employed  to  inhibit  the 
PDE2, such as EHNA, may have not been effective against all possible PDE2 splice 
variants,  expression  of  which  in  the  hippocampus  cannot  be  excluded  to  date. 5 5 5            T T Ta a ar r rg g ge e et t ts s s    f f fo o or r r    N N NO O O    i i in n n    t t th h he e e    h h hi i ip p pp p po o oc c ca a am m mp p pu u us s s    
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Although not known, it may be that BAY 60-7550 has a more efficient inhibitory 
potency towards different variants of PDE2.  
The absence of cGMP-IR in hippocampal pyramidal cell somata may also be 
brought about by the experimental and pharmacological paradigm used in previous 
studies in terms of NO application. The majority of previous work employed the NO 
donor SNP, which is a troublesome NO donor to work with. The interpretation of 
results  generated  from  several  NO  donor  compounds  may  be  complicated  by  the 
production of NO-derivatives other than authentic NO. Decomposition of SNP can 
generate NO
+, NO
- and CN
- in addition to NO and its degradation is dependent on 
light and thiols (Feelisch, 1998; Miller & Megson, 2007). NO donors belonging to the 
family of NONOates on the other hand, including DEA/NO used in the present study, 
have  been  established  to  release  authentic  NO  with  known  half-lives  under 
physiological conditions (Maragos et al., 1991; Morley & Keefer, 1993; Keefer et al., 
1996) and should therefore be used ideally. In this respect, differential stimulation of 
NOGC receptors by SNP and DEA/NO has been reported to take place in cortical 
tissue for instance (Nedvetsky et al., 2002), where application of compounds for the 
same  amount  of  time  revealed  DEA/NO  to  stimulate  NOGC  receptor  activity  with 
greater potency than SNP. Moreover, according to the findings by Nedvetsky et al. 
(2002), DEA/NO, used at a third of the concentration of SNP, evoked higher amounts 
of  cGMP  accumulation  in  various  brain  regions,  including  the  medulla, 
hypothalamus, midbrain, and striatum. Also in the cerebellum there was a slightly 
greater effect of DEA/NO compared to SNP. Only a small number of previous studies 
that investigated NO-responding targets in the hippocampus have employed DEA/NO 
(van  Staveren  et  al.,  2004;  van  Staveren  et  al.,  2005).  However,  in  these  studies 
DEA/NO was dissolved in aCSF and applied to the tissue slices for 10 minutes. The 
NONOates should be dissolved in alkaline solutions and be applied just before it is 
required  to  induce  the  biological  response.  DEA/NO  is  stable  and  kept  in  a  non-
releasing state in alkaline solutions but spontaneously decomposes with a half-life of 
2 minutes at physiological pH and temperature (Morley & Keefer, 1993; Keefer et al., 
1996). Therefore, it is possibly that, given that the NO donor was dissolved in aCSF 
and applied for 10 minutes before inactivating the biological reaction, only minimal 5 5 5            T T Ta a ar r rg g ge e et t ts s s    f f fo o or r r    N N NO O O    i i in n n    t t th h he e e    h h hi i ip p pp p po o oc c ca a am m mp p pu u us s s    
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cGMP production was evoked so that the real scope of cGMP accumulation remained 
undetected, associated with missing the optimal window of NO release.  
 
To  summarise,  the  present  study  revealed  clear  NO-responsiveness  of 
postsynaptic  structures  in  the  hippocampus  as  demonstrated  by  cGMP-IR  in 
pyramidal  cell  bodies  in  different  sub-areas,  explaining  the  previous  mismatch 
between anatomical and functional investigations. The observation of dendritic and 
axonal cGMP accumulation requires more detailed investigation, the identity of the 
latter remaining unresolved in the present work. Overall, the present findings reveal a 
pharmacological paradigm that will be useful to determine NO targets in the brain and 
so  possibly  uncover  new  NO-responsive  structures.  Although  the  majority  of 
pyramidal  cell-cGMP-IR  only  appeared  upon  addition  of  an  NO  donor,  it  can  be 
speculated  that  the  same  cGMP-producing  cells  can  respond  to  endogenous  NO, 
which, however, is beyond the detection limit of the immunohistochemical approach. 
Demonstrating  so  far  unidentified  NO-responding  structures  in  the  CNS  in 
vitro  by  means  of  cGMP-IR  has  certainly  been  a  good  aid  to  clarifying  the 
neurobiological  aspects  of  NO.  However,  immunohistochemistry  only  provides  a 
‘snapshot’  of  the  biological  response,  providing  very  poor  or  no  spatiotemporal 
information. Aspects such as diffusion of cGMP from its initial site of synthesis prior 
to fixation cannot be determined by means of this methodology. The data shown here 
allows  no  firm  conclusion  concerning  the  ‘real’  cGMP-producing  sites  in  the 
hippocampus.  For  example,  it  cannot  be  known  with  certainty  whether  cGMP  is 
mainly synthesised in dendrites and/or closely around the soma membrane and then 
diffuses  globally  into  neuronal  cell  bodies,  or  whether  it  is  originally  produced 
globally  in  pyramidal  neurons.  Given  that  PDE2  is  inhibited  in  conjunction  with 
evidence suggesting this PDE isoform to be located in a ‘ring-like’ appearance around 
the plasma membrane of pyramidal neurons (van Staveren et al., 2003), diffusion of 
cGMP seems likely. Advances in the design of cGMP-sensitive indicators that can be 
expressed in a whole tissue may make it possible to investigate this matter in the 
future. 
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6.1   INTRODUCTION 
 
Based on the numerous functions of cGMP in cellular events and complex 
biological processes, there has been  great interest in the development of sensitive 
tools that would allow monitoring of the spatial and temporal behaviour of cyclic 
nucleotide levels upon receptor stimulation. A commonly-used classical method to 
study  NO-evoked  cGMP  accumulation  has  been  radioimmunoassay  (RIA),  which 
allows the detection of changing levels of biological molecules at the whole tissue 
level.  However,  there  are  a  number  of  downsides  to  this  approach.  In  order  to 
determine cGMP levels, using antibodies directed against the cyclic nucleotide, cells 
or tissues need to be homogenised. Moreover, although RIA has been a useful method 
to monitor endogenous NO levels by measuring cGMP levels that are sensitive to 
NOS inhibition (Griffiths et al., 2002), it has a limit concerning its sensitivity and it 
does not allow examination of free cGMP levels as the antibody will also recognise 
pools of cGMP that are bound to downstream targets. Physiological effects of NO 
without  detectable  cGMP  rises  by  RIA  have  been  reported  (Mergia  et  al.,  2006). 
Mergia et al. (2006) found that aortic rings from mice lacking about 94 % NOGC 
receptors relax in response to NO with the corresponding cGMP accumulation being 
undetectable by means of RIA.  A further important drawback of this biochemical 
assay is its low temporal and no spatial resolution. Previous studies have set out to 
study the temporal characteristics of NO-induced cGMP accumulation in tissues by 
terminating the biological reaction at different time points. However, acquisition of 
time courses in this way is very laborious and has a temporal limit, especially when 
considering the very fast kinetics of NO-evoked cGMP signals (Garthwaite, 2005).  In 
rat cerebellar cells for instance, the kinetics for the reaction rate between NO and its 
receptor were found to be on a sub-second scale (Bellamy & Garthwaite, 2001a), 
significant  increases  in  cGMP  being  observed  at  40  ms.  On  the  other  hand,  the 
importance of resolving cGMP signals spatially is underlined by the concept of cGMP 
compartmentalisation,  which  assumes  different  cGMP  concentrations  in  various 
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NO-evoked cGMP signal. An intriguing aspect of cyclic nucleotide-mediated signal 
transduction  has  certainly  been  how  specific  cellular  responses  are  achieved 
considering  the  vast  number  of  effector  systems  coupled  to  cGMP  signalling.  As 
discussed in more detail in Chapter 1, the spatiotemporal profile of a given cGMP 
signal is not only determined by its rate of synthesis but also by its degradation by 
phosphodiesterase (PDE). In a different respect, it is not only desirable to understand 
the purpose of different cyclic nucleotide-generating systems being present in a given 
cell,  but  also  the  rationale  for  different  PDEs  with  varying  substrate  specificity, 
affinity, and subcellular location occurring not only broadly in a given cell but even in 
microenvironments within that cell. A particular pattern of components present in a 
given  microdomain  of  a  cell  may  greatly  influence  the  outcome  of  the  cyclic 
nucleotide signal in terms of its ability to diffuse away from its site of production as 
well  as  its  duration  and  amplitude,  therefore  determining  the  ensuing  biological 
response based on the targets accessible to a given cGMP signal (Garthwaite, 2005; 
Fischmeister et al., 2006).  
 
Devising tools that would enable one to continuously monitor the changes in 
cGMP concentrations in living cells in real-time at high spatiotemporal resolution 
would substantially enrich our understanding of NO-cGMP signalling. A great deal of 
effort has been put into this objective by scientists in the past. One approach involves 
the use of recombinant CNG channels combined with electrophysiological recordings 
or  Ca
2+-sensitive  dyes,  measuring  or  imaging  the  cation  current  or  change  in 
intracellular  Ca
2+  respectively  that  result  upon  channel  activation  in  response  to 
cGMP elevation. For example, CNG2 channels have been employed as cGMP sensors 
in  rat  cardiomyocytes  (Castro  et  al.,  2006).  The  authors  provided  evidence  for 
compartmentalisation of cGMP signals derived from either the natriuretic peptide- or 
NO-activated  types  of  guanylyl  cyclase.  Castro  and  colleagues  (2006)  found  that, 
while cGMP generated by the natriuretic peptide-activated enzyme was accessible at 
the plasma membrane and controlled exclusively by PDE2 activity, the cGMP signal 
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inhibited. While Castro et al. (2006) derived their findings from recording the Ca
2+ 
current conducted by CNG channels, another study carried out by Piggott et al. (2006) 
also investigated the differential patterning of cGMP responses to NO donors and 
natriuretic  peptide,  finding  also  spatial  segregation  of  cGMP  signals  in  cultured 
vascular smooth muscle cells infected with adenovirus encoding the CNGα2 subunit. 
Here the readout for changes in GMP-modulated CNG channel activity was the Ca
2+ 
influx through the channels using the Ca
2+-sensitive fluorescent dye fura-2 (Piggott et 
al.,  2006).  A  potential  problem  that  may  arise  using  this  method  is  the  fact  that 
activated CNG channels conduct Ca
2+ ions which in turn may influence downstream 
components of the signalling cascade that are sensitive to Ca
2+.  
Another method that has attracted a lot of attention in the context of real-time 
measurements of cGMP dynamics in living cells involves the use of fluorescence 
resonance  energy  transfer  (FRET)-based  cGMP  indicators.  The  principle  of  these 
indicators  constitutes  the  interaction  of  cGMP  with  one  of  its  natural  binding 
domains, such as GAF-domains of PDE2 or PDE5 (Nikolaev et al., 2006; Russwurm 
et al., 2007), or parts of PKG (Sato et al., 2000; Honda et al., 2001; Russwurm et al., 
2007), which are fused between two fluorescent proteins, and which generally vary in 
their  dynamic  range,  cGMP  sensitivity,  and  selectivity.  Binding  of  the  cyclic 
nucleotide  to  the  biosensor  induces  a  conformational  change  which  leads  to  an 
increase or decrease in the distance between the fluorescent proteins which in turn is 
translated  into  a  change  in  FRET.  It  is  the  change  in  FRET  that  is  ultimately 
monitored, providing information concerning the dynamics of cGMP signals.  
 
The  use  of  FRET-based  cGMP  indicators  has  provided  insights  into  the 
spatiotemporal characteristics of cGMP signalling. For example, Cawley et al. (2007) 
provided information concerning temporal cGMP dynamics in cultured aortic smooth 
muscle  cells.  The  authors  demonstrated  the  concerted  influence  of  NOGC  receptor 
activation and PDE5 activity on the kinetic profile of cGMP peaks in the smooth 
muscle cells, observing a sharp increase in cGMP followed by a rapid degradation 
phase,  the  decline  in  the  response  being  prevented  upon  PDE5  inhibition.  Other 6 6 6            C C Ch h ha a ar r ra a ac c ct t te e er r ri i is s sa a at t ti i io o on n n    o o of f f    a a a    n n ne e ew w w    m m me e et t th h ho o od d d    f f fo o or r r    r r re e ea a al l l- - -t t ti i im m me e e    c c ca a ap p pt t tu u ur r re e e    
o o of f f    c c cG G GM M MP P P    s s si i ig g gn n na a al l ls s s    i i in n n    r r re e es s sp p po o on n ns s se e e    t t to o o    c c cl l la a am m mp p pe e ed d d    N N NO O O    
c c co o on n nc c ce e en n nt t tr r ra a at t ti i io o on n ns s s    
 
  228
interesting methods that have been developed recently include a PKG-based FRET 
sensor coupled to α and β subunits of the NOGC receptor (Sato et al., 2005). This 
construct  had  a  detection  limit  of  0.1  nM  NO.  Employing  this  guanylyl  cyclase-
coupled cGMP indicator, the authors demonstrated that 1 nM NO, which is plenty to 
induce vasorelaxation, is generated in cultured vascular endothelial cells even in the 
absence of shear stress. The same laboratory then produced a reporter cell line named 
Piccell (Sato et al., 2006), which can be used to monitor NO levels when grown in co-
culture with the cells of interest. Sato and colleagues (2006) demonstrated remarkable 
NO sensitivity of their new system with a detection limit of 20 pM, and, in the course 
of their study in primary hippocampal neurons, uncovered an oscillatory release of 
picomolar NO concentrations from neurons which was synchronised with periodical 
neuronal Ca
2+ spikes.  
Though  the  use  of  FRET-based  indicators  has  certainly  added  to  the 
knowledge  about  NO-cGMP  signal  transduction,  this  method  suffers  from  several 
disadvantages. Using this approach to study the spatiotemporal dynamics of cGMP 
requires  technically  laborious  dual  emission  detection  systems.  Other  limitations 
include low changes in the overall emission ratio and low sensitivity so that small 
fluctuations in cGMP levels can not be detected. Moreover, low NO concentrations 
are capable of initiating cGMP synthesis (Garthwaite, 2005), the amount of elevation 
of which may be physiologically relevant but yet not detected by the cGMP indicator 
used. Additionally, low selectivity, and poor reversibility and speed are a problem in 
FRET. Lastly, other attributes of available cGMP indicators to be improved include 
the problem of pH sensitivity, no applicability in vivo in mammals, and interactions of 
the biosensor with endogenous proteins, the latter possibly being responsible for the 
low maximal intensity changes observed in living cells (Nausch et al., 2008). Very 
recently,  a  new  non-FRET  based  cGMP  biosensor  named  δ-FlincG  has  been 
developed  and  tested  in  Wolfgang  Dostmann’s  laboratory  in  the  University  of 
Vermont,  and  was  demonstrated  to  have  superior  spectral  characteristics,  fast 
association and dissociation kinetics, allowing capture of the very rapid rise and fall in 
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FlincG and ‘clamped’ NO 
 
The development of δ-FlincG (fluorescence indicator for cGMP) was largely 
based on the concept of non-FRET Ca
2+ indicators (Baird et al., 1999; Nakai et al., 
2001), which since have successfully been employed to visualise Ca
2+ patterns during 
the  cardiac  cycle  in  the  heart  in  vivo  (Tallini  et  al.,  2006).  The  FlincG  indicator 
constitutes two tandem PKG-derived cGMP binding sites that are fused to the N-
terminus of a circularly permutated enhanced  green fluorescent protein (cpEGFP), 
which  permits  substrate-indicator  interactions  to  be  directly  translated  into 
conformational changes and an increase in fluorescence intensity of a single cpEGFP 
molecule (Nausch et al., 2008). A diagram of the FlincG construct is depicted in Fig. 
6.1. The authors removed interactions between endogenous PKG and δ-FlincG by 
deleting the N-terminal domain of the PKG-derived cGMP binding domain which is 
responsible for dimerisation between PKG proteins. This latter modification led to 
improved  maximal  changes  in  fluorescence  intensity.  Furthermore,  δ-FlincG  was 
found  to  benefit  from  high  selectivity  for  cGMP  over  cAMP  (>280-fold)  and  to 
respond to low nanomolar NO-concentrations derived from the short-lived NO donor 
DEA/NO (EC50, DEA/NO = 4 nM; Nausch et al., 2008). Another advantage of δ-FlincG 
was its resistance to small changes in pH under physiological conditions (pKa, δ-FlincG = 
6.1; Nausch et al., 2008). Importantly, Nausch and colleagues (2008) have produced a 
novel  cGMP  biosensor  with  outstanding  high-speed  kinetics.  Rapid  temporal  and 
spatial cGMP changes can be captured more accurately as the fast rates for cGMP 
association and dissociation with or from δ-FlincG ensure that the indicator does not 
act  as  a  sink  for  cGMP.  Moreover,  the  cGMP  binding  constant  of  δ-FlincG  was 
estimated to be 170 nM, which is approximating the cGMP affinity for its endogenous 
binding partners such as PKG and PDE5 in vascular smooth muscle cells (Nausch et 
al., 2008). 
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                                    Fig. 6.1 Diagram of FlincG, published in Nausch et al., 2008. 
 
 
A possible source of error in NO research is the way NO is applied. This has, 
for instance, led to inconsistent reports concerning the potency of NO for its receptor 
(Griffiths  et  al.,  2003;  Garthwaite,  2005).  Numerous  studies  have  and  are  still 
deducing results from experiments in which NO is delivered in constantly changing 
concentrations. The basis of this problem is the continuous decomposition of the NO 
donor over time and the potential of NO to interact with oxygen, the latter known as 
autoxidation  (Ford  et  al.,  1993).  Previously  an  easy-to-use  method  has  been 
developed  to  deliver  NO  concentrations  under  clamped  conditions  so  that  the 
biological response or profile of NOGC receptor activation can be directly related to a 
known concentration of NO (Griffiths et al., 2003). The principle of this method is a 
balanced  state  between  NO  release  at  a  constant  rate  from  an  NO  donor  and  an 
appropriate rate of NO consumption. This is achieved by combining a long-lived NO 
donor with the chemical NO scavenger CPTIO. The rationale of using an NO donor 
with a long half-life is to provide a slow rate of decomposition of the donor relative to 
the duration of the experiment so that a constant rate of NO release is achieved. On 
the other hand, CPTIO, which allegedly does not penetrate the cells (Griffiths et al., 
2003), scavenges NO extracellularly. The end result of combining a state of fast NO 
diffusion into the cells with continuous extracellular removal of NO is an existent 
dynamic equilibrium of NO across the cell barrier (Griffiths et al., 2003).  
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6.2   AIM 
 
The objective of the present study was to investigate NO-evoked cGMP dynamics in a 
heterologous expression system, combining real-time imaging and clamped delivery 
of NO at physiological concentrations. 
 
 
6.3   METHODS 
 
6.3.1   Cell culture of HEK cells 
 
Four different HEK293 cell lines expressing the NOGC receptor and/or PDE5 were 
chosen for study. One of the cell lines, generated by Jeffrey Vernon in the Garthwaite 
lab,  permanently  expresses  the  α1β1  NOGC  receptor  targeted  to  the  cell  plasma 
membrane. Three more HEK cell lines with different expression levels of the NOGC 
receptor  and/or  the  PDE5  were  kindly  provided  by  Doris  Koesling,  University  of 
Bochum. Of these latter three, one had been transfected permanently with the normal 
α1β1 NOGC receptor only. The other two cell lines had been transfected permanently 
with the normal α1β1 NOGC receptor and PDE5, one expressing higher amounts of the 
PDE5  than  the  other  (Mullershausen  et  al.,  2004b).  The  two  respective  PDE5-
expressing cell lines will be referred to as HEK-GC/PDE5 and HEK-GC/PDE5
high. 
The PDE5 activity in HEK-GC/PDE5
high cells is approximately 1.5-times higher than 
in HEK-GC/PDE5 cells (Mullershausen et al., 2004b). 
 
All of the four different HEK cell lines were cultured at 37ºC in a humidified 5% CO2 
atmosphere in DMEM supplemented with 5% heat-denatured fetal bovine serum, 1% 
penicillin  /  streptomycin  and  1%  non-essential  amino  acids,  composing  the  basic 
culture medium for these cells. The basic culture medium for HEK cells expressing 
the  membrane-targeted  α1β1  NOGC  receptor  additionally  contained  the  antibiotic 
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same purpose, basic culture media for the HEK cells expressing PDE5 additionally to 
the  normal  α1β1  NOGC  receptor  contained  the  antibiotics  hygromycin,  G418  and 
zeocin, each being at a final concentration of 200 µg/ml, while cells expressing only 
the normal α1β1 NOGC receptor were cultured in basic growth medium additionally 
containing hygromycin and G418 at 200 µg/ml each. 
 
General procedure for cell maintenance 
 
Cells were grown in filter-capped T175 flasks containing 20-30 ml of basic culture 
medium (see above), replenished with fresh medium approximately every 3-5 days as 
required. At approximately 80% confluence, cells were split as follows. Media were 
removed followed by one wash with 1x DPBS, taking care not to disturb or detach 
cells at this stage. Following removal of DPBS, 3 ml of trypsin solution was added 
and left for approximately 2 min or until cells had detached. In order to stop the 
trypsin reaction, 7 ml of basic culture medium was added, followed by triturating the 
cells. Depending on when confluence of cells was desired, the flask containing fresh 
basic  culture  medium  was  inoculated  with  an  appropriate  volume  of  the  cell 
suspension, the remainder of which was discarded.  
 
6.3.2   Infection of HEK cells with FlincG 
 
FlincG  was  kindly  donated  by  Wolfgang  Dostmann,  University  of  Vermont.  To 
amplify the adenoviral stock, HEK293T cells were used and the procedure according 
to Invitrogen was followed. In brief, the day before the infection, 293T cells were 
trypsinised, counted, and plated at 3 x 10
6 cells per 10 cm plate, plating them in 10 ml 
of  normal  growth  medium  containing  serum.  Once  the  cells  had  reached  80-90% 
confluency,  100  µl  of  crude  adenoviral  stock  was  added  to  the  cells.  Cells  were 
incubated  at  37ºC  in  a  humidified  5%  CO2  atmosphere,  allowing  the  infection  to 
proceed  until  80-90%  of  cells  had  rounded  up  and  were  floating  or  only  lightly 
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containing cells were harvested by squirting cells off the plate with a 10 ml pipette, 
transferring the cells and media to a sterile falcon tube. The tube was then placed at -
80ºC for 30 min, followed by placing the tube in a 37ºC water bath for 15 min to 
thaw. This freeze / thaw cycle was repeated twice. Subsequently, cell lysates were 
centrifuged at 3000 rpm for 15 min at room temperature to pellet the debris. Finally, 
the supernatant containing viral particles were aliquoted under sterile conditions and 
stored at -80ºC. 
 
All HEK cells lines containing the α1β1 NOGC receptor and/or PDE5 were plated in 
basic culture medium (at 2 ml per well) onto poly-D-lysine coated coverslips (No. 0 
thickness, 0.08-0.12 mm; 13 mm diameter; VWR International, Dorset, UK) in 6-well 
plates (Falcon Discovery Labware, Marathon Laboratory Supplies, London, UK) at 
the desired density at least 24 hours prior to infection. Care was taken not to plate too 
densely as this would have made it difficult to select a field with the right balance of 
number of cells and cell-free background. Normally, a density of 30-40% confluence 
prior to infection was aimed for. On the day of infection, several hours before the 
addition of the virus, the medium was changed to basic culture medium devoid of the 
‘selection’ antibiotics (i.e. no zeocin, hygromycin, or G418). For infection of HEK 
cells with the FlincG biosensor, adenovirus (10
7-10
9 per ml presumed titer) was first 
diluted at 1/ 100 in cold DPBS and then added to the wells containing 2 ml of medium 
and 30-40% confluent HEK cells at 1: 30 000, giving a final titer of 3.33 x 10
3-3.33 x 
10
5 particles per ml. Cells were incubated in the presence of the viral construct for 
approximately 36 hours at 37ºC and 5% CO2 atmosphere before imaging. 
 
6.3.3   Imaging 
 
On the day of imaging, approximately 1-2 hours before starting the experiments, the 
medium  containing  the  FlincG-adenovirus  was  removed  and  replenished  with 
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Before each experiment, flow rate and temperature were checked and, if necessary, 
were adjusted to 1.5-1.6 ml/min and 37ºC (± 0.1) respectively. To measure the delay 
between switching to a different solution and that solution reaching the chamber, the 
passage of a deliberately introduced air bubble was timed. All drug applications were 
corrected for this delay. Also, to determine the efficiency of wash-in and wash-out, 
fluorescein (1 nM) was perfused at the end of an experiment, and the equilibration 
parameters determined by fitting the rising and falling phases to the following logistic 
function: 
2
) ( 1
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A A
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=  
Where: 
 
A1 = start of wash-in or wash-off 
A2 = equilibration of wash-in or wash-off 
y = change in fluorescence in the chamber  
x = time (sec) 
x0 = half-time of wash-in or wash-off 
p = slope  
 
A sample analysis is illustrated in Fig. 6.2. Overall, the mean half-time (x0) for wash-
in was 7.5 ± 0.72 sec with a mean slope (p) of 2.2 ± 0.77 (n = 24). For wash-out, the 
corresponding values were 8.6 ± 0.77 sec for x0 and 2.4 ± 0.70 for p (n = 24).  
 
 
 
 
 6 6 6            C C Ch h ha a ar r ra a ac c ct t te e er r ri i is s sa a at t ti i io o on n n    o o of f f    a a a    n n ne e ew w w    m m me e et t th h ho o od d d    f f fo o or r r    r r re e ea a al l l- - -t t ti i im m me e e    c c ca a ap p pt t tu u ur r re e e    
o o of f f    c c cG G GM M MP P P    s s si i ig g gn n na a al l ls s s    i i in n n    r r re e es s sp p po o on n ns s se e e    t t to o o    c c cl l la a am m mp p pe e ed d d    N N NO O O    
c c co o on n nc c ce e en n nt t tr r ra a at t ti i io o on n ns s s    
 
  235
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.2 Wash-in and wash-out of fluorescein for determining the mixing parameters. A: Whole graph 
showing 3 min application of fluorescein. B: Parameters determined for wash-in mixing time. C: 
Parameters determined for wash-out mixing time. 
 
 
A coverslip was placed into the chamber (0.5 ml capacity) and a platinum ring (12 
mm diameter) used to hold it down. The coverslip was perfused with clamp buffer 
and a field of cells brought into focus using the bright field. A field of cells was 
chosen on the basis of morphological criteria and reasonable expression levels of the 
FlincG. In general, the coverslips were screened for a field containing several cells 
positively  expressing  the  FlincG,  avoiding  fields  mainly  containing  very  round  or 
bright cells and/or lacking enough cell-free background space. The acquisition time 
(or frame rate) as well as exposure time were adjusted from one experiment to the 
other as required.  
 
To achieve conditions of ‘clamped’ NO concentrations, the ‘clamp buffer’ contained 
the  NO  scavenger  CPTIO  (100  µM).  Other  constituents  were  urate  (300  µM)  to 
remove NO2 that is formed by the reaction between NO and CPTIO, and SOD (100 
U/ml) to scavenge any superoxide anions that would otherwise react with NO to form 
peroxynitrite (Griffiths et al., 2003). To prevent any endogenous NO production, the 
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clamp buffer also contained the broad-spectrum NOS inhibitor L-NNA (30 µM). The 
potential  problem  of  NO  loss  via  autoxidation  was  negligible  at  the  low 
concentrations of NO used (0.001-30 nM) based on the rate of the reaction between 
NO and oxygen being proportional to the square of the NO concentration (Ford et al., 
1993;  Griffiths  et  al.,  2003).  A  mathematical  model  developed  by  Prof.  John 
Garthwaite in Mathcad was used for determining the concentrations of NO donor and 
CPTIO to be added to the clamp buffer in order to achieve the desired clamped NO 
profile. As an example, Fig. 6.3 shows an outline of the model, depicting the clamped 
profile of 1 nM NO: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.3 Clamped NO concentrations as determined using a Mathcad document written by Prof. J. 
Garthwaite – A: Clamped profile of 1 nM NO. B: CPTIO consumption over time. C: Decomposition of 
NO donor over time. 
 
The following parameters were employed to obtain the above profile: 
 
[Donor]0 = 10 µM, the initial concentration of NO donor added to the clamp buffer 
immediately before application in order to obtain 1 nM of ‘clamped’ NO; 
0 2 4 6
0
5 .10
10
1 .10
9
NO t ( )
t
60
0 2 4 6
9.94 .10
5
9.96 .10
5
9.98 .10
5
1 .10
4
CPTIO t ( )
t
60
0 2 4 6
9.6 .10
6
9.8 .10
6
1 .10
5
D t ( )
t
60
A 
B  C 6 6 6            C C Ch h ha a ar r ra a ac c ct t te e er r ri i is s sa a at t ti i io o on n n    o o of f f    a a a    n n ne e ew w w    m m me e et t th h ho o od d d    f f fo o or r r    r r re e ea a al l l- - -t t ti i im m me e e    c c ca a ap p pt t tu u ur r re e e    
o o of f f    c c cG G GM M MP P P    s s si i ig g gn n na a al l ls s s    i i in n n    r r re e es s sp p po o on n ns s se e e    t t to o o    c c cl l la a am m mp p pe e ed d d    N N NO O O    
c c co o on n nc c ce e en n nt t tr r ra a at t ti i io o on n ns s s    
 
  237
eNO = 1.3, the mol of NO released per mol NO donor; 
[CPTIO]0 = 100 µM, the starting concentration of CPTIO that is added to the clamp 
buffer; 
thalf = 100, the known half life of the NO donor NOC-12 in minutes at 37ºC and pH 
7.4; 
k1 = 1.155 x 10
-4, the rate constant for donor decomposition (s
-1); 
k2 = 1.6 x 10
4, the rate constant for reaction of NO with CPTIO; 
 
Furthermore: 
 
t = time in seconds 
[NO](t) = concentration of NO at time t 
[Donor](t) = concentration of NO donor at time t 
[CPTIO](t) = concentration of CPTIO at time t 
 
Finally, this is solved according to the following equation: 
 
NO Donor
k ¾® ¾
1  
2
2 NO CPTI CPTIO NO
k + ¾® ¾ +  
 
Assuming exponential decay of the donor, the decomposition reaction will follow first 
order kinetics with a rate of 
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Accordingly, the rate of NO formation is given by 
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And will ultimately be determined by the amount of NO being removed by CPTIO, so 
that 
 
) ]( ).[ ]( .[ ). ]( .[ ) (
] [
2 1 t NO t CPTIO k eNO t Donor k t
dt
NO d
- =  
 
The decay of CPTIO will be given by its reaction rate with NO 
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For all experiments, the concentration of CPTIO was kept constant (i.e. at 100 µM) 
and the concentration of NOC-12 to be added was adjusted as required to obtain the 
desired free NO concentration, which ranged from 1 pM to 30 nM. 
 
Cells  were  continuously  perfused  with  clamp  buffer  and  imaged  on  an  inverted 
microscope  (Axiovert  135  TV  Zeiss)  using  a  x40  magnification  oil  immersion 
objective and a 12-bit monochrome camera (Q Imaging Rolera-XR; Microimaging 
Applications Group, Marlow, Buckinghamshire, UK) and a combined filterwheel and 
lamp (Prior Lumen200Pro; Prior Scientific Instruments Ltd). A standard filter set was 
used (Chroma filter set 49002 GFP containing an ET470±40 nm/40x excitation filter, 
a T495LP dichroic mirror and an ET525/50nm emitter; Chroma Technology Corp., 
Dorchester,  Dorset,  UK).  The  images  were  acquired  using  Image-Pro  Plus  6.3 
(MediaCybernetics,  Inc.,  Bethesda,  MD,  USA).  The  FlincG  has  an  absorption 
maximum at 491 nm, excitation at 480 nm yielding an emission maximum at 511 nm, 
which is shifted when cGMP binds (KD ~ 170 nM; Nausch et al., 2008).  Cells were 
imaged at varying acquisition rates depending on their response profile. In general, 
HEK cells only expressing the NOGC receptor were imaged at a frame rate of 0.2 Hz 
acquisition speed, while HEK cells expressing the NOGC receptor and PDE5 at lower 
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adjusted according to the level of FlincG expression and ranged from 90 to 110 msec. 
All inhibitors were pre-incubated for 5 min prior to NO application. The NO donor 
NOC-12 (t1/2 = 100 min at pH 7.4 and 37ºC) was applied for 1 min, unless otherwise 
stated,  at  an  appropriate  concentration  required  to  achieve  the  desired  clamped 
concentration of NO. The cGMP analogue 8-Br-cGMP was perfused for 15 min. NO 
applications were at 10-15 min intervals unless otherwise indicated. 
 
6.3.4   Analysis 
 
FlincG-expressing  cells  that  were  very  bright  (near  to  saturated)  or  moved  were 
excluded from the analysis. The data were analysed using Image-Pro Plus 6.3, Excel 
and OriginPro 8. Areas of interest (AOIs) were selected for each FlincG-expressing 
cell and the mean fluorescence intensity was measured over time. The background 
(F0), which was selected in cell-free areas, was subtracted from all values of the mean 
fluorescence  intensity  (F)  measured  for  the  whole  experiment,  giving   F,  and,  to 
normalise the fluorescence intensity,  F was divided by F0. Following normalisation 
of the data to  F/F0, all cells were averaged to show the mean FlincG readout of the 
experiment.  
 
 
6.4   RESULTS 
 
6.4.1   Evaluation of FlincG as a cGMP sensor  
 
Influence of varying levels of FlincG on response profiles 
 
To ensure that no errors are introduced due to a buffering effect on cGMP the 
cell line exhibiting the fastest response to NO (i.e. HEK-GC/PDE5
high; see later) was 
chosen  for  the  comparison  of  the  cGMP  profiles  among  cells  containing  varying 
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comparing different cells, with some expressing up to 5-fold higher FlincG content 
than others (Fig. 6.4). No change in fluorescence occurred in control experiments 
testing cells which had not been infected with the FlincG-adenoviral construct (Fig. 
6.5). 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
FIG. 6.4 Response profiles to 1 nM NO in HEK-GC/PDE5
high cells containing different amounts of 
FlincG. A: Bright-field image of HEK cells. B: Areas of interest. C: Read-out of areas of interest before 
normalisation to  F/F0. Up to a 5-fold difference in the level of FlincG expression had no noticeable 
impact on the shape of the response to 1 nM NO. D: Averaged traces of cells expressing lowest, 
intermediate, and highest levels of FlincG seen in panel C. 
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FIG. 6.5 Effect of NO in cells not infected with 
the  FlincG.  A:  Bright-field  image  of  cells.  B: 
Areas  of  interest.  C:  Trace  showing  the  mean 
readout of the response to 1 nM NO. No change 
in  fluorescence  intensity  occurred.  Shown  are 
averaged  traces  of  n  =  16,  representative  of  3 
observations. Note: Application time of NOC-12 
is indicated by the horizontal bar. In blue are ± 
SEM. 
 
 
 
Evaluation of FlincG as a sensor for changes in cGMP in response to clamped 
NO using HEK cells expressing the membrane-localised α1β1 NOGC receptor  
 
The first aim was to test whether the fluorescence change in response to NO 
application  was  the  result  of  activation  of  NOGC  receptors  and  ultimately 
corresponding to a change in cGMP. Cells were sequentially exposed to 1 nM NO, 
resulting in successive changes in fluorescence intensity, the response returning back 
to baseline upon removal of NO (Fig. 6.6a,b). The response to NO was abolished in 
the presence of the NOGC receptor inhibitor ODQ, signifying dependence on cGMP 
generation (Fig. 6.6a,b). No change in the baseline occurred during pre-incubation of 
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ODQ.  Additionally,  the  cGMP  analogue  8-Br-cGMP  also  evoked  a  change  in 
fluorescence intensity (Fig. 6.6c,d). 
 
 
 
 
 
 
 
 
 
 
FIG. 6.6 NOGC receptor-dependence of FlincG emitted fluorescence changes in response to NO exposure. A-B: 
Representative trace(A) and averaged traces of n = 4, representative of 3 observations (B) showing cGMP 
responses to 1 min applications of 1 nM clamped NO in the absence or presence of ODQ. C-D: Representative 
trace(C) and averaged traces of n = 5, representative of 4 observations (D) showing cGMP responses to 1 min 
application of 1 nM clamped NO and 8-Br-cGMP. Note, panels C and D depict data obtained in experiments 
shown in Fig. 6.9. Note: Application times of NO and ODQ are indicated by the horizontal bars. Red, mean; blue, 
± SEM. 
 
 
The profile of cGMP signals is determined by its rate of synthesis by NOGC 
receptors  and  its  degradation  by  phosphodiesterase  (PDE;  see  Chapter  1).  Having 
confirmed that the increase in fluorescence intensity is dependent on NOGC receptor 
activation by NO (Fig. 6.6), the aim was to assess whether the falling phase of the 
response upon NO removal was the result of cGMP breakdown by PDE. This test 
would further contribute to validating whether the changes in fluorescence intensity 
are  based  on  changes  in  cGMP  levels.  Application  of  1  nM  NO  resulted  in  the 
characteristic change in fluorescence intensity, gradually returning back to baseline 
upon wash-out of NO. In the presence of the broad-spectrum PDE inhibitor IBMX, 
the  increase  in  fluorescence  intensity  persisted  following  NO  removal  and  only 
returned  to  baseline  upon  wash-out  of  IBMX  (Fig.  6.7).  Wash-out  of  IBMX  and 
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restoration  of  PDE  activity  was  confirmed  by  re-application  and  removal  of  NO 
resulting in the previously mentioned rise and fall in the fluorescence intensity.  
 
 
 
FIG. 6.7 Effect of PDE inhibition on NO-evoked 
cGMP-mediated  FlincG  responses  A: 
Representative trace showing cGMP responses to 
1 nM clamped NO in the absence or presence of 
the broad-spectrum inhibitor IBMX. B: Averaged 
traces of n = 5, representative of 5 observations. 
Note:  Application  times  of  NO  and  IBMX  are 
indicated by the horizontal bars. Red, mean; blue, 
± SEM. 
 
 
 
The next set of experiments investigated the dynamics of the cGMP signal to 
different  clamped  NO  concentrations.  Exposure  of  HEK  cells  expressing  the 
membrane-targeted α1β1 isoform of the NOGC receptor to 1 min of different clamped 
concentrations  of  NO  generated  a  concentration-dependent  increase  in  the  mean 
fluorescence intensity (Fig. 6.8a,b). A clear response was detected at 300 pM NO, the 
FlincG reaching its maximum fluorescence at 10 nM, resulting in a plateau phase of 
the  response.  The  initial  rate  of  the  response  rise  accelerated  with  higher  NO 
concentrations  (Fig.  6.8c,d),  as  did  the  decay  rate  (Fig.  6.8e,f),  the  latter 
corresponding to the response falling back to baseline faster. Exposure to a high (30 
nM)  NO  concentration  was  followed  by  a  second  application  of  1  nM  NO,  the 
response to which appeared reduced and to have a slower rise time but faster decay 
time as compared to the response evoked by the first application of 1 nM NO (Fig. 
6.8g). Overall, the response to the second exposure of 1 nM NO (i.e. ‘post-30 nM 
NO’)  appeared  shallower  with  an  accelerated  rate  of  the  fluorescence  change 
returning to baseline. A submaximal concentration of 1 nM NO was chosen to serve 
as the control signal in all subsequent experiments as this allowed monitoring the 
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progression  of  the  whole  response  without  loss  of  the  peak  due  to  the  FlincG 
saturating. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 6.8 Concentration-response of FlincG to clamped concentrations of NO. A-B: Representative trace (A) and 
averaged traces of n = 7 (B) showing cGMP responses to ascending clamped concentrations of NO, applied for 1 
min. C-F Graphs showing mean initial rates of rise times (C-D) and the decay times (E-F) of responses to 
increasing NO concentrations. Indicated in panels C and E is an example of measurements taken of the initial 
rising phase and response decline. Panel D shows individual traces of mean initial rise times (normalised to zero), 
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the slopes of which are plotted in C. Panel F shows individual traces of mean decay times (normalised to a fixed 
point), the slopes of which are plotted in E. G: Comparison of the mean initial rates of rise and decay times of 
responses to 1 nM NO before (‘1 nM NO pre-30 nM NO’) and after (‘1 nM NO post-30 nM NO’) exposure to 
higher NO concentrations. Indicated in the graph are the slopes. Note: Application times of NO are indicated by 
the horizontal bars. In panel B, red is mean; blue is ± SEM. 
 
 
From the changes in fluorescence intensity, estimations of the corresponding cGMP 
concentrations can be made by rearranging the Michaelis-Menten equation to: 
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Where:  
 
[cGMP] = concentration of cGMP 
r =  F 
Rmax =  Fmax 
n = 1.47, and is the slope of the calibration curve to known [cGMP] (Nausch et al., 
2008) 
EC50 = 150 nM; the [cGMP] causing a half-maximal change in fluorescence (Nausch 
et al., 2008) 
 
In Fig. 6.8,  Fmax was 0.21 units in fluorescence change (corresponding to the mean 
change in fluorescence caused by 3 nM, 10 nM and 30 nM NO), corresponding to 1 
µM  cGMP  (Nausch  et  al.,  2008).  Using  the  equation  above,  the  change  in 
fluorescence in response to 300 pM NO (0.10 units) corresponds to approximately 
141 nM of cGMP, while the responses to the first 1 nM NO application (0.18 units) 
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concentration correspond to approximately 507 nM and 160 nM cGMP respectively. 
From these estimates, it can be suggested that exposure to a high NO concentration 
caused over 60% loss of the response to a subsequent low NO concentration. 
 
As revealed by the data shown in Fig. 6.8, following exposures to successive, 
ascending NO concentrations, the profile of control response to 1 nM NO was altered 
compared to that in response to the first application of 1 nM (Fig. 6.8); the initial 
rising  phase  was  found  to  be  reduced,  whereas  the  decay  rate  was  found  to  be 
increased. The next set of experiments evaluated whether these changes in the control 
response profile  were the result of the relatively  long duration of the  experiment, 
giving several NO challenges, or directly  related to applying a high (30 nM) NO 
concentration. Following a single exposure to a high (30 nM) NO concentration, the 
response profile to the subsequent application of 1 nM exhibited a reduced initial 
rising rate and an accelerated falling phase compared to the control response to the 
first application of 1 nM NO (Fig. 6.9a-c). 
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FIG. 6.9 Changes in the response profile to low NO following exposure to a high NO concentration. A-B: 
Representative trace (A) and averaged traces of n = 5, representative of 4 observations (B) showing cGMP 
responses to submaximal (1 nM) and saturating (30 nM) clamped NO concentrations, applied for 1 min. C: Plotted 
are mean initial rise and fall times of fluorescence changes normalised to zero or a fixed point respectively. Slopes 
are indicated in the graph. Note: Application times of NO and 8-Br-cGMP are indicated by the horizontal bars. In 
panel B, red is mean; blue is ± SEM. 
 
 
6.4.2   NO sensitivity 
 
FlincG response to clamped NO using HEK cells expressing the normal α1β1 
NOGC receptor  
 
The following set of experiments investigated the NO-evoked cGMP profile in 
HEK  cells  expressing  the  normal  α1β1  NOGC  receptor  kindly  provided  by  Doris 
Koesling.  Cells  were  exposed  to  ascending  concentrations  of  NO  revealing 
concentration-dependent increases in fluorescence intensity. A change in fluorescence 
intensity resulted at NO concentrations as low as 3 pM, the FlincG saturating around 
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100 pM. Comparing these data to the concentration-response profile of HEK cells 
expressing the membrane-targeted α1β1 NOGC receptor (Fig. 6.8), it is found that the 
HEK cells used in this set of experiments are nearly 100-fold more sensitive to NO 
(compare concentration-response profile illustrated in Fig. 6.8a,b with Fig. 6.10a,b). 
This observation is also consistent with the response to an approximately 30- to 100-
fold lower concentration of NO exhibiting a similar initial rise time (compare Fig. 
6.8c,d and Fig. 6.10c). Additionally, a much lower concentration of NO was able to 
cause saturation of the FlincG (i.e. 100 pM, Fig. 6.10a,b vs. 10 nM, Fig. 6.8a,b).  
  The remarkable sensitivity of this particular NOGC receptor-HEK cell line was 
exploited to investigate whether a fluorescence change could be detected in response 
to  environmental  NO.  An  increase  in  fluorescence  intensity  was  detected  upon 
removal of the NO scavenger CPTIO, which reversed to baseline when the NOGC 
receptor  inhibitor  ODQ  was  applied  (Fig.  6.10a,b).  Application  of  8-Br-cGMP 
evoked a response also in the presence of ODQ (Fig. 10a,b), confirming that the loss 
of the fluorescence change upon NO exposure in the presence of ODQ is the result of 
NOGC  receptor  inhibition  and  not  due  to  a  direct  effect  on  the  FlincG  indicator. 
Additionally,  this  latter  observation  further  provides  evidence  that  the  changes  in 
fluorescence intensity are associated with changes in cGMP. Comparing the initial 
rise  times  of  fluorescence  changes,  it  was  possible  to  estimate  the  level  of 
environmental NO existing around the recording chamber. The level of environmental 
NO was estimated to be 10 pM (Fig. 6.10c).  
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FIG. 6.10 NO sensitivity. A-B: Representative trace (A) and averaged traces of n = 5 (B) showing cGMP responses 
to ascending concentrations of clamped NO, revealing a FlincG signal to a NO concentration as low as 3 pM. 
Wash-off of the NO scavenger CPTIO resulted in an increase in fluorescence intensity, corresponding to a 
response to environmental NO, which was prevented upon exposure to ODQ. The response to 8-Br-cGMP was 
preserved in the presence of ODQ. C: Plotted are the mean initial rises in fluorescence intensity upon NO 
exposure, normalised to zero. Indicated in the graph are slopes, showing a much steeper rise in response to 100 pM 
NO as compared to 3 pM, corresponding to faster and slower rise times respectively. In red is the initial rise of the 
response to environmental NO. Note: Application times of compounds are indicated by the horizontal bars. In 
panel B, red is mean; blue is ± SEM. 
 
 
6.4.3   Impact of PDE and NOGC receptor activities on the profile of 
FlincG responses 
 
The following series of experiments aimed to characterise the shape of the 
cGMP-mediated FlincG signal in HEK cell lines permanently expressing the normal 
α1β1 NOGC receptor and lower or higher levels of PDE5 (i.e. HEK-GC/PDE5 and 
HEK-GC/PDE5
high respectively; Mullershausen et al., 2004b), which were also kindly 
given to us by Doris Koesling. 
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Concentration-response profile 
 
Exposure  of  HEK-GC/PDE5  and  HEK-GC/PDE5
high  cells  to  NO  evoked 
FlincG responses that were markedly distinct from the ones observed in the forgoing 
experiments using HEK cell lines permanently expressing only NOGC receptors (and 
their native PDE). Application of different clamped NO concentrations resulted in 
concentration-dependent FlincG signals, exhibiting a biphasic shape (Fig. 6.11 and 
Fig. 6.12). The shape of the responses is exemplified in Fig. 6.11c-e and Fig. 6.12c-e 
for HEK-GC/PDE5 and HEK-GC/PDE5
high cells respectively. Each concentration of 
NO  evoked  a  response  comprised  of  a  rapid  rise  and  subsequent  fall  within 
approximately  1  min,  the  rise  times  being  faster  at  higher  NO  concentrations  as 
indicated by the steeper slopes of the initial rising phases (Fig. 11f and Fig. 12f). With 
increasing NO concentrations the rate of the initial rise in the response became steeper 
with faster onset of the response decline (Fig. 11 and Fig. 12). In all cases, the FlincG 
signal in response to NO began to return towards baseline while the cells were still 
being perfused with NO, indicating cGMP-mediated switch-on of PDE5 (Rybalkin et 
al., 2003; Mullershausen et al., 2003). In the HEK-GC/PDE5 cells, at a low (30 pM) 
NO  concentration  the  response  reached  a  plateau  and  started  to  reverse  within 
approximately  40  sec  of  response  onset,  which  was  found  to  be  20-25  sec  and 
approximately 5 sec in the case of 1 nM and 30 nM NO respectively. In the case of 
the HEK-GC/PDE5
high cells, at 1 nM NO the response reached plateau and started to 
reverse within approximately 20 sec of response onset while the NO was still present, 
which was found to be approximately 10 sec in the case of 10 nM NO application. 
One difference that transpired between the HEK-GC/PDE5 and HEK-GC/PDE5
high 
cells  concerned  their  sensitivity  to  NO.  The  threshold  for  detecting  a  response  in 
HEK-GC/PDE5  cells  was  at  10-fold  lower  NO  concentrations  than  in  the  HEK-
GC/PDE5
high  cells  (10  pM  vs.  100  pM;  Fig.  11a,b  and  Fig.  12a,b).  This  latter 
observation is consistent with the HEK-GC/PDE5 having greater NOGC activity than 
the HEK-GC/PDE5
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initial rise times of responses to the same NO concentrations being steeper in the 
HEK-GC/PDE5 cells than in the HEK-GC/PDE5
high cells (Fig. 11f and Fig. 12f).  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 6.11 Concentration-response profile of HEK-GC/PDE5 cells. A-B: Representative trace (A) and averaged 
traces of n = 10, representative of 3 observations (B), showing cGMP responses to ascending concentrations of 
clamped NO, revealing FlincG responses to a NO concentration as low as 10 pM. Notice the almost complete loss 
of the response to a low (100 pM) NO concentration after exposure to a high (30 nM) NO concentration. Also note 
the ‘undershoot’ in the responses to higher NO concentrations. The distinct shapes of the responses to varying 
concentrations of NO are depicted in panels C-E, showing the enlarged traces of the response profiles to 30 pM 
(C), 1 nM (D), and 30 nM NO (E). F-G Graphs showing mean initial rates of rise times of responses to increasing 
NO concentrations. Panel F shows individual traces of mean initial rise times (normalised to zero), the slopes of 
which are plotted in G. Indicated in the graph illustrated in panel F are slopes, being much steeper in the case of 
higher NO concentrations, corresponding to faster rise times. Note: Application times of compounds are indicated 
by the horizontal bars. In panels B-E, red is mean; blue is ± SEM. 
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FIG. 6.12 Concentration-response profile of HEK-GC/PDE5
high cells. A-B: Representative trace (A) and averaged 
traces of n = 12, representative of 3 observations (B), showing cGMP responses to ascending concentrations of 
clamped NO, revealing FlincG responses to a NO concentration as low as 100 pM. Notice the marked loss of the 
response to a low (1 nM) NO concentration after exposure to a high (30 nM) NO concentration. The distinct 
shapes of the responses to varying concentrations of NO are depicted in panels C-E, showing the enlarged traces of 
the response profiles to 1 nM (C), 10 nM (D), and the second application of 1 nM NO after a high NO 
concentration (E). F-G Graphs showing mean initial rates of rise times of responses to increasing NO 
concentrations. Panel F shows individual traces of mean initial rise times (normalised to zero), the slopes of which 
are plotted in G. Indicated in the graph illustrated in panel F are slopes, being much steeper in the case of higher 
NO concentrations, corresponding to faster rise times; in red is the initial rise of the response to re-exposure to a 
low (1 nM) NO concentration after high (30 nM) NO, being slower compared to that measured upon the first 
application of 1 nM NO. Note: Application times of compounds are indicated by the horizontal bars. In panels B-
E, red is mean; blue is ± SEM. 
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As was apparent in the forgoing experiments, the NO-evoked FlincG signal in 
both  HEK-GC/PDE5  and  HEK-GC/PDE5
high  cells  displayed  a  biphasic  profile 
comprising  a  sharp  rise  followed  by  rapid  reversal  of  the  response  back  towards 
baseline while NO was still being perfused. The biphasic nature of the response was 
particularly pronounced in the HEK-GC/PDE5
high cells. The aim of the following set 
of experiments was to investigate the nature of this biphasic shape of the NO-evoked 
FlincG response further. Cells were repeatedly exposed to a submaximal (1 nM) NO 
concentration (i.e. a concentration at which the FlincG had not reached saturation) for 
3 min (instead of 1 min). The first exposure revealed the first phase of the response 
comprising a fast rise, which was followed by a fast drop. The fast decline appeared 
to stabilise about half-way down, revealing the second phase of the response, which 
appeared to be in a steady-state until the NO was washed off (Fig. 6.13a-d). The 
profile of the responses to subsequent NO challenges appeared altered in that they 
almost lacked the initial ‘spike’ phase (Fig. 6.13c-d), with the second ‘plateau’ phase 
appearing to slowly decline while NO was still present (Fig. 6.13a-b).  
 
 
 
  
 
 
 
 
 
 
 
 
FIG. 6.13 Effect of prolonged repeated NO exposure on the response profile in HEK-GC/PDE5
high cells. A-B: 
Representative trace (A) and averaged traces of n = 7 (B) showing cGMP responses to repeated applications of 1 
nM clamped NO, each NO challenge lasting for 3 min. Note the change in the response profile from one 
displaying a distinctive ‘spike’ phase followed by a ‘plateau’ phase seen in response to the first NO exposure, to 
one almost lacking the initial ‘spike-like’ phase of the response. C-D: Enlarged traces of responses to the first (C) 
and last (D) application of NO, indicated in panel B. Note: Application times of NO are indicated by the horizontal 
bars. In panels B-D, red is mean; blue is ± SEM. 
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Testing for basal NOGC receptor activity 
 
It  was  noticed  in  the  forgoing  experiment  that  the  profile  of  the  response 
consisted of an under-shoot passing the initial baseline following NO removal, which 
was particularly pronounced in the HEK-GC/PDE5 cells (Fig. 6.11). This may be the 
result of a basal level of cGMP in the cells, the hydrolysis of which by the active 
PDE5 would be revealed as the fluorescence intensity decreasing beyond the baseline 
level. The next set of experiments assessed whether there was a basal level of cGMP 
in the cells. The prediction is that if there was basal NOGC receptor activity in the 
cells,  then  inhibition  of  PDE5  to  stop  cGMP  degradation  would  reveal  a  FlincG 
response. To avoid a possible interference of NO application, cells were first exposed 
to the PDE5 inhibitor sildenafil, revealing a clear increase in fluorescence intensity 
that  returned  to  baseline  upon  wash  out  of  sildenafil  (Fig.  14a,b).  Subsequent 
exposure to NO resulted in the usual FlincG response. Surprisingly, a response to 
sildenafil was still observed in the presence of the NOGC receptor inhibitor ODQ, 
while  no  FlincG  response  was  evoked  by  NO,  but  the  response  to  8-Br-cGMP 
remained  intact  (Fig.  14a,b).  Closer  examination  revealed  an  over  50%  shallower 
slope  of  the  response  to  sildenafil  in  the  presence  of  ODQ  as  compared  to  the 
response evoked by the first sildenafil exposure (Fig. 14c), indicating that part of the 
initial (faster) response to sildenafil may be ODQ-sensitive and, thus, NOGC receptor-
dependent. Additionally, although not very marked, during pre-incubation of ODQ a 
small  ‘dip’  could  be  seen  in  the  baseline  when  looking  at  the  averaged  traces  of 
individual cells (Fig. 6.14b), which would be supportive of there being a basal cGMP 
level in unstimulated cells. 
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FIG. 6.14 Effect of PDE5 inhibition under basal conditions – HEK-GC/PDE5 cells. A-B: Representative trace (A) 
and averaged traces of n = 15, representative of 3 observations (B). A marked FlincG response resulted upon 
sildenafil exposure prior to any NO application, where sildenafil evoked a response in the absence and presence of 
the NOGC receptor inhibitor ODQ. The response to NO was prevented by ODQ, while 8-Br-cGMP still evoked a 
FlincG signal. C: Plotted are the mean initial rise phases, normalised to zero. Indicated in the graph are the slopes. 
Note the much shallower rise of the response to sildenafil in the presence of ODQ as compared to the first 
application of sildenafil. Note: Application times of compounds are indicated by the horizontal bars. In panel B, 
red is mean; blue is ± SEM. 
 
 
 
-0.2
0.0
0.2
0.4
0 20 40 60 80 100 120
-0.2
0.0
0.2
0.4
D
F
/
F
0
   8-Br-cGMP (1 mM)
   ODQ (3 mM)
   Sildenafil (1 mM)
D
F
/
F
0
Time (min)
   NO 
(100 pM)
   Sildenafil 
     (1 mM)
A 
B 
0 5 10 15 20
0.00
0.02
0.04
0.06
D
D
D
D
F
/
F
0
Time (sec)
Sildenafil 
 0.00373
Sildenafil + ODQ
      0.00157
C 6 6 6            C C Ch h ha a ar r ra a ac c ct t te e er r ri i is s sa a at t ti i io o on n n    o o of f f    a a a    n n ne e ew w w    m m me e et t th h ho o od d d    f f fo o or r r    r r re e ea a al l l- - -t t ti i im m me e e    c c ca a ap p pt t tu u ur r re e e    
o o of f f    c c cG G GM M MP P P    s s si i ig g gn n na a al l ls s s    i i in n n    r r re e es s sp p po o on n ns s se e e    t t to o o    c c cl l la a am m mp p pe e ed d d    N N NO O O    
c c co o on n nc c ce e en n nt t tr r ra a at t ti i io o on n ns s s    
 
  256
6.4.4  Reproducibility of NO-evoked FlincG responses in fast  
responding HEK cells expressing the NOGC receptor  
and PDE5 
 
The  next  series  of  experiments  investigated  the  capacity  of  the  system 
characterised in the present study to provide readout of brief, successive NO-mediated 
responses. Cells expressing different proportions of NOGC receptors and PDE5 were 
stimulated with a submaximal clamped NO concentration (i.e. concentrations at which 
the FlincG had not reached saturation) repeatedly for 30 sec at 2 min intervals. Both 
HEK-GC/PDE5 (Fig. 6.15) and HEK-GC/PDE5
high cells (Fig. 6.16) were found to 
produce a reproducible readout of FlincG responses. 
In the case of HEK-GC/PDE5 cells the main change observed was a subtle 
reduction in the response magnitude (Fig. 6.15a,b), with the initial rates of rise times 
following a fairly stable trend at repeated 100 pM NO exposures (6.15e,f). Comparing 
the response shape arising to the first and last NO exposure, no marked change was 
apparent (Fig. 6.15c,d).  
Also  HEK-GC/PDE5
high  cells  allowed  monitoring  of  reproducible 
fluorescence  changes  in  response  to  successive  NO  challenges  (Fig.  6.16a,  b). 
However, a more pronounced change in the shape of the response was observed when 
comparing the responses to the first and last NO exposures (Fig. 6.16c,d). While the 
cGMP profile resulting in response to the first NO application comprised a distinct 
biphasic shape as observed in foregoing experiments (Fig. 6.16c), the response to the 
last NO exposure appeared to lack the distinct first phase that consisted of a rapid rise 
and  fall  (Fig.  6.16d).  Overall,  the  change  in  the  response  shape  of  the  HEK-
GC/PDE5
high cells is consistent with the observations made in forgoing experiments 
(Fig. 6.13). In the case of the HEK-GC/PDE5
high cells a noticeable drop in the initial 
rising  rate  of  the  response  occurred  upon  the  first  NO  challenge,  the  subsequent 
response  rising  rates  following  a  relatively  stable  trend  with  repeated  1  nM  NO 
exposures (6.16e,f). 
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FIG. 6.15 Reproducibility of NO-evoked FlincG responses – HEK-GC/PDE5 cells. A-B: Representative trace (A) 
and averaged traces of n = 15 (B) showing cGMP responses to recurring NO exposures to a submaximal clamped 
NO concentration, each NO challenge lasting for 30 sec at 2 min intervals. C-D: Enlarged traces of responses 
indicated in panel B, showing the response profiles seen upon the first (C) and last (D) exposures to NO 
respectively. E-F: Illustrated are the individual mean initial rising phases of the fluorescence changes in response 
to NO, normalised to zero (E), the slopes of which are plotted in panel F. Note: Application times of NO are 
indicated by the horizontal bars. In panels B-D, red is mean; blue is ± SEM. 
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FIG. 6.16 Reproducibility of NO-evoked FlincG responses – HEK-GC/PDE5
high cells. A-B: Representative trace 
(A) and averaged traces of n = 13 (B) showing cGMP responses to recurring NO exposures to a submaximal 
clamped NO concentration, each NO challenge lasting for 30 sec at 2 min intervals. C-D: Enlarged traces of 
responses indicated in panel B, showing the response profiles seen upon the first (C) and last (D) exposures to NO 
respectively. E-F: Illustrated are the individual mean initial rising phases of the fluorescence changes in response 
to NO, normalised to zero (E), the slopes of which are plotted in panel F. Note the value of the first point in panel 
F dropping, the subsequent points following a relatively stable trend. Note: Application times of NO are indicated 
by the horizontal bars. In panels B-D, red is mean; blue is ± SEM. 
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6.5   DISCUSSION 
 
The  present  work  combined  the  use  of  the  new  cGMP  biosensor  FlincG 
(Nausch et al., 2008) and the delivery of known, steady-state (i.e. ‘clamped’) NO 
concentrations (Griffiths et al., 2003) to begin to analyse NO transduction in real-
time. Alongside a basic characterisation of this approach, the findings in the present 
work illustrate on a continuous timescale how the interplay between NOGC receptor 
and PDE activities may serve to generate distinct cellular cGMP profiles.  
 
The  first  part  of  the  study  assessed  the  methodology.  All  data  obtained 
provided further evidence that the changes in fluorescence intensity correspond to 
NO-evoked changes in cGMP. Observations supporting this notion included ODQ-
sensitive and concentration-dependent increases in fluorescence intensity upon NO 
exposure,  and  ODQ-insensitive  FlincG  responses  upon  application  of  a  cGMP 
analogue. Additionally,  prevention of the response decline back to baseline in the 
presence of a non-selective PDE inhibitor is consistent with the knowledge that the 
cGMP signal is governed by its rate of synthesis by NOGC receptors and its rate of 
degradation  by  PDE  (Garthwaite,  2005;  Bender  &  Beavo,  2006;  see  Chapter  1), 
indicating the presence of cGMP-hydrolysing PDE(s) in HEK cells.  
Buffering  of  cGMP  by  FlincG  could  alter  free  diffusion  of  cGMP.  If  the 
indicator is relatively immobile, free diffusion of cGMP may be hindered. On the 
other hand, if the indicator is mobile, diffusion may be enhanced as the indicator may 
act as a carrier that limits intrinsic binding to cGMP by cell constituents (e.g. PDE 
and PKG). Thus, high indicator levels may alter the kinetics of the response. This 
issue was assessed in cells that exhibited the fastest responses with a distinct biphasic 
shape, and no noticeable changes were found in the response profile among cells of 
varying brightness (see Fig. 6.4 and Fig. 6.5). The assumption is that the varying 
brightness of FlincG-transfected cells is related to the amount of FlincG. However, 
the  path  length  (i.e.  cell  thickness)  and  basal  cGMP  levels  could  also  affect  the 
brightness, where a thick cell would fluoresce more than a thin cell. Also, the path 6 6 6            C C Ch h ha a ar r ra a ac c ct t te e er r ri i is s sa a at t ti i io o on n n    o o of f f    a a a    n n ne e ew w w    m m me e et t th h ho o od d d    f f fo o or r r    r r re e ea a al l l- - -t t ti i im m me e e    c c ca a ap p pt t tu u ur r re e e    
o o of f f    c c cG G GM M MP P P    s s si i ig g gn n na a al l ls s s    i i in n n    r r re e es s sp p po o on n ns s se e e    t t to o o    c c cl l la a am m mp p pe e ed d d    N N NO O O    
c c co o on n nc c ce e en n nt t tr r ra a at t ti i io o on n ns s s    
 
  260
length may vary if the cell moves imperceptibly on the floor of the coverslip, which 
can cause apparent changes in cGMP. A solution to ensure a more accurate readout of 
changes  in  cGMP  would  be  a  ratiometric  approach.  Characterisation  of  FlincG 
(Nausch et al., 2008) revealed that the indicator displays a second excitation peak at 
410 nm in addition to the 491 excitation maximum. Therefore, as opposed to previous 
FRET-based cGMP biosensors, additionally to the advantage of a single wavelength 
excitation system being employable, the dual excitation spectrum of FlincG offers the 
possibility  to  combine  the  two  excitation  wavelengths  and  carry  out  ratiometric 
analysis which would cancel out issues of varying dye concentration and path length, 
and  can  be  used  to  determine  the  intracellular  cGMP  concentration.  On  the  other 
hand, a ratiometric approach would mean taking two pictures instead of just one for 
each frame, which may be problematic when investigating very fast signals. Further 
refinements are plausible. Due to the rate of bath exchange, it is likely that the initial 
rising rates and falling rates of the responses to NO are underestimates, particularly in 
the  fast-responding  HEK  cells  (i.e.  HEK-GC/PDE5  and  HEK-GC/PDE5
high  cells). 
The  assumption  that  can  be  made  at  this  stage  is  that,  although  the  actual 
concentration of NO in the cells is not at steady-state immediately, the rising and 
falling phases are likely to be proportional to the NO concentration applied. To avoid 
delays arising from a perfusion system (e.g. mixing time of compounds entering the 
chamber), there is the possibility of pressure-applying NO onto a given cell, allowing 
NO to be applied locally within much shorter intervals and acquiring responses at 
millisecond-timescales (Batchelor, unpublished). However, this approach may have a 
number of disadvantages which one would need to correct for, such as variations in 
the location of the pipette in relation to a given cell and uncertain concentration of NO 
a given cell is exposed to. 
 
Four different HEK cell lines were chosen to investigate this novel approach 
of  monitoring  cGMP  signals  in  real-time  in  response  to  known,  steady-state  NO 
concentrations. Some of the cell lines permanently expressed only the NOGC receptor, 
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mechanism by which the profile of NO-cGMP signalling may be regulated and is 
proposed to be the underlying cause of the loss of NO-responsiveness as a result of 
continued  exposure  of  cells  to  NO  is  the  gradual  loss  of  mRNA  levels  of  NOGC 
receptor subunits and protein, which has been demonstrated upon long exposures of 
cultured rat smooth muscle cells to NO donors and to be cGMP-dependent (Filippov 
et al., 1997; Scott & Nakayama, 1998). While this mechanism provides long-term 
regulation, short-term regulation of the sensitivity of the NO-cGMP pathway may be 
provided by NOGC receptor desensitisation, cGMP-consumption by active PDE, or 
both, ultimately shaping acute cellular cGMP responses to NO and likely determining 
the selection of downstream pathways by cGMP (Garthwaite, 2005; Halvey et al., 
2009).  
 ‘Bell-shaped’ responses were recorded in the two HEK cell lines permanently 
expressing NOGC receptors only, which varied about two orders of magnitude in terms 
of their sensitivity to NO, indicating different amounts of NOGC receptor. An increase 
in the initial rate of fluorescence change occurred with increasing NO concentrations, 
demonstrating faster switch-on of the NOGC receptors at higher NO concentrations, 
the  response  decline  being  most  likely  governed  by  PDE-mediated  hydrolysis  of 
cGMP  as  suggested  by  non-selective  PDE  inhibition  locking  the  response  in  a 
sustained plateau that only returned upon wash out of the PDE inhibitor. The plateau, 
which  was  reached  within  the  1  min  NO  application,  reflects  the  point  at  which 
equilibrium exists between the rate of cGMP synthesis and breakdown. Following 
exposure  to  a  high  (30  nM)  NO  concentration,  the  responses  to  low  NO 
concentrations exhibited a slower initial rising rate. This is likely to be the result of 
NOGC receptor desensitisation, where it has been demonstrated in rat platelets that NO 
desensitises its receptor with an EC50 of 10-20 nM, the half-time for recovery being 
16  min  (Halvey  et  al.,  2009).  Additionally,  the  response  decline  to  a  low  NO 
concentration  following  a  desensitising  NO  challenge  was  observed  to  be  steeper 
compared  to  that  of  the  response  recorded  upon  the  first  application  of  low  NO, 
indicating switch-on or acceleration of some factor that results in faster break-down of 
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exposure  to  a  high  NO  concentration,  ultimately  causing  faster  decline  of  the 
subsequent response evoked by a lower NO concentration as the rate of hydrolysis 
would  outcompete  NOGC  receptor  activity.  The  contribution  of  NOGC  receptor 
desensitisation to the shallower initial rise of the response is consistent with estimated 
cGMP accumulation being reduced by  approximately 60% as compared to that in 
response to low NO before a desensitising NO concentration. Additionally, judging 
by the shape of the concentration-response curves of initial rising rates, it appears that 
NO at 10 nM evoked a degree of desensitisation, the initial rising rate to subsequent 
30 nM NO being shallower.  
In  the  HEK  cell  line  that  exhibited  greater  NO  sensitivity,  an  increase  in 
fluorescence was detected at NO concentrations as low as 3 pM, a breakthrough in the 
detection  limit  of  NO-evoked  cGMP  signals  and  a  validation  of  FlincG  as  a 
superlatively  sensitive  biosensor.  As  estimated  from  the  initial  rising  rates  of  the 
responses to different NO concentrations, the environmental NO around the recording 
chamber was approximately 10 pM. Studies in cerebellar astrocytes suggested that an 
NO concentration of only 10 pM could theoretically generate enough cGMP (200 nM) 
to engage targets such as cGMP-dependent protein kinases (PKG; Roy & Garthwaite, 
2006). The potential of small amounts of atmospheric NO generated by traffic and 
industrial combustion to cause cGMP accumulation has been demonstrated previously 
by  studies  on  NOGC  receptors  purified  from  bovine  lung,  which  found  4-10  fold 
activation of NOGC receptors by NO present in the atmosphere in close proximity to 
the Berlin inner city circular highway, which was prevented in the presence of an NO 
scavenger (Friebe et al., 1996a). The sensitivity of NOGC receptors and ensuing cGMP 
production to NO in polluted air highlights the importance of evaluating carefully the 
dependence of a given observation on endogenous NO produced within a tissue. The 
potential effect of environmental NO in vivo is implicated by reports that inhaled NO 
at  amounts  measured  in  atmospheric  NO  (Friebe  et  al.,  1996a)  has  beneficial 
consequences  in  patients  suffering  from  pulmonary  hypertension  (Rossaint  et  al., 
1993).  
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In  the  case  of  the  cells  expressing  NOGC  receptors  and  PDE5,  biphasic 
responses  were  recorded,  which  is  consistent  with  previous  work  that  used  a 
biochemical approach (Mullershausen et al., 2004b). The initial fast rise of the FlincG 
response,  giving  rise  to  the  first  phase  of  the  response,  was  followed  by  a  rapid 
decline of the response while NO was still present. Both the initial rising rates of the 
responses as well as the onset of response decline were accelerated with ascending 
NO  concentrations.  These  observations  are  consistent  with  activation  of  PDE5  by 
cGMP  and  allosteric  enhancement  of  PDE5  activity  by  cGMP  binding  to  the 
enzyme’s GAF domain (Rybalkin et al., 2003; Mullershausen et al., 2003) so that 
PDE5 activity eventually exceeds NOGC receptor activity, causing cGMP levels to 
fall. Additionally, at a non-desensitising NO concentration (Mo et al., 2004; Halvey et 
al., 2009) the initial ‘spike-like’ phase of the response was blunted following repeated 
NO  exposures.  This  latter  observation  was  indicative  of  a  longer-term  negative 
feedback  on  NO-evoked  cGMP  accumulation  unlikely  to  involve  receptor 
desensitisation  at  the  low  NO  concentrations  tested.  Consistent  with  this  idea  are 
findings that sustained enhanced PDE5 activity can be initiated by NO via cGMP-
PKG-mediated  phosphorylation  (Mullershausen  et  al.,  2003;  Mullershuasen  et  al., 
2004b). It has been demonstrated in the same cell line that cGMP not only directly 
activates  PDE5,  therefore  enhancing  its  catalytic  activity,  but  also  leads  to 
phosphorylation of PDE5 which renders the enzyme able to bind cGMP with greater 
affinity and slows the rate at which PDE5 deactivates (Mullershausen et al., 2004b). 
Additionally, endogenous cyclic nucleotide-activated kinase has been reported to be 
present in native HEK cells, and an increase in PDE5 phosphorylation under basal 
conditions  and  after  NO  application  has  been  demonstrated  in  HEK  cells  over-
expressing PKG (Mullershausen et al., 2004b). On the other hand, the present work 
shows that the response to a low NO concentration following a high desensitising NO 
concentration was almost lost in cells expressing NOGC receptors and PDE5, which is 
likely attributable to NOGC receptor desensitisation and PDE5 activity out-competing 
the rate of cGMP synthesis (Garthwaite, 2005; Halvey et al., 2009). A desensitising 
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initial rising rates of the responses of both  HEK cell lines  expressing  both NOGC 
receptor and PDE5, the initial rising rate of the response evoked by 30 nM being 
shallower compared to that of 10 nM NO. This range of NO concentration causing 
NOGC receptor desensitisation is consistent with findings in rat platelets, which found 
an EC50 of 10-20 nM for NO to cause desensitisation (Halvey et al., 2009).  
The promising nature of the method characterised in the present study was 
highlighted by experiments showing reproducible changes in fluorescence intensity in 
cells permanently expressing both NOGC receptors and PDE5 for up to ten successive, 
brief  (30  sec)  exposures  to  low  (non-desensitising)  NO  concentrations  at  2  min 
intervals. The reproducibility of responses to low NO concentrations was indicated by 
the initial rising phases of the response to successive NO applications following a 
relatively stable trend, indicating that no marked desensitisation occurred. However, 
in the case of the cells expressing higher levels of PDE5 (i.e. HEK-GC/PDE5
high), 
blunting  of  the  first  (‘spike-like’)  phase  of  the  biphasic  response  occurred  when 
comparing the first response to the last one, consistent with the idea that there may be 
a long-term change such as PDE5 phosphorylation occurring as discussed above. This 
latter observation could also explain the drop in the initial rising rate upon the first 
NO challenge, which appeared to then continue a relatively stable trend in response to 
subsequent NO exposures. It may be that cGMP accumulation in response to the first 
NO  application  renders  PDE5  more  active,  which  stabilises  in  the  course  of  the 
following NO challenges.  
 
One surprising finding in the present studies on HEK-GC/PDE5 cell lines was 
a  partly  ODQ-insensitive  FlincG  response  recorded  upon  PDE5  inhibition  in  the 
absence of added NO, but in the presence of the NO scavenger CPTIO as well as the 
broad-spectrum NOS inhibitor L-NNA, which would prevent any  endogenous NO 
production. Part of the response seen upon PDE5 inhibition is likely to depend on 
basal NOGC receptor activity as indicated by a much shallower gradient of the initial 
rising  phase  of  the  response  upon  NOGC  receptor  inhibition  as  compared  to  that 
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observed  upon  PDE  inhibition  in  cells  expressing  only  NOGC  receptors.  The 
observation  of  basal  cGMP  production  that  appears  to  vary  among  the  cell  lines 
investigated suggests a possible flaw of procedure. A possible explanation for results 
indicating  basal  cGMP  production  in  one  cell  line  but  not  another  is  the  rate  of 
acquisition. While cells expressing only NOGC receptor were imaged at 0.2 Hz, cells 
expressing both NOGC receptors and PDE5 were imaged at 0.5 or 1.0 Hz. A greater 
speed of acquisition would mean that cells are exposed to more light. A phenomenon 
of light-induced smooth muscle relaxation, referred to as ‘photorelaxation’, has been 
reported  (Ehrreich  & Furchgott, 1968). The  authors deduced that the light-evoked 
relaxation  may  be  related  to  NO  release,  the  suspected  source  being  nitrite  as 
indicated by relaxation of non-photosensitive tissue upon nitrite and light exposure. 
The  phenomenon  of  light-induced  relaxation  has  since  been  investigated  further, 
aiming  to  identify  and  quantify  the  source  that  is  apparently  sensitive  to  light 
exposure and leads to NO liberation. More recent reports from studies in rat aorta are 
in support of S-nitrosothiols and nitrite being a light-sensitive source of NO that is 
independent of NOS activity (Rodriguez et al., 2003; Batenburg et al., 2009). Reynell 
and Batchelor in the Garthwaite lab (unpublished) conducted experiments in which 
cells were exposed to altering intervals of light exposure, finding that increasing the 
interval  reduces  the  effect  on  basal  cGMP  and  vice  versa.  Additionally,  the  NO 
scavenger CPTIO used in the present study is not very fast acting (Garthwaite, 2008), 
and the reaction of CPTIO and urate, which is also contained in the extracellular 
solution, produces nitrite. Hence, based on these latter considerations it is plausible to 
suggest that build up of nitrite may in fact be the source of NOS-independent, light-
evoked  basal  cGMP  production.  This  possible  artefact  may  have  influenced  other 
results obtained in the present work. For example, the existence of basal cGMP levels 
may lead to a continuous state of PDE5 activation. On the other hand, basal cGMP 
production may explain the ‘undershoot’ of the response beyond the initial baseline 
upon NO removal, observed in cells expressing NOGC receptors and PDE5. A possible 
explanation may be that the enhanced PDE5 activity brought about by NO-evoked 
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fluorescence intensity reducing below the initial baseline intensity. Eventually, upon 
subsidence of PDE5 activity, the rate of basal cGMP synthesis may catch up and 
would  reach  equilibrium  with  its  rate  of  hydrolysis,  reverting  back  to  the  initial 
baseline. As artefactual, basal cGMP levels may be reduced by altering the extent of 
light exposure, there is scope for addressing this problem, either technologically or by 
preventing the build-up of NOS-independent NO sources directly.  
As  mentioned  previously,  there  was  also  a  marked  ODQ-insensitive 
component of the sildenafil-evoked response. This may be explained by a tonic cGMP 
level produced by the NO-insensitive, natriuretic peptide-activated guanylyl cyclase. 
Due to the lack of appropriate pharmacological tools this possibility could not be 
investigated. Alternatively, mutations of the haem-coordinating his-105 residue of the 
β1 subunit of the NOGC receptor were shown to give rise to a guanylyl cyclase species 
that  is  NO-insensitive,  haem-depleted,  and  constitutively  active  under  basal 
conditions (Wedel et al., 1994). The failure to prevent the sildenafil-evoked FlincG 
response by ODQ indicates that this effect may in fact be due to the presence of a 
haem-free population of the guanylyl cyclase since inhibition of NOGC receptors by 
ODQ requires haem oxidation (Schrammel et al., 1996). Therefore, it is plausible to 
suggest that the presence of a constitutively active, haem-free receptor species may 
account for the observed sildenafil-evoked effect in the absence of added NO that is 
insensitive to NOGC receptor inhibition by ODQ. 
 
The  physiological  relevance  of  the  various  NO-evoked  FlincG  response 
profiles observed in the expression systems assessed in the present study is indicated 
by the finding of similar NO-evoked cGMP signals occurring in human platelets and 
aortic smooth muscle, as deduced from biochemical measurements (Mullershausen et 
al., 2001). In human platelets, NO has been demonstrated to evoke transient ‘spike-
like’ cGMP responses with the rapid increase in cGMP peaking within approximately 
5 sec and declining to almost basal levels in less then 1 min. This resembles very 
closely the NO-evoked response profiles captured in the HEK-GC/PDE5
high cells. On 
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situation  observed  in  aortic  smooth  muscle  cells,  where  NO-evoked  cGMP  levels 
were  found  to  approach  maximum  at  circa  20-30  sec  with  a  slower  and  less 
pronounced decline of cGMP. While PDE5 is the principal PDE isoform in platelets 
and smooth muscle, PDE2 plays an important role in cGMP hydrolysis in a number of 
brain regions including the hippocampus, cortex and striatum (van Staveren et al., 
2001; Suvarna & O’Donnell, 2002; Wykes et al., 2002; van Staveren et al., 2003). 
Similar to PDE5, PDE2 also contains regulatory GAF domains (Martins et al., 1982; 
Martinez et al., 2002; Bender & Beavo, 2006), so it may function similarly to PDE5. 
The FlincG response profiles recorded in cells expressing only the NOGC receptor on 
the other hand may be more closely related to the situation in real-time in astrocytes. 
For example, in cerebellar astrocytes, which possess high levels of NOGC receptors,  
the combination of rapid NOGC receptor desensitisation and very low PDE activity 
results in a large increase in cGMP accumulation and a sustained plateau in response 
to NO, with the shape of the cGMP response being governed overwhelmingly by 
NOGC  receptor  desensitisation  (Bellamy  et  al.,  2000).  These  properties  may  allow 
astrocytes  to  respond  to  very  low  NO  concentrations,  possibly  derived  from  the 
vasculature and/or neurons (Garthwaite, 2008), since to date there is no good evidence 
for astrocytes themselves synthesising NO.  
 
Although the present study validated the method only on a temporal level, 
there is great potential to also study spatial dynamics of cGMP signalling by means of 
this  novel  approach.  Nausch  and  colleagues  (2008)  illustrated  spatially  confined 
cGMP  elevations  in  cultured  aortic  smooth  muscle  cells,  recording  global  cGMP 
transients in response to NO, but membrane-confined cGMP elevations in response to 
activation of natriuretic peptide-sensitive guanylyl cyclase. The latter was shown to be 
transformed into a global signal upon inhibition of PDE5. This new method waits to 
be  characterised  at  the  single  neuronal  level.  A  recent  study  used  a  FRET-based 
cGMP biosensor expressed in cultured brain slices by viral-mediated gene transfer 
(Hepp et al., 2007). The authors revealed a role of PDE2 in the regulation of basal 
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in experiments monitoring stimulated NOGC receptor activity, concentrations of NO 
were not delivered at known steady-state concentrations, and a very small change in 
FRET started to occur at 50 nM of DEA/NO, with maximal FRET changes occurring 
at  50  µM  and  above,  indicating  poor  sensitivity.  Additionally,  the  readouts  were 
relatively  slow  so  that  fast  signalling  events  could  not  be  monitored  accurately. 
Following  the  characterisation  of  FlincG  in  HEK  cell  lines,  a  further  aim  of  the 
present study was to investigate the spatiotemporal profile of cGMP accumulation in 
response  to  NO  in  cultured  hippocampal  neurons.  As  discussed  in  Chapter  5,  the 
results obtained by means of immunohistochemistry provided only a ‘snap shot’ of 
the  cGMP  response.  Global  cGMP  immunolabelling  occurred  in  pyramidal  cell 
somata throughout the different regions of the rat hippocampal formation, as well as 
in some dendrites and possibly axons (see Chapter 5). However, this result was only 
obtained  by  greatly  amplifying  cGMP  accumulation  in  neurons  by  means  of 
sensitising NOGC receptors to NO (BAY 41-2272), inhibiting PDE2 (BAY 60-7550) 
and  adding  an  NO  donor.  Attempts  were  made  to  express  the  FlincG  in  cultured 
hippocampal neurons by means of a Ca
2+-phosphate transfection approach (Jiang & 
Chen, 2006), using FlincG cDNA provided by Wolfgang Dostman and neurons kindly 
grown  and  provided  by  Lily  Yu.  However,  no  FlincG  expression  at  all  could  be 
obtained in the neurons due to unknown reasons. A promising strategy in the future to 
express  FlincG  in  neurons  may  be  via  Sindbis  virus-mediated  transfer  of  FlincG 
(currently investigated in the Garthwaite lab). Using Sindbis virus-mediated transfer 
of  FlincG,  it  might  be  plausible  to  investigate  the  site  of  cGMP  accumulation  in 
pyramidal neurons, and to characterise the impact of PDE inhibition, Sindbis virus-
mediated  gene  transfer  having  been  shown  to  be  highly  efficient  and  selective  to 
neurons compared to glial cells (Gwag et al., 1998). Solely based on the histological 
evidence illustrated in Chapter 5 the neuronal domains of cGMP accumulation remain 
elusive.  Is  it  localised  only  in  dendrites  and/or  generally  to  membranes,  or  can  it 
accumulate globally within the neuronal soma? If the former were the case, how does 
inhibition of different PDE isoforms impact on the spread of the cGMP signal from a 
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NO concentrations (or shapes of NO episodes) are different PDE isoforms recruited to 
the profiling of the cGMP signal? Unfortunately, due to lack of time, these questions 
could not be addressed as part of the present thesis.  
 
In conclusion, the present study supports the combined use of δ-FlincG and 
the ‘clamped’ delivery method of NO to study fast, repetitive cGMP transients in 
response  to  very  low  NO  concentrations.  Moreover,  the  ability  to  capture  distinct 
changes in cGMP profiles that are based on varying proportions of NOGC receptor 
and/or PDE activities demonstrates the sensitivity of the method and its applicability 
in monitoring different cGMP signals in different types of cells, provided that the 
indicator can be delivered to the cell interior (e.g. astrocytes, neurons). Using this 
method, it may be possible to study the temporal profiles of events such as NOGC 
receptor  desensitisation,  or  even  the  temporal  profile  of  pharmacological  tools 
influencing cGMP signals. For example, it may be a useful tool in the future to assess 
properties  of  pharmacological  agents  acting  on  the  NOGC  receptor,  such  as 
permeability properties, reversibility, and temporal profile of pharmacological action 
of the compound. Additionally, this method has the potential of becoming a valuable 
tool in investigating quantitatively how PDEs hydrolyse cGMP in intact cells, as well 
as in discerning how different PDE isoforms in a given cell may be contributing to 
shaping NO-mediated cGMP signals.  
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